# Official Journal L 348/2010

| | ISSN 1725-2555
  doi:10.3000/17252555.L_2010.348.eng |
| --- | --- |
| Official Journal
  of the European Union | L 348 |
| | |
| English edition | Legislation | Volume 5331 December 2010 |

ISSN 1725-2555

doi:10.3000/17252555.L_2010.348.eng

Official Journal

of the European Union

L 348

English edition

Legislation

Volume 5331 December 2010

---

| Contents | | I   Legislative acts | page |
| --- | --- | --- | --- |
| | | REGULATIONS |
| | * | Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (
  1
  ) | 1 |
| | * | Regulation (EU) No 1236/2010 of the European Parliament and of the Council of 15 December 2010 laying down a scheme of control and enforcement applicable in the area covered by the Convention on future multilateral cooperation in the North-East Atlantic fisheries and repealing Council Regulation (EC) No 2791/1999 | 17 |
| | * | Regulation (EU) No 1237/2010 of the European Parliament and of the Council of 15 December 2010 amending Council Regulation (EC) No 2187/2005 as regards the prohibition of highgrading and restrictions on fishing for flounder and turbot in the Baltic Sea, the Belts and the Sound | 34 |
| | * | Regulation (EU) No 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an international non-proprietary name (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals | 36 |
| | | DIRECTIVES |
| | * | Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (
  1
  ) | 74 |

Contents

I   Legislative acts

page

REGULATIONS

*

Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (
  1
  )

1

1

*

Regulation (EU) No 1236/2010 of the European Parliament and of the Council of 15 December 2010 laying down a scheme of control and enforcement applicable in the area covered by the Convention on future multilateral cooperation in the North-East Atlantic fisheries and repealing Council Regulation (EC) No 2791/1999

17

*

Regulation (EU) No 1237/2010 of the European Parliament and of the Council of 15 December 2010 amending Council Regulation (EC) No 2187/2005 as regards the prohibition of highgrading and restrictions on fishing for flounder and turbot in the Baltic Sea, the Belts and the Sound

34

*

Regulation (EU) No 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an international non-proprietary name (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals

36

DIRECTIVES

*

Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (
  1
  )

1

74

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.
  The titles of all other Acts are printed in bold type and preceded by an asterisk.
  This issue closes the L series for 2010. |
| --- | --- |

EN

Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.

The titles of all other Acts are printed in bold type and preceded by an asterisk.

This issue closes the L series for 2010.

---

I Legislative acts

REGULATIONS

| 31.12.2010 | EN | Official Journal of the European Union | L 348/1 |
| --- | --- | --- | --- |

31.12.2010

EN

Official Journal of the European Union

L 348/1

---

REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 15 December 2010

amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and Article 168(4)(c) thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national parliaments,

Having regard to the opinion of the European Economic and Social Committee (1),

Having regard to the opinion of the Committee of the Regions (2),

Having regard to the opinion of the European Data Protection Supervisor (3),

Acting in accordance with the ordinary legislative procedure (4),

Whereas:

| (1) | Regulation (EC) No 726/2004 (5) creates a Union-wide marketing authorisation procedure for certain categories of medicinal products (the ‘centralised procedure’), lays down rules for the pharmacovigilance of those products and establishes the European Medicines Agency (the ‘Agency’). |
| --- | --- |

(1)

Regulation (EC) No 726/2004 (5) creates a Union-wide marketing authorisation procedure for certain categories of medicinal products (the ‘centralised procedure’), lays down rules for the pharmacovigilance of those products and establishes the European Medicines Agency (the ‘Agency’).

| (2) | Pharmacovigilance rules are necessary for the protection of public health in order to prevent, detect and assess adverse reactions to medicinal products for human use placed on the Union market, as the full safety profile of medicinal products for human use can be known only after they have been placed on the market. |
| --- | --- |

(2)

Pharmacovigilance rules are necessary for the protection of public health in order to prevent, detect and assess adverse reactions to medicinal products for human use placed on the Union market, as the full safety profile of medicinal products for human use can be known only after they have been placed on the market.

| (3) | The pollution of waters and soils with pharmaceutical residues is an emerging environmental problem. Member States should consider measures to monitor and evaluate the risk of environmental effects of such medicinal products for human use, including those which may have an impact on public health. The Commission should, based, inter alia, on data received from the Agency, the European Environment Agency, and Member States, produce a report on the scale of the problem, along with an assessment on whether amendments to Union legislation on medicinal products for human use or other relevant Union legislation are required. |
| --- | --- |

(3)

The pollution of waters and soils with pharmaceutical residues is an emerging environmental problem. Member States should consider measures to monitor and evaluate the risk of environmental effects of such medicinal products for human use, including those which may have an impact on public health. The Commission should, based, inter alia, on data received from the Agency, the European Environment Agency, and Member States, produce a report on the scale of the problem, along with an assessment on whether amendments to Union legislation on medicinal products for human use or other relevant Union legislation are required.

| (4) | In the light of the experience acquired and following an assessment by the Commission of the Union system of pharmacovigilance, it has become clear that it is necessary to take measures in order to improve the operation of Union law on the pharmacovigilance of medicinal products for human use. |
| --- | --- |

(4)

In the light of the experience acquired and following an assessment by the Commission of the Union system of pharmacovigilance, it has become clear that it is necessary to take measures in order to improve the operation of Union law on the pharmacovigilance of medicinal products for human use.

| (5) | The main tasks of the Agency in the area of pharmacovigilance laid down in Regulation (EC) No 726/2004 should be maintained and further developed, in particular as regards the management of the Union pharmacovigilance database and data-processing network (the ‘Eudravigilance database’), the coordination of safety announcements by the Member States and the provision to the public of information regarding safety issues. |
| --- | --- |

(5)

The main tasks of the Agency in the area of pharmacovigilance laid down in Regulation (EC) No 726/2004 should be maintained and further developed, in particular as regards the management of the Union pharmacovigilance database and data-processing network (the ‘Eudravigilance database’), the coordination of safety announcements by the Member States and the provision to the public of information regarding safety issues.

| (6) | In order to allow all competent authorities to receive, access simultaneously and share pharmacovigilance information for medicinal products for human use authorised in the Union, the Eudravigilance database should be maintained and strengthened as the single point of receipt of such information. Member States should therefore not impose any additional reporting requirements on marketing authorisation holders. The database should be fully and permanently accessible to the Member States, the Agency and the Commission, and accessible to an appropriate extent to marketing authorisation holders and the public. |
| --- | --- |

(6)

In order to allow all competent authorities to receive, access simultaneously and share pharmacovigilance information for medicinal products for human use authorised in the Union, the Eudravigilance database should be maintained and strengthened as the single point of receipt of such information. Member States should therefore not impose any additional reporting requirements on marketing authorisation holders. The database should be fully and permanently accessible to the Member States, the Agency and the Commission, and accessible to an appropriate extent to marketing authorisation holders and the public.

| (7) | In order to increase transparency as regards pharmacovigilance issues, a European medicines web-portal should be created and maintained by the Agency. |
| --- | --- |

(7)

In order to increase transparency as regards pharmacovigilance issues, a European medicines web-portal should be created and maintained by the Agency.

| (8) | In order to ensure the availability of the necessary expertise and resources for pharmacovigilance assessments at Union level, it is appropriate to create a new scientific committee within the Agency: the Pharmacovigilance Risk Assessment Committee. That committee should be composed of members appointed by Member States who are competent in the safety of medicines including the detection, assessment, minimisation and communication of risk, and in the design of post-authorisation safety studies and pharmacovigilance audits, and of members appointed by the Commission, who are independent scientific experts, or representatives of healthcare professionals and patients. |
| --- | --- |

(8)

In order to ensure the availability of the necessary expertise and resources for pharmacovigilance assessments at Union level, it is appropriate to create a new scientific committee within the Agency: the Pharmacovigilance Risk Assessment Committee. That committee should be composed of members appointed by Member States who are competent in the safety of medicines including the detection, assessment, minimisation and communication of risk, and in the design of post-authorisation safety studies and pharmacovigilance audits, and of members appointed by the Commission, who are independent scientific experts, or representatives of healthcare professionals and patients.

| (9) | The rules on Scientific Committees of the Agency laid down in Regulation (EC) No 726/2004 should apply to the Pharmacovigilance Risk Assessment Committee. |
| --- | --- |

(9)

The rules on Scientific Committees of the Agency laid down in Regulation (EC) No 726/2004 should apply to the Pharmacovigilance Risk Assessment Committee.

| (10) | In order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (6) should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee with regard to any question relating to the pharmacovigilance of medicinal products for human use. However, for the sake of consistency and continuity of the safety assessments, the final responsibility for issuing an opinion on the risk-benefit assessment of medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004 should remain with the Committee for Medicinal Products for Human Use and with the authorities competent for the granting of marketing authorisations. |
| --- | --- |

(10)

In order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (6) should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee with regard to any question relating to the pharmacovigilance of medicinal products for human use. However, for the sake of consistency and continuity of the safety assessments, the final responsibility for issuing an opinion on the risk-benefit assessment of medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004 should remain with the Committee for Medicinal Products for Human Use and with the authorities competent for the granting of marketing authorisations.

| (11) | It is appropriate that the Pharmacovigilance Risk Assessment Committee should give a recommendation as part of any Union-wide post-authorisation assessment based on pharmacovigilance data relating to medicinal products for human use and it should be responsible for making recommendations on risk management systems and monitoring their effectiveness. Such Union-wide assessments should follow the procedures laid down in Directive 2001/83/EC also for medicinal products for human use that were authorised through the centralised procedure. |
| --- | --- |

(11)

It is appropriate that the Pharmacovigilance Risk Assessment Committee should give a recommendation as part of any Union-wide post-authorisation assessment based on pharmacovigilance data relating to medicinal products for human use and it should be responsible for making recommendations on risk management systems and monitoring their effectiveness. Such Union-wide assessments should follow the procedures laid down in Directive 2001/83/EC also for medicinal products for human use that were authorised through the centralised procedure.

| (12) | In accordance with Directive 2001/83/EC the Agency provides the secretariat to the coordination group. In view of the enlarged mandate of the coordination group in the area of pharmacovigilance, the technical and administrative support by the secretariat of the Agency to the coordination group should be reinforced. Provision should be made for the Agency to ensure appropriate coordination between the coordination group and the Agency’s Scientific Committees. |
| --- | --- |

(12)

In accordance with Directive 2001/83/EC the Agency provides the secretariat to the coordination group. In view of the enlarged mandate of the coordination group in the area of pharmacovigilance, the technical and administrative support by the secretariat of the Agency to the coordination group should be reinforced. Provision should be made for the Agency to ensure appropriate coordination between the coordination group and the Agency’s Scientific Committees.

| (13) | In order to protect public health, the pharmacovigilance activities of the Agency should be adequately funded. It should be ensured that adequate funding is possible for pharmacovigilance activities by empowering the Agency to charge fees to marketing authorisation holders. However, the management of those collected funds should be under the permanent control of the Management Board in order to guarantee the independence of the Agency. |
| --- | --- |

(13)

In order to protect public health, the pharmacovigilance activities of the Agency should be adequately funded. It should be ensured that adequate funding is possible for pharmacovigilance activities by empowering the Agency to charge fees to marketing authorisation holders. However, the management of those collected funds should be under the permanent control of the Management Board in order to guarantee the independence of the Agency.

| (14) | To ensure the highest levels of expertise and the functioning of the Pharmacovigilance Risk Assessment Committee, rapporteurs providing assessments for Union pharmacovigilance procedures, periodic safety update reports, post-authorisation safety study protocols and risk management systems should receive payment through the Agency. |
| --- | --- |

(14)

To ensure the highest levels of expertise and the functioning of the Pharmacovigilance Risk Assessment Committee, rapporteurs providing assessments for Union pharmacovigilance procedures, periodic safety update reports, post-authorisation safety study protocols and risk management systems should receive payment through the Agency.

| (15) | Therefore, the Agency should be empowered to charge fees in return for performing the activities of the coordination group within the Union system of pharmacovigilance, as provided for in Directive 2001/83/EC, and the rapporteurs within the coordination group should, in turn, be paid by the Agency. |
| --- | --- |

(15)

Therefore, the Agency should be empowered to charge fees in return for performing the activities of the coordination group within the Union system of pharmacovigilance, as provided for in Directive 2001/83/EC, and the rapporteurs within the coordination group should, in turn, be paid by the Agency.

| (16) | It is necessary, from a public health perspective, to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, also about the efficacy of medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004. The Commission should therefore be empowered to impose on the marketing authorisation holder the obligation to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose that obligation at the time of granting the marketing authorisation or later, and it should be a condition of the marketing authorisation. Such studies may be aimed at collecting data to enable the assessment of safety or efficacy of medicinal products for human use in everyday medical practice. |
| --- | --- |

(16)

It is necessary, from a public health perspective, to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, also about the efficacy of medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004. The Commission should therefore be empowered to impose on the marketing authorisation holder the obligation to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose that obligation at the time of granting the marketing authorisation or later, and it should be a condition of the marketing authorisation. Such studies may be aimed at collecting data to enable the assessment of safety or efficacy of medicinal products for human use in everyday medical practice.

| (17) | It is essential that a strengthened system of pharmacovigilance not lead to the premature granting of marketing authorisations. However, some medicinal products for human use are authorised subject to additional monitoring. This includes all medicinal products for human use with a new active substance and biological medicinal products, including biosimilars, which are priorities for pharmacovigilance. Competent authorities may also require additional monitoring for specific medicinal products for human use that are subject to the obligation to conduct a post-authorisation safety study or to conditions or restrictions with regard to the safe and effective use of the medicinal product that will be specified in the risk management plan. Risk management plans are normally required for new active substances, biosimilars, medicinal products for paediatric use and for medicinal products for human use involving a significant change in the marketing authorisation, including a new manufacturing process of a biotechnologically-derived medicinal product. Medicinal products for human use subject to additional monitoring should be identified as such by a black symbol, which will be selected by the Commission on the basis of a recommendation by the Pharmacovigilance Risk Assessment Committee, and an appropriate standardised explanatory sentence in the summary of product characteristics and in the package leaflet. The Agency should keep an up-to-date, publicly available list of such medicinal products. |
| --- | --- |

(17)

It is essential that a strengthened system of pharmacovigilance not lead to the premature granting of marketing authorisations. However, some medicinal products for human use are authorised subject to additional monitoring. This includes all medicinal products for human use with a new active substance and biological medicinal products, including biosimilars, which are priorities for pharmacovigilance. Competent authorities may also require additional monitoring for specific medicinal products for human use that are subject to the obligation to conduct a post-authorisation safety study or to conditions or restrictions with regard to the safe and effective use of the medicinal product that will be specified in the risk management plan. Risk management plans are normally required for new active substances, biosimilars, medicinal products for paediatric use and for medicinal products for human use involving a significant change in the marketing authorisation, including a new manufacturing process of a biotechnologically-derived medicinal product. Medicinal products for human use subject to additional monitoring should be identified as such by a black symbol, which will be selected by the Commission on the basis of a recommendation by the Pharmacovigilance Risk Assessment Committee, and an appropriate standardised explanatory sentence in the summary of product characteristics and in the package leaflet. The Agency should keep an up-to-date, publicly available list of such medicinal products.

| (18) | Experience has shown that the responsibilities of marketing authorisation holders with regard to pharmacovigilance of authorised medicinal products for human use should be clarified. The marketing authorisation holder should be responsible for continuously monitoring the safety of its medicinal products for human use, for informing the authorities of any changes that might have an impact on the marketing authorisation, and for ensuring that the product information is kept up to date. As medicinal products for human use could be used outside the terms of the marketing authorisation, the marketing authorisation holder’s responsibilities should include providing all available information, including the results of clinical trials or other studies, as well as reporting any use of the medicinal product which is outside the terms of the marketing authorisation. It is also appropriate to ensure that all relevant information collected on the safety of the medicinal product for human use is taken into account when the marketing authorisation is being renewed. |
| --- | --- |

(18)

Experience has shown that the responsibilities of marketing authorisation holders with regard to pharmacovigilance of authorised medicinal products for human use should be clarified. The marketing authorisation holder should be responsible for continuously monitoring the safety of its medicinal products for human use, for informing the authorities of any changes that might have an impact on the marketing authorisation, and for ensuring that the product information is kept up to date. As medicinal products for human use could be used outside the terms of the marketing authorisation, the marketing authorisation holder’s responsibilities should include providing all available information, including the results of clinical trials or other studies, as well as reporting any use of the medicinal product which is outside the terms of the marketing authorisation. It is also appropriate to ensure that all relevant information collected on the safety of the medicinal product for human use is taken into account when the marketing authorisation is being renewed.

| (19) | Scientific and medical literature is an important source of information on suspected adverse reaction case reports. Currently, for active substances included in more than one medicinal product for human use, literature cases are reported in adverse reaction case reports in a duplicative way. In order to enhance the efficiency of reporting, the Agency should monitor a defined list of literature for a defined list of active substances used in medicinal products for which there are several marketing authorisations. |
| --- | --- |

(19)

Scientific and medical literature is an important source of information on suspected adverse reaction case reports. Currently, for active substances included in more than one medicinal product for human use, literature cases are reported in adverse reaction case reports in a duplicative way. In order to enhance the efficiency of reporting, the Agency should monitor a defined list of literature for a defined list of active substances used in medicinal products for which there are several marketing authorisations.

| (20) | As a result of the submission of all suspected adverse reaction data for medicinal products for human use authorised by the Member States directly to the Eudravigilance database, it is not necessary to provide for different reporting rules for medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004. The rules on suspected adverse reaction recording and reporting laid down in Directive 2001/83/EC should therefore apply to medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004. |
| --- | --- |

(20)

As a result of the submission of all suspected adverse reaction data for medicinal products for human use authorised by the Member States directly to the Eudravigilance database, it is not necessary to provide for different reporting rules for medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004. The rules on suspected adverse reaction recording and reporting laid down in Directive 2001/83/EC should therefore apply to medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004.

| (21) | It is necessary to increase the shared use of resources between competent authorities for the assessment of periodic safety update reports. The assessment procedures provided for in Directive 2001/83/EC should therefore apply for the single assessment of periodic safety update reports for different medicinal products for human use containing the same active substance or the same combination of active substances, including joint assessments of medicinal products for human use authorised both nationally and through the centralised procedure. |
| --- | --- |

(21)

It is necessary to increase the shared use of resources between competent authorities for the assessment of periodic safety update reports. The assessment procedures provided for in Directive 2001/83/EC should therefore apply for the single assessment of periodic safety update reports for different medicinal products for human use containing the same active substance or the same combination of active substances, including joint assessments of medicinal products for human use authorised both nationally and through the centralised procedure.

| (22) | It is appropriate to strengthen the supervisory role for medicinal products for human use authorised through the centralised procedure by providing that the supervisory authority for pharmacovigilance should be the competent authority of the Member State in which the pharmacovigilance system master file of the marketing authorisation holder is located. |
| --- | --- |

(22)

It is appropriate to strengthen the supervisory role for medicinal products for human use authorised through the centralised procedure by providing that the supervisory authority for pharmacovigilance should be the competent authority of the Member State in which the pharmacovigilance system master file of the marketing authorisation holder is located.

| (23) | This Regulation shall apply without prejudice to Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (7) and Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (8). In order to detect, assess, understand and prevent adverse reactions, and to identify and take actions to reduce the risks of, and increase the benefits from, medicinal products for human use for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting the Union legislation relating to data protection. The purpose of safeguarding public health constitutes a substantial public interest and consequently the processing of personal data can be justified if identifiable health data are processed only when necessary and only when the parties involved assess this necessity at every stage of the pharmacovigilance process. |
| --- | --- |

(23)

This Regulation shall apply without prejudice to Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (7) and Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (8). In order to detect, assess, understand and prevent adverse reactions, and to identify and take actions to reduce the risks of, and increase the benefits from, medicinal products for human use for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting the Union legislation relating to data protection. The purpose of safeguarding public health constitutes a substantial public interest and consequently the processing of personal data can be justified if identifiable health data are processed only when necessary and only when the parties involved assess this necessity at every stage of the pharmacovigilance process.

| (24) | This Regulation and Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (9) widen the tasks of the Agency with regard to pharmacovigilance, including the monitoring of literature cases, the improved use of information technology tools and the provision of more information to the general public. The Agency should be enabled to fund these activities from fees charged to marketing authorisation holders. These fees should not cover tasks carried out by national competent authorities for which such authorities charge fees in accordance with Directive 2001/83/EC. |
| --- | --- |

(24)

This Regulation and Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (9) widen the tasks of the Agency with regard to pharmacovigilance, including the monitoring of literature cases, the improved use of information technology tools and the provision of more information to the general public. The Agency should be enabled to fund these activities from fees charged to marketing authorisation holders. These fees should not cover tasks carried out by national competent authorities for which such authorities charge fees in accordance with Directive 2001/83/EC.

| (25) | The pharmacovigilance activities provided for in this Regulation require that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well as the minimum requirements for the quality system for the performance of pharmacovigilance activities by the Agency, the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities, and the minimum requirements for the monitoring of the data contained in the Eudravigilance database to determine whether there are new risks or whether risks have changed. The format and content of the electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans as well as the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In accordance with Article 291 of the Treaty on the Functioning of the European Union (TFEU), rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (10) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable. |
| --- | --- |

(25)

The pharmacovigilance activities provided for in this Regulation require that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well as the minimum requirements for the quality system for the performance of pharmacovigilance activities by the Agency, the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities, and the minimum requirements for the monitoring of the data contained in the Eudravigilance database to determine whether there are new risks or whether risks have changed. The format and content of the electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans as well as the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In accordance with Article 291 of the Treaty on the Functioning of the European Union (TFEU), rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (10) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable.

| (26) | The Commission should be empowered to adopt delegated acts in accordance with Article 290 TFEU in order to supplement the provisions in point (cc) of Article 9(4) and in point (b) of Article 10a(1) of Regulation (EC) No 726/2004. The Commission should be empowered to adopt supplementary measures laying down the situations in which post-authorisation efficacy studies may be required. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. |
| --- | --- |

(26)

The Commission should be empowered to adopt delegated acts in accordance with Article 290 TFEU in order to supplement the provisions in point (cc) of Article 9(4) and in point (b) of Article 10a(1) of Regulation (EC) No 726/2004. The Commission should be empowered to adopt supplementary measures laying down the situations in which post-authorisation efficacy studies may be required. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level.

| (27) | The provisions on the monitoring of medicinal products for human use in Regulation (EC) No 726/2004 constitute specific provisions in the meaning of Article 15(2) of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products (11). |
| --- | --- |

(27)

The provisions on the monitoring of medicinal products for human use in Regulation (EC) No 726/2004 constitute specific provisions in the meaning of Article 15(2) of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products (11).

| (28) | Proper coordination between the newly established Pharmacovigilance Risk Assessment Committee and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Committee for Orphan Medicinal Products and the Committee for Advanced Therapies established under Regulation (EC) No 1394/2007 (12) should be ensured. |
| --- | --- |

(28)

Proper coordination between the newly established Pharmacovigilance Risk Assessment Committee and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Committee for Orphan Medicinal Products and the Committee for Advanced Therapies established under Regulation (EC) No 1394/2007 (12) should be ensured.

| (29) | Regulations (EC) No 726/2004 and (EC) No 1394/2007 should therefore be amended accordingly, |
| --- | --- |

(29)

Regulations (EC) No 726/2004 and (EC) No 1394/2007 should therefore be amended accordingly,

HAVE ADOPTED THIS REGULATION:

Article 1

Amendments to Regulation (EC) No 726/2004

Regulation (EC) No 726/2004 is hereby amended as follows:

| 1. | in Article 5(2) the following sentence is added:

  ‘For the fulfilment of its pharmacovigilance tasks, including the approval of risk management systems and monitoring their effectiveness provided for under this Regulation, the Committee for Medicinal Products for Human Use shall rely on the scientific assessment and recommendations of the Pharmacovigilance Risk Assessment Committee referred to in Article 56(1)(aa).’; |
| --- | --- |

1.

in Article 5(2) the following sentence is added:

‘For the fulfilment of its pharmacovigilance tasks, including the approval of risk management systems and monitoring their effectiveness provided for under this Regulation, the Committee for Medicinal Products for Human Use shall rely on the scientific assessment and recommendations of the Pharmacovigilance Risk Assessment Committee referred to in Article 56(1)(aa).’;

| 2. | Article 9(4) is amended as follows:






  (a) | the following point is inserted:






  ‘(aa) | a recommendation on the frequency of submission of periodic safety update reports;’; |
| --- | --- | --- | --- |

2.

Article 9(4) is amended as follows:

(a)

the following point is inserted:

‘(aa)

a recommendation on the frequency of submission of periodic safety update reports;’;

| (b) | the following points are inserted:






  ‘(ca) | details of any recommended measures for ensuring the safe use of the medicinal product to be included in the risk management system; |
| --- | --- | --- |

(b)

the following points are inserted:

‘(ca)

details of any recommended measures for ensuring the safe use of the medicinal product to be included in the risk management system;

| (cb) | if appropriate, details of any recommended obligation to conduct post-authorisation safety studies or to comply with obligations on the recording or reporting of suspected adverse reactions which are stricter than those referred to in Chapter 3; |
| --- | --- |

(cb)

if appropriate, details of any recommended obligation to conduct post-authorisation safety studies or to comply with obligations on the recording or reporting of suspected adverse reactions which are stricter than those referred to in Chapter 3;

| (cc) | if appropriate, details of any recommended obligation to conduct post-authorisation efficacy studies where concerns relating to some aspects of the efficacy of the medicinal product are identified and can be resolved only after the medicinal product has been marketed. Such an obligation to conduct such studies shall be based on the delegated acts adopted pursuant to Article 10b while taking into account the scientific guidance referred to in Article 108a of Directive 2001/83/EC;’; |
| --- | --- |

(cc)

if appropriate, details of any recommended obligation to conduct post-authorisation efficacy studies where concerns relating to some aspects of the efficacy of the medicinal product are identified and can be resolved only after the medicinal product has been marketed. Such an obligation to conduct such studies shall be based on the delegated acts adopted pursuant to Article 10b while taking into account the scientific guidance referred to in Article 108a of Directive 2001/83/EC;’;

| (c) | point (e) is replaced by the following:






  ‘(e) | the assessment report as regards the results of the pharmaceutical and pre-clinical tests and of the clinical trials, and as regards the risk management system and the pharmacovigilance system for the medicinal product concerned.’; |
| --- | --- | --- |

(c)

point (e) is replaced by the following:

‘(e)

the assessment report as regards the results of the pharmaceutical and pre-clinical tests and of the clinical trials, and as regards the risk management system and the pharmacovigilance system for the medicinal product concerned.’;

| 3. | Article 10 is amended as follows:






  (a) | paragraph 1 is replaced by the following:

  ‘1.   Within 15 days after receipt of the opinion referred to in Article 5(2), the Commission shall prepare a draft of the decision to be taken in respect of the application.
  Where a draft decision envisages the granting of a marketing authorisation, it shall include or make reference to the documents mentioned in points (a) to (d) of Article 9(4).
  Where a draft decision envisages the granting of a marketing authorisation subject to the conditions referred to in points (c), (ca), (cb), or (cc) of Article 9(4), it shall lay down deadlines for the fulfilment of the conditions, where necessary.
  Where the draft decision differs from the opinion of the Agency, the Commission shall attach a detailed explanation of the reasons for the differences.
  The draft decision shall be forwarded to Member States and the applicant.’; |
| --- | --- | --- |

3.

Article 10 is amended as follows:

(a)

paragraph 1 is replaced by the following:

‘1.   Within 15 days after receipt of the opinion referred to in Article 5(2), the Commission shall prepare a draft of the decision to be taken in respect of the application.

Where a draft decision envisages the granting of a marketing authorisation, it shall include or make reference to the documents mentioned in points (a) to (d) of Article 9(4).

Where a draft decision envisages the granting of a marketing authorisation subject to the conditions referred to in points (c), (ca), (cb), or (cc) of Article 9(4), it shall lay down deadlines for the fulfilment of the conditions, where necessary.

Where the draft decision differs from the opinion of the Agency, the Commission shall attach a detailed explanation of the reasons for the differences.

The draft decision shall be forwarded to Member States and the applicant.’;

| (b) | paragraph 6 is replaced by the following:

  ‘6.   The Agency shall disseminate the documents referred to in points (a) to (d) of Article 9(4), together with any deadlines laid down pursuant to the third subparagraph of paragraph 1 of this Article.’; |
| --- | --- |

(b)

paragraph 6 is replaced by the following:

‘6.   The Agency shall disseminate the documents referred to in points (a) to (d) of Article 9(4), together with any deadlines laid down pursuant to the third subparagraph of paragraph 1 of this Article.’;

| 4. | the following Articles are inserted:

  ‘Article 10a

  1.   After the granting of a marketing authorisation, the Agency may impose an obligation on the marketing authorisation holder:






  (a) | to conduct a post-authorisation safety study if there are concerns about the risks of an authorised medicinal product. If the same concerns apply to more than one medicinal product, the Agency shall, following consultation with the Pharmacovigilance Risk Assessment Committee, encourage the marketing authorisation holders concerned to conduct a joint post-authorisation safety study; |
| --- | --- | --- |

4.

the following Articles are inserted:

‘Article 10a

1.   After the granting of a marketing authorisation, the Agency may impose an obligation on the marketing authorisation holder:

(a)

to conduct a post-authorisation safety study if there are concerns about the risks of an authorised medicinal product. If the same concerns apply to more than one medicinal product, the Agency shall, following consultation with the Pharmacovigilance Risk Assessment Committee, encourage the marketing authorisation holders concerned to conduct a joint post-authorisation safety study;

| (b) | to conduct a post-authorisation efficacy study when the understanding of the disease or the clinical methodology indicate that previous efficacy evaluations might have to be revised significantly. The obligation to conduct the post-authorisation efficacy study shall be based on the delegated acts adopted pursuant to Article 10b while taking into account the scientific guidance referred to in Article 108a of Directive 2001/83/EC. |
| --- | --- |

(b)

to conduct a post-authorisation efficacy study when the understanding of the disease or the clinical methodology indicate that previous efficacy evaluations might have to be revised significantly. The obligation to conduct the post-authorisation efficacy study shall be based on the delegated acts adopted pursuant to Article 10b while taking into account the scientific guidance referred to in Article 108a of Directive 2001/83/EC.

The imposition of such an obligation shall be duly justified, notified in writing, and shall include the objectives and timeframe for submission and conduct of the study.

2.   The Agency shall provide the marketing authorisation holder with an opportunity to present written observations in response to the imposition of the obligation within a time limit which it shall specify, if the marketing authorisation holder so requests within 30 days of receipt of the written notification of the obligation.

3.   On the basis of the written observations submitted by the marketing authorisation holder, and of the opinion of the Agency, the Commission shall withdraw or confirm the obligation. Where the Commission confirms the obligation, the marketing authorisation shall be varied to include the obligation as a condition of the marketing authorisation and the risk management system shall be updated accordingly.

Article 10b

1.   In order to determine the situations in which post-authorisation efficacy studies may be required under point (cc) of Article 9(4) and point (b) of Article 10a(1) of this Regulation, the Commission may adopt, by means of delegated acts in accordance with Article 87b, and subject to the conditions of Articles 87c and 87d, measures supplementing the provisions in point (cc) of Article 9(4) and point (b) of Article 10a(1).

2.   When adopting such delegated acts, the Commission shall act in accordance with the provisions of this Regulation.’;

| 5. | Article 14 is amended as follows:






  (a) | the second subparagraph of paragraph 2 is replaced by the following:
  ‘To this end, the marketing authorisation holder shall provide the Agency with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Chapter 3, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.’; |
| --- | --- | --- |

5.

Article 14 is amended as follows:

(a)

the second subparagraph of paragraph 2 is replaced by the following:

‘To this end, the marketing authorisation holder shall provide the Agency with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Chapter 3, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.’;

| (b) | paragraph 3 is replaced by the following:

  ‘3.   Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the Commission decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.’; |
| --- | --- |

(b)

paragraph 3 is replaced by the following:

‘3.   Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the Commission decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.’;

| (c) | paragraph 8 is replaced by the following:

  ‘8.   In exceptional circumstances and following consultation with the applicant, the marketing authorisation may be granted subject to certain conditions, in particular relating to the safety of the medicinal product, notification to the competent authorities of any incident relating to its use, and action to be taken. The marketing authorisation may be granted only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use, for objective, verifiable reasons and must be based on one of the grounds set out in Annex I to Directive 2001/83/EC. Continuation of the marketing authorisation shall be linked to the annual reassessment of these conditions.’; |
| --- | --- |

(c)

paragraph 8 is replaced by the following:

‘8.   In exceptional circumstances and following consultation with the applicant, the marketing authorisation may be granted subject to certain conditions, in particular relating to the safety of the medicinal product, notification to the competent authorities of any incident relating to its use, and action to be taken. The marketing authorisation may be granted only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use, for objective, verifiable reasons and must be based on one of the grounds set out in Annex I to Directive 2001/83/EC. Continuation of the marketing authorisation shall be linked to the annual reassessment of these conditions.’;

| 6. | the following Article is inserted:

  ‘Article 14a
  The marketing authorisation holder shall incorporate any conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in Article 10a, or in Article 14(7) and (8) in his risk management system.’; |
| --- | --- |

6.

the following Article is inserted:

‘Article 14a

The marketing authorisation holder shall incorporate any conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in Article 10a, or in Article 14(7) and (8) in his risk management system.’;

| 7. | Article 16 is replaced by the following:

  ‘Article 16

  1.   After a marketing authorisation has been granted in accordance with this Regulation, the marketing authorisation holder shall, in respect of the methods of manufacture and control provided for in points (d) and (h) of Article 8(3) of Directive 2001/83/EC, take account of scientific and technical progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods. He shall apply for approval of corresponding variations in accordance with this Regulation.


  2.   The marketing authorisation holder shall forthwith provide the Agency, the Commission and the Member States with any new information which might entail the amendment of the particulars or documents referred to in Article 8(3), Article 10, 10a, 10b and 11, or Article 32(5) of Directive 2001/83/EC, in Annex I thereto, or in Article 9(4) of this Regulation.
  In particular, the marketing authorisation holder shall forthwith inform the Agency and the Commission of any prohibition or restriction imposed by the competent authorities of any country in which the medicinal product is marketed and of any other new information which might influence the evaluation of the benefits and risks of the medicinal product concerned. The information shall include both positive and negative results of clinical trials or other studies in all indications and populations, whether or not included in the marketing authorisation, as well as data on the use of the medicinal product where such use is outside the terms of the marketing authorisation.


  3.   The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26.


  4.   In order to be able to continuously assess the risk-benefit balance, the Agency may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.
  The Agency may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest 7 days after receipt of the request.’; |
| --- | --- |

7.

Article 16 is replaced by the following:

‘Article 16

1.   After a marketing authorisation has been granted in accordance with this Regulation, the marketing authorisation holder shall, in respect of the methods of manufacture and control provided for in points (d) and (h) of Article 8(3) of Directive 2001/83/EC, take account of scientific and technical progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods. He shall apply for approval of corresponding variations in accordance with this Regulation.

2.   The marketing authorisation holder shall forthwith provide the Agency, the Commission and the Member States with any new information which might entail the amendment of the particulars or documents referred to in Article 8(3), Article 10, 10a, 10b and 11, or Article 32(5) of Directive 2001/83/EC, in Annex I thereto, or in Article 9(4) of this Regulation.

In particular, the marketing authorisation holder shall forthwith inform the Agency and the Commission of any prohibition or restriction imposed by the competent authorities of any country in which the medicinal product is marketed and of any other new information which might influence the evaluation of the benefits and risks of the medicinal product concerned. The information shall include both positive and negative results of clinical trials or other studies in all indications and populations, whether or not included in the marketing authorisation, as well as data on the use of the medicinal product where such use is outside the terms of the marketing authorisation.

3.   The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26.

4.   In order to be able to continuously assess the risk-benefit balance, the Agency may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.

The Agency may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest 7 days after receipt of the request.’;

| 8. | Article 18 is amended as follows:






  (a) | paragraph 1 is replaced by the following:

  ‘1.   In the case of medicinal products manufactured within the Union, the supervisory authorities for manufacturing shall be the competent authorities of the Member State or Member States which granted the manufacturing authorisation provided for in Article 40(1) of Directive 2001/83/EC in respect of the medicinal product concerned.’; |
| --- | --- | --- |

8.

Article 18 is amended as follows:

(a)

paragraph 1 is replaced by the following:

‘1.   In the case of medicinal products manufactured within the Union, the supervisory authorities for manufacturing shall be the competent authorities of the Member State or Member States which granted the manufacturing authorisation provided for in Article 40(1) of Directive 2001/83/EC in respect of the medicinal product concerned.’;

| (b) | in paragraph 2, the first subparagraph is replaced by the following:
  ‘In the case of medicinal products imported from third countries, the supervisory authorities for imports shall be the competent authorities of the Member State or Member States that granted the authorisation provided for in Article 40(3) of Directive 2001/83/EC to the importer, unless appropriate agreements have been made between the Union and the exporting country to ensure that those controls are carried out in the exporting country and that the manufacturer applies standards of good manufacturing practice at least equivalent to those laid down by the Union.’; |
| --- | --- |

(b)

in paragraph 2, the first subparagraph is replaced by the following:

‘In the case of medicinal products imported from third countries, the supervisory authorities for imports shall be the competent authorities of the Member State or Member States that granted the authorisation provided for in Article 40(3) of Directive 2001/83/EC to the importer, unless appropriate agreements have been made between the Union and the exporting country to ensure that those controls are carried out in the exporting country and that the manufacturer applies standards of good manufacturing practice at least equivalent to those laid down by the Union.’;

| (c) | the following paragraph is added:

  ‘3.   The supervisory authority for pharmacovigilance shall be the competent authority of the Member State in which the pharmacovigilance system master file is located.’; |
| --- | --- |

(c)

the following paragraph is added:

‘3.   The supervisory authority for pharmacovigilance shall be the competent authority of the Member State in which the pharmacovigilance system master file is located.’;

| 9. | Article 19 is amended as follows:






  (a) | paragraph 1 is replaced by the following:

  ‘1.   The supervisory authorities for manufacturing and imports shall be responsible for verifying on behalf of the Union that the marketing authorisation holder for the medicinal product or the manufacturer or importer established within the Union satisfies the requirements concerning manufacturing and imports laid down in Titles IV and XI of Directive 2001/83/EC.
  The supervisory authorities for pharmacovigilance shall be responsible for verifying on behalf of the Union that the marketing authorisation holder for the medicinal product satisfies the pharmacovigilance requirements laid down in Titles IX and XI of Directive 2001/83/EC. They may, if this is considered necessary, conduct pre-authorisation inspections to verify the accuracy and successful implementation of the pharmacovigilance system as it has been described by the applicant in support of his application.’; |
| --- | --- | --- |

9.

Article 19 is amended as follows:

(a)

paragraph 1 is replaced by the following:

‘1.   The supervisory authorities for manufacturing and imports shall be responsible for verifying on behalf of the Union that the marketing authorisation holder for the medicinal product or the manufacturer or importer established within the Union satisfies the requirements concerning manufacturing and imports laid down in Titles IV and XI of Directive 2001/83/EC.

The supervisory authorities for pharmacovigilance shall be responsible for verifying on behalf of the Union that the marketing authorisation holder for the medicinal product satisfies the pharmacovigilance requirements laid down in Titles IX and XI of Directive 2001/83/EC. They may, if this is considered necessary, conduct pre-authorisation inspections to verify the accuracy and successful implementation of the pharmacovigilance system as it has been described by the applicant in support of his application.’;

| (b) | in paragraph 3, the second subparagraph is replaced by the following:
  ‘The inspection shall be undertaken by inspectors from the Member States who possess the appropriate qualifications. They may be accompanied by a rapporteur or expert appointed by the Committee referred to in paragraph 2. The report of the inspectors shall be made available electronically to the Commission, the Member States and the Agency.’; |
| --- | --- |

(b)

in paragraph 3, the second subparagraph is replaced by the following:

‘The inspection shall be undertaken by inspectors from the Member States who possess the appropriate qualifications. They may be accompanied by a rapporteur or expert appointed by the Committee referred to in paragraph 2. The report of the inspectors shall be made available electronically to the Commission, the Member States and the Agency.’;

| 10. | Article 20 is amended as follows:






  (a) | paragraph 3 is replaced by the following:

  ‘3.   Following an opinion by the Agency, the Commission shall adopt the necessary provisional measures, which shall be applied immediately.
  A final decision in respect of the medicinal product concerned shall be adopted within 6 months, in accordance with the regulatory procedure referred to in Article 87(2).
  The Commission may also adopt a decision addressed to the Member States pursuant to Article 127a of Directive 2001/83/EC.’; |
| --- | --- | --- |

10.

Article 20 is amended as follows:

(a)

paragraph 3 is replaced by the following:

‘3.   Following an opinion by the Agency, the Commission shall adopt the necessary provisional measures, which shall be applied immediately.

A final decision in respect of the medicinal product concerned shall be adopted within 6 months, in accordance with the regulatory procedure referred to in Article 87(2).

The Commission may also adopt a decision addressed to the Member States pursuant to Article 127a of Directive 2001/83/EC.’;

| (b) | the following paragraphs are added:

  ‘8.   Notwithstanding paragraphs 1 to 7 of this Article, the Union procedures laid down in Article 31 and Article 107i of Directive 2001/83/EC shall apply, as appropriate, where the reason for the Member State or the Commission to consider taking decisions or measures referred to in this Article is based on the evaluation of data resulting from pharmacovigilance activities.


  9.   By way of derogation from paragraphs 1 to 7 of this Article, where a procedure under Article 31 or Articles 107i to 107k of Directive 2001/83/EC concerns a range of medicinal products or a therapeutic class, medicinal products that are authorised in accordance with this Regulation and that belong to that range or class shall only be included in the procedure under Article 31, or Articles 107i to 107k of that Directive.’; |
| --- | --- |

(b)

the following paragraphs are added:

‘8.   Notwithstanding paragraphs 1 to 7 of this Article, the Union procedures laid down in Article 31 and Article 107i of Directive 2001/83/EC shall apply, as appropriate, where the reason for the Member State or the Commission to consider taking decisions or measures referred to in this Article is based on the evaluation of data resulting from pharmacovigilance activities.

9.   By way of derogation from paragraphs 1 to 7 of this Article, where a procedure under Article 31 or Articles 107i to 107k of Directive 2001/83/EC concerns a range of medicinal products or a therapeutic class, medicinal products that are authorised in accordance with this Regulation and that belong to that range or class shall only be included in the procedure under Article 31, or Articles 107i to 107k of that Directive.’;

| 11. | Chapter 3 of Title II is replaced by the following:


  ‘CHAPTER 3


  PHARMACOVIGILANCE



  Article 21

  1.   The obligations of marketing authorisation holders laid down in Article 104 of Directive 2001/83/EC shall apply to marketing authorisation holders for medicinal products for human use authorised in accordance with this Regulation.
  Without prejudice to paragraphs 2, 3 and 4 of this Article, holders of marketing authorisations granted before 2 July 2012 shall, by way of derogation from Article 104(3)(c) of Directive 2001/83/EC not be required to operate a risk management system for each medicinal product.


  2.   The Agency may impose an obligation on a marketing authorisation holder to operate a risk management system, as referred to in point (c) of Article 104(3) of Directive 2001/83/EC, if there are concerns about the risks affecting the risk-benefit balance of an authorised medicinal product. In that context, the Agency shall also oblige the marketing authorisation holder to submit a detailed description of the risk-management system which he intends to introduce for the medicinal product concerned.
  The imposition of such obligations shall be duly justified, notified in writing, and shall include the timeframe for submission of the detailed description of the risk-management system.


  3.   The Agency shall provide the marketing authorisation holder with an opportunity to present written observations in response to the imposition of the obligation within a time limit which it shall specify, if the marketing authorisation holder so requests within 30 days of receipt of the written notification of the obligation.


  4.   On the basis of the written observations submitted by the marketing authorisation holder, and of the opinion of the Agency, the Commission shall withdraw or confirm the obligation. Where the Commission confirms the obligation, the marketing authorisation shall be varied accordingly, to include the measures to be taken as part of the risk management system as conditions of the marketing authorisation referred to in point (ca) of Article 9(4).



  Article 22
  The obligations of marketing authorisation holders laid down in Article 106a(1) of Directive 2001/83/EC, and the obligations of the Member States, the Agency and the Commission laid down in paragraphs 2, 3 and 4 of that Article shall apply to the safety announcements referred to in point (e) of Article 57(1) of this Regulation concerning medicinal products for human use authorised in accordance with this Regulation.


  Article 23

  1.   The Agency shall, in collaboration with the Member States, set up, maintain and make public a list of medicinal products that are subject to additional monitoring.
  That list shall include the names and active substances of:






  (a) | medicinal products authorised in the Union that contain a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the Union; |
| --- | --- | --- |

11.

Chapter 3 of Title II is replaced by the following:

‘CHAPTER 3

PHARMACOVIGILANCE

Article 21

1.   The obligations of marketing authorisation holders laid down in Article 104 of Directive 2001/83/EC shall apply to marketing authorisation holders for medicinal products for human use authorised in accordance with this Regulation.

Without prejudice to paragraphs 2, 3 and 4 of this Article, holders of marketing authorisations granted before 2 July 2012 shall, by way of derogation from Article 104(3)(c) of Directive 2001/83/EC not be required to operate a risk management system for each medicinal product.

2.   The Agency may impose an obligation on a marketing authorisation holder to operate a risk management system, as referred to in point (c) of Article 104(3) of Directive 2001/83/EC, if there are concerns about the risks affecting the risk-benefit balance of an authorised medicinal product. In that context, the Agency shall also oblige the marketing authorisation holder to submit a detailed description of the risk-management system which he intends to introduce for the medicinal product concerned.

The imposition of such obligations shall be duly justified, notified in writing, and shall include the timeframe for submission of the detailed description of the risk-management system.

3.   The Agency shall provide the marketing authorisation holder with an opportunity to present written observations in response to the imposition of the obligation within a time limit which it shall specify, if the marketing authorisation holder so requests within 30 days of receipt of the written notification of the obligation.

4.   On the basis of the written observations submitted by the marketing authorisation holder, and of the opinion of the Agency, the Commission shall withdraw or confirm the obligation. Where the Commission confirms the obligation, the marketing authorisation shall be varied accordingly, to include the measures to be taken as part of the risk management system as conditions of the marketing authorisation referred to in point (ca) of Article 9(4).

Article 22

The obligations of marketing authorisation holders laid down in Article 106a(1) of Directive 2001/83/EC, and the obligations of the Member States, the Agency and the Commission laid down in paragraphs 2, 3 and 4 of that Article shall apply to the safety announcements referred to in point (e) of Article 57(1) of this Regulation concerning medicinal products for human use authorised in accordance with this Regulation.

Article 23

1.   The Agency shall, in collaboration with the Member States, set up, maintain and make public a list of medicinal products that are subject to additional monitoring.

That list shall include the names and active substances of:

(a)

medicinal products authorised in the Union that contain a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the Union;

| (b) | any biological medicinal product not covered by point (a) that was authorised after 1 January 2011. |
| --- | --- |

(b)

any biological medicinal product not covered by point (a) that was authorised after 1 January 2011.

2.   At the request of the Commission, following consultation with the Pharmacovigilance Risk Assessment Committee, medicinal products that are authorised pursuant to this Regulation subject to conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4), or in Articles 10a, Article 14(7) and (8) and in Article 21(2), may also be included in the list.

At the request of a national competent authority, following consultation with the Pharmacovigilance Risk Assessment Committee, medicinal products that are authorised pursuant to Directive 2001/83/EC, subject to the conditions referred to in Articles 21a, 22, 22a and 104a of that Directive, may also be included in the list.

3.   The list shall include an electronic link to the product information and to the summary of the risk management plan.

4.   The Agency shall remove a medicinal product from the list 5 years after the Union reference date referred to in Article 107c(5) of Directive 2001/83/EC.

However, the Commission or the national competent authority, as appropriate, may, following a recommendation of the Pharmacovigilance Risk Assessment Committee, extend that period until such time as they conclude that the conditions referred to in Article 14a and Article 21(2) of this Regulation or referred to in Articles 22b and 104a of Directive 2001/83/EC have been fulfilled.

5.   For medicinal products included in that list, the summary of product characteristics and the package leaflet shall include the statement “This medicinal product is subject to additional monitoring”. That statement shall be preceded by a black symbol which shall be selected by the Commission following a recommendation of the Pharmacovigilance Risk Assessment Committee by 2 January 2012, and shall be followed by an appropriate standardised explanatory sentence.

Article 24

1.   The Agency shall, in collaboration with the Member States and the Commission, set up and maintain a database and data processing network (hereinafter the “Eudravigilance database”) to collate pharmacovigilance information regarding medicinal products authorised in the Union and to allow competent authorities to access that information simultaneously and to share it.

The Eudravigilance database shall contain information on suspected adverse reactions in human beings arising from use of the medicinal product within the terms of the marketing authorisation as well as from uses outside the terms of the marketing authorisation, and on those occurring in the course of post-authorisation studies with the medicinal product or associated with occupational exposure.

2.   The Agency shall, in collaboration with the Member States and the Commission, draw up the functional specifications for the Eudravigilance database, together with a timeframe for their implementation.

The Agency shall prepare an annual report on the Eudravigilance database and send it to the European Parliament, the Council and the Commission. The first annual report shall be prepared by 2 January 2013.

The Management Board of the Agency shall on the basis of an independent audit report that takes into account the recommendation of the Pharmacovigilance Risk Assessment Committee confirm and announce when the Eudravigilance database has achieved full functionality and the system meets the functional specifications drawn up pursuant to the first subparagraph.

Any substantial change to the Eudravigilance database and the functional specifications shall take into account the recommendations of the Pharmacovigilance Risk Assessment Committee.

The Eudravigilance database shall be fully accessible to the competent authorities of the Member States and to the Agency and the Commission. It shall also be accessible to marketing authorisation holders to the extent necessary for them to comply with their pharmacovigilance obligations.

The Agency shall ensure that healthcare professionals and the public have appropriate levels of access to the Eudravigilance database, while guaranteeing personal data protection. The Agency shall work together with all stakeholders, including research institutions, healthcare professionals, and patient and consumer organisations, in order to define the “appropriate level of access” for healthcare professionals and the public to the Eudravigilance database.

The data held on the Eudravigilance database shall be made publicly accessible in an aggregated format together with an explanation of how to interpret the data.

3.   The Agency shall, in collaboration either with the marketing authorisation holder or with the Member State that submitted an individual suspected adverse reaction report to the Eudravigilance database, be responsible for operating procedures that ensure the quality and integrity of the information collected in the Eudravigilance database.

4.   Individual suspected adverse reaction reports and follow-ups submitted to the Eudravigilance database by marketing authorisation holders shall be transmitted electronically upon receipt to the competent authority of the Member State where the reaction occurred.

Article 25

The Agency shall, in collaboration with the Member States, develop standard web-based structured forms for the reporting of suspected adverse reactions by healthcare professionals and patients in accordance with the provisions referred to in Article 107a of Directive 2001/83/EC.

Article 25a

The Agency shall, in collaboration with the national competent authorities and the Commission, set up and maintain a repository for periodic safety update reports (hereinafter the “repository”) and the corresponding assessment reports so that they are fully and permanently accessible to the Commission, the national competent authorities, the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use and the coordination group referred to in Article 27 of Directive 2001/83/EC (hereinafter the “coordination group”).

The Agency shall, in collaboration with the national competent authorities and the Commission, and after consultation with the Pharmacovigilance Risk Assessment Committee, draw up the functional specifications for the repository.

The Management Board of the Agency shall, on the basis of an independent audit report that takes into account the recommendations of the Pharmacovigilance Risk Assessment Committee, confirm and announce when the repository has achieved full functionality and meets the functional specifications drawn up pursuant to the second paragraph.

Any substantial change to the repository and the functional specifications shall always take into account the recommendations of the Pharmacovigilance Risk Assessment Committee.

Article 26

1.   The Agency shall, in collaboration with the Member States and the Commission, set up and maintain a European medicines web-portal for the dissemination of information on medicinal products authorised in the Union. By means of that portal, the Agency shall make public at least the following:

| (a) | the names of members of the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and the members of the coordination group, together with their professional qualifications and with the declarations referred to in Article 63(2) of this Regulation; |
| --- | --- |

(a)

the names of members of the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and the members of the coordination group, together with their professional qualifications and with the declarations referred to in Article 63(2) of this Regulation;

| (b) | agendas and minutes from each meeting of the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and of the coordination group as regards pharmacovigilance activities; |
| --- | --- |

(b)

agendas and minutes from each meeting of the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and of the coordination group as regards pharmacovigilance activities;

| (c) | a summary of the risk management plans for medicinal products authorised in accordance with this Regulation; |
| --- | --- |

(c)

a summary of the risk management plans for medicinal products authorised in accordance with this Regulation;

| (d) | the list of medicinal products referred to in Article 23 of this Regulation; |
| --- | --- |

(d)

the list of medicinal products referred to in Article 23 of this Regulation;

| (e) | a list of the locations in the Union where pharmacovigilance system master files are kept and contact information for pharmacovigilance enquiries, for all medicinal products authorised in the Union; |
| --- | --- |

(e)

a list of the locations in the Union where pharmacovigilance system master files are kept and contact information for pharmacovigilance enquiries, for all medicinal products authorised in the Union;

| (f) | information about how to report to national competent authorities suspected adverse reactions to medicinal products and the standard structured forms referred to in Article 25 for their web-based reporting by patients and healthcare professionals, including links to national websites; |
| --- | --- |

(f)

information about how to report to national competent authorities suspected adverse reactions to medicinal products and the standard structured forms referred to in Article 25 for their web-based reporting by patients and healthcare professionals, including links to national websites;

| (g) | Union reference dates and frequency of submission of periodic safety update reports established in accordance with Article 107c of Directive 2001/83/EC; |
| --- | --- |

(g)

Union reference dates and frequency of submission of periodic safety update reports established in accordance with Article 107c of Directive 2001/83/EC;

| (h) | protocols and public abstracts of results of the post-authorisation safety studies referred to in Articles 107n and 107p of Directive 2001/83/EC; |
| --- | --- |

(h)

protocols and public abstracts of results of the post-authorisation safety studies referred to in Articles 107n and 107p of Directive 2001/83/EC;

| (i) | the initiation of the procedure provided for in Articles 107i to 107k of Directive 2001/83/EC, the active substances or medicinal products concerned and the issue being addressed, any public hearings pursuant to that procedure and information on how to submit information and to participate in public hearings; |
| --- | --- |

(i)

the initiation of the procedure provided for in Articles 107i to 107k of Directive 2001/83/EC, the active substances or medicinal products concerned and the issue being addressed, any public hearings pursuant to that procedure and information on how to submit information and to participate in public hearings;

| (j) | conclusions of assessments, recommendations, opinions, approvals and decisions taken by the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and by the coordination group, the national competent authorities and the Commission in the framework of the procedures of Articles 28, 28a and 28b of this Regulation and of sections 2 and 3 of Chapter 3 and Chapter 4 of Title IX of Directive 2001/83/EC. |
| --- | --- |

(j)

conclusions of assessments, recommendations, opinions, approvals and decisions taken by the Committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and by the coordination group, the national competent authorities and the Commission in the framework of the procedures of Articles 28, 28a and 28b of this Regulation and of sections 2 and 3 of Chapter 3 and Chapter 4 of Title IX of Directive 2001/83/EC.

2.   Before the launch of this portal, and during subsequent reviews, the Agency shall consult relevant stakeholders, including patient and consumer groups, healthcare professionals and industry representatives.

Article 27

1.   The Agency shall monitor selected medical literature for reports of suspected adverse reactions to medicinal products containing certain active substances. It shall publish the list of active substances being monitored and the medical literature subject to this monitoring.

2.   The Agency shall enter into the Eudravigilance database relevant information from the selected medical literature.

3.   The Agency shall, in consultation with the Commission, Member States and interested parties, draw up a detailed guide regarding the monitoring of medical literature and the entry of relevant information into the Eudravigilance database.

Article 28

1.   The obligations of marketing authorisation holders and of Member States laid down in Articles 107 and 107a of Directive 2001/83/EC shall apply to the recording and reporting of suspected adverse reactions for medicinal products for human use authorised in accordance with this Regulation.

2.   The obligations of marketing authorisation holders laid down in Article 107b of Directive 2001/83/EC and the procedures under Article 107b and Article 107c of that Directive shall apply to the submission of periodic safety update reports, the establishment of Union reference dates and changes to the frequency of submission of periodic safety update reports for medicinal products for human use authorised in accordance with this Regulation.

The provisions applicable to the submission of periodic safety update reports laid down in the second subparagraph of Article 107c(2) of that Directive shall apply to holders of marketing authorisations which were granted before 2 July 2012 and for which the frequency and dates of submission of the periodic safety update reports are not laid down as a condition to the marketing authorisation until such time as another frequency or other dates of submission of the reports are laid down in the marketing authorisation or are determined in accordance with Article 107c of that Directive.

3.   The assessment of the periodic safety update reports shall be conducted by a rapporteur appointed by the Pharmacovigilance Risk Assessment Committee. The rapporteur shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use or the Reference Member State for the medicinal products concerned.

The rapporteur shall prepare an assessment report within 60 days of receipt of the periodic safety update report and send it to the Agency and to the members of the Pharmacovigilance Risk Assessment Committee. The Agency shall send the report to the marketing authorisation holder.

Within 30 days of receipt of the assessment report, the marketing authorisation holder and the members of the Pharmacovigilance Risk Assessment Committee may submit comments to the Agency and to the rapporteur.

Following the receipt of the comments referred to in the third subparagraph, the rapporteur shall within 15 days update the assessment report taking into account any comments submitted, and forward it to the Pharmacovigilance Risk Assessment Committee. The Pharmacovigilance Risk Assessment Committee shall adopt the assessment report with or without further changes at its next meeting and issue a recommendation. The recommendation shall mention the divergent positions with the grounds on which they are based. The Agency shall include the adopted assessment report and the recommendation in the repository set up under Article 25a, and forward both to the marketing authorisation holder.

4.   In the case of an assessment report that recommends any action concerning the marketing authorisation, the Committee for Medicinal Products for Human Use shall, within 30 days of receipt of the report by the Pharmacovigilance Risk Assessment Committee, consider the report and adopt an opinion on the maintenance, variation, suspension or revocation of the marketing authorisation concerned, including a timetable for the implementation of the opinion. Where this opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

Where the opinion states that regulatory action concerning the marketing authorisation is necessary, the Commission shall adopt a decision to vary, suspend or revoke the marketing authorisation. Article 10 of this Regulation shall apply to the adoption of that decision. Where the Commission adopts such a decision, it may also adopt a decision addressed to the Member States pursuant to Article 127a of Directive 2001/83/EC.

5.   In the case of a single assessment of periodic safety update reports concerning more than one marketing authorisation in accordance with Article 107e(1) of Directive 2001/83/EC which includes at least one marketing authorisation granted in accordance with this Regulation, the procedure laid down in Articles 107e and 107g of that Directive shall apply.

6.   The final recommendations, opinions and decisions referred to in paragraphs 3 to 5 of this Article shall be made public by means of the European medicines web-portal referred to in Article 26.

Article 28a

1.   Regarding medicinal products for human use authorised in accordance with this Regulation, the Agency shall, in collaboration with the Member States, take the following measures:

| (a) | monitor the outcome of risk minimisation measures contained in risk management plans and of conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in points (a) and (b) of Article 10a(1), and in Article 14(7) and (8); |
| --- | --- |

(a)

monitor the outcome of risk minimisation measures contained in risk management plans and of conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in points (a) and (b) of Article 10a(1), and in Article 14(7) and (8);

| (b) | assess updates to the risk management system; |
| --- | --- |

(b)

assess updates to the risk management system;

| (c) | monitor the data in the Eudravigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance. |
| --- | --- |

(c)

monitor the data in the Eudravigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance.

2.   The Pharmacovigilance Risk Assessment Committee shall perform the initial analysis and prioritisation of signals of new risks or risks that have changed or changes to the risk-benefit balance. Where it considers that follow-up action may be necessary, the assessment of those signals and agreement on any subsequent action concerning the marketing authorisation shall be conducted in a timescale commensurate with the extent and seriousness of the issue.

3.   The Agency and national competent authorities and the marketing authorisation holder shall inform each other in the event of new risks or risks that have changed or changes to the risk-benefit balance being detected.

Article 28b

1.   For non-interventional post-authorisation safety studies concerning medicinal products for human use authorised in accordance with this Regulation which fulfil one of the requirements referred to in Articles 10 and 10a of this Regulation, the procedure provided for in paragraphs 3 to 7 of Article 107m, Articles 107n to 107p and Article 107q(1) of Directive 2001/83/EC shall apply.

2.   Where, in accordance with the procedure referred to in paragraph 1 of this Article, the Pharmacovigilance Risk Assessment Committee issues recommendations for the variation, suspension or revocation of the marketing authorisation, the Committee on Medicinal Products for Human Use shall adopt an opinion taking into account the recommendation, and the Commission shall adopt a decision in accordance with Article 10.

Where the opinion of the Committee on Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee on Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences, together with the recommendation.

Article 28c

1.   The Agency shall collaborate with the World Health Organisation in matters of pharmacovigilance and shall take the necessary steps to submit to it, promptly, appropriate and adequate information regarding the measures taken in the Union which may have a bearing on public health protection in third countries.

The Agency shall make available promptly all suspected adverse reaction reports occurring in the Union to the World Health Organisation.

2.   The Agency and the European Monitoring Centre for Drugs and Drug Addiction shall exchange information that they receive on the abuse of medicinal products including information related to illicit drugs.

Article 28d

At the request of the Commission, the Agency shall participate in collaboration with the Member States in international harmonisation and standardisation of technical measures in relation to pharmacovigilance.

Article 28e

The Agency and the Member States shall cooperate to continuously develop pharmacovigilance systems capable of achieving high standards of public health protection for all medicinal products, regardless of the routes of marketing authorisation, including the use of collaborative approaches, to maximise use of resources available within the Union.

Article 28f

The Agency shall perform regular independent audits of its pharmacovigilance tasks and report the results to its Management Board on a 2-yearly basis.

Article 29

The Commission shall make public a report on the performance of pharmacovigilance tasks by the Agency on 2 January 2014 at the latest and subsequently every 3 years thereafter.’;

| 12. | Article 56(1) is amended as follows:






  (a) | the following point is inserted:






  ‘(aa) | the Pharmacovigilance Risk Assessment Committee, which shall be responsible for providing recommendations to the Committee for Medicinal Products for Human Use and the coordination group on any question relating to pharmacovigilance activities in respect of medicinal products for human use and on risk management systems and it shall be responsible for monitoring the effectiveness of those risk management systems;’; |
| --- | --- | --- | --- |

12.

Article 56(1) is amended as follows:

(a)

the following point is inserted:

‘(aa)

the Pharmacovigilance Risk Assessment Committee, which shall be responsible for providing recommendations to the Committee for Medicinal Products for Human Use and the coordination group on any question relating to pharmacovigilance activities in respect of medicinal products for human use and on risk management systems and it shall be responsible for monitoring the effectiveness of those risk management systems;’;

| (b) | point (f) is replaced by the following:






  ‘(f) | a Secretariat, which shall provide technical, scientific and administrative support for the Committees and ensure appropriate coordination between them, and which shall provide technical and administrative support for the coordination group and ensure appropriate coordination between it and the Committees.’; |
| --- | --- | --- |

(b)

point (f) is replaced by the following:

‘(f)

a Secretariat, which shall provide technical, scientific and administrative support for the Committees and ensure appropriate coordination between them, and which shall provide technical and administrative support for the coordination group and ensure appropriate coordination between it and the Committees.’;

| 13. | Article 57 is amended as follows:






  (a) | in paragraph 1, points (c) to (f) are replaced by the following:






  ‘(c) | coordinating the monitoring of medicinal products for human use which have been authorised within the Union and providing advice on the measures necessary to ensure the safe and effective use of these medicinal products for human use, in particular by coordinating the evaluation and implementation of pharmacovigilance obligations and systems and the monitoring of such implementation; |
| --- | --- | --- | --- |

13.

Article 57 is amended as follows:

(a)

in paragraph 1, points (c) to (f) are replaced by the following:

‘(c)

coordinating the monitoring of medicinal products for human use which have been authorised within the Union and providing advice on the measures necessary to ensure the safe and effective use of these medicinal products for human use, in particular by coordinating the evaluation and implementation of pharmacovigilance obligations and systems and the monitoring of such implementation;

| (d) | ensuring the collation and dissemination of information on suspected adverse reactions to medicinal products for human use authorised in the Union by means of a database permanently accessible to all Member States; |
| --- | --- |

(d)

ensuring the collation and dissemination of information on suspected adverse reactions to medicinal products for human use authorised in the Union by means of a database permanently accessible to all Member States;

| (e) | assisting Member States with the rapid communication of information on pharmacovigilance concerns to healthcare professionals and coordinating the safety announcements of the national competent authorities; |
| --- | --- |

(e)

assisting Member States with the rapid communication of information on pharmacovigilance concerns to healthcare professionals and coordinating the safety announcements of the national competent authorities;

| (f) | distributing appropriate information on pharmacovigilance concerns to the general public, in particular by setting up and maintaining a European medicines web-portal;’; |
| --- | --- |

(f)

distributing appropriate information on pharmacovigilance concerns to the general public, in particular by setting up and maintaining a European medicines web-portal;’;

| (b) | in paragraph 2, the following subparagraph is inserted after the first subparagraph:

  ‘For the purposes of the database, the Agency shall set up and maintain a list of all medicinal products for human use authorised in the Union. To this effect the following measures shall be taken:






  (a) | the Agency shall, by 2 July 2011 at the latest, make public a format for the electronic submission of information on medicinal products for human use; |
| --- | --- | --- |

(b)

in paragraph 2, the following subparagraph is inserted after the first subparagraph:

‘For the purposes of the database, the Agency shall set up and maintain a list of all medicinal products for human use authorised in the Union. To this effect the following measures shall be taken:

(a)

the Agency shall, by 2 July 2011 at the latest, make public a format for the electronic submission of information on medicinal products for human use;

| (b) | marketing authorisation holders shall, by 2 July 2012 at the latest, electronically submit to the Agency information on all medicinal products for human use authorised or registered in the Union, using the format referred to in point (a); |
| --- | --- |

(b)

marketing authorisation holders shall, by 2 July 2012 at the latest, electronically submit to the Agency information on all medicinal products for human use authorised or registered in the Union, using the format referred to in point (a);

| (c) | from the date set out in point (b), marketing authorisation holders shall inform the Agency of any new or varied marketing authorisations granted in the Union, using the format referred to in point (a).’; |
| --- | --- |

(c)

from the date set out in point (b), marketing authorisation holders shall inform the Agency of any new or varied marketing authorisations granted in the Union, using the format referred to in point (a).’;

| 14. | the following Article is inserted:

  ‘Article 61a

  1.   The Pharmacovigilance Risk Assessment Committee shall be composed of the following:






  (a) | one member and one alternate member appointed by each Member State, in accordance with paragraph 3 of this Article; |
| --- | --- | --- |

14.

the following Article is inserted:

‘Article 61a

1.   The Pharmacovigilance Risk Assessment Committee shall be composed of the following:

(a)

one member and one alternate member appointed by each Member State, in accordance with paragraph 3 of this Article;

| (b) | six members appointed by the Commission, with a view to ensuring that the relevant expertise is available within the Committee, including clinical pharmacology and pharmacoepidemiology, on the basis of a public call for expressions of interest; |
| --- | --- |

(b)

six members appointed by the Commission, with a view to ensuring that the relevant expertise is available within the Committee, including clinical pharmacology and pharmacoepidemiology, on the basis of a public call for expressions of interest;

| (c) | one member and one alternate member appointed by the Commission, on the basis of a public call for expressions of interest, after consulting the European Parliament, in order to represent healthcare professionals; |
| --- | --- |

(c)

one member and one alternate member appointed by the Commission, on the basis of a public call for expressions of interest, after consulting the European Parliament, in order to represent healthcare professionals;

| (d) | one member and one alternate member appointed by the Commission, on the basis of a public call for expressions of interest, after consulting the European Parliament, in order to represent patient organisations. |
| --- | --- |

(d)

one member and one alternate member appointed by the Commission, on the basis of a public call for expressions of interest, after consulting the European Parliament, in order to represent patient organisations.

The alternate members shall represent and vote for the members in their absence. The alternate members referred to in point (a) may be appointed to act as rapporteurs in accordance with Article 62.

2.   A Member State may delegate its tasks in the Pharmacovigilance Risk Assessment Committee to another Member State. Each Member State may represent no more than one other Member State.

3.   The members and alternate members of the Pharmacovigilance Risk Assessment Committee shall be appointed on the basis of their relevant expertise in pharmacovigilance matters and risk assessment of medicinal products for human use, in order to guarantee the highest levels of specialist qualifications and a broad spectrum of relevant expertise. For this purpose, Member States shall liaise with the Management Board and the Commission in order to ensure that the final composition of the Committee covers the scientific areas relevant to its tasks.

4.   The members and alternate members of the Pharmacovigilance Risk Assessment Committee shall be appointed for a term of 3 years, which may be prolonged once and thereafter renewed following the procedures referred to in paragraph 1. The Committee shall elect its Chairman from among its members for a term of 3 years, which may be prolonged once.

5.   Paragraphs 3, 4, 6, 7 and 8 of Article 61 shall apply to the Pharmacovigilance Risk Assessment Committee.

6.   The mandate of the Pharmacovigilance Risk Assessment Committee shall cover all aspects of the risk management of the use of medicinal products for human use including the detection, assessment, minimisation and communication relating to the risk of adverse reactions, having due regard to the therapeutic effect of the medicinal product for human use, the design and evaluation of post-authorisation safety studies and pharmacovigilance audit.’;

| 15. | Article 62 is amended as follows:






  (a) | paragraph 1 is amended as follows:






  (i) | the first subparagraph is replaced by the following:
  ‘Where, in accordance with this Regulation, any of the Committees referred to in Article 56(1) is required to evaluate a medicinal product for human use, it shall appoint one of its members to act as rapporteur, taking into account existing expertise in the Member State. The Committee concerned may appoint a second member to act as co-rapporteur.
  A rapporteur appointed for this purpose by the Pharmacovigilance Risk Assessment Committee shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use or the Reference Member State for the medicinal product for human use concerned.’; |
| --- | --- | --- | --- |

15.

Article 62 is amended as follows:

(a)

paragraph 1 is amended as follows:

(i)

the first subparagraph is replaced by the following:

‘Where, in accordance with this Regulation, any of the Committees referred to in Article 56(1) is required to evaluate a medicinal product for human use, it shall appoint one of its members to act as rapporteur, taking into account existing expertise in the Member State. The Committee concerned may appoint a second member to act as co-rapporteur.

A rapporteur appointed for this purpose by the Pharmacovigilance Risk Assessment Committee shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use or the Reference Member State for the medicinal product for human use concerned.’;

| (ii) | the fourth subparagraph is replaced by the following:
  ‘If there is a request for re-examination of one of its opinions where this possibility is provided for in Union law, the Committee concerned shall appoint a different rapporteur and, where necessary, a different co-rapporteur from those appointed for the initial opinion. The re-examination procedure may deal only with the points of the opinion initially identified by the applicant and may be based only on the scientific data available when the Committee adopted the initial opinion. The applicant may request that the Committee consult a scientific advisory group in connection with the re-examination.’; |
| --- | --- |

(ii)

the fourth subparagraph is replaced by the following:

‘If there is a request for re-examination of one of its opinions where this possibility is provided for in Union law, the Committee concerned shall appoint a different rapporteur and, where necessary, a different co-rapporteur from those appointed for the initial opinion. The re-examination procedure may deal only with the points of the opinion initially identified by the applicant and may be based only on the scientific data available when the Committee adopted the initial opinion. The applicant may request that the Committee consult a scientific advisory group in connection with the re-examination.’;

| (b) | in paragraph 2, the first subparagraph is replaced by the following:
  ‘Member States shall transmit to the Agency the names of national experts with proven experience in the evaluation of medicinal products for human use who, taking into account Article 63(2), would be available to serve on working parties or scientific advisory groups of any of the Committees referred to in Article 56(1), together with an indication of their qualifications and specific areas of expertise.’; |
| --- | --- |

(b)

in paragraph 2, the first subparagraph is replaced by the following:

‘Member States shall transmit to the Agency the names of national experts with proven experience in the evaluation of medicinal products for human use who, taking into account Article 63(2), would be available to serve on working parties or scientific advisory groups of any of the Committees referred to in Article 56(1), together with an indication of their qualifications and specific areas of expertise.’;

| (c) | in paragraph 3, the following subparagraph is added:
  ‘The first and second subparagraphs shall also apply to the work of rapporteurs in the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC.’; |
| --- | --- |

(c)

in paragraph 3, the following subparagraph is added:

‘The first and second subparagraphs shall also apply to the work of rapporteurs in the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC.’;

| 16. | Article 64(2) is amended as follows:






  (a) | point (b) is replaced by the following:






  ‘(b) | for managing all the Agency resources necessary for conducting the activities of the Committees referred to in Article 56(1), including making available appropriate scientific and technical support to those Committees, and for making available appropriate technical support to the coordination group;’; |
| --- | --- | --- | --- |

16.

Article 64(2) is amended as follows:

(a)

point (b) is replaced by the following:

‘(b)

for managing all the Agency resources necessary for conducting the activities of the Committees referred to in Article 56(1), including making available appropriate scientific and technical support to those Committees, and for making available appropriate technical support to the coordination group;’;

| (b) | point (d) is replaced by the following:






  ‘(d) | for ensuring appropriate coordination between the Committees referred to in Article 56(1) and, where necessary, between the Committees and the coordination group;’; |
| --- | --- | --- |

(b)

point (d) is replaced by the following:

‘(d)

for ensuring appropriate coordination between the Committees referred to in Article 56(1) and, where necessary, between the Committees and the coordination group;’;

| 17. | in Article 66(g), the words ‘Article 67’ are replaced by the words ‘Article 68’; |
| --- | --- |

17.

in Article 66(g), the words ‘Article 67’ are replaced by the words ‘Article 68’;

| 18. | Article 67 is amended as follows:






  (a) | in paragraph 3, the first subparagraph is replaced by the following:
  ‘The Agency’s revenue shall consist of a contribution from the Union and fees paid by undertakings for obtaining and maintaining Union marketing authorisations and for other services provided by the Agency, or by the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC.’; |
| --- | --- | --- |

18.

Article 67 is amended as follows:

(a)

in paragraph 3, the first subparagraph is replaced by the following:

‘The Agency’s revenue shall consist of a contribution from the Union and fees paid by undertakings for obtaining and maintaining Union marketing authorisations and for other services provided by the Agency, or by the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC.’;

| (b) | paragraph 4 is replaced by the following:

  ‘4.   Activities relating to pharmacovigilance, to the operation of communications networks and to market surveillance shall be under the permanent control of the Management Board in order to guarantee the independence of the Agency. This shall not preclude the Agency from charging fees to marketing authorisation holders for performing these activities by the Agency on the condition that its independence is strictly guaranteed.’; |
| --- | --- |

(b)

paragraph 4 is replaced by the following:

‘4.   Activities relating to pharmacovigilance, to the operation of communications networks and to market surveillance shall be under the permanent control of the Management Board in order to guarantee the independence of the Agency. This shall not preclude the Agency from charging fees to marketing authorisation holders for performing these activities by the Agency on the condition that its independence is strictly guaranteed.’;

| 19. | Article 82(3) is replaced by the following:

  ‘3.   Without prejudice to the unique, Union nature of the content of the documents referred to in points (a) to (d) of Article 9(4) and in points (a) to (e) of Article 34(4), this Regulation shall not prohibit the use of two or more commercial designs for a given medicinal product for human use covered by a single marketing authorisation.’; |
| --- | --- |

19.

Article 82(3) is replaced by the following:

‘3.   Without prejudice to the unique, Union nature of the content of the documents referred to in points (a) to (d) of Article 9(4) and in points (a) to (e) of Article 34(4), this Regulation shall not prohibit the use of two or more commercial designs for a given medicinal product for human use covered by a single marketing authorisation.’;

| 20. | in Article 83(6), the second sentence is replaced by the following:

  ‘Article 28(1) and (2) shall apply mutatis mutandis.’; |
| --- | --- |

20.

in Article 83(6), the second sentence is replaced by the following:

‘Article 28(1) and (2) shall apply mutatis mutandis.’;

mutatis mutandis

| 21. | the following Articles are inserted:

  ‘Article 87a
  In order to harmonise the performance of the pharmacovigilance activities provided for in this Regulation, the Commission shall adopt implementing measures as provided for in Article 108 of Directive 2001/83/EC covering the following areas:






  (a) | the content and maintenance of the pharmacovigilance system master file kept by the marketing authorisation holder; |
| --- | --- | --- |

21.

the following Articles are inserted:

‘Article 87a

In order to harmonise the performance of the pharmacovigilance activities provided for in this Regulation, the Commission shall adopt implementing measures as provided for in Article 108 of Directive 2001/83/EC covering the following areas:

(a)

the content and maintenance of the pharmacovigilance system master file kept by the marketing authorisation holder;

| (b) | the minimum requirements for the quality system for the performance of pharmacovigilance activities by the Agency; |
| --- | --- |

(b)

the minimum requirements for the quality system for the performance of pharmacovigilance activities by the Agency;

| (c) | the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities; |
| --- | --- |

(c)

the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities;

| (d) | the minimum requirements for the monitoring of data included in the Eudravigilance database to determine whether there are new risks or whether risks have changed; |
| --- | --- |

(d)

the minimum requirements for the monitoring of data included in the Eudravigilance database to determine whether there are new risks or whether risks have changed;

| (e) | the format and content of electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders; |
| --- | --- |

(e)

the format and content of electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders;

| (f) | the format and content of electronic periodic safety update reports and risk management plans; |
| --- | --- |

(f)

the format and content of electronic periodic safety update reports and risk management plans;

| (g) | the format of protocols, abstracts and final study reports of the post-authorisation safety studies. |
| --- | --- |

(g)

the format of protocols, abstracts and final study reports of the post-authorisation safety studies.

Those measures shall take account of the work on international harmonisation carried out in the area of pharmacovigilance and shall, where necessary, be revised to take account of technical and scientific progress. Those measures shall be adopted in accordance with the regulatory procedure referred to in Article 87(2).

Article 87b

1.   The power to adopt the delegated acts referred to in Article 10b shall be conferred on the Commission for a period of 5 years from 1 January 2011. The Commission shall draw up a report in respect of the delegated powers not later than 6 months before the end of the 5 year period. The delegation of powers shall be automatically extended for periods of an identical duration, unless the European Parliament or the Council revokes it in accordance with Article 87c.

2.   As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.

3.   The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in Articles 87c and 87d.

Article 87c

1.   The delegation of powers referred to in Article 10b may be revoked at any time by the European Parliament or by the Council.

2.   The institution which has commenced an internal procedure for deciding whether to revoke the delegation of powers shall endeavour to inform the other institution and the Commission within a reasonable time before the final decision is taken, indicating the delegated powers which could be subject to revocation and possible reasons for a revocation.

3.   The decision of revocation shall put an end to the delegation of the powers specified in that decision. It shall take effect immediately or at a later date specified therein. It shall not affect the validity of the delegated acts already in force. It shall be published in the Official Journal of the European Union.

Article 87d

1.   The European Parliament or the Council may object to a delegated act within a period of 2 months from the date of notification.

At the initiative of the European Parliament or the Council that period shall be extended by 2 months.

2.   If, on expiry of the period referred to in paragraph 1, neither the European Parliament nor the Council has objected to the delegated act, it shall be published in the Official Journal of the European Union and shall enter into force on the date stated therein.

The delegated act may be published in the Official Journal of the European Union and enter into force before the expiry of that period if the European Parliament and the Council have both informed the Commission of their intention not to raise objections.

3.   If either the European Parliament or the Council objects to the delegated act within the period referred to in paragraph 1, it shall not enter into force. The institution which objects shall state the reasons for objecting to the delegated act.’.

Article 2

Amendments to Regulation (EC) No 1394/2007

Article 20(3) of Regulation (EC) No 1394/2007 is replaced by the following:

‘3.   The Executive Director of the Agency shall ensure appropriate coordination between the Committee for Advanced Therapies and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Pharmacovigilance Risk Assessment Committee and the Committee for Orphan Medicinal Products, their working parties and any other scientific advisory groups.’.

Article 3

Transitional provisions

1.   The obligation on the part of the marketing authorisation holder to maintain and make available on request a pharmacovigilance system master file in respect of one or more medicinal products for human use provided for in Article 104(3)(b) of Directive 2001/83/EC as amended by Directive 2010/84/EU, which applies to medicinal products for human use authorised pursuant to Regulation (EC) No 726/2004 by virtue of Article 21 of Regulation (EC) No 726/2004 as amended by this Regulation, shall apply to marketing authorisations granted before 2 July 2012 as from either:

| (a) | the date on which those marketing authorisations are renewed; or |
| --- | --- |

(a)

the date on which those marketing authorisations are renewed; or

| (b) | the expiry of a period of 3 years starting from 2 July 2012, |
| --- | --- |

(b)

the expiry of a period of 3 years starting from 2 July 2012,

whichever is the earlier.

2.   The procedure provided for in Articles 107m to 107q of Directive 2001/83/EC as amended by Directive 2010/84/EU, which apply by virtue of Article 28b of Regulation (EC) No 726/2004 as amended by this Regulation, shall apply only to studies which have commenced after 2 July 2012.

3.   The obligation of the Agency under the second subparagraph of Article 28c(1) of Regulation (EC) No 726/2004 as amended by this Regulation shall apply once the full functionality of Eudravigilance has been announced by the Management Board.

Article 4

Entry into force and application

This Regulation shall enter into force on the day following its publication in the Official Journal of the European Union.

Official Journal of the European Union

It shall apply from 2 July 2012.

Done at Strasbourg, 15 December 2010.

For the European Parliament

The President

J. BUZEK

For the Council

The President

O. CHASTEL

---

(1)  
  OJ C 306, 16.12.2009, p. 22.

1

(2)  
  OJ C 79, 27.3.2010, p. 50.

2

(3)  
  OJ C 229, 23.9.2009, p. 19.

3

(4)  Position of the European Parliament of 22 September 2010 (not yet published in the Official Journal) and Council Decision of 29 November 2010.

4

(5)  
  OJ L 136, 30.4.2004, p. 1.

5

(6)  
  OJ L 311, 28.11.2001, p. 67.

6

(7)  
  OJ L 281, 23.11.1995, p. 31.

7

(8)  
  OJ L 8, 12.1.2001, p. 1.

8

(9)  See page 74 of this Official Journal.

9

(10)  
  OJ L 184, 17.7.1999, p. 23.

10

(11)  
  OJ L 218, 13.8.2008, p. 30.

11

(12)  
  OJ L 324, 10.12.2007, p. 121.

12

---

| 31.12.2010 | EN | Official Journal of the European Union | L 348/17 |
| --- | --- | --- | --- |

31.12.2010

EN

Official Journal of the European Union

L 348/17

---

REGULATION (EU) No 1236/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 15 December 2010

laying down a scheme of control and enforcement applicable in the area covered by the Convention on future multilateral cooperation in the North-East Atlantic fisheries and repealing Council Regulation (EC) No 2791/1999

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 43(2) thereof,

Having regard to the proposal from the European Commission,

Having regard to the opinion of the European Economic and Social Committee (1),

Acting in accordance with the ordinary legislative procedure (2),

Whereas:

| (1) | The Convention on future multilateral cooperation in the North-East Atlantic fisheries (the Convention), was approved by the Council in Decision 81/608/EEC (3) and entered into force on 17 March 1982. |
| --- | --- |

(1)

The Convention on future multilateral cooperation in the North-East Atlantic fisheries (the Convention), was approved by the Council in Decision 81/608/EEC (3) and entered into force on 17 March 1982.

| (2) | The Convention provides for an appropriate framework for multilateral cooperation on the rational conservation and management of fishery resources in the Area defined by the Convention (the Convention Area). |
| --- | --- |

(2)

The Convention provides for an appropriate framework for multilateral cooperation on the rational conservation and management of fishery resources in the Area defined by the Convention (the Convention Area).

| (3) | The North-East Atlantic Fisheries Commission (NEAFC), at its Annual Meeting on 15 November 2006, adopted a recommendation establishing a scheme of control and enforcement (the Scheme) applicable to fishing vessels operating in the waters of the Convention Area which lie beyond the waters under the fisheries jurisdiction of the Contracting Parties (the Regulatory Area). The Scheme, which came into force on 1 May 2007, was amended by several recommendations at the Annual Meetings in November 2007, 2008 and 2009. |
| --- | --- |

(3)

The North-East Atlantic Fisheries Commission (NEAFC), at its Annual Meeting on 15 November 2006, adopted a recommendation establishing a scheme of control and enforcement (the Scheme) applicable to fishing vessels operating in the waters of the Convention Area which lie beyond the waters under the fisheries jurisdiction of the Contracting Parties (the Regulatory Area). The Scheme, which came into force on 1 May 2007, was amended by several recommendations at the Annual Meetings in November 2007, 2008 and 2009.

| (4) | Under Articles 12 and 15 of the Convention, these recommendations came into force on 9 February 2008, 6 and 8 January 2009, and 6 February 2010 respectively. |
| --- | --- |

(4)

Under Articles 12 and 15 of the Convention, these recommendations came into force on 9 February 2008, 6 and 8 January 2009, and 6 February 2010 respectively.

| (5) | The Scheme provides for control and enforcement measures applicable to vessels flying the flag of Contracting Parties and operating in the Regulatory Area, and arrangements for inspection at sea which include inspection and surveillance procedures and infringement procedures which must be implemented by the Contracting Parties. |
| --- | --- |

(5)

The Scheme provides for control and enforcement measures applicable to vessels flying the flag of Contracting Parties and operating in the Regulatory Area, and arrangements for inspection at sea which include inspection and surveillance procedures and infringement procedures which must be implemented by the Contracting Parties.

| (6) | The Scheme provides for a new Port State Control system which will effectively close European ports to landings and transhipments of frozen fish which have not been verified to be legal by the flag state of fishing vessels flying the flag of a Contracting Party other than the port state. |
| --- | --- |

(6)

The Scheme provides for a new Port State Control system which will effectively close European ports to landings and transhipments of frozen fish which have not been verified to be legal by the flag state of fishing vessels flying the flag of a Contracting Party other than the port state.

| (7) | Certain control provisions adopted by NEAFC have been incorporated into Union law by way of the yearly TAC and quotas Regulation, and most recently by Council Regulation (EC) No 43/2009 of 16 January 2009 fixing for 2009 the fishing opportunities and associated conditions for certain fish stocks and groups of fish stocks, applicable in Community waters and, for Community vessels, in waters where catch limitations are required (4). For the sake of legal certainty, such provisions which are not of a temporary nature should be the subject of a new separate regulation. |
| --- | --- |

(7)

Certain control provisions adopted by NEAFC have been incorporated into Union law by way of the yearly TAC and quotas Regulation, and most recently by Council Regulation (EC) No 43/2009 of 16 January 2009 fixing for 2009 the fishing opportunities and associated conditions for certain fish stocks and groups of fish stocks, applicable in Community waters and, for Community vessels, in waters where catch limitations are required (4). For the sake of legal certainty, such provisions which are not of a temporary nature should be the subject of a new separate regulation.

| (8) | The Scheme also comprises provisions to promote compliance by vessels flying the flag of a non-Contracting Party with the control and enforcement measures in order to ensure full respect of conservation and management measures adopted by NEAFC. NEAFC recommended removing a number of vessels from the list of vessels that have been confirmed to have engaged in illegal, unreported and unregulated fisheries. The incorporation of those recommendations into Union law should be ensured. |
| --- | --- |

(8)

The Scheme also comprises provisions to promote compliance by vessels flying the flag of a non-Contracting Party with the control and enforcement measures in order to ensure full respect of conservation and management measures adopted by NEAFC. NEAFC recommended removing a number of vessels from the list of vessels that have been confirmed to have engaged in illegal, unreported and unregulated fisheries. The incorporation of those recommendations into Union law should be ensured.

| (9) | Article 5(2) of Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (5) provides that Member States shall control access to waters and resources and control activities outside EU waters carried out by vessels flying their flag. Provision should therefore be made for Member States whose vessels are authorised to fish in the Regulatory Area to assign inspectors to the Scheme to undertake monitoring and surveillance as well as adequate resources for inspection. |
| --- | --- |

(9)

Article 5(2) of Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (5) provides that Member States shall control access to waters and resources and control activities outside EU waters carried out by vessels flying their flag. Provision should therefore be made for Member States whose vessels are authorised to fish in the Regulatory Area to assign inspectors to the Scheme to undertake monitoring and surveillance as well as adequate resources for inspection.

| (10) | In order to ensure the monitoring of fishing activities in the Convention Area, it is necessary for Member States to cooperate with one another and with the Commission and the body designated by it in applying the Scheme. |
| --- | --- |

(10)

In order to ensure the monitoring of fishing activities in the Convention Area, it is necessary for Member States to cooperate with one another and with the Commission and the body designated by it in applying the Scheme.

| (11) | It is the responsibility of Member States to ensure that their inspectors comply with the inspection procedures laid down by NEAFC. |
| --- | --- |

(11)

It is the responsibility of Member States to ensure that their inspectors comply with the inspection procedures laid down by NEAFC.

| (12) | The Commission should be empowered to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union (TFEU) in respect of detailed rules concerning lists of the fishery resources to be notified, procedures for prior notification of entry into port and for the cancellation thereof as well as authorisation to land or tranship. The Commission should also be empowered to adopt delegated acts in respect of the incorporation into Union law of future amendments of those measures of the Scheme which form the subject matter of certain expressly defined non-essential elements of this Regulation and which become binding upon the Union in accordance with the terms of the Convention. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. |
| --- | --- |

(12)

The Commission should be empowered to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union (TFEU) in respect of detailed rules concerning lists of the fishery resources to be notified, procedures for prior notification of entry into port and for the cancellation thereof as well as authorisation to land or tranship. The Commission should also be empowered to adopt delegated acts in respect of the incorporation into Union law of future amendments of those measures of the Scheme which form the subject matter of certain expressly defined non-essential elements of this Regulation and which become binding upon the Union in accordance with the terms of the Convention. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level.

| (13) | The measures necessary for the implementation of this Regulation should be adopted by the Commission by means of implementing acts in accordance with Article 291 TFEU. According to that Article, rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (6) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable. |
| --- | --- |

(13)

The measures necessary for the implementation of this Regulation should be adopted by the Commission by means of implementing acts in accordance with Article 291 TFEU. According to that Article, rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (6) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable.

| (14) | As this Regulation will establish new rules concerning control and enforcement in the Convention Area, Council Regulation (EC) No 2791/1999 of 16 December 1999 laying down certain control measures applicable in the area covered by the Convention on future multilateral cooperation in the North-East Atlantic fisheries (7) should be repealed, |
| --- | --- |

(14)

As this Regulation will establish new rules concerning control and enforcement in the Convention Area, Council Regulation (EC) No 2791/1999 of 16 December 1999 laying down certain control measures applicable in the area covered by the Convention on future multilateral cooperation in the North-East Atlantic fisheries (7) should be repealed,

HAVE ADOPTED THIS REGULATION:

CHAPTER I

GENERAL PROVISIONS

Article 1

Subject matter

This Regulation lays down the general rules and conditions for the application by the Union of the Scheme adopted by NEAFC.

Article 2

Scope

Unless otherwise stated, this Regulation shall apply to all EU vessels used or intended for use for fishing activities carried out in respect of fishery resources in the Regulatory Area.

Article 3

Definitions

For the purpose of this Regulation, the following definitions shall apply:

| 1. | ‘Convention’ means the Convention on future multilateral cooperation in North-East Atlantic fisheries, as amended; |
| --- | --- |

1.

‘Convention’ means the Convention on future multilateral cooperation in North-East Atlantic fisheries, as amended;

| 2. | ‘Convention Area’ means the Convention Area as defined in Article 1(1) of the Convention; |
| --- | --- |

2.

‘Convention Area’ means the Convention Area as defined in Article 1(1) of the Convention;

| 3. | ‘Regulatory Area’ means the waters of the Convention Area which lie beyond the waters under the fisheries jurisdiction of the Contracting Parties; |
| --- | --- |

3.

‘Regulatory Area’ means the waters of the Convention Area which lie beyond the waters under the fisheries jurisdiction of the Contracting Parties;

| 4. | ‘Contracting Parties’ means the Contracting Parties to the Convention; |
| --- | --- |

4.

‘Contracting Parties’ means the Contracting Parties to the Convention;

| 5. | ‘NEAFC’ means the North-East Atlantic Fisheries Commission; |
| --- | --- |

5.

‘NEAFC’ means the North-East Atlantic Fisheries Commission;

| 6. | ‘fishing activities’ means fishing, including joint fishing operations, fish processing operations, the transhipment or landing of fish or fish products and any other commercial activity in preparation for or related to fishing; |
| --- | --- |

6.

‘fishing activities’ means fishing, including joint fishing operations, fish processing operations, the transhipment or landing of fish or fish products and any other commercial activity in preparation for or related to fishing;

| 7. | ‘fishery resources’ means the resources referred to in Article 1(2) of the Convention; |
| --- | --- |

7.

‘fishery resources’ means the resources referred to in Article 1(2) of the Convention;

| 8. | ‘regulated resources’ means those fishery resources which are subject to recommendations under the Convention and are listed in the Annex; |
| --- | --- |

8.

‘regulated resources’ means those fishery resources which are subject to recommendations under the Convention and are listed in the Annex;

| 9. | ‘fishing vessel’ means any vessel used or intended for use for the purposes of the commercial exploitation of fishery resources, including fish processing vessels and vessels engaged in transhipment; |
| --- | --- |

9.

‘fishing vessel’ means any vessel used or intended for use for the purposes of the commercial exploitation of fishery resources, including fish processing vessels and vessels engaged in transhipment;

| 10. | ‘non-Contracting Party vessel’ means any fishing vessel not flagged in a Contracting Party, including vessels for which there are reasonable grounds for suspecting them to be without nationality; |
| --- | --- |

10.

‘non-Contracting Party vessel’ means any fishing vessel not flagged in a Contracting Party, including vessels for which there are reasonable grounds for suspecting them to be without nationality;

| 11. | ‘joint fishing operation’ means any operations between two or more vessels where catch is taken from the fishing gear of one fishing vessel to another; |
| --- | --- |

11.

‘joint fishing operation’ means any operations between two or more vessels where catch is taken from the fishing gear of one fishing vessel to another;

| 12. | ‘transhipment operation’ means the unloading of all or any fishery products on board a fishing vessel onto another fishing vessel; |
| --- | --- |

12.

‘transhipment operation’ means the unloading of all or any fishery products on board a fishing vessel onto another fishing vessel;

| 13. | ‘port’ means any place used for landing or a place close to the shore designated by a Contracting Party for transhipping fishery resources. |
| --- | --- |

13.

‘port’ means any place used for landing or a place close to the shore designated by a Contracting Party for transhipping fishery resources.

Article 4

Contact points

1.   Member States shall designate the competent authority which shall act as the contact point for the purposes of receiving surveillance and inspection reports in accordance with Articles 12, 19, 20 and 27 and for receiving notifications and issuing authorisations in accordance with Articles 24 and 25.

2.   Contact points for receiving notifications and issuing authorisations in accordance with Articles 24 and 25 shall be available 24 hours a day.

3.   Member States shall send to the Commission or to the body designated by it and to the NEAFC Secretary the telephone number, e-mail address and fax number of the designated contact point.

4.   Any subsequent changes to the information concerning the contact points referred to in paragraphs 1 and 3 shall be notified to the Commission or the body designated by it and to the NEAFC Secretary no later than 15 days before the change comes into force.

5.   The format for transmission of the information referred to in paragraphs 1 and 3 shall be established in accordance with Article 50(2).

CHAPTER II

MONITORING MEASURES

Article 5

Union participation

1.   Member States shall send to the Commission, in a computer-readable form, a list of all vessels flying their flag and registered in the Union which are authorised to fish in the Regulatory Area, in particular the vessels authorised to fish directly for one or more regulated resources together with any amendments to the list. This information shall be sent no later than 15 December each year or no later than 5 days before the vessel enters the Regulatory Area. The Commission shall forward the information promptly to the NEAFC Secretary.

2.   The format for transmission of the list referred to in paragraph 1 shall be determined in accordance with Article 50(2).

Article 6

Marking of gear

1.   Member States shall ensure that gear used by their fishing vessels in the Regulatory Area is marked in accordance with Commission Regulation (EC) No 356/2005 of 1 March 2005 laying down detailed rules for the marking and identification of passive fishing gear and beam trawls (8).

2.   Member States may remove and dispose of fixed gear that is not marked in accordance with Regulation (EC) No 356/2005 or that contravenes in any other way recommendations adopted by NEAFC, as well as fish that are found in the gear.

Article 7

Retrieval of lost gear

1.   The competent authority of the flag Member State shall send without delay to the NEAFC Secretary the information provided to it pursuant to Article 48(3) of Regulation (EC) No 1224/2009 as well as the call sign of the vessel that has lost the gear.

2.   Member States shall undertake to retrieve on a regular basis lost gears belonging to vessels flying their flag.

Article 8

Recording of catches

1.   In addition to the information specified in Article 6 of Council Regulation (EEC) No 2847/93 of 12 October 1993 establishing a control system applicable to the common fisheries policy (9), the masters of EU fishing vessels shall record, either in a bound paginated fishing logbook or by electronic means, the following:

| (a) | each entry into and exit from the Regulatory Area; |
| --- | --- |

(a)

each entry into and exit from the Regulatory Area;

| (b) | on a daily basis and/or for each haul the estimated cumulative catches retained on board since the last entry into the Regulatory Area; |
| --- | --- |

(b)

on a daily basis and/or for each haul the estimated cumulative catches retained on board since the last entry into the Regulatory Area;

| (c) | on a daily basis and/or for each haul the amount of fish discarded; |
| --- | --- |

(c)

on a daily basis and/or for each haul the amount of fish discarded;

| (d) | immediately after each communication pursuant to Article 9, the date and time, according to Universal Coordinated Time (UTC), of transmission of a report and, in the case of radio transmission, the name of the radio station through which the report was transmitted; |
| --- | --- |

(d)

immediately after each communication pursuant to Article 9, the date and time, according to Universal Coordinated Time (UTC), of transmission of a report and, in the case of radio transmission, the name of the radio station through which the report was transmitted;

| (e) | the fishing depth, where appropriate. |
| --- | --- |

(e)

the fishing depth, where appropriate.

2.   The masters of EU fishing vessels engaged in fishing activities carried out in respect of regulated resources and which process and/or freeze their catch shall:

| (a) | record their cumulative production by species and product form in a production logbook; and |
| --- | --- |

(a)

record their cumulative production by species and product form in a production logbook; and

| (b) | stow in the hold all processed catch in such a way that the location of each species can be identified from a stowage plan maintained on board the fishing vessel. |
| --- | --- |

(b)

stow in the hold all processed catch in such a way that the location of each species can be identified from a stowage plan maintained on board the fishing vessel.

3.   By way of derogation from paragraph 1, Member States may exempt from the obligation to record in a fishing logbook or electronically a vessel engaged in transhipment operations which on-loads quantities on board. Vessels benefiting from this derogation shall specify in a stowage plan the location in the hold of frozen fish referred to in Article 14(1) and record in a production logbook:

| (a) | the date and time, according to UTC, of transmission of a report referred to in Article 9; |
| --- | --- |

(a)

the date and time, according to UTC, of transmission of a report referred to in Article 9;

| (b) | in the case of radio transmission, the name of the radio station through which the report was transmitted; |
| --- | --- |

(b)

in the case of radio transmission, the name of the radio station through which the report was transmitted;

| (c) | the date and time, according to UTC, of the transhipment operation; |
| --- | --- |

(c)

the date and time, according to UTC, of the transhipment operation;

| (d) | the location (latitude/longitude) of the transhipment operation; |
| --- | --- |

(d)

the location (latitude/longitude) of the transhipment operation;

| (e) | the quantities of each species on-loaded; |
| --- | --- |

(e)

the quantities of each species on-loaded;

| (f) | the name and international radio call sign of the fishing vessel from which the catch has been off-loaded. |
| --- | --- |

(f)

the name and international radio call sign of the fishing vessel from which the catch has been off-loaded.

4.   Detailed rules for the implementation of this Article shall be determined in accordance with Article 50(2).

Article 9

Reporting of catches of regulated resources

1.   The masters of EU fishing vessels engaged in fishing activities carried out in respect of regulated resources shall communicate catch reports by electronic means to their Fisheries Monitoring Centre, as defined in point (15) of Article 4 of Regulation (EC) No 1224/2009. The data contained in such reports shall be accessible to the Commission on request. Reports shall include the following:

| (a) | reports on the quantities held on board when entering the Regulatory Area. Such reports shall be transmitted no earlier than 12 hours and no later than 2 hours before each entry into the Regulatory Area; |
| --- | --- |

(a)

reports on the quantities held on board when entering the Regulatory Area. Such reports shall be transmitted no earlier than 12 hours and no later than 2 hours before each entry into the Regulatory Area;

| (b) | reports on weekly catches. Such reports shall be transmitted for the first time no later than the end of the seventh day following the entry of the vessel into the Regulatory Area or, when fishing trips take more than 7 days, no later than Monday noon for catches taken in the Regulatory Area during the preceding week ending at midnight on Sunday. This report shall include the number of fishing days since the start of fishing, or since the last catch report; |
| --- | --- |

(b)

reports on weekly catches. Such reports shall be transmitted for the first time no later than the end of the seventh day following the entry of the vessel into the Regulatory Area or, when fishing trips take more than 7 days, no later than Monday noon for catches taken in the Regulatory Area during the preceding week ending at midnight on Sunday. This report shall include the number of fishing days since the start of fishing, or since the last catch report;

| (c) | reports on catches on board when exiting the Regulatory Area. Such reports shall be transmitted no earlier than 8 hours and no later than 2 hours before each departure from the Regulatory Area. Such reports shall include, where appropriate, the number of fishing days and the catch taken in the Regulatory Area since the start of fishing, or since the last catch report; |
| --- | --- |

(c)

reports on catches on board when exiting the Regulatory Area. Such reports shall be transmitted no earlier than 8 hours and no later than 2 hours before each departure from the Regulatory Area. Such reports shall include, where appropriate, the number of fishing days and the catch taken in the Regulatory Area since the start of fishing, or since the last catch report;

| (d) | reports on the quantities on-loaded and off-loaded for each transhipment of fish during the vessel’s stay in the Regulatory Area. Donor vessels shall make this report no later than 24 hours before the transhipment, and receiving vessels no later than 1 hour after the transhipment. The report shall include the date, time and geographical position of the planned transhipment as well as the total round weight by species which are to be off-loaded or which have been on-loaded in kilograms and the call signs of the donor and receiving vessels. Without prejudice to Chapter IV, at least 24 hours before any landing, the receiving vessel shall report the total catch on board, the total weight to be landed, the name of the port and the estimated date and time of landing. |
| --- | --- |

(d)

reports on the quantities on-loaded and off-loaded for each transhipment of fish during the vessel’s stay in the Regulatory Area. Donor vessels shall make this report no later than 24 hours before the transhipment, and receiving vessels no later than 1 hour after the transhipment. The report shall include the date, time and geographical position of the planned transhipment as well as the total round weight by species which are to be off-loaded or which have been on-loaded in kilograms and the call signs of the donor and receiving vessels. Without prejudice to Chapter IV, at least 24 hours before any landing, the receiving vessel shall report the total catch on board, the total weight to be landed, the name of the port and the estimated date and time of landing.

2.   The reports on catches referred to in this Article shall be expressed in kilograms (rounded to the nearest 100 kg). The total round weight shall be reported by species, using the FAO codes. The total quantity of species for which the total round weight by species is less than 1 tonne may be reported under the 3-alpha code MZZ (marine fish not specified).

3.   Member States shall record the data contained in the catch reports in the database referred to in Article 109(1) of Regulation (EC) No 1224/2009.

4.   The detailed rules for the implementation of this Article and in particular the format and the specifications for the transmissions shall be determined in accordance with Article 50(2).

Article 10

Global reporting of catches and fishing effort

1.   Member States shall inform the Commission by computer transmission before the 15th day of each month of the quantities of fishery resources caught in the Regulatory Area by vessels flying their flag which have been landed or transhipped during the preceding month.

2.   Without prejudice to Article 33(2) of Regulation (EC) No 1224/2009, Member States shall also inform the Commission by computer transmission before the 15th day of each month of the quantities of regulated resources caught in areas under the national fisheries jurisdiction of third countries and in EU waters of the Convention Area by vessels flying their flag which have been landed or transhipped during the preceding month.

3.   The format for transmission of the data pursuant to paragraphs 1 and 2 shall be determined in accordance with Article 50(2).

The list of the fishery resources referred to in paragraph 1 shall be adopted in accordance with the procedure laid down in Articles 46 to 49.

4.   The Commission shall compile the data referred to in paragraphs 1 and 2 for all Member States and forward them to the NEAFC Secretary within 30 days following the calendar month in which the catches were landed or transhipped.

Article 11

Vessel Monitoring System

Member States shall ensure the automatic and electronic transmission to the NEAFC Secretary of information obtained by the vessel monitoring system (VMS) concerning vessels flying their flag which fish or plan to fish in the Regulatory Area. The format and the specifications of these transmissions shall be determined in accordance with Article 50(2).

Article 12

Communication of information

1.   Member States shall communicate the reports and the information referred to in Articles 9 and 11 without delay to the NEAFC Secretary. In the event of technical malfunction, however, such reports and information shall be transmitted to the NEAFC Secretary within 24 hours of receipt. Member States shall ensure that all reports and messages forwarded by them are numbered sequentially.

2.   Member States shall ensure that the reports and information transmitted to the NEAFC Secretary are in accordance with the data exchange formats and protocols determined in accordance with Article 50(2).

Article 13

Transhipments and joint fishing operations

1.   EU fishing vessels shall engage in transhipment activities in the Regulatory Area only if they have received prior authorisation from the competent authorities in their flag Member State.

2.   EU fishing vessels may only engage in transhipment operations or joint fishing operations with vessels flying the flag of a Contracting Party and vessels of a non-Contracting Party granted the status of a cooperating non-Contracting Party by NEAFC.

3.   EU fishing vessels engaged in transhipment operations which on-load quantities on board shall not engage in other fishing activities, including joint fishing operations, during the same trip, with the exception of fish-processing operations and landings.

Article 14

Separate stowage

1.   EU fishing vessels which carry on board frozen fishery resources caught in the Convention Area by more than one fishing vessel may stow the fish from each of those vessels in more than one part of the hold but shall keep it clearly separate from fish caught by other vessels, in particular by using plastic, plywood or netting.

2.   All catches taken inside the Convention Area shall be stowed separately from all catches taken outside the area.

Article 15

Labelling of frozen fish

When frozen, all fish caught in the Convention Area shall be identified with a clearly legible label or stamp. The label or stamp shall be placed at the time of stowage on each box or block of frozen fish and shall indicate the species, the production date, the ICES sub-area and division where the catch was taken and the name of the vessel which caught the fish.

CHAPTER III

INSPECTIONS AT SEA

Article 16

NEAFC inspectors

1.   Member States whose fishing vessels are authorised to fish in the Regulatory Area shall assign inspectors to the Scheme to carry out surveillance and inspection (NEAFC inspectors).

2.   Member States shall issue a special identity document to each NEAFC inspector. The form of this document shall be determined in accordance with Article 50(2).

3.   Each NEAFC inspector shall carry and produce the special identity document when boarding a fishing vessel.

Article 17

General provisions for inspection and surveillance

1.   The Commission or the body designated by it shall coordinate the surveillance and inspection activities for the Union and shall draw up each year, in concert with the Member States concerned, a joint deployment plan for Union participation in the Scheme in the following year. This deployment plan shall, inter alia, determine the number of inspections to be carried out.

Where at any time more than ten EU fishing vessels are engaged in fishing activities carried out in respect of regulated resources in the Regulatory Area, the Commission or the body designated by it shall ensure that an inspection vessel from a Member State is present during that time in the Regulatory Area or that an agreement has been concluded with another Contracting Party to ensure the presence of an inspection vessel.

2.   Member States shall ensure that the inspections by their NEAFC inspectors are carried out in a non-discriminatory manner and in accordance with the Scheme. The number of inspections shall be based on fleet size, taking into account the time spent by fishing vessels in the Regulatory Area.

3.   The Commission or the body designated by it shall seek to ensure, through an equitable distribution of inspections, equal treatment of all Contracting Parties with fishing vessels operating in the Regulatory Area.

4.   Member States shall take steps to ensure that NEAFC inspectors from another Contracting Party are permitted to carry out inspections on board vessels flying their flag.

5.   NEAFC inspectors shall avoid the use of force except in cases of legitimate self-defence. When carrying out inspections on board fishing vessels, NEAFC inspectors shall not carry fire-arms. This paragraph shall be without prejudice to national provisions concerning the prohibition of the use of force.

6.   NEAFC inspectors shall avoid causing any inconvenience to the fishing vessel or interfering with its activities and the catch retained on board, except when and to the degree necessary to carry out their mandates.

Article 18

Means to carry out inspection

1.   Member States shall make available to their NEAFC inspectors adequate means to enable them to carry out their surveillance and inspection tasks. To that end they shall assign inspection vessels and aircraft to the Scheme.

2.   The Commission or the body designated by it shall send to the NEAFC Secretary before 1 January each year details of the plan together with the names of the NEAFC inspectors and special inspection vessels as well as the types of aircraft and their identification details (registration number, name, radio call-sign) which Member States are assigning to the Scheme during that year. Where appropriate, this information shall be taken from the list of inspectors referred to in Article 79(1) of Regulation (EC) No 1224/2009. Member States shall send changes to this list to the Commission or the body designated by it which in turn shall forward them to the NEAFC Secretary and the other Member States 1 month before the changes are due to come into effect.

3.   Any vessel assigned to the Scheme and carrying NEAFC inspectors, as well as the boarding craft deployed by that vessel, shall display the NEAFC inspection special signal to indicate that NEAFC inspectors on board may carry out inspection duties in accordance with the Scheme. Aircraft assigned to the Scheme shall have their international radio call-sign clearly displayed. The form of the special signal shall be determined in accordance with Article 50(2).

4.   For each Union inspection vessel or aircraft assigned to the Scheme, the Commission or the body designated by it shall keep a record of the date and hour of the start and termination of their duties under the Scheme as set out in the form determined in accordance with Article 50(2).

Article 19

Surveillance procedure

1.   Surveillance shall be based on sightings of fishing vessels by NEAFC inspectors from a vessel or aircraft assigned to the Scheme. NEAFC inspectors shall forward a copy of each sighting report for every vessel without delay, by electronic transmission in the form set out in accordance with Article 50(2), to the flag state of the vessel concerned, to the Commission or the body designated by it and to the NEAFC Secretary. A hard copy of each sighting report and any photographs shall be forwarded on request to the flag state of the vessel concerned.

2.   NEAFC inspectors shall record their sightings in a surveillance report using a form established in accordance with Article 50(2).

Article 20

Inspection procedure

1.   NEAFC inspectors shall not board any fishing vessel without prior notice being transmitted by radio to that vessel or without that vessel being given the appropriate signal using the International Code of Signals, including the identity of the inspection platform; however, it shall not be necessary for such notice to be acknowledged as received.

2.   NEAFC inspectors shall have the authority to examine all relevant areas, decks and rooms of the fishing vessels, catch (whether processed or not), nets or other gear, equipment, and any relevant documents which they deem necessary to verify compliance with the conservation and management measures adopted by NEAFC and to question the master or a person designated by the master.

3.   The fishing vessel to be boarded shall not be required to stop or manoeuvre when fishing, shooting or hauling. The NEAFC inspectors may order that the hauling of the fishing gear be interrupted or delayed until they have boarded the fishing vessel but may not do so in any event more than 30 minutes after the fishing vessel has received the signal referred to in paragraph 1.

4.   Masters of inspection platforms shall ensure that they manoeuvre at a safe distance from the fishing vessels in accordance with good seamanship.

5.   NEAFC inspectors may instruct a fishing vessel to delay its entry into or exit from the Regulatory Area for up to 6 hours from the time of transmission by the fishing vessel of the reports referred to in Article 9(1)(a) and (c).

6.   The duration of an inspection shall not exceed 4 hours, or the time it takes to haul in the net and to inspect the net and the catch, whichever is longer. Where an infringement is detected the NEAFC inspectors may stay on board for the time necessary for the completion of the measures provided for in Article 29(1)(b).

7.   In special circumstances relating to the size of a fishing vessel and the quantities of fish retained on board, the duration of the inspection may exceed the limits laid down in paragraph 6. In such a situation, NEAFC inspectors shall under no circumstances stay on board the fishing vessel longer than the time required to complete the inspection. The reasons for exceeding the limit laid down in paragraph 6 shall be recorded in the inspection report referred to in paragraph 9.

8.   No more than two NEAFC inspectors assigned by a Member State shall board a fishing vessel of another Contracting Party. In carrying out their inspection, the NEAFC inspectors may request the master to provide any assistance which is required. NEAFC inspectors shall not interfere with the master’s ability to communicate with the authorities of the flag state during the boarding and inspection.

9.   Each inspection shall be documented by the completion of an inspection report in the format established in accordance with Article 50(2). The master may add his comments to the inspection report which shall be signed by the NEAFC inspectors at the end of the inspection. A copy of the inspection report shall be given to the master of the fishing vessel. A copy of each inspection report shall be transmitted without delay to the flag state of the inspected vessel and to the Commission or the body designated by it. The Commission or the body designated by it shall forward the copy promptly to the NEAFC Secretary. The original or a certified copy of each inspection report shall be forwarded on request to the flag state of the inspected vessel.

Article 21

Obligations of the master of the vessel during the inspection procedure

The master of a fishing vessel shall:

| (a) | facilitate prompt and safe boarding and disembarkation pursuant to specifications adopted in accordance with Article 50(2); |
| --- | --- |

(a)

facilitate prompt and safe boarding and disembarkation pursuant to specifications adopted in accordance with Article 50(2);

| (b) | cooperate with and assist in the inspection of the fishing vessel conducted pursuant to this Regulation, not obstruct, intimidate or interfere with the NEAFC inspectors in the performance of their duties and ensure their safety; |
| --- | --- |

(b)

cooperate with and assist in the inspection of the fishing vessel conducted pursuant to this Regulation, not obstruct, intimidate or interfere with the NEAFC inspectors in the performance of their duties and ensure their safety;

| (c) | allow the NEAFC inspectors to communicate with the authorities of the flag state and the inspecting state; |
| --- | --- |

(c)

allow the NEAFC inspectors to communicate with the authorities of the flag state and the inspecting state;

| (d) | provide access to any areas, decks and rooms of the fishing vessel, catch (whether processed or not), nets or other gear, equipment, and to any relevant information or documents which the NEAFC inspectors deem necessary in accordance with Article 20(2); |
| --- | --- |

(d)

provide access to any areas, decks and rooms of the fishing vessel, catch (whether processed or not), nets or other gear, equipment, and to any relevant information or documents which the NEAFC inspectors deem necessary in accordance with Article 20(2);

| (e) | provide copies of documents as required by the NEAFC inspectors; and |
| --- | --- |

(e)

provide copies of documents as required by the NEAFC inspectors; and

| (f) | provide NEAFC inspectors with reasonable facilities, including, where appropriate, food and accommodation when they remain on board the vessel in accordance with Article 32(3). |
| --- | --- |

(f)

provide NEAFC inspectors with reasonable facilities, including, where appropriate, food and accommodation when they remain on board the vessel in accordance with Article 32(3).

CHAPTER IV

PORT STATE CONTROL OF FISHING VESSELS FLYING THE FLAG OF ANOTHER CONTRACTING PARTY

Article 22

Scope

Without prejudice to Regulation (EC) No 1224/2009 and to Council Regulation (EC) No 1005/2008 of 29 September 2008 establishing a Community system to prevent, deter and eliminate illegal, unreported and unregulated fishing (10), the provisions set out in this Chapter shall apply to landing or transhipping in ports of Member States of fishery resources frozen after being caught in the Convention Area by fishing vessels flying the flag of another Contracting Party.

10

Article 23

Designated ports

Member States shall designate and notify the Commission of ports where the landing or transhipment of fishery resources frozen after being caught in the Convention Area by fishing vessels flying the flag of another Contracting Party are permitted. The Commission shall notify the NEAFC Secretary of these ports and of any changes to the list of ports designated at least 15 days before the change comes into force.

Landings and transhipments of fish frozen after being caught in the Convention Area by fishing vessels flying the flag of another Contracting Party shall be allowed only in designated ports.

Article 24

Prior notification of entry into port

1.   In accordance with Article 6 of Regulation (EC) No 1005/2008, when the master of a fishing vessel carrying fish referred to in Article 22 of this Regulation intends to call into a port to land or tranship fish, the master of the vessel, or his representative, shall notify the competent authorities of the Member State of the port he wishes to use no later than three working days before the estimated time of arrival.

However, a Member State may make provision for another notification period, taking into account, in particular, the distance between the fishing grounds and its ports. In such a case, the Member State shall inform the Commission, or the body designated by it, and the NEAFC Secretary thereof without delay.

2.   Masters or their representatives may cancel a prior notification by notifying the competent authorities of the port they wish to use no later than 24 hours before the notified estimated time of arrival in that port. The notification shall be accompanied by a copy of the original notification form with the word ‘CANCELLED’ written across it.

However, a Member State may make provision for another notification period for cancellation. In such a case, the Member State shall inform the Commission, or the body designated by it, and the NEAFC Secretary thereof without delay.

3.   The competent authorities of the port Member State shall forward without delay a copy of the notifications referred to in paragraphs 1 and 2 to the flag state of the fishing vessel and to the flag state or states of the donor vessels when the fishing vessel has engaged in transhipment operations. A copy of the notification referred to in paragraph 2 shall also be forwarded without delay to the NEAFC Secretary.

4.   The format and the specifications of the notifications shall be determined in accordance with Article 50(2).

As far as necessary, further detailed rules on the notification and cancellation procedures under this Article, including periods, shall be adopted in accordance with the procedure laid down in Articles 46 to 49.

Article 25

Authorisation to land or tranship

1.   The flag state of the fishing vessel intending to land or tranship or, where the fishing vessel has engaged in transhipment operations outside EU waters, the flag state or states of the donor vessels, shall, by returning a copy of the prior notification referred to in Article 24 to the competent authorities of the port Member State, confirm that:

| (a) | the fishing vessel which declared having caught the fish had sufficient quota for the species declared; |
| --- | --- |

(a)

the fishing vessel which declared having caught the fish had sufficient quota for the species declared;

| (b) | the quantities of fish on board have been duly reported and taken into account for the calculation of any catch or effort limitations that may be applicable; |
| --- | --- |

(b)

the quantities of fish on board have been duly reported and taken into account for the calculation of any catch or effort limitations that may be applicable;

| (c) | the fishing vessel which declared having caught the fish had authorisation to fish in the areas declared; |
| --- | --- |

(c)

the fishing vessel which declared having caught the fish had authorisation to fish in the areas declared;

| (d) | the presence of the fishing vessel in the area of catch declared has been verified according to VMS data. |
| --- | --- |

(d)

the presence of the fishing vessel in the area of catch declared has been verified according to VMS data.

2.   Landing or transhipment operations may only start after authorisation has been given by the competent authorities of the port Member State. Such authorisation shall only be given if the confirmation from the flag state referred to in paragraph 1 has been received.

3.   By way of derogation from paragraph 2, the competent authorities of the port Member State may authorise all or part of a landing in the absence of the confirmation referred to in paragraph 1, but in such cases they shall keep the fish concerned in storage under their control. The fish shall only be released to be sold, taken over or transported once the confirmation referred to in paragraph 1 has been received. If the confirmation has not been received within 14 days of the landing the competent authorities of the port Member State may confiscate and dispose of the fish in accordance with national rules.

4.   The competent authorities of the port Member State shall without delay notify their decision on whether or not to authorise the landing or transhipment to the master and shall inform the NEAFC Secretary thereof.

5.   Detailed rules on the authorisation to land or tranship under this Article shall be adopted in accordance with the procedure laid down in Articles 46 to 49.

Article 26

Port inspections

1.   Each Member State shall carry out inspections of at least 15 % of landings or transhipments in its ports during each reporting year.

2.   Inspections shall involve the monitoring of the entire discharge or transhipment and include a cross-check between the quantities by species recorded in the prior notification of landing and the quantities by species landed or transhipped. When the landing or transhipment has been completed, the inspector shall verify and note the quantities by species of fish remaining on board.

3.   National inspectors shall make all possible efforts to avoid delaying a vessel unduly and to ensure that the vessel suffers the minimum interference and inconvenience and that degradation of the quality of the fish is avoided.

4.   The port Member State may invite inspectors of other Contracting Parties to accompany their own inspectors and observe the inspection of landings or transhipment operations of fishery resources caught by fishing vessels flying the flag of another Contracting Party.

Article 27

Inspection reports

1.   Each inspection shall be documented by the completion of an inspection report using the form established in accordance with Article 50(2).

2.   The master may add his comments to the inspection report, which shall be signed by the inspector and the master at the end of the inspection. A copy of the inspection report shall be given to the master of the fishing vessel.

3.   A copy of each inspection report shall be transmitted without delay to the flag state of the inspected fishing vessel, to the flag state or states of the donor vessels where the vessel has engaged in transhipment operations, to the Commission or the body designated by it and to the NEAFC Secretary. The original or a certified copy of each inspection report shall be forwarded on request to the flag state of the inspected vessel.

CHAPTER V

INFRINGEMENTS

Article 28

Scope

Without prejudice to Regulation (EC) No 1224/2009 and to Regulation (EC) No 1005/2008 the provisions set out in this Chapter shall apply to EU fishing vessels and to fishing vessels flying the flag of another Contracting Party used or intended for use for fishing activities carried out in respect of fishery resources in the Regulatory Area.

Article 29

Infringement procedures

1.   Where inspectors find that there are clear grounds for believing that a fishing vessel has engaged in any activity contrary to the conservation and management measures adopted by NEAFC they shall:

| (a) | record the infringement in the report referred to in Articles 19(2), 20(9) or 27; |
| --- | --- |

(a)

record the infringement in the report referred to in Articles 19(2), 20(9) or 27;

| (b) | take all necessary measures to ensure security and continuity of the evidence. An identification mark may be affixed securely to any part of the fishing gear which appears to the inspector to be or to have been in contravention of applicable measures; |
| --- | --- |

(b)

take all necessary measures to ensure security and continuity of the evidence. An identification mark may be affixed securely to any part of the fishing gear which appears to the inspector to be or to have been in contravention of applicable measures;

| (c) | attempt immediately to communicate with an inspector or designated authority of the flag state of the inspected fishing vessel; |
| --- | --- |

(c)

attempt immediately to communicate with an inspector or designated authority of the flag state of the inspected fishing vessel;

| (d) | transmit the inspection report promptly to the Commission or the body designated by it. |
| --- | --- |

(d)

transmit the inspection report promptly to the Commission or the body designated by it.

2.   The Member State carrying out the inspection shall communicate in writing the details of the infringement to the designated authority of the flag state of the inspected vessel and to the Commission or the body designated by it and, whenever possible, shall do so during the first working day following the start of the inspection.

3.   The Member State carrying out the inspection shall send without delay the original of the surveillance or inspection report with any supporting documents to the competent authorities of the flag state of the inspected fishing vessel as well as a copy to the Commission or the body designated by it, which shall forward a copy to the NEAFC Secretary.

Article 30

Follow-up in the case of infringement

1.   Where a Member State is notified by another Contracting Party or another Member State of an infringement committed by a fishing vessel flying its flag, it shall take prompt action in conformity with its national law to obtain and consider the evidence of the infringement and to conduct any further investigation necessary for the follow-up to the infringement and, whenever possible, to inspect the fishing vessel concerned.

2.   Member States shall designate the competent authorities which are to receive evidence of infringement and shall inform the Commission or the body designated by it of the address of those authorities and of any change in this information. The Commission or the body designated by it shall subsequently forward the information to the NEAFC Secretary.

Article 31

Serious infringements

For the purpose of this Regulation, the following infringements shall be considered to be serious:

| (a) | fishing without a valid authorisation issued by the flag state; |
| --- | --- |

(a)

fishing without a valid authorisation issued by the flag state;

| (b) | fishing without quota or after its exhaustion; |
| --- | --- |

(b)

fishing without quota or after its exhaustion;

| (c) | use of prohibited fishing gear; |
| --- | --- |

(c)

use of prohibited fishing gear;

| (d) | serious misrecording of catches; |
| --- | --- |

(d)

serious misrecording of catches;

| (e) | repeated failure to comply with Articles 9 or 11; |
| --- | --- |

(e)

repeated failure to comply with Articles 9 or 11;

| (f) | landing or transhipping in a port not designated in accordance with Article 23; |
| --- | --- |

(f)

landing or transhipping in a port not designated in accordance with Article 23;

| (g) | failure to comply with Article 24; |
| --- | --- |

(g)

failure to comply with Article 24;

| (h) | landing or transhipment without authorisation of the port state as referred to in Article 25; |
| --- | --- |

(h)

landing or transhipment without authorisation of the port state as referred to in Article 25;

| (i) | preventing an inspector from carrying out his duties; |
| --- | --- |

(i)

preventing an inspector from carrying out his duties;

| (j) | directed fishing for a stock which is subject to a moratorium or for which fishing is prohibited; |
| --- | --- |

(j)

directed fishing for a stock which is subject to a moratorium or for which fishing is prohibited;

| (k) | falsifying or concealing the markings, identity or registration of a fishing vessel; |
| --- | --- |

(k)

falsifying or concealing the markings, identity or registration of a fishing vessel;

| (l) | concealing, tampering with or disposing of evidence relating to an investigation; |
| --- | --- |

(l)

concealing, tampering with or disposing of evidence relating to an investigation;

| (m) | multiple violations which together constitute a serious disregard of conservation and management measures; |
| --- | --- |

(m)

multiple violations which together constitute a serious disregard of conservation and management measures;

| (n) | engaging in transhipment or joint fishing operations with vessels of a non-Contracting Party which has not been accorded the status of a cooperating non-Contracting Party by NEAFC; |
| --- | --- |

(n)

engaging in transhipment or joint fishing operations with vessels of a non-Contracting Party which has not been accorded the status of a cooperating non-Contracting Party by NEAFC;

| (o) | supplying any provisions, fuel or other services to vessels that have been placed on the list referred to in Article 44. |
| --- | --- |

(o)

supplying any provisions, fuel or other services to vessels that have been placed on the list referred to in Article 44.

Article 32

Follow-up in the case of serious infringements

1.   If an inspector considers that there are clear grounds for believing that a fishing vessel has committed a serious infringement under Article 31, that inspector shall promptly notify that infringement to the Commission or the body designated by it, the competent authorities of the flag state of the inspected fishing vessel and the flag state or states of the donor vessels where the inspected vessel has engaged in transhipment operations, in accordance with Article 29(3), and shall also transmit a copy to the NEAFC Secretary.

2.   In order to preserve the evidence, the inspector shall take all necessary measures to ensure the security and continuity thereof whilst minimising inconvenience to the vessel and interference with its operation.

3.   The inspector shall be entitled to remain on board the fishing vessel for the period necessary to provide information on the infringement to the duly authorised inspector referred to in Article 33, or until receiving a reply from the flag state requesting him to leave the fishing vessel.

Article 33

Follow-up in the case of serious infringements by an EU fishing vessel

1.   Flag Member States shall respond to the notification referred to in Article 32(1) without delay and shall ensure that the fishing vessel concerned is inspected within 72 hours by an inspector duly authorised in relation to the infringement. The duly authorised inspector shall board the fishing vessel concerned and examine the evidence of the suspected infringement established by the inspector, and forward the results of the examination as quickly as possible to the competent authority in the flag Member State and to the Commission or the body designated by it.

2.   Following notification of the results of the examination referred to in paragraph 1, flag Member States shall, if the evidence so warrants, require the fishing vessel to proceed immediately, and in any case within 24 hours, to a port designated by that flag Member State, for a thorough inspection under its authority.

3.   The flag Member State may authorise the inspecting state to bring without delay the fishing vessel to a port designated by the flag Member State.

4.   If the fishing vessel is not called to port, the flag Member State must provide due justification in a timely manner to the Commission or the body designated by it and to the inspecting state. The Commission or the body designated by it shall forward such justification to the NEAFC Secretary.

5.   Where a fishing vessel is required to proceed to port for a thorough inspection pursuant to paragraphs 2 or 3, a NEAFC inspector from another Contracting Party may, subject to the consent of the flag Member State of the fishing vessel, board and remain on board the fishing vessel as it proceeds to port, and may be present during the inspection of the fishing vessel in port.

6.   Flag Member States shall inform promptly the Commission or the body designated by it of the outcome of the thorough inspection and of the measures that they have adopted as a result of the infringement.

7.   The detailed rules for the implementation of this Article shall be determined in accordance with Article 50(2).

Article 34

Reporting and follow-up of infringements

1.   By 15 February each year, Member States shall report to the Commission or the body designated by it on the status of the proceedings concerning infringements of the conservation and management measures adopted by NEAFC which were committed during the previous calendar year. The infringements shall continue to be listed in each subsequent report until the proceedings are concluded in accordance with the relevant provisions of national law. The Commission or the body designated by it shall forward the reports to the NEAFC Secretary before 1 March of the same year.

2.   The report referred to in paragraph 1 shall indicate the current status of the proceedings and in particular whether the case is pending, under appeal or still under investigation. The report shall describe in specific terms any sanctions imposed, stating in particular the level of fines, the value of forfeited fish and/or gear and any written warnings given and, if no action has been taken, it shall state the reasons thereof.

Article 35

Treatment of inspection reports

Without prejudice to Article 77 of Regulation (EC) No 1224/2009, Member States shall collaborate with each other and with other Contracting Parties in order to facilitate judicial or other proceedings arising from a report submitted by an inspector under the Scheme, subject to the rules governing the admissibility of evidence in domestic judicial or other systems.

Article 36

Reports on surveillance and inspection activities

1.   Each Member State shall report to the Commission or the body designated by it by 15 February each year for the previous calendar year:

| (a) | the number of inspections it has carried out under Articles 19, 20 and 26, specifying the number of inspections on the vessels of each Contracting Party and, where an infringement has been committed, the date and position of the inspection of the individual vessel concerned and the nature of the infringement; |
| --- | --- |

(a)

the number of inspections it has carried out under Articles 19, 20 and 26, specifying the number of inspections on the vessels of each Contracting Party and, where an infringement has been committed, the date and position of the inspection of the individual vessel concerned and the nature of the infringement;

| (b) | the number of hours flown and the number of days at sea on NEAFC patrols, the number of sightings of both Contracting Party vessels and non-Contracting Party vessels, and the list of individual vessels for which a surveillance report has been completed. |
| --- | --- |

(b)

the number of hours flown and the number of days at sea on NEAFC patrols, the number of sightings of both Contracting Party vessels and non-Contracting Party vessels, and the list of individual vessels for which a surveillance report has been completed.

2.   The Commission or the body designated by it shall compile a Union report on the basis of the reports of the Member States. It shall send the Union report to the NEAFC Secretary by 1 March each year.

CHAPTER VI

MEASURES TO PROMOTE COMPLIANCE BY NON-CONTRACTING PARTY FISHING VESSELS

Article 37

Scope

1.   This Chapter shall apply to non-Contracting Parties’ fishing vessels used or intended for use for fishing activities carried out in respect of fishery resources in the Convention Area.

2.   This Chapter shall be without prejudice to Regulation (EC) No 1224/2009 and to Regulation (EC) No 1005/2008.

Article 38

Sightings and identifications of non-Contracting Party vessels

1.   Member States shall transmit without delay to the Commission or the body designated by it any information regarding non-Contracting Party vessels sighted or otherwise identified as engaging in fishing activities in the Convention Area. The Commission or the body designated by it shall inform promptly the NEAFC Secretary and all other Member States of each sighting report it receives.

2.   The Member State which sighted the non-Contracting Party vessel shall attempt to inform that vessel without delay that it has been sighted or otherwise identified as engaging in fishing activities in the Convention Area and is consequently presumed, unless its flag state has been accorded the status of cooperating non-Contracting Party by NEAFC, to be undermining the NEAFC conservation and management measures.

3.   In the case of a non-Contracting Party vessel sighted or otherwise identified as engaging in transhipment activities, the presumption of undermining the NEAFC conservation and management measures shall apply to any other non-Contracting Party vessel that has been identified as having engaged in such activities with that vessel.

Article 39

Inspections at sea

1.   NEAFC inspectors shall request permission to board and inspect non-Contracting Party vessels sighted or otherwise identified by a Contracting Party as engaging in fishing activities in the Convention Area. If the master consents to the boarding and inspection of the vessel, the inspection shall be documented by the completion of an inspection report, as referred to Article 20(9).

2.   NEAFC inspectors shall without delay transmit a copy of the inspection report to the Commission or the body designated by it, to the NEAFC Secretary and to the master of the non-Contracting Party vessel. Where the evidence in that report so warrants, a Member State may take such action as may be appropriate in accordance with international law. Member States are encouraged to examine whether their national measures are appropriate for the exercise of jurisdiction over such vessels.

3.   If the master does not consent to the boarding and inspection of his vessel or does not fulfil any one of the obligations laid down in Article 21(a) to (d), the vessel shall be presumed to have engaged in illegal, unreported and unregulated fishing activities (IUU activities). The NEAFC Inspector shall inform without delay the Commission or the body designated by it thereof. In turn the Commission or the body designated by it shall promptly inform the NEAFC Secretary thereof.

Article 40

Entry into port

1.   The master of a non-Contracting Party fishing vessel may only call into a port designated in accordance with Article 23. The master intending to call into a port of a Member State shall notify the competent authorities of the port Member State in accordance with the provisions of Article 24. The port Member State concerned shall forward this information without delay to the flag state of the vessel and to the Commission or the body designated by it. In turn, the Commission or the body designated by it shall forward this information to the NEAFC Secretary.

2.   The port Member State shall prohibit the entry into its ports of vessels that have not given the required prior notification of entry into port as referred to in Article 24.

Article 41

Inspections in port

1.   Member States shall ensure that all non-Contracting Party vessels entering one of their ports are inspected. The vessel shall not be allowed to land or tranship any fish until this inspection has been completed. Each inspection shall be documented by the completion of an inspection report as provided for in Article 27. Where the master of the vessel has failed to fulfil any one of the obligations laid down in Article 21(a) to (d), the vessel shall be presumed to have engaged in IUU activities.

2.   Information on the results of all inspections of non-Contracting Party vessels conducted in the ports of Member States, and concerning subsequent action, shall immediately be transmitted to the Commission or the body designated by it, which shall forward such information to the NEAFC Secretary.

Article 42

Landings and transhipments

1.   Landings and transhipments may only start after authorisation has been given by the competent authorities of the port state.

2.   Landings and transhipments from a non-Contracting Party vessel which has been inspected pursuant to Article 41 shall be prohibited in the ports and waters of all Member States if such an inspection reveals that the vessel has species on board which are subject to recommendations established under the Convention, unless the master of the vessel provides satisfactory evidence to the competent authorities proving that the fish were caught outside the Regulatory Area or in compliance with all relevant recommendations established under the Convention.

3.   The vessel shall not be authorised to engage in landings or transhipments if the flag state of the vessel, or the flag state or states of the donor vessels, where the vessel has engaged in transhipment operations, does not provide the confirmation referred to in Article 25.

4.   Furthermore, landings and transhipments shall be prohibited where the master of the vessel has failed to fulfil any one of the obligations laid down in Article 21(a) to (d).

Article 43

Reports on non-Contracting Parties activities

1.   Each Member State shall report to the Commission or the body designated by it by 15 February each year for the previous calendar year:

| (a) | the number of inspections of non-Contracting Party vessels that it conducted under this Scheme at sea or in its ports, the names of the vessels inspected and their respective flag states, the dates of the inspections and the names of any ports where the inspections were conducted, and the results of such inspections; and |
| --- | --- |

(a)

the number of inspections of non-Contracting Party vessels that it conducted under this Scheme at sea or in its ports, the names of the vessels inspected and their respective flag states, the dates of the inspections and the names of any ports where the inspections were conducted, and the results of such inspections; and

| (b) | where fish are landed or transhipped following an inspection pursuant to this Scheme, the evidence provided pursuant to Article 42. |
| --- | --- |

(b)

where fish are landed or transhipped following an inspection pursuant to this Scheme, the evidence provided pursuant to Article 42.

2.   In addition to surveillance reports and information on inspections, Member States may at any time submit to the Commission or the body designated by it any further information which might be relevant for the identification of non-Contracting Party vessels that might be carrying out IUU activities in the Convention Area.

3.   On the basis of this information, the Commission or the body designated by it shall send a global report on non-Contracting Parties’ activities to the NEAFC Secretary by 1 March each year.

Article 44

Vessels engaged in IUU activities

1.   Member States shall ensure that vessels appearing in the provisional list of vessels engaged in IUU activities established by NEAFC (‘A’ list) are:

| (a) | inspected in accordance with the provisions of Article 41 when they enter their ports; |
| --- | --- |

(a)

inspected in accordance with the provisions of Article 41 when they enter their ports;

| (b) | not authorised to land or tranship in their ports or in the waters under their jurisdiction; |
| --- | --- |

(b)

not authorised to land or tranship in their ports or in the waters under their jurisdiction;

| (c) | not given assistance by fishing vessels, support vessels, refuel vessels, the mother-ship and cargo vessels flying their flag or permitted to participate in any transhipment or joint fishing operation with such vessels; |
| --- | --- |

(c)

not given assistance by fishing vessels, support vessels, refuel vessels, the mother-ship and cargo vessels flying their flag or permitted to participate in any transhipment or joint fishing operation with such vessels;

| (d) | not supplied with provisions, fuel or other services. |
| --- | --- |

(d)

not supplied with provisions, fuel or other services.

2.   The provisions laid down in paragraph 1(b) and (d) shall not be applied to any vessel appearing on the ‘A’ list where a recommendation has been made to NEAFC that the vessel in question should be removed from the ‘A’ list.

CHAPTER VII

FINAL PROVISIONS

Article 45

Confidentiality

1.   In addition to the obligations laid down in Articles 112 and 113 of Regulation (EC) No 1224/2009, Member States shall ensure confidential treatment of electronic reports and messages transmitted to and received from the NEAFC Secretary pursuant to Articles 11, 12 and 19(1).

2.   The detailed rules for the implementation of this Article shall be determined in accordance with Article 50(2).

Article 46

Delegation of powers

1.   The Commission may adopt, by means of delegated acts in accordance with Article 47 and subject to the conditions of Articles 48 and 49 the detailed rules for the application of Article 25, as well as the list of fishery resources referred to in Article 10(1) and detailed rules on the notification and cancellation procedures, including periods, as referred to in the second subparagraph of Article 24(4).

2.   When adopting such delegated acts, the Commission shall act in accordance with the provisions of this Regulation.

Article 47

Exercise of the delegation

1.   The power to adopt delegated acts referred to in Article 46 shall be conferred on the Commission for a period of 3 years from 1 January 2011. The Commission shall make a report in respect of the delegated powers at the latest 6 months before the end of the three-year period. The delegation of power shall be automatically extended for periods of an identical duration, unless the European Parliament or the Council revokes it in accordance with Article 48.

2.   As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.

3.   The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in Articles 48 and 49.

Article 48

Revocation of the delegation

1.   The delegation of power referred to in Article 46 may be revoked at any time by the European Parliament or by the Council.

2.   The institution which has commenced an internal procedure for deciding whether to revoke the delegation of power shall endeavour to inform the other institution and the Commission within a reasonable time before the final decision is taken, indicating the delegated powers which could be subject to revocation and possible reasons for a revocation.

3.   The decision of revocation shall put an end to the delegation of the powers specified in that decision. It shall take effect immediately or at a later date specified therein. It shall not affect the validity of the delegated acts already in force. It shall be published in the Official Journal of the European Union.

Article 49

Objections to delegated acts

1.   The European Parliament or the Council may object to a delegated act within a period of 2 months from the date of notification.

At the initiative of the European Parliament or the Council this period shall be extended by 2 months.

2.   If, on expiry of that period, neither the European Parliament nor the Council has objected to the delegated act it shall be published in the Official Journal of the European Union and shall enter into force at the date stated therein.

The delegated act may be published in the Official Journal of the European Union and enter into force before the expiry of that period if the European Parliament and the Council have both informed the Commission of their intention not to raise objections.

3.   If the European Parliament or the Council objects to a delegated act, it shall not enter into force. The institution which objects shall state the reasons for objecting to the delegated act.

Article 50

Implementation

1.   The Commission shall be assisted by a Management Committee for Fisheries and Aquaculture.

2.   Where reference is made to this paragraph, Articles 4 and 7 of Decision 1999/468/EC shall apply. The period referred to in Article 4(3) of Decision 1999/468/EC shall be set at 3 months.

Article 51

Procedure for amendments

As far as is necessary, in order to incorporate into Union law amendments to the existing provisions of the Scheme which become obligatory for the Union, the Commission may amend the provisions of this Regulation by means of delegated acts in accordance with Article 47 and subject to the conditions set out in Articles 48 and 49, concerning:

| (a) | participation of Contracting Parties in the fishery in the Regulatory area as referred to in Article 5; |
| --- | --- |

(a)

participation of Contracting Parties in the fishery in the Regulatory area as referred to in Article 5;

| (b) | removal and disposal of fixed gear and the retrieval of lost gear as referred to in Articles 6 and 7; |
| --- | --- |

(b)

removal and disposal of fixed gear and the retrieval of lost gear as referred to in Articles 6 and 7;

| (c) | use of VMS as referred to in Article 11; |
| --- | --- |

(c)

use of VMS as referred to in Article 11;

| (d) | cooperation and communication of information to the NEAFC Secretary as referred to in Article 12; |
| --- | --- |

(d)

cooperation and communication of information to the NEAFC Secretary as referred to in Article 12;

| (e) | requirements for separate stowage and labelling of frozen fishery resources as referred to in Articles 14 and 15; |
| --- | --- |

(e)

requirements for separate stowage and labelling of frozen fishery resources as referred to in Articles 14 and 15;

| (f) | assignment of NEAFC inspectors as referred to in Article 16; |
| --- | --- |

(f)

assignment of NEAFC inspectors as referred to in Article 16;

| (g) | measures to promote compliance with the Scheme by non-Contracting Party fishing vessels under Chapter VI; |
| --- | --- |

(g)

measures to promote compliance with the Scheme by non-Contracting Party fishing vessels under Chapter VI;

| (h) | the list of regulated resources set out in the Annex. |
| --- | --- |

(h)

the list of regulated resources set out in the Annex.

When adopting such delegated acts, the Commission shall act in accordance with the provisions of this Regulation.

Article 52

Repeal

Regulation (EC) No 2791/1999 is hereby repealed.

Article 53

Entry into force

This Regulation shall enter into force on the day following its publication in the Official Journal of the European Union.

Official Journal of the European Union

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Strasbourg, 15 December 2010.

For the European Parliament

The President

J. BUZEK

For the Council

The President

O. CHASTEL

---

(1)  Opinion of 17 March 2010 (not yet published in the Official Journal).

1

(2)  Position of the European Parliament of 19 October 2010 (not yet published in the Official Journal) and decision of the Council of 29 November 2010.

2

(3)  
  OJ L 227, 12.8.1981, p. 21.

3

(4)  
  OJ L 22, 26.1.2009, p. 1.

4

(5)  
  OJ L 343, 22.12.2009, p. 1.

5

(6)  
  OJ L 184, 17.7.1999, p. 23.

6

(7)  
  OJ L 337, 30.12.1999, p. 1.

7

(8)  
  OJ L 56, 2.3.2005, p. 8.

8

(9)  
  OJ L 261, 20.10.1993, p. 1.

9

(10)  
  OJ L 286, 29.10.2008, p. 1.

10

---

ANNEX

REGULATED RESOURCES

A)   Pelagic and oceanic species

| Stock (common name) | FAO code | Scientific Name | ICES subareas and divisions |
| --- | --- | --- | --- |
| Redfish | REB | Sebastes mentella | I, II, V, XII, XIV |
| Norwegian Spring Spawning Herring (Atlanto Scandian) | HER | Clupea harengus | I, II |
| Blue whiting | WHB | Micromesistius poutassou | IIa, IVa, Vb, VI, VII, XII, XIV |
| Mackerel | MAC | Scomber scombrus | IIa, IV, V, VI, VII, XII |
| Haddock | HAD | Melanogrammus aeglefinus | VIb |

Stock (common name)

FAO code

Scientific Name

ICES subareas and divisions

Redfish

REB

Sebastes mentella

I, II, V, XII, XIV

Norwegian Spring Spawning Herring (Atlanto Scandian)

HER

Clupea harengus

I, II

Blue whiting

WHB

Micromesistius poutassou

IIa, IVa, Vb, VI, VII, XII, XIV

Mackerel

MAC

Scomber scombrus

IIa, IV, V, VI, VII, XII

Haddock

HAD

Melanogrammus aeglefinus

VIb

B)   Deep-Sea Species

| Stock (common name) | FAO code | Scientific Name | ICES subareas |
| --- | --- | --- | --- |
| Baird’s smoothhead | ALC | Alepocehalus bairdii | I to XIV |
| Risso’s smoothhead | PHO | Alepocephalus rostratus | I to XIV |
| Blue antimora (Blue hake) | ANT | Antimora rostrata | I to XIV |
| Black scabbardfish | BSF | Aphanopus carbo | I to XIV |
| Iceland catshark | API | Apristurus spp. | I to XIV |
| Greater silver smelt | ARG | Argentina silus | I to XIV |
| Alfonsinos | ALF | Beryx spp. | I to XIV |
| Tusk | USK | Brosme brosme | I to XIV |
| Gulper shark | GUP | Centrophorus granulosus | I to XIV |
| Leafscale gulper shark | GUQ | Centrophorus squamosus | I to XIV |
| Black dogfish | CFB | Centroscyllium fabricii | I to XIV |
| Portuguese dogfish | CYO | Centroscymnus coelolepis | I to XIV |
| Longnose velvet dogfish | CYP | Centroscymnus crepidater | I to XIV |
| Deep-water red crab | KEF | Chaceon (Geryon) affinis | I to XIV |
| Rabbit fish (Rattail) | CMO | Chimaera monstrosa | I to XIV |
| Frilled shark | HXC | Chlamydoselachus anguineus | I to XIV |
| Conger eel | COE | Conger conger | I to XIV |
| Roundnose grenadier | RNG | Coryphaenoides rupestris | I to XIV |
| Kitefin shark | SCK | Dalatias licha | I to XIV |
| Birdbeak dogfish | DCA | Deania calceus | I to XIV |
| Black (Deep-water) cardinal fish | EPI | Epigonus telescopus | I to XIV |
| Greater lanternshark | SHL | Etmopterus princeps | I to XIV |
| Velvet belly | SHL | Etmopterus spinax | I to XIV |
| Blackmouth dogfish | SHO | Galeus melastomus | I to XIV |
| Mouse catshark | GAM | Galeus murinus | I to XIV |
| Bluemouth (Blue mouth redfish) | BRF | Helicolenus dactylopterus | I to XIV |
| Bluntnose six-gilled shark | SBL | Hexanchus griseus | I to XIV |
| Orange roughy | ORY | Hoplostethus atlanticus | I to XIV |
| Silver roughy (Pink) | HPR | Hoplostethus mediterraneus | I to XIV |
| Large-eyed rabbit fish (Ratfish) | CYH | Hydrolagus mirabilis | I to XIV |
| Silver scabbard fish (Cutlass fish) | SFS | Lepidopus caudatus | I to XIV |
| Eelpout | ELP | Lycodes esmarkii | I to XIV |
| Roughhead grenadier (Rough rattail) | RHG | Macrourus berglax | I to XIV |
| Blue ling | BLI | Molva dypterygia | I to XIV |
| Ling | LIN | Molva molva | I to XIV |
| Common mora | RIB | Mora moro | I to XIV |
| Sailfin roughshark (Sharpback shark) | OXN | Oxynotus paradoxus | I to XIV |
| Red (blackspot) seabream | SBR | Pagellus bogaraveo | I to XIV |
| Forkbeards | GFB | Phycis spp. | I to XIV |
| Wreckfish | WRF | Polyprion americanus | I to XIV |
| Round skate | RJY | Raja fyllae | I to XIV |
| Arctic skate | RJG | Raja hyperborea | I to XIV |
| Norwegian skate | JAD | Raja nidarosiensis | I to XIV |
| Greenland halibut | GHL | Rheinhardtius hippoglossoides | I to XIV |
| Straightnose rabbitfish | RCT | Rhinochimaera atlantica | I to XIV |
| Knifetooth dogfish | SYR | Scymnodon ringens | I to XIV |
| Small redfish (Norway haddock) | SFV | Sebastes viviparus | I to XIV |
| Greenland shark | GSK | Somniosus microcephalus | I to XIV |
| Spiny (Deep-sea) Scorpionfish | TJX | Trachyscorpia cristulata | I to XIV |

Stock (common name)

FAO code

Scientific Name

ICES subareas

Baird’s smoothhead

ALC

Alepocehalus bairdii

I to XIV

Risso’s smoothhead

PHO

Alepocephalus rostratus

I to XIV

Blue antimora (Blue hake)

ANT

Antimora rostrata

I to XIV

Black scabbardfish

BSF

Aphanopus carbo

I to XIV

Iceland catshark

API

Apristurus spp.

I to XIV

Greater silver smelt

ARG

Argentina silus

I to XIV

Alfonsinos

ALF

Beryx spp.

I to XIV

Tusk

USK

Brosme brosme

I to XIV

Gulper shark

GUP

Centrophorus granulosus

I to XIV

Leafscale gulper shark

GUQ

Centrophorus squamosus

I to XIV

Black dogfish

CFB

Centroscyllium fabricii

I to XIV

Portuguese dogfish

CYO

Centroscymnus coelolepis

I to XIV

Longnose velvet dogfish

CYP

Centroscymnus crepidater

I to XIV

Deep-water red crab

KEF

Chaceon (Geryon) affinis

I to XIV

Rabbit fish (Rattail)

CMO

Chimaera monstrosa

I to XIV

Frilled shark

HXC

Chlamydoselachus anguineus

I to XIV

Conger eel

COE

Conger conger

I to XIV

Roundnose grenadier

RNG

Coryphaenoides rupestris

I to XIV

Kitefin shark

SCK

Dalatias licha

I to XIV

Birdbeak dogfish

DCA

Deania calceus

I to XIV

Black (Deep-water) cardinal fish

EPI

Epigonus telescopus

I to XIV

Greater lanternshark

SHL

Etmopterus princeps

I to XIV

Velvet belly

SHL

Etmopterus spinax

I to XIV

Blackmouth dogfish

SHO

Galeus melastomus

I to XIV

Mouse catshark

GAM

Galeus murinus

I to XIV

Bluemouth (Blue mouth redfish)

BRF

Helicolenus dactylopterus

I to XIV

Bluntnose six-gilled shark

SBL

Hexanchus griseus

I to XIV

Orange roughy

ORY

Hoplostethus atlanticus

I to XIV

Silver roughy (Pink)

HPR

Hoplostethus mediterraneus

I to XIV

Large-eyed rabbit fish (Ratfish)

CYH

Hydrolagus mirabilis

I to XIV

Silver scabbard fish (Cutlass fish)

SFS

Lepidopus caudatus

I to XIV

Eelpout

ELP

Lycodes esmarkii

I to XIV

Roughhead grenadier (Rough rattail)

RHG

Macrourus berglax

I to XIV

Blue ling

BLI

Molva dypterygia

I to XIV

Ling

LIN

Molva molva

I to XIV

Common mora

RIB

Mora moro

I to XIV

Sailfin roughshark (Sharpback shark)

OXN

Oxynotus paradoxus

I to XIV

Red (blackspot) seabream

SBR

Pagellus bogaraveo

I to XIV

Forkbeards

GFB

Phycis spp.

I to XIV

Wreckfish

WRF

Polyprion americanus

I to XIV

Round skate

RJY

Raja fyllae

I to XIV

Arctic skate

RJG

Raja hyperborea

I to XIV

Norwegian skate

JAD

Raja nidarosiensis

I to XIV

Greenland halibut

GHL

Rheinhardtius hippoglossoides

I to XIV

Straightnose rabbitfish

RCT

Rhinochimaera atlantica

I to XIV

Knifetooth dogfish

SYR

Scymnodon ringens

I to XIV

Small redfish (Norway haddock)

SFV

Sebastes viviparus

I to XIV

Greenland shark

GSK

Somniosus microcephalus

I to XIV

Spiny (Deep-sea) Scorpionfish

TJX

Trachyscorpia cristulata

I to XIV

Appendix

Statements on Article 51

‘The European Parliament, the Council and the Commission note that any of the provisions of a non-essential character of the basic legislative act, which now are listed under Article 51 of the Regulation (delegation of powers), can become at any time in the future a significant element of the existing NEAFC control scheme from a political point of view, in which case the European Parliament, the Council and the Commission recall that either of the legislators, the Council or the European Parliament, can immediately exercise either the right to object to a draft Commission delegated act or the right to revoke the delegated powers as provided under Article 48 and Article 49 of the Regulation respectively.’

‘The Council and the Parliament agree that the inclusion of any provision of the NEAFC control scheme into this Regulation as a non-essential element, now listed under Article 51, does not imply per se that such provisions will automatically be considered by the legislators to be of a non-essential character in any future Regulations.’

‘The European Parliament, the Council and the Commission declare that the provisions of this Regulation shall be without prejudice to any future position of the institutions as regards the implementation of Article 290 TFEU or individual legislative acts containing such provisions.’

---

| 31.12.2010 | EN | Official Journal of the European Union | L 348/34 |
| --- | --- | --- | --- |

31.12.2010

EN

Official Journal of the European Union

L 348/34

---

REGULATION (EU) No 1237/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 15 December 2010

amending Council Regulation (EC) No 2187/2005 as regards the prohibition of highgrading and restrictions on fishing for flounder and turbot in the Baltic Sea, the Belts and the Sound

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 43(2) thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national parliaments,

Having regard to the opinion of the European Economic and Social Committee (1),

Acting in accordance with the ordinary legislative procedure (2),

Whereas:

| (1) | Council Regulation (EC) No 2187/2005 (3) lays down specific technical measures for the conservation of fishery resources in the Baltic Sea, the Belts and the Sound, and in particular restrictions on fishing as regards certain species, mesh sizes and areas. |
| --- | --- |

(1)

Council Regulation (EC) No 2187/2005 (3) lays down specific technical measures for the conservation of fishery resources in the Baltic Sea, the Belts and the Sound, and in particular restrictions on fishing as regards certain species, mesh sizes and areas.

| (2) | Council Regulation (EC) No 1226/2009 of 20 November 2009 fixing the fishing opportunities and associated conditions for certain fish stocks and groups of fish stocks applicable in the Baltic Sea for 2010 (4) provides for the prohibition of highgrading and for restrictions on fishing for flounder and turbot. |
| --- | --- |

(2)

Council Regulation (EC) No 1226/2009 of 20 November 2009 fixing the fishing opportunities and associated conditions for certain fish stocks and groups of fish stocks applicable in the Baltic Sea for 2010 (4) provides for the prohibition of highgrading and for restrictions on fishing for flounder and turbot.

| (3) | This prohibition and these restrictions are technical measures of a permanent nature which should no longer be included in the regulatory framework establishing annual fishing opportunities. From January 2011, they should therefore be incorporated into Regulation (EC) No 2187/2005. |
| --- | --- |

(3)

This prohibition and these restrictions are technical measures of a permanent nature which should no longer be included in the regulatory framework establishing annual fishing opportunities. From January 2011, they should therefore be incorporated into Regulation (EC) No 2187/2005.

| (4) | The term ‘Community’ used in the enacting terms of Regulation (EC) No 2187/2005 should be changed following the entry into force of the Treaty of Lisbon on 1 December 2009. |
| --- | --- |

(4)

The term ‘Community’ used in the enacting terms of Regulation (EC) No 2187/2005 should be changed following the entry into force of the Treaty of Lisbon on 1 December 2009.

| (5) | Regulation (EC) No 2187/2005 should therefore be amended accordingly. |
| --- | --- |

(5)

Regulation (EC) No 2187/2005 should therefore be amended accordingly.

| (6) | In order to ensure the continuous application of the measures provided for in this Regulation, it should enter into force on the day following its publication in the Official Journal of the European Union, |
| --- | --- |

(6)

In order to ensure the continuous application of the measures provided for in this Regulation, it should enter into force on the day following its publication in the Official Journal of the European Union,

HAVE ADOPTED THIS REGULATION:

Article 1

Regulation (EC) No 2187/2005 is hereby amended as follows:

| 1. | the following article is inserted:

  ‘Article 15a
  Prohibition of highgrading
  Any species which is subject to a quota and which is caught during fishing operations shall be brought aboard the vessel and subsequently landed unless this would be contrary to obligations laid down in Union fisheries regulations establishing technical, control and conservation measures in particular in this Regulation, in Regulation (EC) No 2371/2002 or in Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (*1).


  (*1)  
  OJ L 343, 22.12.2009, p. 1.’;" |
| --- | --- |

1.

the following article is inserted:

‘Article 15a

Prohibition of highgrading

Any species which is subject to a quota and which is caught during fishing operations shall be brought aboard the vessel and subsequently landed unless this would be contrary to obligations laid down in Union fisheries regulations establishing technical, control and conservation measures in particular in this Regulation, in Regulation (EC) No 2371/2002 or in Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (*1).

(*1)  
  OJ L 343, 22.12.2009, p. 1.’;"

*1

| 2. | the following article is inserted:

  ‘Article 18a
  Restrictions on fishing for flounder and turbot

  1.   The retention on board of the following species of fish shall be prohibited where they are caught within the geographical areas and during the periods mentioned below:







  Species | Geographical area | Period |
| --- | --- | --- | --- |
| Flounder (Platichthys flesus) | Subdivisions 26, 27, 28 and 29 south of 59° 30′ N | 15 February to 15 May |
| Subdivision 32 | 15 February to 31 May |
| Turbot (Psetta maxima) | Subdivisions 25, 26 and 28 south of 56° 50′ N | 1 June to 31 July |

2.

the following article is inserted:

‘Article 18a

Restrictions on fishing for flounder and turbot

1.   The retention on board of the following species of fish shall be prohibited where they are caught within the geographical areas and during the periods mentioned below:

Species

Geographical area

Period

Flounder (Platichthys flesus)

Subdivisions 26, 27, 28 and 29 south of 59° 30′ N

15 February to 15 May

Subdivision 32

15 February to 31 May

Turbot (Psetta maxima)

Subdivisions 25, 26 and 28 south of 56° 50′ N

1 June to 31 July

2.   By way of derogation from paragraph 1, when fishing with trawls, Danish seines or similar gears with a mesh size equal to or greater than 105 mm or with gillnets, entangling nets or trammel nets with a mesh size equal to or greater than 100 mm, by-catches of flounder and turbot may be retained on board and landed within a limit of 10 % by live weight of the total catch retained on board and landed during the periods of prohibition referred to in paragraph 1.’;

| 3. | in Article 26(1) and (2), the noun ‘Community’, or the corresponding adjective, is replaced by the noun ‘Union’, or the corresponding adjective, and any grammatical adjustments needed as a consequence of this replacement shall be made. |
| --- | --- |

3.

in Article 26(1) and (2), the noun ‘Community’, or the corresponding adjective, is replaced by the noun ‘Union’, or the corresponding adjective, and any grammatical adjustments needed as a consequence of this replacement shall be made.

Article 2

This Regulation shall enter into force on the day following its publication in the Official Journal of the European Union.

It shall apply from 1 January 2011.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Strasbourg, 15 December 2010.

For the European Parliament

The President

J. BUZEK

For the Council

The President

O. CHASTEL

---

(1)  Opinion of 15 September 2010 (not yet published in the Official Journal).

1

(2)  Position of the European Parliament of 23 November 2010 (not yet published in the Official Journal) and decision of the Council of 6 December 2010.

2

(3)  
  OJ L 349, 31.12.2005, p. 1.

3

(4)  
  OJ L 330, 16.12.2009, p. 1.

4

---

| 31.12.2010 | EN | Official Journal of the European Union | L 348/36 |
| --- | --- | --- | --- |

31.12.2010

EN

Official Journal of the European Union

L 348/36

---

REGULATION (EU) No 1238/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 15 December 2010

amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 207 thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national parliaments,

Acting in accordance with the ordinary legislative procedure (1),

Whereas:

| (1) | In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty-free treatment should be granted to pharmaceutical products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization, specified salts, esters and hydrates of such INNs, and designated pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals. |
| --- | --- |

(1)

In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty-free treatment should be granted to pharmaceutical products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization, specified salts, esters and hydrates of such INNs, and designated pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals.

| (2) | The results of the discussions, as set out in the Record of Discussions, were incorporated into the tariff schedules of the participants annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (GATT) 1994. |
| --- | --- |

(2)

The results of the discussions, as set out in the Record of Discussions, were incorporated into the tariff schedules of the participants annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (GATT) 1994.

| (3) | Participants concluded that representatives of World Trade Organization (WTO) members, party to the Record of Discussions, would meet under the auspices of the Council for Trade in Goods of the WTO, normally at least once every three years, to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination. |
| --- | --- |

(3)

Participants concluded that representatives of World Trade Organization (WTO) members, party to the Record of Discussions, would meet under the auspices of the Council for Trade in Goods of the WTO, normally at least once every three years, to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination.

| (4) | Three such reviews have taken place with the result that a certain number of additional INNs and pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals have been granted duty-free treatment, that some of those intermediates have been transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs has been expanded. |
| --- | --- |

(4)

Three such reviews have taken place with the result that a certain number of additional INNs and pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals have been granted duty-free treatment, that some of those intermediates have been transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs has been expanded.

| (5) | A fourth review was deemed appropriate and was launched in 2009. It concluded that a certain number of additional INNs and pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals should be granted duty-free treatment, that some of those intermediates already included in the pharmaceutical sectoral arrangement and its revisions should be transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. |
| --- | --- |

(5)

A fourth review was deemed appropriate and was launched in 2009. It concluded that a certain number of additional INNs and pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals should be granted duty-free treatment, that some of those intermediates already included in the pharmaceutical sectoral arrangement and its revisions should be transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded.

| (6) | Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (2) established the Combined Nomenclature (CN) and set out the conventional duty rates of the Common Customs Tariff. |
| --- | --- |

(6)

Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (2) established the Combined Nomenclature (CN) and set out the conventional duty rates of the Common Customs Tariff.

| (7) | Regulation (EEC) No 2658/87 should therefore be amended accordingly. |
| --- | --- |

(7)

Regulation (EEC) No 2658/87 should therefore be amended accordingly.

| (8) | In order to ensure that the measures provided for in this Regulation apply from 1 January 2011, it should enter into force on the day following that of its publication, |
| --- | --- |

(8)

In order to ensure that the measures provided for in this Regulation apply from 1 January 2011, it should enter into force on the day following that of its publication,

HAVE ADOPTED THIS REGULATION:

Article 1

Annexes 3, 4 and 6 of Section II of Part Three of Annex I to Regulation (EEC) No 2658/87 (Lists of pharmaceutical substances which qualify for duty-free treatment) are hereby amended as follows:

| 1. | As from 1 January 2011 the Union shall extend duty-free treatment to the INNs listed in Annex I. |
| --- | --- |

1.

As from 1 January 2011 the Union shall extend duty-free treatment to the INNs listed in Annex I.

| 2. | As from 1 January 2011 the list of prefixes and suffixes which, in combination with the INNs included in the pharmaceutical sectoral arrangement and its revisions, describe the salts, esters or hydrates of INNs which are also eligible for duty-free treatment, on condition that they are classifiable in the same six-digit HS subheading as the corresponding INN, shall be amended as set out in Annex II. |
| --- | --- |

2.

As from 1 January 2011 the list of prefixes and suffixes which, in combination with the INNs included in the pharmaceutical sectoral arrangement and its revisions, describe the salts, esters or hydrates of INNs which are also eligible for duty-free treatment, on condition that they are classifiable in the same six-digit HS subheading as the corresponding INN, shall be amended as set out in Annex II.

| 3. | As from 1 January 2011 the Union shall extend duty-free treatment to the pharmaceutical intermediates used in the production and manufacture of finished pharmaceuticals, listed in Annex III. |
| --- | --- |

3.

As from 1 January 2011 the Union shall extend duty-free treatment to the pharmaceutical intermediates used in the production and manufacture of finished pharmaceuticals, listed in Annex III.

| 4. | As from 1 January 2011 the pharmaceutical intermediates listed in Annex IV shall be withdrawn from the list of such compounds receiving duty-free treatment. |
| --- | --- |

4.

As from 1 January 2011 the pharmaceutical intermediates listed in Annex IV shall be withdrawn from the list of such compounds receiving duty-free treatment.

Article 2

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union.

It shall apply from 1 January 2011.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Strasbourg, 15 December 2010.

For the European Parliament

The President

J. BUZEK

For the Council

The President

O. CHASTEL

---

(1)  Position of the European Parliament of 23 November 2010 (not yet published in the Official Journal) and decision of the Council of 10 December 2010.

1

(2)  
  OJ L 256, 7.9.1987, p. 1.

2

---

ANNEX I

List of international non-proprietary names (INNs) to be added to the list of products receiving duty-free treatment included in Annex 3 to Annex I to Regulation (EEC) No 2658/87

| CN code | CAS RN | Name |
| --- | --- | --- |
| 2842 90 80 | 119175-48-3 | fermagate |
| 2843 90 90 | 759457-82-4 | padeliporfin |
| 2844 40 30 | 123748-56-1 | iodofiltic acid (



  ) |
| 2904 10 00 | 21668-77-9 | eprodisate |
| 2906 19 00 | 199798-84-0 | elocalcitol |
| 2909 30 90 | 24150-24-1 | terameprocol |
| 2916 19 95 | 81485-25-8 | peretinoin |
| 2916 39 00 | 51543-40-9 | tarenflurbil |
| 2918 19 98 | 174022-42-5 | bevirimat |
| 2919 90 00 | 258516-89-1 | fospropofol |
| 2920 90 85 | 163133-43-5 | naproxcinod |
| 2921 19 99 | 3687-18-1 | tramiprosate |
| 2922 19 85 | 68392-35-8 | afimoxifene |
| 2922 19 85 | 753449-67-1 | ronacaleret |
| 2922 29 00 | 433265-65-7 | faxeladol |
| 2922 50 00 | 121524-08-1 | amibegron |
| 2922 50 00 | 329773-35-5 | cinaciguat |
| 2922 50 00 | 643094-49-9 | fasobegron |
| 2923 10 00 | 856676-23-8 | choline fenofibrate |
| 2924 29 98 | 847353-30-4 | arbaclofen placarbil |
| 2924 29 98 | 194785-19-8 | bedoradrine |
| 2924 29 98 | 194085-75-1 | carisbamate |
| 2924 29 98 | 254750-02-2 | emricasan |
| 2924 29 98 | 355129-15-6 | eprotirome |
| 2924 29 98 | 402567-16-2 | firategrast |
| 2924 29 98 | 478296-72-9 | gabapentin enacarbil |
| 2924 29 98 | 15866-90-7 | incyclinide |
| 2924 29 98 | 202844-10-8 | indantadol |
| 2924 29 98 | 96847-55-1 | levomilnacipran |
| 2924 29 98 | 608137-32-2 | lisdexamfetamine |
| 2924 29 98 | 652990-07-3 | milveterol |
| 2924 29 98 | 181816-48-8 | ombrabulin |
| 2924 29 98 | 289656-45-7 | senicapoc |
| 2925 19 95 | 19171-19-8 | pomalidomide |
| 2928 00 90 | 22033-87-0 | olesoxime |
| 2928 00 90 | 2675-35-6 | sivifene |
| 2928 00 90 | 816458-31-8 | tecovirimat |
| 2928 00 90 | 238750-77-1 | tosedostat |
| 2928 00 90 | 149647-78-9 | vorinostat |
| 2929 90 00 | 31645-39-3 | palifosfamide |
| 2930 90 99 | 608141-41-9 | apremilast |
| 2930 90 99 | 216167-92-9 | camobucol |
| 2930 90 99 | 211513-37-0 | dalcetrapib |
| 2930 90 99 | 69819-86-9 | darinaparsin |
| 2930 90 99 | 488832-69-5 | elesclomol |
| 2930 90 99 | 216167-95-2 | elsibucol |
| 2930 90 99 | 168682-53-9 | ezatiostat |
| 2930 90 99 | 58569-55-4 | metenkefalin |
| 2930 90 99 | 887148-69-8 | monepantel |
| 2930 90 99 | 603139-19-1 | odanacatib |
| 2930 90 99 | 162520-00-5 | salirasib |
| 2930 90 99 | 216167-82-7 | succinobucol |
| 2930 90 99 | 125961-82-2 | tipelukast |
| 2931 00 99 | 125973-56-0 | amsilarotene |
| 2932 19 00 | 253128-41-5 | eribulin |
| 2932 19 00 | 186953-56-0 | pafuramidine |
| 2932 29 85 | 195883-06-8 | omtriptolide |
| 2932 99 00 | 664338-39-0 | arterolane |
| 2932 99 00 | 183133-96-2 | cabazitaxel |
| 2932 99 00 | 401925-43-7 | celivarone |
| 2932 99 00 | 461432-26-8 | dapagliflozin |
| 2932 99 00 | 118457-15-1 | dexnebivolol |
| 2932 99 00 | 156294-36-9 | larotaxel |
| 2932 99 00 | 118457-16-2 | levonebivolol |
| 2932 99 00 | 83461-56-7 | mifamurtide |
| 2932 99 00 | 117570-53-3 | vadimezan |
| 2933 19 90 | 496775-61-2 | eltrombopag |
| 2933 19 90 | 206884-98-2 | niraxostat |
| 2933 19 90 | 410528-02-8 | palovarotene |
| 2933 19 90 | 376592-42-6 | totrombopag |
| 2933 29 90 | 183659-72-5 | catramilast |
| 2933 29 90 | 944263-65-4 | demiditraz |
| 2933 29 90 | 867153-61-5 | dulanermin |
| 2933 29 90 | 320367-13-3 | lixisenatide |
| 2933 29 90 | 698389-00-3 | rolipoltide |
| 2933 29 90 | 697766-75-9 | velafermin |
| 2933 39 99 | 147084-10-4 | alcaftadine |
| 2933 39 99 | 54-96-6 | amifampridine |
| 2933 39 99 | 249921-19-5 | anamorelin |
| 2933 39 99 | 319460-85-0 | axitinib |
| 2933 39 99 | 208110-64-9 | befiradol |
| 2933 39 99 | 330942-05-7 | betrixaban |
| 2933 39 99 | 201034-75-5 | daporinad |
| 2933 39 99 | 209783-80-2 | entinostat |
| 2933 39 99 | 412950-27-7 | goxalapladib |
| 2933 39 99 | 218791-21-0 | imisopasem manganese |
| 2933 39 99 | 103129-82-4 | levamlodipine |
| 2933 39 99 | 154357-42-3 | levonadifloxacin |
| 2933 39 99 | 108147-54-2 | migalastat |
| 2933 39 99 | 453562-69-1 | motesanib |
| 2933 39 99 | 139145-27-0 | parogrelil |
| 2933 39 99 | 459856-18-9 | pexacerfont |
| 2933 39 99 | 706779-91-1 | pimavanserin |
| 2933 39 99 | 362665-56-3 | pitolisant |
| 2933 39 99 | 861151-12-4 | rosonabant |
| 2933 39 99 | 701977-09-5 | taranabant |
| 2933 39 99 | 189950-11-6 | tropantiol |
| 2933 39 99 | 793655-64-8 | vapitadine |
| 2933 39 99 | 139290-65-6 | volinaserin |
| 2933 49 90 | 141388-76-3 | besifloxacin |
| 2933 49 90 | 697761-98-1 | elvitegravir |
| 2933 49 90 | 185055-67-8 | ferroquine |
| 2933 49 90 | 445041-75-8 | intiquinatine |
| 2933 49 90 | 378746-64-6 | nemonoxacin |
| 2933 49 90 | 245765-41-7 | ozenoxacin |
| 2933 49 90 | 412950-08-4 | rilapladib |
| 2933 49 90 | 871224-64-5 | almorexant |
| 2933 49 90 | 863029-99-6 | balamapimod |
| 2933 49 90 | 698387-09-6 | neratinib |
| 2933 49 90 | 154652-83-2 | tezampanel |
| 2933 49 90 | 128253-31-6 | veliflapon |
| 2933 59 95 | 791828-58-5 | aderbasib |
| 2933 59 95 | 840486-93-3 | adipiplon |
| 2933 59 95 | 850649-61-5 | alogliptin |
| 2933 59 95 | 859212-16-1 | bafetinib |
| 2933 59 95 | 380843-75-4 | bosutinib |
| 2933 59 95 | 839712-12-8 | cariprazine |
| 2933 59 95 | 414910-27-3 | casopitant |
| 2933 59 95 | 288383-20-0 | cediranib |
| 2933 59 95 | 849550-05-6 | cevipabulin |
| 2933 59 95 | 827318-97-8 | danusertib |
| 2933 59 95 | 356057-34-6 | darapladib |
| 2933 59 95 | 501000-36-8 | dutacatib |
| 2933 59 95 | 247257-48-3 | fimasartan |
| 2933 59 95 | 3432-99-3 | folitixorin |
| 2933 59 95 | 668270-12-0 | linagliptin |
| 2933 59 95 | 441798-33-0 | macitentan |
| 2933 59 95 | 641571-10-0 | nilotinib |
| 2933 59 95 | 763113-22-0 | olaparib |
| 2933 59 95 | 686344-29-6 | otenabant |
| 2933 59 95 | 625115-55-1 | riociguat |
| 2933 59 95 | 486460-32-6 | sitagliptin |
| 2933 59 95 | 425637-18-9 | sotrastaurin |
| 2933 59 95 | 309913-83-5 | talmapimod |
| 2933 59 95 | 113857-87-7 | talotrexin |
| 2933 59 95 | 274693-27-5 | ticagrelor |
| 2933 59 95 | 306296-47-9 | vicriviroc |
| 2933 69 80 | 775351-65-0 | imeglimin |
| 2933 79 00 | 461443-59-4 | aplaviroc |
| 2933 79 00 | 189691-06-3 | bremelanotide |
| 2933 79 00 | 813452-18-5 | carmegliptin |
| 2933 79 00 | 405169-16-6 | dovitinib |
| 2933 79 00 | 536748-46-6 | eribaxaban |
| 2933 79 00 | 473289-62-2 | ilepatril |
| 2933 79 00 | 180694-97-7 | mimopezil |
| 2933 79 00 | 579475-18-6 | orvepitant |
| 2933 79 00 | 449811-01-2 | pamapimod |
| 2933 79 00 | 248282-01-1 | paquinimod |
| 2933 79 00 | 380917-97-5 | perampanel |
| 2933 79 00 | 552292-08-7 | rolapitant |
| 2933 79 00 | 425386-60-3 | semagacestat |
| 2933 79 00 | 515814-01-4 | voclosporin |
| 2933 99 80 | 481629-87-2 | aleplasinin |
| 2933 99 80 | 394730-60-0 | boceprevir |
| 2933 99 80 | 649735-63-7 | brivanib alaninate |
| 2933 99 80 | 483369-58-0 | denagliptin |
| 2933 99 80 | 284019-34-7 | denibulin |
| 2933 99 80 | 481631-45-2 | diaplasinin |
| 2933 99 80 | 272105-42-7 | disitertide |
| 2933 99 80 | 227318-71-0 | epetirimod |
| 2933 99 80 | 259793-96-9 | favipiravir |
| 2933 99 80 | 871576-03-3 | flovagatran |
| 2933 99 80 | 229305-39-9 | golotimod |
| 2933 99 80 | 258818-34-7 | larazotide |
| 2933 99 80 | 571170-77-9 | laropiprant |
| 2933 99 80 | 616202-92-7 | lorcaserin |
| 2933 99 80 | 868771-57-7 | melogliptin |
| 2933 99 80 | 803712-67-6 | obatoclax |
| 2933 99 80 | 404950-80-7 | panobinostat |
| 2933 99 80 | 625114-41-2 | piragliatin |
| 2933 99 80 | 74847-35-1 | pyronaridine |
| 2933 99 80 | 872178-65-9 | rabeximod |
| 2933 99 80 | 355151-12-1 | rotigaptide |
| 2933 99 80 | 497221-38-2 | rusalatide |
| 2933 99 80 | 187602-11-5 | sofigatran |
| 2933 99 80 | 227318-75-4 | sotirimod |
| 2933 99 80 | 402957-28-2 | telaprevir |
| 2933 99 80 | 848084-83-3 | tigapotide |
| 2933 99 80 | 393105-53-8 | tiplasinin |
| 2933 99 80 | 620948-93-8 | vabicaserin |
| 2933 99 80 | 794466-70-9 | vernakalant |
| 2934 10 00 | 544417-40-5 | capadenoson |
| 2934 10 00 | 302962-49-8 | dasatinib |
| 2934 10 00 | 223132-37-4 | inolitazone |
| 2934 10 00 | 241479-67-4 | isavuconazole |
| 2934 10 00 | 338990-84-4 | isavuconazonium chloride |
| 2934 10 00 | 607723-33-1 | lobeglitazone |
| 2934 10 00 | 280782-97-0 | managlinat dialanetil |
| 2934 10 00 | 790299-79-5 | masitinib |
| 2934 10 00 | 223673-61-8 | mirabegron |
| 2934 10 00 | 501948-05-6 | rosabulin |
| 2934 10 00 | 447406-78-2 | sodelglitazar |
| 2934 10 00 | 760937-92-6 | teneligliptin |
| 2934 20 80 | 848344-36-5 | bentamapimod |
| 2934 20 80 | 870093-23-5 | talarozole |
| 2934 99 90 | 320345-99-1 | aclidinium bromide |
| 2934 99 90 | 222551-17-9 | adoprazine |
| 2934 99 90 | 207623-20-9 | agatolimod |
| 2934 99 90 | 475479-34-6 | aleglitazar |
| 2934 99 90 | 870524-46-2 | amolimogene bepiplasmid |
| 2934 99 90 | 875446-37-0 | anacetrapib |
| 2934 99 90 | 250386-15-3 | apadenoson |
| 2934 99 90 | 541550-19-0 | apilimod |
| 2934 99 90 | 160707-69-7 | apricitabine |
| 2934 99 90 | 147403-03-0 | azilsartan |
| 2934 99 90 | 863031-21-4 | azilsartan medoxomil |
| 2934 99 90 | 757942-43-1 | bederocin |
| 2934 99 90 | 627861-07-8 | beperminogene perplasmid |
| 2934 99 90 | 959961-96-7 | bevasiranib |
| 2934 99 90 | 769901-96-4 | capeserod |
| 2934 99 90 | 868540-17-4 | carfilzomib |
| 2934 99 90 | 872847-66-0 | cenersen |
| 2934 99 90 | 80295-38-1 | conestat alfa |
| 2934 99 90 | 903916-27-8 | custirsen |
| 2934 99 90 | 187865-22-1 | derquantel |
| 2934 99 90 | 134379-77-4 | dexelvucitabine |
| 2934 99 90 | 247046-52-2 | dilopetine |
| 2934 99 90 | 480449-70-5 | edoxaban |
| 2934 99 90 | 188181-42-2 | elacytarabine |
| 2934 99 90 | 98819-76-2 | esreboxetine |
| 2934 99 90 | 763903-67-9 | fosalvudine tidoxil |
| 2934 99 90 | 172673-20-0 | fosaprepitant |
| 2934 99 90 | 522664-63-7 | ibodutant |
| 2934 99 90 | 405159-59-3 | idrabiotaparinux sodium |
| 2934 99 90 | 188116-07-6 | imepitoin |
| 2934 99 90 | 335619-18-6 | inakalant |
| 2934 99 90 | 1391-36-2 | lancovutide |
| 2934 99 90 | 189059-71-0 | lapaquistat |
| 2934 99 90 | 327026-93-7 | lensiprazine |
| 2934 99 90 | 170632-47-0 | lificiguat |
| 2934 99 90 | 852313-25-8 | litenimod |
| 2934 99 90 | 1000120-98-8 | mipomersen |
| 2934 99 90 | 62253-63-8 | nepidermin |
| 2934 99 90 | 26833-87-4 | omacetaxine mepesuccinate |
| 2934 99 90 | 269718-84-5 | pardoprunox |
| 2934 99 90 | 219923-85-0 | pramiconazole |
| 2934 99 90 | 377727-87-2 | preladenant |
| 2934 99 90 | 524684-52-4 | prinaberel |
| 2934 99 90 | 865311-47-3 | quarfloxin |
| 2934 99 90 | 869884-78-6 | radezolid |
| 2934 99 90 | 496054-87-6 | radiprodil |
| 2934 99 90 | 518048-05-0 | raltegravir |
| 2934 99 90 | 787548-03-2 | regrelor |
| 2934 99 90 | 820957-38-8 | retosiban |
| 2934 99 90 | 572924-54-0 | ridaforolimus |
| 2934 99 90 | 128517-07-7 | romidepsin |
| 2934 99 90 | 93265-81-7 | ropidoxuridine |
| 2934 99 90 | 151823-14-2 | sapacitabine |
| 2934 99 90 | 379231-04-6 | saracatinib |
| 2934 99 90 | 791635-59-1 | simotaxel |
| 2934 99 90 | 119567-79-2 | taribavirin |
| 2934 99 90 | 332012-40-5 | telatinib |
| 2934 99 90 | 925681-61-4 | trabedersen |
| 2934 99 90 | 189003-92-7 | trelanserin |
| 2934 99 90 | 296251-72-4 | velimogene aliplasmid |
| 2934 99 90 | 904302-98-3 | viquidacin |
| 2934 99 90 | 872525-61-6 | votucalis |
| 2934 99 90 | 221877-54-9 | zotarolimus |
| 2935 00 90 | 197904-84-0 | apricoxib |
| 2935 00 90 | 769169-27-9 | begacestat |
| 2935 00 90 | 414864-00-9 | belinostat |
| 2935 00 90 | 313682-08-5 | brecanavir |
| 2935 00 90 | 839673-52-8 | cevoglitazar |
| 2935 00 90 | 358970-97-5 | drinabant |
| 2935 00 90 | 865200-20-0 | giripladib |
| 2935 00 90 | 464213-10-3 | ibipinabant |
| 2935 00 90 | 173424-77-6 | laromustine |
| 2935 00 90 | 398507-55-6 | lodenafil carbonate |
| 2935 00 90 | 136564-68-6 | masilukast |
| 2935 00 90 | 170569-88-7 | mavacoxib |
| 2935 00 90 | 862189-95-5 | mirodenafil |
| 2935 00 90 | 439687-69-1 | nelivaptan |
| 2935 00 90 | 691852-58-1 | nesbuvir |
| 2935 00 90 | 778576-62-8 | oglemilast |
| 2935 00 90 | 444731-52-6 | pazopanib |
| 2935 00 90 | 362505-84-8 | relacatib |
| 2935 00 90 | 243984-11-4 | resatorvid |
| 2935 00 90 | 519055-62-0 | tasisulam |
| 2935 00 90 | 186497-07-4 | zibotentan |
| 2936 29 00 | 104121-92-8 | eldecalcitol |
| 2936 29 00 | 31690-09-2 | levomefolic acid |
| 2937 19 00 | 782500-75-8 | albiglutide |
| 2937 19 00 | 348119-84-6 | obinepitide |
| 2937 19 00 | 295350-45-7 | ozarelix |
| 2937 19 00 | 275371-94-3 | taspoglutide |
| 2937 19 00 | 218949-48-5 | tesamorelin |
| 2937 19 00 | 22006-64-0 | tridecactide |
| 2937 22 00 | 132245-57-9 | dexamethasone cipecilate |
| 2937 22 00 | 397864-44-7 | fluticasone furoate |
| 2937 29 00 | 211254-73-8 | lonaprisan |
| 2937 50 00 | 333963-42-1 | cobiprostone |
| 2937 50 00 | 172740-14-6 | posaraprost |
| 2937 90 00 | 834153-87-6 | elagolix |
| 2937 90 00 | 609799-22-6 | tasimelteon |
| 2937 90 00 | 342577-38-2 | velneperit |
| 2939 19 00 | 73232-52-7 | methylnaltrexone bromide |
| 2939 59 00 | 136199-02-5 | rolofylline |
| 2939 99 00 | 850607-58-8 | darotropium bromide |
| 2939 99 00 | 187852-63-7 | delimotecan |
| 2940 00 00 | 9007-72-1 | ferric carboxymaltose |
| 2940 00 00 | 442201-24-3 | remogliflozin etabonate |
| 2940 00 00 | 408504-26-7 | sergliflozin etabonate |
| 2941 90 00 | 467214-20-6 | alvespimycin |
| 2941 90 00 | 677017-23-1 | berubicin |
| 2941 90 00 | 229016-73-3 | ceftaroline fosamil |
| 2941 90 00 | 318498-76-9 | flopristin |
| 2941 90 00 | 145435-72-9 | gamithromycin |
| 2941 90 00 | 325965-23-9 | linopristin |
| 2941 90 00 | 857402-23-4 | retaspimycin |
| 2941 90 00 | 305841-29-6 | sagopilone |
| 2941 90 00 | 75747-14-7 | tanespimycin |
| 2941 90 00 | 328898-40-4 | tildipirosin |
| 2941 90 00 | 222400-20-6 | tomopenem |
| 2941 90 00 | 63409-12-1 | tylvalosin |
| 3001 90 91 | 9041-08-1 | semuloparin sodium |
| 3002 10 91 | 792921-10-9 | abagovomab |
| 3002 10 91 | 910649-32-0 | anrukinzumab |
| 3002 10 91 | 648904-28-3 | bavituximab |
| 3002 10 91 | 402710-27-4
  (light chain)
  402710-25-2
  (heavy chain) | canakinumab |
| 3002 10 99 | 945228-49-9 | citatuzumab bogatox |
| 3002 10 91 | 880486-59-9 | dacetuzumab |
| 3002 10 91 | 615258-40-7 | denosumab |
| 3002 10 91 | 762260-74-2 | efungumab |
| 3002 10 91 | 89957-37-9 | gantenerumab |
| 3002 10 91 | 680188-33-4 | ibalizumab |
| 3002 10 91 | 477202-00-9 | ipilimumab |
| 3002 10 91 | 640735-09-7 | iratumumab |
| 3002 10 91 | 845816-02-6 | lexatumumab |
| 3002 10 91 | 903512-50-5 | lucatumumab |
| 3002 10 91 | 899796-83-9 | milatuzumab |
| 3002 10 91 | 677010-34-3 | motavizumab |
| 3002 10 91 | 676258-98-3 | naptumomab estafenatox |
| 3002 10 91 | 828933-51-3 | nimotuzumab |
| 3002 10 91 | 949142-50-1 | obinutuzumab |
| 3002 10 91 | 637334-45-3 | ocrelizumab |
| 3002 10 91 | 881191-44-2 | otelixizumab |
| 3002 10 91 | 372075-37-1 | sontuzumab |
| 3002 10 91 | 705287-60-1 | stamulumab |
| 3002 10 91 | 339086-80-5 | tadocizumab |
| 3002 10 91 | 592557-43-2
  (light chain)
  592557-41-0
  (heavy chain) | tenatumomab |
| 3002 10 91 | 876387-05-2 | teplizumab |
| 3002 10 91 | 918127-53-4 | tigatuzumab |
| 3002 10 91 | 745013-59-6 | tremelimumab |
| 3002 10 91 | 339986-90-2 | tucotuzumab celmoleukin |
| 3002 10 91 | 728917-18-8 | veltuzumab |
| 3002 10 91 | 896731-82-1 | conatumumab |
| 3002 10 91 | 892553-42-3 | etaracizumab |
| 3002 10 91 | 944548-38-3 | foravirumab |
| 3002 10 91 | 944548-37-2 | rafivirumab |
| 3002 10 91 | 880266-57-9 | tanezumab |
| 3002 10 91 | 815610-63-0 | ustekinumab |
| 3002 10 95 | 862111-32-8 | aflibercept |
| 3002 10 95 | 845264-92-8 | atacicept |
| 3002 10 95 | 909110-25-4 | baminercept |
| 3002 10 95 | 9001-27-8 | beroctocog alfa |
| 3002 10 95 | 879555-13-2 | epoetin kappa |
| 3002 10 95 | 762263-14-9 | epoetin theta |
| 3002 10 95 | 501081-76-1 | rilonacept |
| 3002 10 95 | 267639-76-9 | romiplostim |
| 3002 10 95 | 869858-13-9 | thrombin alfa |
| 3002 10 95 | 897936-89-9 | vatreptacog alfa (activated) |
| 3002 10 95 | 472960-22-8 | albinterferon alfa-2b |
| 3002 10 95 | 869881-54-9 | briobacept |
| 3002 10 95 | 606138-08-3 | catridecacog |
| 3002 10 95 | 716840-32-3 | denenicokin |
| 3002 10 95 | 931101-84-7 | troplasminogen alfa |
| 3002 10 99 | 934216-54-3 | alacizumab pegol |
| 3002 20 00 | 181477-43-0 | disomotide |
| 3002 20 00 | 181477-91-8 | ovemotide |
| 3002 20 00 | 915019-08-8 | tertomotide |
| 3002 20 00 | 295371-00-5 | verpasep caltespen |
| 3002 90 90 | 473553-86-5 | alferminogene tadenovec |
| 3002 90 90 | 929881-05-0 | alipogene tiparvovec |
| 3002 90 90 | 600735-73-7 | contusugene ladenovec |
| 3002 90 90 | 851199-59-2 | linaclotide |
| 3002 90 90 | 898830-54-1 | sitimagene ceradenovec |
| 3002 90 90 | 721946-42-5 | transferrin aldifitox |
| 3507 90 90 | 9026-00-0 | bucelipase alfa |
| 3507 90 90 | 885051-90-1 | pegloticase |
| 3507 90 90 | 884604-91-5 | velaglucerase alfa |
| 3911 90 99 | 892497-01-7 | azoximer bromide |

CN code

CAS RN

Name

2842 90 80

119175-48-3

fermagate

2843 90 90

759457-82-4

padeliporfin

2844 40 30

123748-56-1

Formula

2904 10 00

21668-77-9

eprodisate

2906 19 00

199798-84-0

elocalcitol

2909 30 90

24150-24-1

terameprocol

2916 19 95

81485-25-8

peretinoin

2916 39 00

51543-40-9

tarenflurbil

2918 19 98

174022-42-5

bevirimat

2919 90 00

258516-89-1

fospropofol

2920 90 85

163133-43-5

naproxcinod

2921 19 99

3687-18-1

tramiprosate

2922 19 85

68392-35-8

afimoxifene

2922 19 85

753449-67-1

ronacaleret

2922 29 00

433265-65-7

faxeladol

2922 50 00

121524-08-1

amibegron

2922 50 00

329773-35-5

cinaciguat

2922 50 00

643094-49-9

fasobegron

2923 10 00

856676-23-8

choline fenofibrate

2924 29 98

847353-30-4

arbaclofen placarbil

2924 29 98

194785-19-8

bedoradrine

2924 29 98

194085-75-1

carisbamate

2924 29 98

254750-02-2

emricasan

2924 29 98

355129-15-6

eprotirome

2924 29 98

402567-16-2

firategrast

2924 29 98

478296-72-9

gabapentin enacarbil

2924 29 98

15866-90-7

incyclinide

2924 29 98

202844-10-8

indantadol

2924 29 98

96847-55-1

levomilnacipran

2924 29 98

608137-32-2

lisdexamfetamine

2924 29 98

652990-07-3

milveterol

2924 29 98

181816-48-8

ombrabulin

2924 29 98

289656-45-7

senicapoc

2925 19 95

19171-19-8

pomalidomide

2928 00 90

22033-87-0

olesoxime

2928 00 90

2675-35-6

sivifene

2928 00 90

816458-31-8

tecovirimat

2928 00 90

238750-77-1

tosedostat

2928 00 90

149647-78-9

vorinostat

2929 90 00

31645-39-3

palifosfamide

2930 90 99

608141-41-9

apremilast

2930 90 99

216167-92-9

camobucol

2930 90 99

211513-37-0

dalcetrapib

2930 90 99

69819-86-9

darinaparsin

2930 90 99

488832-69-5

elesclomol

2930 90 99

216167-95-2

elsibucol

2930 90 99

168682-53-9

ezatiostat

2930 90 99

58569-55-4

metenkefalin

2930 90 99

887148-69-8

monepantel

2930 90 99

603139-19-1

odanacatib

2930 90 99

162520-00-5

salirasib

2930 90 99

216167-82-7

succinobucol

2930 90 99

125961-82-2

tipelukast

2931 00 99

125973-56-0

amsilarotene

2932 19 00

253128-41-5

eribulin

2932 19 00

186953-56-0

pafuramidine

2932 29 85

195883-06-8

omtriptolide

2932 99 00

664338-39-0

arterolane

2932 99 00

183133-96-2

cabazitaxel

2932 99 00

401925-43-7

celivarone

2932 99 00

461432-26-8

dapagliflozin

2932 99 00

118457-15-1

dexnebivolol

2932 99 00

156294-36-9

larotaxel

2932 99 00

118457-16-2

levonebivolol

2932 99 00

83461-56-7

mifamurtide

2932 99 00

117570-53-3

vadimezan

2933 19 90

496775-61-2

eltrombopag

2933 19 90

206884-98-2

niraxostat

2933 19 90

410528-02-8

palovarotene

2933 19 90

376592-42-6

totrombopag

2933 29 90

183659-72-5

catramilast

2933 29 90

944263-65-4

demiditraz

2933 29 90

867153-61-5

dulanermin

2933 29 90

320367-13-3

lixisenatide

2933 29 90

698389-00-3

rolipoltide

2933 29 90

697766-75-9

velafermin

2933 39 99

147084-10-4

alcaftadine

2933 39 99

54-96-6

amifampridine

2933 39 99

249921-19-5

anamorelin

2933 39 99

319460-85-0

axitinib

2933 39 99

208110-64-9

befiradol

2933 39 99

330942-05-7

betrixaban

2933 39 99

201034-75-5

daporinad

2933 39 99

209783-80-2

entinostat

2933 39 99

412950-27-7

goxalapladib

2933 39 99

218791-21-0

imisopasem manganese

2933 39 99

103129-82-4

levamlodipine

2933 39 99

154357-42-3

levonadifloxacin

2933 39 99

108147-54-2

migalastat

2933 39 99

453562-69-1

motesanib

2933 39 99

139145-27-0

parogrelil

2933 39 99

459856-18-9

pexacerfont

2933 39 99

706779-91-1

pimavanserin

2933 39 99

362665-56-3

pitolisant

2933 39 99

861151-12-4

rosonabant

2933 39 99

701977-09-5

taranabant

2933 39 99

189950-11-6

tropantiol

2933 39 99

793655-64-8

vapitadine

2933 39 99

139290-65-6

volinaserin

2933 49 90

141388-76-3

besifloxacin

2933 49 90

697761-98-1

elvitegravir

2933 49 90

185055-67-8

ferroquine

2933 49 90

445041-75-8

intiquinatine

2933 49 90

378746-64-6

nemonoxacin

2933 49 90

245765-41-7

ozenoxacin

2933 49 90

412950-08-4

rilapladib

2933 49 90

871224-64-5

almorexant

2933 49 90

863029-99-6

balamapimod

2933 49 90

698387-09-6

neratinib

2933 49 90

154652-83-2

tezampanel

2933 49 90

128253-31-6

veliflapon

2933 59 95

791828-58-5

aderbasib

2933 59 95

840486-93-3

adipiplon

2933 59 95

850649-61-5

alogliptin

2933 59 95

859212-16-1

bafetinib

2933 59 95

380843-75-4

bosutinib

2933 59 95

839712-12-8

cariprazine

2933 59 95

414910-27-3

casopitant

2933 59 95

288383-20-0

cediranib

2933 59 95

849550-05-6

cevipabulin

2933 59 95

827318-97-8

danusertib

2933 59 95

356057-34-6

darapladib

2933 59 95

501000-36-8

dutacatib

2933 59 95

247257-48-3

fimasartan

2933 59 95

3432-99-3

folitixorin

2933 59 95

668270-12-0

linagliptin

2933 59 95

441798-33-0

macitentan

2933 59 95

641571-10-0

nilotinib

2933 59 95

763113-22-0

olaparib

2933 59 95

686344-29-6

otenabant

2933 59 95

625115-55-1

riociguat

2933 59 95

486460-32-6

sitagliptin

2933 59 95

425637-18-9

sotrastaurin

2933 59 95

309913-83-5

talmapimod

2933 59 95

113857-87-7

talotrexin

2933 59 95

274693-27-5

ticagrelor

2933 59 95

306296-47-9

vicriviroc

2933 69 80

775351-65-0

imeglimin

2933 79 00

461443-59-4

aplaviroc

2933 79 00

189691-06-3

bremelanotide

2933 79 00

813452-18-5

carmegliptin

2933 79 00

405169-16-6

dovitinib

2933 79 00

536748-46-6

eribaxaban

2933 79 00

473289-62-2

ilepatril

2933 79 00

180694-97-7

mimopezil

2933 79 00

579475-18-6

orvepitant

2933 79 00

449811-01-2

pamapimod

2933 79 00

248282-01-1

paquinimod

2933 79 00

380917-97-5

perampanel

2933 79 00

552292-08-7

rolapitant

2933 79 00

425386-60-3

semagacestat

2933 79 00

515814-01-4

voclosporin

2933 99 80

481629-87-2

aleplasinin

2933 99 80

394730-60-0

boceprevir

2933 99 80

649735-63-7

brivanib alaninate

2933 99 80

483369-58-0

denagliptin

2933 99 80

284019-34-7

denibulin

2933 99 80

481631-45-2

diaplasinin

2933 99 80

272105-42-7

disitertide

2933 99 80

227318-71-0

epetirimod

2933 99 80

259793-96-9

favipiravir

2933 99 80

871576-03-3

flovagatran

2933 99 80

229305-39-9

golotimod

2933 99 80

258818-34-7

larazotide

2933 99 80

571170-77-9

laropiprant

2933 99 80

616202-92-7

lorcaserin

2933 99 80

868771-57-7

melogliptin

2933 99 80

803712-67-6

obatoclax

2933 99 80

404950-80-7

panobinostat

2933 99 80

625114-41-2

piragliatin

2933 99 80

74847-35-1

pyronaridine

2933 99 80

872178-65-9

rabeximod

2933 99 80

355151-12-1

rotigaptide

2933 99 80

497221-38-2

rusalatide

2933 99 80

187602-11-5

sofigatran

2933 99 80

227318-75-4

sotirimod

2933 99 80

402957-28-2

telaprevir

2933 99 80

848084-83-3

tigapotide

2933 99 80

393105-53-8

tiplasinin

2933 99 80

620948-93-8

vabicaserin

2933 99 80

794466-70-9

vernakalant

2934 10 00

544417-40-5

capadenoson

2934 10 00

302962-49-8

dasatinib

2934 10 00

223132-37-4

inolitazone

2934 10 00

241479-67-4

isavuconazole

2934 10 00

338990-84-4

isavuconazonium chloride

2934 10 00

607723-33-1

lobeglitazone

2934 10 00

280782-97-0

managlinat dialanetil

2934 10 00

790299-79-5

masitinib

2934 10 00

223673-61-8

mirabegron

2934 10 00

501948-05-6

rosabulin

2934 10 00

447406-78-2

sodelglitazar

2934 10 00

760937-92-6

teneligliptin

2934 20 80

848344-36-5

bentamapimod

2934 20 80

870093-23-5

talarozole

2934 99 90

320345-99-1

aclidinium bromide

2934 99 90

222551-17-9

adoprazine

2934 99 90

207623-20-9

agatolimod

2934 99 90

475479-34-6

aleglitazar

2934 99 90

870524-46-2

amolimogene bepiplasmid

2934 99 90

875446-37-0

anacetrapib

2934 99 90

250386-15-3

apadenoson

2934 99 90

541550-19-0

apilimod

2934 99 90

160707-69-7

apricitabine

2934 99 90

147403-03-0

azilsartan

2934 99 90

863031-21-4

azilsartan medoxomil

2934 99 90

757942-43-1

bederocin

2934 99 90

627861-07-8

beperminogene perplasmid

2934 99 90

959961-96-7

bevasiranib

2934 99 90

769901-96-4

capeserod

2934 99 90

868540-17-4

carfilzomib

2934 99 90

872847-66-0

cenersen

2934 99 90

80295-38-1

conestat alfa

2934 99 90

903916-27-8

custirsen

2934 99 90

187865-22-1

derquantel

2934 99 90

134379-77-4

dexelvucitabine

2934 99 90

247046-52-2

dilopetine

2934 99 90

480449-70-5

edoxaban

2934 99 90

188181-42-2

elacytarabine

2934 99 90

98819-76-2

esreboxetine

2934 99 90

763903-67-9

fosalvudine tidoxil

2934 99 90

172673-20-0

fosaprepitant

2934 99 90

522664-63-7

ibodutant

2934 99 90

405159-59-3

idrabiotaparinux sodium

2934 99 90

188116-07-6

imepitoin

2934 99 90

335619-18-6

inakalant

2934 99 90

1391-36-2

lancovutide

2934 99 90

189059-71-0

lapaquistat

2934 99 90

327026-93-7

lensiprazine

2934 99 90

170632-47-0

lificiguat

2934 99 90

852313-25-8

litenimod

2934 99 90

1000120-98-8

mipomersen

2934 99 90

62253-63-8

nepidermin

2934 99 90

26833-87-4

omacetaxine mepesuccinate

2934 99 90

269718-84-5

pardoprunox

2934 99 90

219923-85-0

pramiconazole

2934 99 90

377727-87-2

preladenant

2934 99 90

524684-52-4

prinaberel

2934 99 90

865311-47-3

quarfloxin

2934 99 90

869884-78-6

radezolid

2934 99 90

496054-87-6

radiprodil

2934 99 90

518048-05-0

raltegravir

2934 99 90

787548-03-2

regrelor

2934 99 90

820957-38-8

retosiban

2934 99 90

572924-54-0

ridaforolimus

2934 99 90

128517-07-7

romidepsin

2934 99 90

93265-81-7

ropidoxuridine

2934 99 90

151823-14-2

sapacitabine

2934 99 90

379231-04-6

saracatinib

2934 99 90

791635-59-1

simotaxel

2934 99 90

119567-79-2

taribavirin

2934 99 90

332012-40-5

telatinib

2934 99 90

925681-61-4

trabedersen

2934 99 90

189003-92-7

trelanserin

2934 99 90

296251-72-4

velimogene aliplasmid

2934 99 90

904302-98-3

viquidacin

2934 99 90

872525-61-6

votucalis

2934 99 90

221877-54-9

zotarolimus

2935 00 90

197904-84-0

apricoxib

2935 00 90

769169-27-9

begacestat

2935 00 90

414864-00-9

belinostat

2935 00 90

313682-08-5

brecanavir

2935 00 90

839673-52-8

cevoglitazar

2935 00 90

358970-97-5

drinabant

2935 00 90

865200-20-0

giripladib

2935 00 90

464213-10-3

ibipinabant

2935 00 90

173424-77-6

laromustine

2935 00 90

398507-55-6

lodenafil carbonate

2935 00 90

136564-68-6

masilukast

2935 00 90

170569-88-7

mavacoxib

2935 00 90

862189-95-5

mirodenafil

2935 00 90

439687-69-1

nelivaptan

2935 00 90

691852-58-1

nesbuvir

2935 00 90

778576-62-8

oglemilast

2935 00 90

444731-52-6

pazopanib

2935 00 90

362505-84-8

relacatib

2935 00 90

243984-11-4

resatorvid

2935 00 90

519055-62-0

tasisulam

2935 00 90

186497-07-4

zibotentan

2936 29 00

104121-92-8

eldecalcitol

2936 29 00

31690-09-2

levomefolic acid

2937 19 00

782500-75-8

albiglutide

2937 19 00

348119-84-6

obinepitide

2937 19 00

295350-45-7

ozarelix

2937 19 00

275371-94-3

taspoglutide

2937 19 00

218949-48-5

tesamorelin

2937 19 00

22006-64-0

tridecactide

2937 22 00

132245-57-9

dexamethasone cipecilate

2937 22 00

397864-44-7

fluticasone furoate

2937 29 00

211254-73-8

lonaprisan

2937 50 00

333963-42-1

cobiprostone

2937 50 00

172740-14-6

posaraprost

2937 90 00

834153-87-6

elagolix

2937 90 00

609799-22-6

tasimelteon

2937 90 00

342577-38-2

velneperit

2939 19 00

73232-52-7

methylnaltrexone bromide

2939 59 00

136199-02-5

rolofylline

2939 99 00

850607-58-8

darotropium bromide

2939 99 00

187852-63-7

delimotecan

2940 00 00

9007-72-1

ferric carboxymaltose

2940 00 00

442201-24-3

remogliflozin etabonate

2940 00 00

408504-26-7

sergliflozin etabonate

2941 90 00

467214-20-6

alvespimycin

2941 90 00

677017-23-1

berubicin

2941 90 00

229016-73-3

ceftaroline fosamil

2941 90 00

318498-76-9

flopristin

2941 90 00

145435-72-9

gamithromycin

2941 90 00

325965-23-9

linopristin

2941 90 00

857402-23-4

retaspimycin

2941 90 00

305841-29-6

sagopilone

2941 90 00

75747-14-7

tanespimycin

2941 90 00

328898-40-4

tildipirosin

2941 90 00

222400-20-6

tomopenem

2941 90 00

63409-12-1

tylvalosin

3001 90 91

9041-08-1

semuloparin sodium

3002 10 91

792921-10-9

abagovomab

3002 10 91

910649-32-0

anrukinzumab

3002 10 91

648904-28-3

bavituximab

3002 10 91

402710-27-4

(light chain)

402710-25-2

(heavy chain)

canakinumab

3002 10 99

945228-49-9

citatuzumab bogatox

3002 10 91

880486-59-9

dacetuzumab

3002 10 91

615258-40-7

denosumab

3002 10 91

762260-74-2

efungumab

3002 10 91

89957-37-9

gantenerumab

3002 10 91

680188-33-4

ibalizumab

3002 10 91

477202-00-9

ipilimumab

3002 10 91

640735-09-7

iratumumab

3002 10 91

845816-02-6

lexatumumab

3002 10 91

903512-50-5

lucatumumab

3002 10 91

899796-83-9

milatuzumab

3002 10 91

677010-34-3

motavizumab

3002 10 91

676258-98-3

naptumomab estafenatox

3002 10 91

828933-51-3

nimotuzumab

3002 10 91

949142-50-1

obinutuzumab

3002 10 91

637334-45-3

ocrelizumab

3002 10 91

881191-44-2

otelixizumab

3002 10 91

372075-37-1

sontuzumab

3002 10 91

705287-60-1

stamulumab

3002 10 91

339086-80-5

tadocizumab

3002 10 91

592557-43-2

(light chain)

592557-41-0

(heavy chain)

tenatumomab

3002 10 91

876387-05-2

teplizumab

3002 10 91

918127-53-4

tigatuzumab

3002 10 91

745013-59-6

tremelimumab

3002 10 91

339986-90-2

tucotuzumab celmoleukin

3002 10 91

728917-18-8

veltuzumab

3002 10 91

896731-82-1

conatumumab

3002 10 91

892553-42-3

etaracizumab

3002 10 91

944548-38-3

foravirumab

3002 10 91

944548-37-2

rafivirumab

3002 10 91

880266-57-9

tanezumab

3002 10 91

815610-63-0

ustekinumab

3002 10 95

862111-32-8

aflibercept

3002 10 95

845264-92-8

atacicept

3002 10 95

909110-25-4

baminercept

3002 10 95

9001-27-8

beroctocog alfa

3002 10 95

879555-13-2

epoetin kappa

3002 10 95

762263-14-9

epoetin theta

3002 10 95

501081-76-1

rilonacept

3002 10 95

267639-76-9

romiplostim

3002 10 95

869858-13-9

thrombin alfa

3002 10 95

897936-89-9

vatreptacog alfa (activated)

3002 10 95

472960-22-8

albinterferon alfa-2b

3002 10 95

869881-54-9

briobacept

3002 10 95

606138-08-3

catridecacog

3002 10 95

716840-32-3

denenicokin

3002 10 95

931101-84-7

troplasminogen alfa

3002 10 99

934216-54-3

alacizumab pegol

3002 20 00

181477-43-0

disomotide

3002 20 00

181477-91-8

ovemotide

3002 20 00

915019-08-8

tertomotide

3002 20 00

295371-00-5

verpasep caltespen

3002 90 90

473553-86-5

alferminogene tadenovec

3002 90 90

929881-05-0

alipogene tiparvovec

3002 90 90

600735-73-7

contusugene ladenovec

3002 90 90

851199-59-2

linaclotide

3002 90 90

898830-54-1

sitimagene ceradenovec

3002 90 90

721946-42-5

transferrin aldifitox

3507 90 90

9026-00-0

bucelipase alfa

3507 90 90

885051-90-1

pegloticase

3507 90 90

884604-91-5

velaglucerase alfa

3911 90 99

892497-01-7

azoximer bromide

---

ANNEX II

List of prefixes and suffixes which, in combination with the INNs of Annex 3 to Annex I to Regulation (EEC) No 2658/87, describe the salts, esters or hydrates of INNs; these salts, esters and hydrates are free of duty, on condition that they are classifiable in the same six-digit HS subheading as the corresponding INN

The references to ‘International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals and groups, comprehensive list 2004’ are replaced by ‘International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals, groups and others, comprehensive list 2007’.

The following prefixes or suffixes are added to the list included in Annex 4 to Annex I to Regulation (EEC) No 2658/87:

| Preferred prefix or suffix | Synonym | Systematic name when different |
| --- | --- | --- |
| alanetil (INNRG) | | [(S)-1-ethoxy-1-oxo-propan-2-yl]amino (INNCN) |
| alaninate (INNRG) | | L-alaninate (INNCN) |
| alapivoxil (INNRG) | | L-alanyl, [(2,2-dimethylpropanoyl)oxy]metyl (INNCN) |
| aldifitox (INNRG) | | (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an N-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from Corynebacterium diphtheriae-(26-560)-peptide (INNCN) |
| besudotox (INNRG) | | L-lysyl-L-alanyl-L-serylglycylglycine (linker) fusion protein with des-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (toxin with region IA and first 16 residues of region IB deleted) (INNCN) |
| ceribate (INNRG) | | rac-2,3-dihydroxypropyl carbonate (ester) (INNCN) |
| cipecilate (INNRG) | | cyclohexanecarboxylate (ester), cyclopropanecarboxylate (ester) (INNCN) |
| dalanated (INNRG) | | des-B30-alanine (INNCN) |
| enacarbil (INNRG) | | {rac-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl (INNCN) |
| estafenatox (INNRG) | | glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus aureus)-(32-230)-peptide (synthetic superantigen SEA/E-120) (INNCN) |
| etexilate (INNRG) | | ethyl, (hexyloxy)carbonyl |
| fosamil (INNRG) | | phosphono (INNCN) |
| glucuronide (INNRG) | | β-D-glucopyranosiduronic acid [oside] (INNCN) |
| medocaril (INNRG) | | [(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl (INNCN) |
| paptox (INNRG) | | protein PAP (Phytolacca americana antiviral) (INNCN) |
| placarbil (INNRG) | | (R)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy}carbonyl) (INNCN) |

Preferred prefix or suffix

Synonym

Systematic name when different

alanetil (INNRG)

[(S)-1-ethoxy-1-oxo-propan-2-yl]amino (INNCN)

alaninate (INNRG)

L-alaninate (INNCN)

alapivoxil (INNRG)

L-alanyl, [(2,2-dimethylpropanoyl)oxy]metyl (INNCN)

aldifitox (INNRG)

(4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an N-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from Corynebacterium diphtheriae-(26-560)-peptide (INNCN)

besudotox (INNRG)

L-lysyl-L-alanyl-L-serylglycylglycine (linker) fusion protein with des-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (toxin with region IA and first 16 residues of region IB deleted) (INNCN)

ceribate (INNRG)

rac-2,3-dihydroxypropyl carbonate (ester) (INNCN)

cipecilate (INNRG)

cyclohexanecarboxylate (ester), cyclopropanecarboxylate (ester) (INNCN)

dalanated (INNRG)

des-B30-alanine (INNCN)

enacarbil (INNRG)

{rac-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl (INNCN)

estafenatox (INNRG)

glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus aureus)-(32-230)-peptide (synthetic superantigen SEA/E-120) (INNCN)

etexilate (INNRG)

ethyl, (hexyloxy)carbonyl

fosamil (INNRG)

phosphono (INNCN)

glucuronide (INNRG)

β-D-glucopyranosiduronic acid [oside] (INNCN)

medocaril (INNRG)

[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl (INNCN)

paptox (INNRG)

protein PAP (Phytolacca americana antiviral) (INNCN)

placarbil (INNRG)

(R)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy}carbonyl) (INNCN)

The systematic name of the following prefix or suffix is amended as follows:

| Preferred prefix or suffix | Synonym | Systematic name when different |
| --- | --- | --- |
| aritox (INNRG) | | ricin A chain (INNCN) |

Preferred prefix or suffix

Synonym

Systematic name when different

aritox (INNRG)

ricin A chain (INNCN)

---

ANNEX III

List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be added to the list of products receiving duty-free treatment included in Annex 6 to Annex I to Regulation (EEC) No 2658/87

| CN code | CAS RN | Name |
| --- | --- | --- |
| 2843 29 00 | 22199-08-2 | [4-amino-N-(pyrimidin-2(1H)-ylidene-κN1)benzenesulfonamidato-κO]silver |
| 2905 39 95 | 281214-27-5 | (2R,3R)-2,3-dimethylbutane-1,4-diyl bis(4-methylbenzenesulfonate) |
| 2905 59 98 | 441002-17-1 | 4-chlorobutyl 2-nitrobenzenesulfonate |
| 2909 30 90 | 92878-95-0 | 2-(3-chloropropoxy)-1-methoxy-4-nitrobenzene |
| 2909 30 | 503070-57-3 | 2-({2-[(6-bromohexyl)oxy]ethoxy}methyl)-1,3-dichlorobenzene |
| 2909 30 | 461432-23-5 | 4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether |
| 2909 49 80 | 185954-75-0 | (3R)-3-methoxydecan-1-ol |
| 2909 49 80 | 85309-91-7 | 2-[(2,6-dichlorobenzyl)oxy]ethanol |
| 2909 49 80 | 160969-03-9 | 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl methanesulfonate |
| 2909 50 00 | 167145-13-3 | 2-[2-(3-methoxyphenyl)ethyl]phenol |
| 2910 20 00 | 15448-47-2 | (2R)-2-methyloxirane |
| 2910 90 00 | 62600-71-9 | (2R)-2-(3-chlorophenyl)oxirane |
| 2910 90 00 | 702687-42-1 | (2R)-2-[(5-bromo-2,3-difluorophenoxy)methyl]oxirane |
| 2910 90 00 | 683276-64-4 | [(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzenesulfonate |
| 2913 00 00 | 90035-34-0 | 4′-(trifluoromethyl)biphenyl-4-carbaldehyde |
| 2914 40 90 | 17752-16-8 | (3β)-3-hydroxycholest-5-en-24-one |
| 2914 50 00 | 974-23-2 | (3β,16α)-3-hydroxy-16,17-epoxypregn-5-en-20-one |
| 2914 70 00 | 13054-81-4 | 4-chloro-heptane-3,5-dione |
| 2914 70 00 | 10226-30-9 | 6-chlorohexan-2-one |
| 2915 60 90 | 53064-79-2 | iodomethyl pivalate |
| 2915 90 00 | 22328-90-1 | (3R)-3-methylhexanoic acid |
| 2915 90 00 | 1069-66-5 | sodium 2-propylpentanoate |
| 2916 20 00 | 211515-46-7 | 1-(2-ethylbutyl)cyclohexanecarbonyl chloride |
| 2916 20 00 | 381209-09-2 | 1-(2-ethylbutyl)cyclohexanecarboxylic acid |
| 2916 20 00 | 7077-05-6 | trans-4-(propan-2-yl)cyclohexanecarboxylic acid |
| 2916 39 00 | 21900-39-0 | 5-fluoro-2-methylbenzoyl chloride |
| 2916 39 00 | 17625-03-5 | sodium hydrogen 3-sulfonatobenzoate |
| 2917 19 90 | 76-72-2 | diethyl ethyl(pentan-2-yl)propanedioate |
| 2918 29 00 | 376592-58-4 | 5′-chloro-2′-hydroxy-3′-nitrobiphenyl-3-carboxylic acid |
| 2918 99 90 | 709031-28-7 | (3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)acetic acid |
| 2918 99 90 | 35480-52-5 | 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid |
| 2918 99 90 | 4651-67-6 | (3α,5β)-3-hydroxy-7-oxocholan-24-oic acid |
| 2918 99 90 | 52179-28-9 | ethyl 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoate |
| 2918 99 90 | 530141-60-7 | methyl 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-hydroxyphenyl)propanoate |
| 2920 90 10 | 91526-18-0 | 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one |
| 2921 49 00 | 334477-60-0 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine |
| 2921 49 00 | 376608-71-8 | (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate |
| 2921 49 00 | 1034457-07-2 | 2-(2,3-dihydro-1H-inden-2-yl)propan-2-amine hydrochloride |
| 2921 49 00 | 945717-05-5 | 2-(4-chloro-3-ethylphenyl)ethanamine hydrochloride |
| 2921 49 00 | 89-97-4 | 2-chlorobenzylamine |
| 2921 49 00 | 945717-43-1 | N-(4-tert-butylbenzyl)-2-(4-chloro-3-ethylphenyl)ethanamine |
| 2921 51 90 | 150812-21-8 | N4-[(4-fluorophenyl)methyl]-2-nitro-1,4-benzenediamine |
| 2922 19 85 | 1035455-90-3 | (2R)-1-(5-bromo-2,3-difluorophenoxy)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}propan-2-ol hydrochloride |
| 2922 19 85 | 0-00-0 | [2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride |
| 2922 19 85 | 133-51-7 | antimonic acid – 1-deoxy-1-(methylamino)-D-glucitol (1:1) |
| 2922 19 85 | 1035455-87-8 | ethyl (2E)-3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)prop-2-enoate hydrochloride |
| 2922 19 85 | 702686-97-3 | ethyl 3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)propanoate hydrochloride |
| 2922 29 00 | 20059-73-8 | 2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamine |
| 2922 49 85 | 848133-35-7 | (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride |
| 2922 49 85 | 610300-07-7 | (3S,5R)-3-amino-5-methyloctanoic acid |
| 2922 49 85 | 610300-00-0 | (3S,5R)-3-amino-5-methyloctanoic acid hydrochloride |
| 2922 49 85 | 143785-86-8 | 4-(1-aminocyclopropyl)-2,3,5-trifluorobenzoic acid |
| 2922 49 85 | 848949-85-9 | 4-fluoro-L-leucine – ethyl hydrogen sulfate (1:1) |
| 2922 49 85 | 39068-93-4 | methyl 2-(dimethylamino)-2-phenylbutanoate |
| 2922 49 85 | 168619-25-8 | methyl 3′-aminobiphenyl-3-carboxylate |
| 2922 49 85 | 82834-12-6 | N-[(2S)-1-ethoxy-1-oxopentan-2-yl]-L-alanine |
| 2922 49 85 | 94133-84-3 | sodium 2-amino-2-phenylbutanoate |
| 2922 50 00 | 503070-58-4 | triphenylacetic acid – 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) |
| 2924 19 00 | 62009-47-6 | 2-aminomalonamide |
| 2924 19 00 | 7355-58-0 | N-(2-chloroethyl)acetamide |
| 2924 29 98 | 361442-00-4 | {2-[(tert-butoxycarbonyl)amino]-3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl}acetic acid |
| 2924 29 98 | 266993-72-0 | 2,3-diaminobenzamide dihydrochloride |
| 2924 29 98 | 168080-49-7 | 2-chloro-4-{[(5-fluoro-2-methylphenyl)carbonyl]amino}benzoic acid |
| 2924 29 98 | 317374-08-6 | 2-methyl-4-{[(2-methylphenyl)carbonyl]amino}benzoic acid |
| 2924 29 98 | 143785-84-6 | 4-(1-carbamoylcyclopropyl)-2,3,5-trifluorobenzoic acid |
| 2924 29 98 | 143785-87-9 | 4-[1-(acetylamino)cyclopropyl]-2,3,5-trifluorobenzoic acid |
| 2924 29 98 | 108166-22-9 | 4-{[(2-methylphenyl)carbonyl]amino}benzoic acid |
| 2924 29 98 | 150812-23-0 | ethyl {4-[(4-fluorobenzyl)amino]-2-nitrophenyl}carbamate |
| 2924 29 98 | 22316-45-6 | ethyl 3-[(5-chloro-2-nitrophenyl)(phenyl)amino]-3-oxopropanoate |
| 2924 29 98 | 316173-29-2 | methyl (1S,2S,3S,4R)-3-[(1S)-1-amino-2-ethylbutyl]-4-[(tert-butoxycarbonyl)amino]-2-hydroxycyclopentanecarboxylate |
| 2924 29 98 | 1142-20-7 | N-benzyloxycarbonyl-L-alanine |
| 2924 29 98 | 84996-93-0 | N-cyclohexyl-5-hydroxypentanamide |
| 2924 29 98 | 579494-66-9 | propyl {4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl}acetate |
| 2925 19 95 | 265136-65-0 | ethyl 3-amino-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]but-2-enoate |
| 2926 90 95 | 855425-38-6 | 1-(2-ethylbutyl)cyclohexanecarbonitrile |
| 2926 90 95 | 846023-24-3 | 2-cyano-N-(2,4-dichloro-5-methoxyphenyl)acetamide |
| 2926 90 95 | 591769-05-0 | 3-cyclopentylprop-2-enenitrile |
| 2926 90 95 | 20099-89-2 | 4-(bromoacetyl)benzonitrile |
| 2926 90 95 | 474554-45-5 | 4,5-diethoxy-3-fluorobenzene-1,2-dicarbonitrile |
| 2926 90 95 | 79370-78-8 | 5-hydroxybenzene-1,3-dicarbonitrile |
| 2926 90 95 | 139481-28-0 | methyl 2-{[(2′-cyanobiphenyl-4-yl)methyl]amino}-3-nitrobenzoate |
| 2928 00 90 | 860035-10-5 | 1-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)ethyl 2-methylpropanoate |
| 2928 00 90 | 910656-45-0 | 2-hydroxy-2-(trifluoromethyl)butanehydrazide |
| 2928 00 90 | 95759-10-7 | 4-chloro-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoic acid |
| 2928 00 90 | 473927-63-8 | ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate |
| 2928 00 90 | 158671-29-5 | N,2-dihydroxy-4-methylbenzamide |
| 2928 00 90 | 84080-68-2 | tert-butyl (2Z)-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate |
| 2928 00 90 | 268544-50-9 | tert-butyl-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate |
| 2930 90 99 | 13459-62-6 | {2-[(4-chlorophenyl)sulfanyl]phenyl}acetic acid |
| 2930 90 99 | 211513-21-2 | 1-(2-ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide |
| 2930 90 99 | 860035-07-0 | 1-{[(methylsulfanyl)carbonyl]oxy}ethyl 2-methylpropanoate |
| 2930 90 99 | 893407-18-6 | 2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethanone |
| 2930 90 99 | 60759-00-4 | 3,4-diethoxybenzenecarbothioamide |
| 2930 90 99 | 21048-05-5 | N-methylbenzenecarbothiohydrazide |
| 2931 00 99 | 13682-94-5 | (2-bromoethenyl)(trimethyl)silane |
| 2931 00 99 | 914922-89-7 | (2R,4R)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methoxy-N,2-dimethyl-7-oxoheptanamide |
| 2931 00 99 | 914922-88-6 | (2R,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N,2-dimethyloct-7-enamide |
| 2931 00 99 | 871355-80-5 | (4R)-2-bromo-7-{[tert-butyl(diphenyl)silyl]oxy}hept-1-en-4-yl 4-methylbenzenesulfonate |
| 2931 00 99 | 89694-48-4 | (5-chloro-2-methoxyphenyl)boronic acid |
| 2931 00 99 | 701278-08-2 | [(1R,5S)-5-[dimethyl(phenyl)silyl]-2-{[(2-methoxypropan-2-yl)oxy]methyl}cyclopent-2-en-1-yl]methanol |
| 2931 00 99 | 701278-09-3 | {(4S,5R)-5-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]cyclopent-1-en-1-yl}methanol |
| 2931 00 99 | 796967-18-5 | 1-(2-fluoro-5-methylphenyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea |
| 2931 00 99 | 172732-52-4 | 2-(1,3,2-dioxaborinan-2-yl)benzonitrile |
| 2931 00 99 | 185411-12-5 | methyl 3-(trimethylsilyl)pent-4-enoate |
| 2932 19 00 | 253128-10-8 | (1S)-1,5:7,10-dianhydro-12,13-bis-O-[tert-butyl(dimethyl)silyl]-2,3,4,6,8,11-hexadeoxy-1-{2-[(2S,5S)-5-(3-hydroxypropyl)-3-methylidenetetrahydrofuran-2-yl]ethyl}-3-methyl-9-O-methyl-4-methylidene-8-[(phenylsulfonyl)methyl]-D-arabino-D-altro-tridecitol |
| 2932 19 00 | 441045-17-6 | (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one methanesulfonate |
| 2932 29 85 | 916069-80-2 | (4S)-4-(fluoromethyl)dihydrofuran-2(3H)-one |
| 2932 29 85 | 63106-93-4 | 1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one |
| 2932 29 85 | 7734-80-7 | 2-oxo-2H-chromene-6-carboxylic acid |
| 2932 29 85 | 0-00-0 | 4-(4-fluorophenyl)-7-(isothiocyanatomethyl)-2H-chromen-2-one |
| 2932 29 85 | 947408-91-5 | 6-[(2,4-dihydroxyphenyl)carbonyl]-2H-chromen-2-one |
| 2932 29 85 | 947408-90-4 | 6-[(2,4-dimethoxyphenyl)carbonyl]-2H-chromen-2-one |
| 2932 99 00 | 452342-08-4 | (1R)-2-(benzylamino)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol |
| 2932 99 00 | 99541-23-8 | (1R,2S,3R,4R,5R)-4-azido-2-{[(4aR,6S,7R,8S,8aR)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy}-6,8-dioxabicyclo[3.2.1]oct-3-yl acetate |
| 2932 99 00 | 461432-25-7 | (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol |
| 2932 99 00 | 196597-79-2 | (2E)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile |
| 2932 99 00 | 3308-94-9 | 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane |
| 2932 99 00 | 274693-53-7 | [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]carbamate |
| 2932 99 00 | 185954-98-7 | [6(2Z,3R)]-3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-(3-metoxydecyl)-6-methyl-2-[(1-oxo-11-octadecenyl)amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-D-glucopyranose 1-(dihydrogen phosphate) tetrasodium salt |
| 2932 99 00 | 136172-58-2 | 1,6-di-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-glucopyranose |
| 2932 99 00 | 196597-80-5 | 2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethanamine hydrochloride |
| 2932 99 00 | 666860-59-9 | 2-amino-2-oxoethyl{3-[trans-5-(6-methoxynaphthalen-1-yl)-1,3-dioxan-2-yl]propyl}carbamate |
| 2932 99 00 | 117661-72-0 | 5-(chloromethyl)-6-methyl-1,3-benzodioxole |
| 2932 99 00 | 959624-24-9 | 6-(hydroxymethyl)-4-phenyl-3,4-dihydro-2H-chromen-2-ol |
| 2932 99 00 | 960404-59-5 | but-2-yne-1,4-diol – methyl 1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-α-D-glucopyranoside (1:1) |
| 2932 99 00 | 15826-37-6 | disodium 5,5′-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate) |
| 2932 99 00 | 204254-84-2 | ethyl (3aR,7R,7aR)-2,2-dimethyl-7-[(methylsulfonyl)oxy]-3a,6,7,7a-tetrahydro-1,3-benzodioxole-5-carboxylate |
| 2932 99 00 | 99541-26-1 | methyl (2S,3S,4S,5S,6S)-6-{[(1S,2S,3S,4R,5R)-3-(acetyloxy)-4-azido-6,8-dioxabicyclo[3.2.1]oct-2-yl]methyl}-4,5-bis(benzyloxy)-3-hydroxytetrahydro-2H-pyran-2-carboxylate |
| 2932 99 00 | 114869-97-5 | methyl 6-O-acetyl-4-O-(2-O-acetyl-3-O-benzyl-6-methyl-α-L-idopyranuronosyl)-3-O-benzyl-2-{[(benzyloxy)carbonyl]amino}-2-deoxy-α-D-glucopyranoside |
| 2933 19 90 | 1035677-60-1 | (4S)-3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide 2,3-dihydroxybutanedioate |
| 2933 19 90 | 18048-64-1 | 2-(3,4-dimethylphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one |
| 2933 19 90 | 1035675-24-1 | 3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide |
| 2933 19 90 | 1028026-83-6 | 5-methyl-1-(propan-2-yl)-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one |
| 2933 19 90 | 473921-12-9 | 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile |
| 2933 29 90 | 65902-59-2 | 2-bromo-4-nitro-1H-imidazole |
| 2933 29 90 | 57531-37-0 | 2-chloro-4-nitro-1H-imidazole |
| 2933 29 90 | 1000164-35-1 | 3-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-L-histidyl-2-methylalanyl-L-α-glutamylglycine |
| 2933 29 90 | 152074-97-0 | L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine |
| 2933 29 90 | 781666-30-6 | L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine tetraacetate |
| 2933 29 90 | 451470-33-0 | methyl 3′-(2-methyl-4,5-dihydro-1H-imidazol-1-yl)biphenyl-3-carboxylate |
| 2933 39 99 | 925978-49-0 | (+)-5-[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]-1-azabicyclo[3.2.1]octane |
| 2933 39 99 | 876170-44-4 | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| 2933 39 99 | 741705-70-4 | (2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride |
| 2933 39 99 | 414910-13-7 | (2S)-hydroxy(phenyl)ethanoic acid – (2R)-2-(4-fluoro-2-methylphenyl)piperidin-4-one (1:1) |
| 2933 39 99 | 0-00-0 | (3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole 4-methylbenzenesulfonate |
| 2933 39 99 | 370882-57-8 | (3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride |
| 2933 39 99 | 334618-23-4 | (3R)-piperidin-3-amine dihydrochloride |
| 2933 39 99 | 1062580-52-2 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
| 2933 39 99 | 27262-47-1 | (S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide |
| 2933 39 99 | 105812-81-5 | [(3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl]methanol |
| 2933 39 99 | 876068-51-8 | [(3S,4S)-4-amino-1-(5,6-dichloropyridin-3-yl)pyrrolidin-3-yl]methanol |
| 2933 39 99 | 871022-14-9 | 1-({4-[({[2-oxo-3-(propan-2-yl)-2,3-dihydro-1H-benzimidazol-1-yl]carbonyl}amino)methyl]piperidin-1-yl}methyl)cyclobutanecarboxylic acid |
| 2933 39 99 | 5421-92-1 | 1-(pyridin-4-yl)pyridinium chloride hydrochloride |
| 2933 39 99 | 272776-12-2 | 1,1′-binaphthalene-2,2′-diol –5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole (1:1) |
| 2933 39 99 | 871022-19-4 | 1-[(4-{[(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)methyl]cyclobutanecarboxylic acid |
| 2933 39 99 | 3613-73-8 | 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole |
| 2933 39 99 | 179687-79-7 | 2-[(2-chloro-4-nitrophenoxy)methyl]pyridine |
| 2933 39 99 | 122321-04-4 | 2-[methyl(pyridin-2-yl)amino]ethanol |
| 2933 39 99 | 945405-37-8 | 2-methyl-3-[(2S)-pyrrolidin-2-ylmethoxy]pyridine 2,3-dihydroxybutanedioate |
| 2933 39 99 | 936637-40-0 | 3,3′-piperidine-1,4-diyldipropan-1-ol 4-methylbenzenesulfonate |
| 2933 39 99 | 88150-62-3 | 3-ethyl-5-methyl-4-(2-chlorophenyl)-2-{[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| 2933 39 99 | 84100-54-9 | 4-(ethylamino)piperidine-4-carboxamide |
| 2933 39 99 | 873546-30-6 | 4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis(N′-hydroxybenzenecarboximidamide) |
| 2933 39 99 | 873546-74-8 | 4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis[N′-(acetyloxy)benzenecarboximidamide] |
| 2933 39 99 | 873546-38-4 | 4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzenecarboximidamide trihydrochloride pentahydrate |
| 2933 39 99 | 873546-80-6 | 4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzonitrile |
| 2933 39 99 | 78750-61-5 | 4-[(3-nitropyridin-2-yl)amino]phenol |
| 2933 39 99 | 866109-93-5 | 4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenol 4-methylbenzenesulfonate |
| 2933 39 99 | 927889-51-8 | 4-bromo-2,6-diethylpyridine 4-methylbenzenesulfonate |
| 2933 39 99 | 691882-47-0 | 4-hydroxybenzoic acid – (2S,4E)-N-methyl-5-[5-(propan-2-yloxy)pyridin-3-yl]pent-4-en-2-amine (1:1) |
| 2933 39 99 | 876068-46-1 | 5,6-dichloro-N-(2,2-dimethoxyethyl)pyridin-3-amine |
| 2933 39 99 | 1072-98-6 | 5-chloropyridin-2-amine |
| 2933 39 99 | 298692-34-9 | 6-(chloroacetyl)pyridine-2-carboxylic acid |
| 2933 39 99 | 550349-58-1 | 7-chloro-3-(6-methoxypyridin-3-yl)-N,N,5-trimethyl-4-oxo-4,5-dihydro-3H-pyridazino[4,5-b]indole-1-carboxamide |
| 2933 39 99 | 414909-98-1 | benzyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate |
| 2933 39 99 | 56880-11-6 | ethyl [(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetate |
| 2933 39 99 | 548797-97-3 | N-(2-{[(2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl]oxy}-4-hydroxyphenyl)acetamide |
| 2933 39 99 | 0-00-0 | N-[(S)-1-azabicyclo[2.2.2]oct-2-yl(phenyl)methyl]-2,6-dichloro-3-(trifluoromethyl)benzamide hydrochloride |
| 2933 39 99 | 329003-65-8 | sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate hemipentahydrate |
| 2933 49 10 | 417716-92-8 | 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide methanesulfonate |
| 2933 49 90 | 503291-53-0 | 2-ethylbutyl (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylate 4-methylbenzenesulfonate |
| 2933 49 90 | 103733-32-0 | benzyl (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride |
| 2933 49 90 | 503293-98-9 | (3S,4aS,6S,8aR)-6-hydroxy-2-(methoxycarbonyl)decahydroisoquinoline-3-carboxylic acid |
| 2933 49 90 | 503290-66-2 | (3S,4aS,6S,8aR)-6-[3-chloro-2-(2H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylic acid hydrochloride |
| 2933 49 90 | 134388-95-7 | (3S,4aS,8aR)-2-(methoxycarbonyl)-6-oxodecahydroisoquinoline-3-carboxylic acid – (1R)-1-phenylethanamine (1:1) |
| 2933 49 90 | 868210-14-4 | 4-(4-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}phenoxy)-2,2-dimethylbutanoic acid |
| 2933 49 90 | 00-00-0 | methyl 2-[(3R)-3-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-({[1-(hydroxymethyl)cyclopropyl]methyl}sulfanyl)propyl]benzoate hydrochloride |
| 2933 49 90 | 848133-76-6 | N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide |
| 2933 59 95 | 869490-23-3 | (3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone |
| 2933 59 95 | 941685-40-1 | (3R)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |
| 2933 59 95 | 941678-49-5 | (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |
| 2933 59 95 | 941685-41-2 | (3S)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |
| 2933 59 95 | 957187-34-7 | [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetic acid |
| 2933 59 95 | 356058-42-9 | {2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl}acetic acid |
| 2933 59 95 | 0-00-0 | 2,3-dihydroxy-2,3-bis(phenylcarbonyl)butanedioic acid – ethyl [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate (1:1) |
| 2933 59 95 | 90213-66-4 | 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine |
| 2933 59 95 | 3934-20-1 | 2,4-dichloropyrimidine |
| 2933 59 95 | 451487-18-6 | 2-[(4-fluorobenzyl)sulfanyl]-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one |
| 2933 59 95 | 865758-96-9 | 2-[(6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]benzonitrile |
| 2933 59 95 | 934815-71-1 | 2-[3-(6-{[2-(2,4-dichlorophenyl)ethyl]amino}-2-methoxypyrimidin-4-yl)phenyl]-2-methylpropanoic acid phosphate |
| 2933 59 95 | 722543-31-9 | 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate |
| 2933 59 95 | 1032066-96-8 | 2-amino-9-{(1S,3R,4S)-3-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]-2-methylidenecyclopentyl}-1,9-dihydro-6H-purin-6-one – methanesulfonate (2:1) |
| 2933 59 95 | 540737-29-9 | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate |
| 2933 59 95 | 1137917-12-4 | 3-{[6-(ethylsulfonyl)pyridin-3-yl]oxy}-5-{[(2S)-1-hydroxypropan-2-yl]oxy}benzoic acid – 1,4-diazabicyclo[2.2.2]octane (2:1) |
| 2933 59 95 | 941685-39-8 | 3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |
| 2933 59 95 | 941685-27-4 | 4-(1H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine |
| 2933 59 95 | 1780-26-3 | 4,6-dichloro-2-methylpyrimidine |
| 2933 59 95 | 145783-14-8 | 4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine |
| 2933 59 95 | 3680-69-1 | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine |
| 2933 59 95 | 61379-64-4 | 4-cyclopentylpiperazin-1-amine |
| 2933 59 95 | 55112-42-0 | 4-methylpiperazine-1-carbonyl chloride hydrochloride |
| 2933 59 95 | 0-00-0 | 5-(benzylamino)-2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)[1,2,4]triazolo[1,5-a]quinoline-4-carbonitrile – (2E)-but-2-enedioate (2:1) hydrate |
| 2933 59 95 | 55293-96-4 | 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde |
| 2933 59 95 | 179688-01-8 | 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one |
| 2933 59 95 | 444731-74-2 | N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine |
| 2933 59 95 | 0-00-0 | N-(5-fluoro-3-methyl-1H-indol-1-yl)-4-methyl-2-(pyridin-2-yl)pyrimidine-5-carboxamide |
| 2933 79 00 | 586414-48-4 | (-)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide |
| 2933 79 00 | 425663-71-4 | (1S)-1-amino-3-methyl-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one hydrochloride |
| 2933 79 00 | 813452-14-1 | (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one dihydrochloride |
| 2933 79 00 | 5162-90-3 | 3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine |
| 2933 79 00 | 536760-29-9 | 3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one |
| 2933 79 00 | 4876-10-2 | 4-(bromomethyl)quinolin-2(1H)-one |
| 2933 79 00 | 5057-12-5 | 4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione |
| 2933 79 00 | 54197-66-9 | 6-hydroxy-3,4-dihydroquinolin-2(1H)-one |
| 2933 79 00 | 22246-18-0 | 7-hydroxy-3,4-dihydroquinolin-2(1H)-one |
| 2933 79 00 | 536759-91-8 | ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate |
| 2933 79 00 | 503614-91-3 | ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate |
| 2933 79 00 | 586379-61-5 | methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate |
| 2933 99 80 | 709031-45-8 | (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate |
| 2933 99 80 | 649735-46-6 | (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol |
| 2933 99 80 | 51077-14-6 | (2S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid |
| 2933 99 80 | 631916-97-7 | (2S)-N-{4-[(Z)-amino(methoxyimino)methyl]benzyl}-1-{(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyethanoyl}azetidine-2-carboxamide – benzenesulphonic acid (1:1) |
| 2933 99 80 | 80875-98-5 | (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid |
| 2933 99 80 | 948846-40-0 | (2S,3S)-2,3-bis[(phenylcarbonyl)oxy]butanedioic acid – ethyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (1:1) |
| 2933 99 80 | 1000164-36-2 | (5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S)-5-(3-amino-3-oxopropyl)-20-benzyl-23-[(2S)-butan-2-yl]-14,38-bis{4-[(tert-butoxycarbonyl)amino]butyl}-29-{[1-(tert-butoxycarbonyl)-1H-indol-3-yl]methyl}-17-(3-tert-butoxy-3-oxopropyl)-1-(1H-fluoren-9-yl)-8,11,26,41,41-pentamethyl-32-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-35-(propan-2-yl)-2-oxa-4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazadotetracontan-42-oic acid |
| 2933 99 80 | 22162-51-2 | 1-(2-nitrobenzyl)-1H-pyrrole-2-carbaldehyde |
| 2933 99 80 | 35681-40-4 | 1-(propan-2-yl)-1,3-dihydro-2H-benzimidazol-2-one |
| 2933 99 80 | 166170-15-6 | 1-(tert-butoxycarbonyl)-2-methyl-D-proline |
| 2933 99 80 | 796967-16-3 | 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea |
| 2933 99 80 | 0-00-0 | 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea hydrochloride |
| 2933 99 80 | 444731-72-0 | 2,3-dimethyl-2H-indazol-6-amine |
| 2933 99 80 | 19686-05-6 | 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole |
| 2933 99 80 | 912444-00-9 | 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide |
| 2933 99 80 | 912445-36-4 | 2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide dihydrochloride |
| 2933 99 80 | 163457-23-6 | 3,3-difluoropyrrolidine hydrochloride |
| 2933 99 80 | 239463-85-5 | 3-{5-[(2R)-2-aminopropyl]-7-cyano-2,3-dihydro-1H-indol-1-yl}propyl benzoate (2R,3R)-2,3-dihydroxybutanedioate |
| 2933 99 80 | 55321-99-8 | 3-oxo-3,4-dihydropyrazine-2-carboxamide |
| 2933 99 80 | 952490-01-6 | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate |
| 2933 99 80 | 942436-93-3 | 4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide |
| 2933 99 80 | 942437-37-8 | 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide |
| 2933 99 80 | 288385-88-6 | 4-fluoro-2-methyl-1H-indol-5-ol |
| 2933 99 80 | 503293-47-8 | 5-(2-chloro-6-fluorophenyl)-2H-tetrazole |
| 2933 99 80 | 73963-42-5 | 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole |
| 2933 99 80 | 606143-52-6 | 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 2933 99 80 | 0-00-0 | 5-fluoro-1-(3-fluorobenzyl)-N-(1H-indol-5-yl)-1H-indole-2-carboxamide |
| 2933 99 80 | 872206-47-8 | 5-methyl-4-oxo-1,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate |
| 2933 99 80 | 259793-88-9 | 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxamide |
| 2933 99 80 | 1137606-74-6 | 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carbonitrile – N-cyclohexylcyclohexanamine (1:1) |
| 2933 99 80 | 261953-36-0 | 6-iodo-1H-indazole |
| 2933 99 80 | 80076-47-7 | 8,9-difluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid |
| 2933 99 80 | 52602-39-8 | 9H-carbazol-4-ol |
| 2933 99 80 | 145641-35-6 | benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride |
| 2933 99 80 | 87269-87-2 | benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride |
| 2933 99 80 | 1012065-72-3 | ethyl 2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylate |
| 2933 99 80 | 131707-24-9 | ethyl 6-bromo-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate |
| 2933 99 80 | 105152-95-2 | ethyl 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate |
| 2933 99 80 | 139481-44-0 | methyl 1-[(2′-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate |
| 2933 99 80 | 0-00-0 | methyl 1-tert-butyl-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate |
| 2933 99 80 | 21688-11-9 | N2-[(benzyloxy)carbonyl]-L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide |
| 2933 99 80 | 361440-67-7 | tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate |
| 2933 99 80 | 709031-38-9 | tert-butyl (2S)-2-carbamoyl-2,3-dihydro-1H-pyrrole-1-carboxylate |
| 2933 99 80 | 709031-43-6 | tert-butyl [(1S)-2-[(1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)-2-oxoethyl]carbamate |
| 2933 49 90 | 936359-25-0 | methyl 2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl)benzoate |
| 2934 10 00 | 110130-88-6 | (2Z)-[(acetyloxy)imino](2-amino-1,3-thiazol-4-yl)ethanoic acid |
| 2934 10 00 | 68672-66-2 | (2Z)-{[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino}[2-(tritylamino)-1,3-thiazol-4-yl]ethanoic acid |
| 2934 10 00 | 291536-35-1 | (5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione |
| 2934 10 00 | 302964-24-5 | 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide |
| 2934 10 00 | 866920-24-3 | 3-[2-chloro-4-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methoxy)phenyl]-1,2,4-oxadiazol-5(4H)-one |
| 2934 10 00 | 752253-39-7 | 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(prop-2-yn-1-yl)-1,3-thiazol-2-amine |
| 2934 10 00 | 914361-45-8 | L-lysine – {[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl]oxy}methyl dihydrogen phosphate – ethanol (1:1:1) |
| 2934 10 00 | 302964-08-5 | N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide |
| 2934 10 00 | 127660-04-2 | sodium (2Z)-(2-amino-1,3-thiazol-4-yl)(hydroxyimino)ethanoate |
| 2934 99 90 | 17381-54-3 | (1-benzothiophen-5-yl)acetic acid |
| 2934 99 90 | 630100-90-2 | (1R)-1,2-anhydro-4-C-{(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carboxylato-4-cycloheptylpiperazin-2-yl)-6,9-dihydroxy-2,6-dimethyl-11-oxooxacyclododec-3-en-1-yl]penta-1,3-dien-1-yl}-3,5-dideoxy-1-[(2R,3S)-3-hydroxypentan-2-yl]-D-erythropentitol |
| 2934 99 90 | 220099-91-2 | (2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridine] |
| 2934 99 90 | 220100-81-2 | (2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridine] (S,S)-2,3-dihydroxybutanedioate |
| 2934 99 90 | 161599-46-8 | (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2-fluoro-5-methyltetrahydrofuran-3,4-diyl diacetate |
| 2934 99 90 | 690270-65-6 | (2R,3S,4R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-{[(2-methylpropanoyl)oxy]methyl}tetrahydrofuran-3,4-diyl bis(2-methylpropanoate) hydrochloride |
| 2934 99 90 | 265121-04-8 | (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(2-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid – 1-deoxy-1-(methylamino)-D-glucitol (1:2) |
| 2934 99 90 | 163680-80-6 | (3S)-10-[1-(acetylamino)cyclopropyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| 2934 99 90 | 132335-46-7 | (3S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine |
| 2934 99 90 | 133413-70-4 | (3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzyl-4,10,12,16,22,24-hexamethyl-3,9,15,21-tetrakis(2-methylpropyl)-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosane-2,5,8,11,14,17,20,23-octone |
| 2934 99 90 | 503068-36-8 | (5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one |
| 2934 99 90 | 452339-73-0 | (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one |
| 2934 99 90 | 877130-28-4 | (6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one |
| 2934 99 90 | 132335-44-5 | (S)-3-(dimethylamino)-1-(thiophen-2-yl)propan-1-ol |
| 2934 99 90 | 812647-80-6 | {(2R,3S,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-bis[(phenylcarbonyl)oxy]tetrahydrofuran-2-yl}methyl 3-chlorobenzoate |
| 2934 99 90 | 00-00-0 | 1-(1-{4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butyl}-1,2,3,6-tetrahydropyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one |
| 2934 99 90 | 1029716-44-6 | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |
| 2934 99 90 | 165172-60-1 | 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione – 1-methylpyrrolidin-2-one (1:1) |
| 2934 99 90 | 519187-97-4 | 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-3-azetidinol – (2Z)-2-butenedioate (1:1) |
| 2934 99 90 | 127000-90-2 | 1-{[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiran-2-yl]methyl}-1H-1,2,4-triazole |
| 2934 99 90 | 710281-33-7 | 2-({[(1R,3S)-3-{[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}cyclohexyl]oxy}methyl)-6-methylbenzoic acid |
| 2934 99 90 | 96803-30-4 | 2-(1-benzothiophen-5-yl)ethanol |
| 2934 99 90 | 913695-00-8 | 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1Hbenzimidazole, sodium salt (1:1) |
| 2934 99 90 | 376608-74-1 | 2-{[(3aR,4S,6R,6aS)-6-{[5-amino-6-chloro-2-(propylsulfanyl)pyrimidin-4-yl]amino}-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol |
| 2934 99 90 | 474554-48-8 | 2-bromo-1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethanone |
| 2934 99 90 | 530141-72-1 | 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-[(3-hydroxy-1,2-benzoxazol-6-yl)methoxy]phenyl)propanoic acid |
| 2934 99 90 | 519188-55-7 | 3-[2-(1-benzothiophen-5-yl)ethoxy]-1-(3-hydroxyazetidin-1-yl)propan-1-one |
| 2934 99 90 | 519188-42-2 | 3-[2-(1-benzothiophen-5-yl)ethoxy]propionic acid |
| 2934 99 90 | 753015-42-8 | 3-{(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl}-5-(tetrahydro-2H-pyran-4-yloxy)pyridine |
| 2934 99 90 | 26638-53-9 | 3-chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide |
| 2934 99 90 | 499785-81-8 | 3-oxo-4-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide |
| 2934 99 90 | 356782-84-8 | 3-oxo-4-(β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide |
| 2934 99 90 | 6504-57-0 | 4-[3-hydroxy-3-phenyl-3-(thiophen-2-yl)propyl]-4-methylmorpholin-4-ium methyl sulfate |
| 2934 99 90 | 871484-32-1 | 4-[4-({3-[(4-deoxy-4-fluoro-b-D-glucopyranosyl)oxy]-5-(propan-2-yl)-1H-pyrazol-4-yl}methyl)phenyl]-N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]butanamide |
| 2934 99 90 | 166964-09-6 | 4-chloro-3-methyl-1,2-oxazol-5-amine |
| 2934 99 90 | 655233-39-3 | 4-nitrobenzyl(6R,7R)-7-amino-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride |
| 2920 90 85 | 89729-09-9 | 5,7-dioxa-6-thiaspiro[2.5]octane-6-oxide |
| 2934 99 90 | 388082-75-5 | 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarboxaldehyde – 4-methylbenzenesulfonate (1:1) |
| 2934 99 90 | 4923-87-9 | 5-bromo-1-benzothiophene |
| 2934 99 90 | 947408-95-9 | 6-(bromomethyl)-2-triphenylmethyl-1,2-benzisoxazol-3(2H)-one |
| 2934 99 90 | 947408-94-8 | 6-methyl-2-trityl-1,2-benzoxazol-3(2H)-one |
| 2934 99 90 | 67978-05-6 | diphenylmethyl(2R)-3-methyl-2-[(1R,5S)-3-(4-methylphenyl)-7-oxo-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-6-yl]but-3-enoate |
| 2934 99 90 | 1001859-46-6 | DNA (synthetic plasmid vector pCOR human interferon beta signal peptide fusion protein with 21-154-human acidic fibroblast growth factor-specifying) |
| 2934 99 90 | 665058-78-6 | DNA, d(T-sp-C-G-sp-T-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-G-sp-A-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-Gsp-T-sp-C-G-sp-T-sp-T) |
| 2934 99 90 | 923591-06-4 | methyl (5R,7S,10S)-10-tert-butyl-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxylate |
| 2934 99 90 | 59337-92-7 | methyl 3-(chlorosulfonyl)thiophene-2-carboxylate |
| 2934 99 90 | 947409-01-0 | methyl 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(2-triphenylmethyl-1,2-benzisoxazol-3(2H)-on-6-yl)methoxy]phenyl]propionate |
| 2934 99 90 | 85006-31-1 | methyl 3-amino-4-methylthiophene-2-carboxylate |
| 2934 99 90 | 893428-72-3 | N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine – (2E)-2-butenedioate (1:2) |
| 2934 99 90 | 390800-88-1 | N,N′,N′′-(boroxin-2,4,6-triyltris{[(1S)-3-methylbutane-1,1-diyl]imino[(2S)-1-oxo-3-phenylpropane-1,2-diyl]})tripyrazine-2-carboxamide |
| 2934 99 90 | 112913-94-7 | N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide |
| 2934 99 90 | 120788-03-6 | S-[(1R,3S)-1-oxidotetrahydrothiophen-3-yl] ethanethioate |
| 2935 00 90 | 1198178-65-2 | (1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropanaminium 4-methylbenzenesulfonate |
| 2935 00 90 | 39570-96-2 | (2R)-3-(benzylsulfanyl)-N-[(2S)-1-{[(2S,3S)-1-hydrazinyl-3-methyl-1-oxopentan-2-yl]amino}-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-{[(4-methylphenyl)sulfonyl]amino}propanamide |
| 2935 00 90 | 24310-36-9 | 1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one |
| 2935 00 90 | 0-00-0 | 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide di[(2E)-but-2-enedioate] hydrate |
| 2935 00 90 | 941690-55-7 | 3-[(methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide |
| 2935 00 90 | 6973-09-7 | 5-amino-2-methylbenzenesulfonamide |
| 2935 00 90 | 193686-76-9 | 7-chloro-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one |
| 2935 00 90 | 123664-84-6 | N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide |
| 2935 00 90 | 149457-03-4 | N-[4-(N-formylglycyl)-5-hydroxy-2-phenoxyphenyl]methanesulfonamide |
| 2935 00 90 | 149456-98-4 | N-[4-(N-formylglycyl)-5-methoxy-2-phenoxyphenyl]methanesulfonamide |
| 2935 00 90 | 141450-48-8 | N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide hydrochloride |
| 2935 00 90 | 289042-10-0 | N-{5-[(diphenylphosphoryl)methyl]-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl}-N-methylmethanesulfonamide |
| 2939 99 00 | 7689-03-4 | (4S)-4-ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione |
| 2939 99 00 | 477-29-2 | colchicoside |
| 2940 00 00 | 604-69-3 | 1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose |
| 2940 00 00 | 647834-15-9 | 2-(4-methoxybenzyl)thiophen-3-yl β-D-glucopyranoside |
| 2941 90 00 | 76610-92-9 | (6R,7R)-7-({N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| 3907 20 99 | 913976-27-9 | poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy, diester with 21N6, 21′N6-[[(N2, N6-dicarboxy-L-lysyl-β-alanyl)imino]bis(1-oxo-2, 1-ethanediyl)]bis[N-acetylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] cyclic (6→15), (6′→15′) bis(disulfide) |

CN code

CAS RN

Name

2843 29 00

22199-08-2

[4-amino-N-(pyrimidin-2(1H)-ylidene-κN1)benzenesulfonamidato-κO]silver

2905 39 95

281214-27-5

(2R,3R)-2,3-dimethylbutane-1,4-diyl bis(4-methylbenzenesulfonate)

2905 59 98

441002-17-1

4-chlorobutyl 2-nitrobenzenesulfonate

2909 30 90

92878-95-0

2-(3-chloropropoxy)-1-methoxy-4-nitrobenzene

2909 30

503070-57-3

2-({2-[(6-bromohexyl)oxy]ethoxy}methyl)-1,3-dichlorobenzene

2909 30

461432-23-5

4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether

2909 49 80

185954-75-0

(3R)-3-methoxydecan-1-ol

2909 49 80

85309-91-7

2-[(2,6-dichlorobenzyl)oxy]ethanol

2909 49 80

160969-03-9

2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl methanesulfonate

2909 50 00

167145-13-3

2-[2-(3-methoxyphenyl)ethyl]phenol

2910 20 00

15448-47-2

(2R)-2-methyloxirane

2910 90 00

62600-71-9

(2R)-2-(3-chlorophenyl)oxirane

2910 90 00

702687-42-1

(2R)-2-[(5-bromo-2,3-difluorophenoxy)methyl]oxirane

2910 90 00

683276-64-4

[(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzenesulfonate

2913 00 00

90035-34-0

4′-(trifluoromethyl)biphenyl-4-carbaldehyde

2914 40 90

17752-16-8

(3β)-3-hydroxycholest-5-en-24-one

2914 50 00

974-23-2

(3β,16α)-3-hydroxy-16,17-epoxypregn-5-en-20-one

2914 70 00

13054-81-4

4-chloro-heptane-3,5-dione

2914 70 00

10226-30-9

6-chlorohexan-2-one

2915 60 90

53064-79-2

iodomethyl pivalate

2915 90 00

22328-90-1

(3R)-3-methylhexanoic acid

2915 90 00

1069-66-5

sodium 2-propylpentanoate

2916 20 00

211515-46-7

1-(2-ethylbutyl)cyclohexanecarbonyl chloride

2916 20 00

381209-09-2

1-(2-ethylbutyl)cyclohexanecarboxylic acid

2916 20 00

7077-05-6

trans-4-(propan-2-yl)cyclohexanecarboxylic acid

2916 39 00

21900-39-0

5-fluoro-2-methylbenzoyl chloride

2916 39 00

17625-03-5

sodium hydrogen 3-sulfonatobenzoate

2917 19 90

76-72-2

diethyl ethyl(pentan-2-yl)propanedioate

2918 29 00

376592-58-4

5′-chloro-2′-hydroxy-3′-nitrobiphenyl-3-carboxylic acid

2918 99 90

709031-28-7

(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)acetic acid

2918 99 90

35480-52-5

2,5-bis(2,2,2-trifluoroethoxy)benzoic acid

2918 99 90

4651-67-6

(3α,5β)-3-hydroxy-7-oxocholan-24-oic acid

2918 99 90

52179-28-9

ethyl 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoate

2918 99 90

530141-60-7

methyl 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-hydroxyphenyl)propanoate

2920 90 10

91526-18-0

4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one

2921 49 00

334477-60-0

(1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine

2921 49 00

376608-71-8

(1R,2S)-2-(3,4-difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate

2921 49 00

1034457-07-2

2-(2,3-dihydro-1H-inden-2-yl)propan-2-amine hydrochloride

2921 49 00

945717-05-5

2-(4-chloro-3-ethylphenyl)ethanamine hydrochloride

2921 49 00

89-97-4

2-chlorobenzylamine

2921 49 00

945717-43-1

N-(4-tert-butylbenzyl)-2-(4-chloro-3-ethylphenyl)ethanamine

2921 51 90

150812-21-8

N4-[(4-fluorophenyl)methyl]-2-nitro-1,4-benzenediamine

2922 19 85

1035455-90-3

(2R)-1-(5-bromo-2,3-difluorophenoxy)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}propan-2-ol hydrochloride

2922 19 85

0-00-0

[2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride

2922 19 85

133-51-7

antimonic acid – 1-deoxy-1-(methylamino)-D-glucitol (1:1)

2922 19 85

1035455-87-8

ethyl (2E)-3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)prop-2-enoate hydrochloride

2922 19 85

702686-97-3

ethyl 3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)propanoate hydrochloride

2922 29 00

20059-73-8

2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamine

2922 49 85

848133-35-7

(2E)-4-(dimethylamino)but-2-enoic acid hydrochloride

2922 49 85

610300-07-7

(3S,5R)-3-amino-5-methyloctanoic acid

2922 49 85

610300-00-0

(3S,5R)-3-amino-5-methyloctanoic acid hydrochloride

2922 49 85

143785-86-8

4-(1-aminocyclopropyl)-2,3,5-trifluorobenzoic acid

2922 49 85

848949-85-9

4-fluoro-L-leucine – ethyl hydrogen sulfate (1:1)

2922 49 85

39068-93-4

methyl 2-(dimethylamino)-2-phenylbutanoate

2922 49 85

168619-25-8

methyl 3′-aminobiphenyl-3-carboxylate

2922 49 85

82834-12-6

N-[(2S)-1-ethoxy-1-oxopentan-2-yl]-L-alanine

2922 49 85

94133-84-3

sodium 2-amino-2-phenylbutanoate

2922 50 00

503070-58-4

triphenylacetic acid – 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1)

2924 19 00

62009-47-6

2-aminomalonamide

2924 19 00

7355-58-0

N-(2-chloroethyl)acetamide

2924 29 98

361442-00-4

{2-[(tert-butoxycarbonyl)amino]-3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl}acetic acid

2924 29 98

266993-72-0

2,3-diaminobenzamide dihydrochloride

2924 29 98

168080-49-7

2-chloro-4-{[(5-fluoro-2-methylphenyl)carbonyl]amino}benzoic acid

2924 29 98

317374-08-6

2-methyl-4-{[(2-methylphenyl)carbonyl]amino}benzoic acid

2924 29 98

143785-84-6

4-(1-carbamoylcyclopropyl)-2,3,5-trifluorobenzoic acid

2924 29 98

143785-87-9

4-[1-(acetylamino)cyclopropyl]-2,3,5-trifluorobenzoic acid

2924 29 98

108166-22-9

4-{[(2-methylphenyl)carbonyl]amino}benzoic acid

2924 29 98

150812-23-0

ethyl {4-[(4-fluorobenzyl)amino]-2-nitrophenyl}carbamate

2924 29 98

22316-45-6

ethyl 3-[(5-chloro-2-nitrophenyl)(phenyl)amino]-3-oxopropanoate

2924 29 98

316173-29-2

methyl (1S,2S,3S,4R)-3-[(1S)-1-amino-2-ethylbutyl]-4-[(tert-butoxycarbonyl)amino]-2-hydroxycyclopentanecarboxylate

2924 29 98

1142-20-7

N-benzyloxycarbonyl-L-alanine

2924 29 98

84996-93-0

N-cyclohexyl-5-hydroxypentanamide

2924 29 98

579494-66-9

propyl {4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl}acetate

2925 19 95

265136-65-0

ethyl 3-amino-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]but-2-enoate

2926 90 95

855425-38-6

1-(2-ethylbutyl)cyclohexanecarbonitrile

2926 90 95

846023-24-3

2-cyano-N-(2,4-dichloro-5-methoxyphenyl)acetamide

2926 90 95

591769-05-0

3-cyclopentylprop-2-enenitrile

2926 90 95

20099-89-2

4-(bromoacetyl)benzonitrile

2926 90 95

474554-45-5

4,5-diethoxy-3-fluorobenzene-1,2-dicarbonitrile

2926 90 95

79370-78-8

5-hydroxybenzene-1,3-dicarbonitrile

2926 90 95

139481-28-0

methyl 2-{[(2′-cyanobiphenyl-4-yl)methyl]amino}-3-nitrobenzoate

2928 00 90

860035-10-5

1-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)ethyl 2-methylpropanoate

2928 00 90

910656-45-0

2-hydroxy-2-(trifluoromethyl)butanehydrazide

2928 00 90

95759-10-7

4-chloro-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoic acid

2928 00 90

473927-63-8

ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate

2928 00 90

158671-29-5

N,2-dihydroxy-4-methylbenzamide

2928 00 90

84080-68-2

tert-butyl (2Z)-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate

2928 00 90

268544-50-9

tert-butyl-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate

2930 90 99

13459-62-6

{2-[(4-chlorophenyl)sulfanyl]phenyl}acetic acid

2930 90 99

211513-21-2

1-(2-ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide

2930 90 99

860035-07-0

1-{[(methylsulfanyl)carbonyl]oxy}ethyl 2-methylpropanoate

2930 90 99

893407-18-6

2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethanone

2930 90 99

60759-00-4

3,4-diethoxybenzenecarbothioamide

2930 90 99

21048-05-5

N-methylbenzenecarbothiohydrazide

2931 00 99

13682-94-5

(2-bromoethenyl)(trimethyl)silane

2931 00 99

914922-89-7

(2R,4R)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methoxy-N,2-dimethyl-7-oxoheptanamide

2931 00 99

914922-88-6

(2R,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N,2-dimethyloct-7-enamide

2931 00 99

871355-80-5

(4R)-2-bromo-7-{[tert-butyl(diphenyl)silyl]oxy}hept-1-en-4-yl 4-methylbenzenesulfonate

2931 00 99

89694-48-4

(5-chloro-2-methoxyphenyl)boronic acid

2931 00 99

701278-08-2

[(1R,5S)-5-[dimethyl(phenyl)silyl]-2-{[(2-methoxypropan-2-yl)oxy]methyl}cyclopent-2-en-1-yl]methanol

2931 00 99

701278-09-3

{(4S,5R)-5-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]cyclopent-1-en-1-yl}methanol

2931 00 99

796967-18-5

1-(2-fluoro-5-methylphenyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea

2931 00 99

172732-52-4

2-(1,3,2-dioxaborinan-2-yl)benzonitrile

2931 00 99

185411-12-5

methyl 3-(trimethylsilyl)pent-4-enoate

2932 19 00

253128-10-8

(1S)-1,5:7,10-dianhydro-12,13-bis-O-[tert-butyl(dimethyl)silyl]-2,3,4,6,8,11-hexadeoxy-1-{2-[(2S,5S)-5-(3-hydroxypropyl)-3-methylidenetetrahydrofuran-2-yl]ethyl}-3-methyl-9-O-methyl-4-methylidene-8-[(phenylsulfonyl)methyl]-D-arabino-D-altro-tridecitol

2932 19 00

441045-17-6

(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one methanesulfonate

2932 29 85

916069-80-2

(4S)-4-(fluoromethyl)dihydrofuran-2(3H)-one

2932 29 85

63106-93-4

1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one

2932 29 85

7734-80-7

2-oxo-2H-chromene-6-carboxylic acid

2932 29 85

0-00-0

4-(4-fluorophenyl)-7-(isothiocyanatomethyl)-2H-chromen-2-one

2932 29 85

947408-91-5

6-[(2,4-dihydroxyphenyl)carbonyl]-2H-chromen-2-one

2932 29 85

947408-90-4

6-[(2,4-dimethoxyphenyl)carbonyl]-2H-chromen-2-one

2932 99 00

452342-08-4

(1R)-2-(benzylamino)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol

2932 99 00

99541-23-8

(1R,2S,3R,4R,5R)-4-azido-2-{[(4aR,6S,7R,8S,8aR)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy}-6,8-dioxabicyclo[3.2.1]oct-3-yl acetate

2932 99 00

461432-25-7

(1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol

2932 99 00

196597-79-2

(2E)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile

2932 99 00

3308-94-9

2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane

2932 99 00

274693-53-7

[(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]carbamate

2932 99 00

185954-98-7

[6(2Z,3R)]-3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-(3-metoxydecyl)-6-methyl-2-[(1-oxo-11-octadecenyl)amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-D-glucopyranose 1-(dihydrogen phosphate) tetrasodium salt

2932 99 00

136172-58-2

1,6-di-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-glucopyranose

2932 99 00

196597-80-5

2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethanamine hydrochloride

2932 99 00

666860-59-9

2-amino-2-oxoethyl{3-[trans-5-(6-methoxynaphthalen-1-yl)-1,3-dioxan-2-yl]propyl}carbamate

2932 99 00

117661-72-0

5-(chloromethyl)-6-methyl-1,3-benzodioxole

2932 99 00

959624-24-9

6-(hydroxymethyl)-4-phenyl-3,4-dihydro-2H-chromen-2-ol

2932 99 00

960404-59-5

but-2-yne-1,4-diol – methyl 1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-α-D-glucopyranoside (1:1)

2932 99 00

15826-37-6

disodium 5,5′-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate)

2932 99 00

204254-84-2

ethyl (3aR,7R,7aR)-2,2-dimethyl-7-[(methylsulfonyl)oxy]-3a,6,7,7a-tetrahydro-1,3-benzodioxole-5-carboxylate

2932 99 00

99541-26-1

methyl (2S,3S,4S,5S,6S)-6-{[(1S,2S,3S,4R,5R)-3-(acetyloxy)-4-azido-6,8-dioxabicyclo[3.2.1]oct-2-yl]methyl}-4,5-bis(benzyloxy)-3-hydroxytetrahydro-2H-pyran-2-carboxylate

2932 99 00

114869-97-5

methyl 6-O-acetyl-4-O-(2-O-acetyl-3-O-benzyl-6-methyl-α-L-idopyranuronosyl)-3-O-benzyl-2-{[(benzyloxy)carbonyl]amino}-2-deoxy-α-D-glucopyranoside

2933 19 90

1035677-60-1

(4S)-3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide 2,3-dihydroxybutanedioate

2933 19 90

18048-64-1

2-(3,4-dimethylphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one

2933 19 90

1035675-24-1

3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide

2933 19 90

1028026-83-6

5-methyl-1-(propan-2-yl)-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one

2933 19 90

473921-12-9

5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile

2933 29 90

65902-59-2

2-bromo-4-nitro-1H-imidazole

2933 29 90

57531-37-0

2-chloro-4-nitro-1H-imidazole

2933 29 90

1000164-35-1

3-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-L-histidyl-2-methylalanyl-L-α-glutamylglycine

2933 29 90

152074-97-0

L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine

2933 29 90

781666-30-6

L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine tetraacetate

2933 29 90

451470-33-0

methyl 3′-(2-methyl-4,5-dihydro-1H-imidazol-1-yl)biphenyl-3-carboxylate

2933 39 99

925978-49-0

(+)-5-[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]-1-azabicyclo[3.2.1]octane

2933 39 99

876170-44-4

(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

2933 39 99

741705-70-4

(2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride

2933 39 99

414910-13-7

(2S)-hydroxy(phenyl)ethanoic acid – (2R)-2-(4-fluoro-2-methylphenyl)piperidin-4-one (1:1)

2933 39 99

0-00-0

(3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole 4-methylbenzenesulfonate

2933 39 99

370882-57-8

(3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride

2933 39 99

334618-23-4

(3R)-piperidin-3-amine dihydrochloride

2933 39 99

1062580-52-2

(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

2933 39 99

27262-47-1

(S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

2933 39 99

105812-81-5

[(3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl]methanol

2933 39 99

876068-51-8

[(3S,4S)-4-amino-1-(5,6-dichloropyridin-3-yl)pyrrolidin-3-yl]methanol

2933 39 99

871022-14-9

1-({4-[({[2-oxo-3-(propan-2-yl)-2,3-dihydro-1H-benzimidazol-1-yl]carbonyl}amino)methyl]piperidin-1-yl}methyl)cyclobutanecarboxylic acid

2933 39 99

5421-92-1

1-(pyridin-4-yl)pyridinium chloride hydrochloride

2933 39 99

272776-12-2

1,1′-binaphthalene-2,2′-diol –5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole (1:1)

2933 39 99

871022-19-4

1-[(4-{[(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)methyl]cyclobutanecarboxylic acid

2933 39 99

3613-73-8

2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole

2933 39 99

179687-79-7

2-[(2-chloro-4-nitrophenoxy)methyl]pyridine

2933 39 99

122321-04-4

2-[methyl(pyridin-2-yl)amino]ethanol

2933 39 99

945405-37-8

2-methyl-3-[(2S)-pyrrolidin-2-ylmethoxy]pyridine 2,3-dihydroxybutanedioate

2933 39 99

936637-40-0

3,3′-piperidine-1,4-diyldipropan-1-ol 4-methylbenzenesulfonate

2933 39 99

88150-62-3

3-ethyl-5-methyl-4-(2-chlorophenyl)-2-{[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

2933 39 99

84100-54-9

4-(ethylamino)piperidine-4-carboxamide

2933 39 99

873546-30-6

4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis(N′-hydroxybenzenecarboximidamide)

2933 39 99

873546-74-8

4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis[N′-(acetyloxy)benzenecarboximidamide]

2933 39 99

873546-38-4

4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzenecarboximidamide trihydrochloride pentahydrate

2933 39 99

873546-80-6

4,4′-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzonitrile

2933 39 99

78750-61-5

4-[(3-nitropyridin-2-yl)amino]phenol

2933 39 99

866109-93-5

4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenol 4-methylbenzenesulfonate

2933 39 99

927889-51-8

4-bromo-2,6-diethylpyridine 4-methylbenzenesulfonate

2933 39 99

691882-47-0

4-hydroxybenzoic acid – (2S,4E)-N-methyl-5-[5-(propan-2-yloxy)pyridin-3-yl]pent-4-en-2-amine (1:1)

2933 39 99

876068-46-1

5,6-dichloro-N-(2,2-dimethoxyethyl)pyridin-3-amine

2933 39 99

1072-98-6

5-chloropyridin-2-amine

2933 39 99

298692-34-9

6-(chloroacetyl)pyridine-2-carboxylic acid

2933 39 99

550349-58-1

7-chloro-3-(6-methoxypyridin-3-yl)-N,N,5-trimethyl-4-oxo-4,5-dihydro-3H-pyridazino[4,5-b]indole-1-carboxamide

2933 39 99

414909-98-1

benzyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate

2933 39 99

56880-11-6

ethyl [(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetate

2933 39 99

548797-97-3

N-(2-{[(2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl]oxy}-4-hydroxyphenyl)acetamide

2933 39 99

0-00-0

N-[(S)-1-azabicyclo[2.2.2]oct-2-yl(phenyl)methyl]-2,6-dichloro-3-(trifluoromethyl)benzamide hydrochloride

2933 39 99

329003-65-8

sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate hemipentahydrate

2933 49 10

417716-92-8

4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide methanesulfonate

2933 49 90

503291-53-0

2-ethylbutyl (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylate 4-methylbenzenesulfonate

2933 49 90

103733-32-0

benzyl (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride

2933 49 90

503293-98-9

(3S,4aS,6S,8aR)-6-hydroxy-2-(methoxycarbonyl)decahydroisoquinoline-3-carboxylic acid

2933 49 90

503290-66-2

(3S,4aS,6S,8aR)-6-[3-chloro-2-(2H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylic acid hydrochloride

2933 49 90

134388-95-7

(3S,4aS,8aR)-2-(methoxycarbonyl)-6-oxodecahydroisoquinoline-3-carboxylic acid – (1R)-1-phenylethanamine (1:1)

2933 49 90

868210-14-4

4-(4-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}phenoxy)-2,2-dimethylbutanoic acid

2933 49 90

00-00-0

methyl 2-[(3R)-3-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-({[1-(hydroxymethyl)cyclopropyl]methyl}sulfanyl)propyl]benzoate hydrochloride

2933 49 90

848133-76-6

N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide

2933 59 95

869490-23-3

(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone

2933 59 95

941685-40-1

(3R)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile

2933 59 95

941678-49-5

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile

2933 59 95

941685-41-2

(3S)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile

2933 59 95

957187-34-7

[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetic acid

2933 59 95

356058-42-9

{2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl}acetic acid

2933 59 95

0-00-0

2,3-dihydroxy-2,3-bis(phenylcarbonyl)butanedioic acid – ethyl [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate (1:1)

2933 59 95

90213-66-4

2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

2933 59 95

3934-20-1

2,4-dichloropyrimidine

2933 59 95

451487-18-6

2-[(4-fluorobenzyl)sulfanyl]-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one

2933 59 95

865758-96-9

2-[(6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]benzonitrile

2933 59 95

934815-71-1

2-[3-(6-{[2-(2,4-dichlorophenyl)ethyl]amino}-2-methoxypyrimidin-4-yl)phenyl]-2-methylpropanoic acid phosphate

2933 59 95

722543-31-9

2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate

2933 59 95

1032066-96-8

2-amino-9-{(1S,3R,4S)-3-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]-2-methylidenecyclopentyl}-1,9-dihydro-6H-purin-6-one – methanesulfonate (2:1)

2933 59 95

540737-29-9

3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

2933 59 95

1137917-12-4

3-{[6-(ethylsulfonyl)pyridin-3-yl]oxy}-5-{[(2S)-1-hydroxypropan-2-yl]oxy}benzoic acid – 1,4-diazabicyclo[2.2.2]octane (2:1)

2933 59 95

941685-39-8

3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile

2933 59 95

941685-27-4

4-(1H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine

2933 59 95

1780-26-3

4,6-dichloro-2-methylpyrimidine

2933 59 95

145783-14-8

4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine

2933 59 95

3680-69-1

4-chloro-7H-pyrrolo[2,3-d]pyrimidine

2933 59 95

61379-64-4

4-cyclopentylpiperazin-1-amine

2933 59 95

55112-42-0

4-methylpiperazine-1-carbonyl chloride hydrochloride

2933 59 95

0-00-0

5-(benzylamino)-2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)[1,2,4]triazolo[1,5-a]quinoline-4-carbonitrile – (2E)-but-2-enedioate (2:1) hydrate

2933 59 95

55293-96-4

5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde

2933 59 95

179688-01-8

7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one

2933 59 95

444731-74-2

N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine

2933 59 95

0-00-0

N-(5-fluoro-3-methyl-1H-indol-1-yl)-4-methyl-2-(pyridin-2-yl)pyrimidine-5-carboxamide

2933 79 00

586414-48-4

(-)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide

2933 79 00

425663-71-4

(1S)-1-amino-3-methyl-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one hydrochloride

2933 79 00

813452-14-1

(4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one dihydrochloride

2933 79 00

5162-90-3

3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine

2933 79 00

536760-29-9

3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one

2933 79 00

4876-10-2

4-(bromomethyl)quinolin-2(1H)-one

2933 79 00

5057-12-5

4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione

2933 79 00

54197-66-9

6-hydroxy-3,4-dihydroquinolin-2(1H)-one

2933 79 00

22246-18-0

7-hydroxy-3,4-dihydroquinolin-2(1H)-one

2933 79 00

536759-91-8

ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate

2933 79 00

503614-91-3

ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate

2933 79 00

586379-61-5

methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate

2933 99 80

709031-45-8

(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate

2933 99 80

649735-46-6

(2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol

2933 99 80

51077-14-6

(2S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid

2933 99 80

631916-97-7

(2S)-N-{4-[(Z)-amino(methoxyimino)methyl]benzyl}-1-{(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyethanoyl}azetidine-2-carboxamide – benzenesulphonic acid (1:1)

2933 99 80

80875-98-5

(2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid

2933 99 80

948846-40-0

(2S,3S)-2,3-bis[(phenylcarbonyl)oxy]butanedioic acid – ethyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (1:1)

2933 99 80

1000164-36-2

(5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S)-5-(3-amino-3-oxopropyl)-20-benzyl-23-[(2S)-butan-2-yl]-14,38-bis{4-[(tert-butoxycarbonyl)amino]butyl}-29-{[1-(tert-butoxycarbonyl)-1H-indol-3-yl]methyl}-17-(3-tert-butoxy-3-oxopropyl)-1-(1H-fluoren-9-yl)-8,11,26,41,41-pentamethyl-32-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-35-(propan-2-yl)-2-oxa-4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazadotetracontan-42-oic acid

2933 99 80

22162-51-2

1-(2-nitrobenzyl)-1H-pyrrole-2-carbaldehyde

2933 99 80

35681-40-4

1-(propan-2-yl)-1,3-dihydro-2H-benzimidazol-2-one

2933 99 80

166170-15-6

1-(tert-butoxycarbonyl)-2-methyl-D-proline

2933 99 80

796967-16-3

1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea

2933 99 80

0-00-0

1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea hydrochloride

2933 99 80

444731-72-0

2,3-dimethyl-2H-indazol-6-amine

2933 99 80

19686-05-6

2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole

2933 99 80

912444-00-9

2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide

2933 99 80

912445-36-4

2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide dihydrochloride

2933 99 80

163457-23-6

3,3-difluoropyrrolidine hydrochloride

2933 99 80

239463-85-5

3-{5-[(2R)-2-aminopropyl]-7-cyano-2,3-dihydro-1H-indol-1-yl}propyl benzoate (2R,3R)-2,3-dihydroxybutanedioate

2933 99 80

55321-99-8

3-oxo-3,4-dihydropyrazine-2-carboxamide

2933 99 80

952490-01-6

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate

2933 99 80

942436-93-3

4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide

2933 99 80

942437-37-8

4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide

2933 99 80

288385-88-6

4-fluoro-2-methyl-1H-indol-5-ol

2933 99 80

503293-47-8

5-(2-chloro-6-fluorophenyl)-2H-tetrazole

2933 99 80

73963-42-5

5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole

2933 99 80

606143-52-6

5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide

2933 99 80

0-00-0

5-fluoro-1-(3-fluorobenzyl)-N-(1H-indol-5-yl)-1H-indole-2-carboxamide

2933 99 80

872206-47-8

5-methyl-4-oxo-1,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate

2933 99 80

259793-88-9

6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxamide

2933 99 80

1137606-74-6

6-fluoro-3-oxo-3,4-dihydropyrazine-2-carbonitrile – N-cyclohexylcyclohexanamine (1:1)

2933 99 80

261953-36-0

6-iodo-1H-indazole

2933 99 80

80076-47-7

8,9-difluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid

2933 99 80

52602-39-8

9H-carbazol-4-ol

2933 99 80

145641-35-6

benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride

2933 99 80

87269-87-2

benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride

2933 99 80

1012065-72-3

ethyl 2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylate

2933 99 80

131707-24-9

ethyl 6-bromo-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate

2933 99 80

105152-95-2

ethyl 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate

2933 99 80

139481-44-0

methyl 1-[(2′-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate

2933 99 80

0-00-0

methyl 1-tert-butyl-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

2933 99 80

21688-11-9

N2-[(benzyloxy)carbonyl]-L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide

2933 99 80

361440-67-7

tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate

2933 99 80

709031-38-9

tert-butyl (2S)-2-carbamoyl-2,3-dihydro-1H-pyrrole-1-carboxylate

2933 99 80

709031-43-6

tert-butyl [(1S)-2-[(1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)-2-oxoethyl]carbamate

2933 49 90

936359-25-0

methyl 2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl)benzoate

2934 10 00

110130-88-6

(2Z)-[(acetyloxy)imino](2-amino-1,3-thiazol-4-yl)ethanoic acid

2934 10 00

68672-66-2

(2Z)-{[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino}[2-(tritylamino)-1,3-thiazol-4-yl]ethanoic acid

2934 10 00

291536-35-1

(5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione

2934 10 00

302964-24-5

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

2934 10 00

866920-24-3

3-[2-chloro-4-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methoxy)phenyl]-1,2,4-oxadiazol-5(4H)-one

2934 10 00

752253-39-7

4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(prop-2-yn-1-yl)-1,3-thiazol-2-amine

2934 10 00

914361-45-8

L-lysine – {[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl]oxy}methyl dihydrogen phosphate – ethanol (1:1:1)

2934 10 00

302964-08-5

N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide

2934 10 00

127660-04-2

sodium (2Z)-(2-amino-1,3-thiazol-4-yl)(hydroxyimino)ethanoate

2934 99 90

17381-54-3

(1-benzothiophen-5-yl)acetic acid

2934 99 90

630100-90-2

(1R)-1,2-anhydro-4-C-{(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carboxylato-4-cycloheptylpiperazin-2-yl)-6,9-dihydroxy-2,6-dimethyl-11-oxooxacyclododec-3-en-1-yl]penta-1,3-dien-1-yl}-3,5-dideoxy-1-[(2R,3S)-3-hydroxypentan-2-yl]-D-erythropentitol

2934 99 90

220099-91-2

(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridine]

2934 99 90

220100-81-2

(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridine] (S,S)-2,3-dihydroxybutanedioate

2934 99 90

161599-46-8

(2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2-fluoro-5-methyltetrahydrofuran-3,4-diyl diacetate

2934 99 90

690270-65-6

(2R,3S,4R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-{[(2-methylpropanoyl)oxy]methyl}tetrahydrofuran-3,4-diyl bis(2-methylpropanoate) hydrochloride

2934 99 90

265121-04-8

(3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(2-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid – 1-deoxy-1-(methylamino)-D-glucitol (1:2)

2934 99 90

163680-80-6

(3S)-10-[1-(acetylamino)cyclopropyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid

2934 99 90

132335-46-7

(3S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine

2934 99 90

133413-70-4

(3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzyl-4,10,12,16,22,24-hexamethyl-3,9,15,21-tetrakis(2-methylpropyl)-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosane-2,5,8,11,14,17,20,23-octone

2934 99 90

503068-36-8

(5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

2934 99 90

452339-73-0

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

2934 99 90

877130-28-4

(6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one

2934 99 90

132335-44-5

(S)-3-(dimethylamino)-1-(thiophen-2-yl)propan-1-ol

2934 99 90

812647-80-6

{(2R,3S,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-bis[(phenylcarbonyl)oxy]tetrahydrofuran-2-yl}methyl 3-chlorobenzoate

2934 99 90

00-00-0

1-(1-{4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butyl}-1,2,3,6-tetrahydropyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

2934 99 90

1029716-44-6

1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

2934 99 90

165172-60-1

1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione – 1-methylpyrrolidin-2-one (1:1)

2934 99 90

519187-97-4

1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-3-azetidinol – (2Z)-2-butenedioate (1:1)

2934 99 90

127000-90-2

1-{[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiran-2-yl]methyl}-1H-1,2,4-triazole

2934 99 90

710281-33-7

2-({[(1R,3S)-3-{[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}cyclohexyl]oxy}methyl)-6-methylbenzoic acid

2934 99 90

96803-30-4

2-(1-benzothiophen-5-yl)ethanol

2934 99 90

913695-00-8

2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1Hbenzimidazole, sodium salt (1:1)

2934 99 90

376608-74-1

2-{[(3aR,4S,6R,6aS)-6-{[5-amino-6-chloro-2-(propylsulfanyl)pyrimidin-4-yl]amino}-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol

2934 99 90

474554-48-8

2-bromo-1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethanone

2934 99 90

530141-72-1

3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-[(3-hydroxy-1,2-benzoxazol-6-yl)methoxy]phenyl)propanoic acid

2934 99 90

519188-55-7

3-[2-(1-benzothiophen-5-yl)ethoxy]-1-(3-hydroxyazetidin-1-yl)propan-1-one

2934 99 90

519188-42-2

3-[2-(1-benzothiophen-5-yl)ethoxy]propionic acid

2934 99 90

753015-42-8

3-{(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl}-5-(tetrahydro-2H-pyran-4-yloxy)pyridine

2934 99 90

26638-53-9

3-chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide

2934 99 90

499785-81-8

3-oxo-4-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide

2934 99 90

356782-84-8

3-oxo-4-(β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide

2934 99 90

6504-57-0

4-[3-hydroxy-3-phenyl-3-(thiophen-2-yl)propyl]-4-methylmorpholin-4-ium methyl sulfate

2934 99 90

871484-32-1

4-[4-({3-[(4-deoxy-4-fluoro-b-D-glucopyranosyl)oxy]-5-(propan-2-yl)-1H-pyrazol-4-yl}methyl)phenyl]-N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]butanamide

2934 99 90

166964-09-6

4-chloro-3-methyl-1,2-oxazol-5-amine

2934 99 90

655233-39-3

4-nitrobenzyl(6R,7R)-7-amino-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride

2920 90 85

89729-09-9

5,7-dioxa-6-thiaspiro[2.5]octane-6-oxide

2934 99 90

388082-75-5

5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarboxaldehyde – 4-methylbenzenesulfonate (1:1)

2934 99 90

4923-87-9

5-bromo-1-benzothiophene

2934 99 90

947408-95-9

6-(bromomethyl)-2-triphenylmethyl-1,2-benzisoxazol-3(2H)-one

2934 99 90

947408-94-8

6-methyl-2-trityl-1,2-benzoxazol-3(2H)-one

2934 99 90

67978-05-6

diphenylmethyl(2R)-3-methyl-2-[(1R,5S)-3-(4-methylphenyl)-7-oxo-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-6-yl]but-3-enoate

2934 99 90

1001859-46-6

DNA (synthetic plasmid vector pCOR human interferon beta signal peptide fusion protein with 21-154-human acidic fibroblast growth factor-specifying)

2934 99 90

665058-78-6

DNA, d(T-sp-C-G-sp-T-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-G-sp-A-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-Gsp-T-sp-C-G-sp-T-sp-T)

2934 99 90

923591-06-4

methyl (5R,7S,10S)-10-tert-butyl-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxylate

2934 99 90

59337-92-7

methyl 3-(chlorosulfonyl)thiophene-2-carboxylate

2934 99 90

947409-01-0

methyl 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(2-triphenylmethyl-1,2-benzisoxazol-3(2H)-on-6-yl)methoxy]phenyl]propionate

2934 99 90

85006-31-1

methyl 3-amino-4-methylthiophene-2-carboxylate

2934 99 90

893428-72-3

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine – (2E)-2-butenedioate (1:2)

2934 99 90

390800-88-1

N,N′,N′′-(boroxin-2,4,6-triyltris{[(1S)-3-methylbutane-1,1-diyl]imino[(2S)-1-oxo-3-phenylpropane-1,2-diyl]})tripyrazine-2-carboxamide

2934 99 90

112913-94-7

N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide

2934 99 90

120788-03-6

S-[(1R,3S)-1-oxidotetrahydrothiophen-3-yl] ethanethioate

2935 00 90

1198178-65-2

(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropanaminium 4-methylbenzenesulfonate

2935 00 90

39570-96-2

(2R)-3-(benzylsulfanyl)-N-[(2S)-1-{[(2S,3S)-1-hydrazinyl-3-methyl-1-oxopentan-2-yl]amino}-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-{[(4-methylphenyl)sulfonyl]amino}propanamide

2935 00 90

24310-36-9

1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one

2935 00 90

0-00-0

2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide di[(2E)-but-2-enedioate] hydrate

2935 00 90

941690-55-7

3-[(methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide

2935 00 90

6973-09-7

5-amino-2-methylbenzenesulfonamide

2935 00 90

193686-76-9

7-chloro-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one

2935 00 90

123664-84-6

N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide

2935 00 90

149457-03-4

N-[4-(N-formylglycyl)-5-hydroxy-2-phenoxyphenyl]methanesulfonamide

2935 00 90

149456-98-4

N-[4-(N-formylglycyl)-5-methoxy-2-phenoxyphenyl]methanesulfonamide

2935 00 90

141450-48-8

N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide hydrochloride

2935 00 90

289042-10-0

N-{5-[(diphenylphosphoryl)methyl]-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl}-N-methylmethanesulfonamide

2939 99 00

7689-03-4

(4S)-4-ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

2939 99 00

477-29-2

colchicoside

2940 00 00

604-69-3

1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose

2940 00 00

647834-15-9

2-(4-methoxybenzyl)thiophen-3-yl β-D-glucopyranoside

2941 90 00

76610-92-9

(6R,7R)-7-({N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

3907 20 99

913976-27-9

poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy, diester with 21N6, 21′N6-[[(N2, N6-dicarboxy-L-lysyl-β-alanyl)imino]bis(1-oxo-2, 1-ethanediyl)]bis[N-acetylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] cyclic (6→15), (6′→15′) bis(disulfide)

---

ANNEX IV

List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be withdrawn from the list of products receiving duty-free treatment included in Annex 6 to Annex I to Regulation (EEC) No 2658/87 due to their transfer to the list of products receiving duty-free treatment included in Annex 3 to Annex I to Regulation (EEC) No 2658/87

| CN code | CAS RN | Name |
| --- | --- | --- |
| 2915 39 00


  2937 29 00 | 7753-60-8 | 17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate
  see anecortave (INN) |
| 2920 90 85 | 163133-43-5 | 4-(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl) propanoate
  see naproxcinod (INN) |
| 2924 29 98 | 194085-75-1 | 2-(2-chlorophenyl)-2-hydroxyethyl carbamate
  see carisbamate (INN) |
| 2933 39 99 | 103129-82-4 | 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
  see levamlodipine (INN) |
| 2933 39 99 | 319460-85-0 | N-methyl-2-{[3-((E)-2-pyridin-2-ylvinyl)-1H-indazol-6-yl]sulfanyl}benzamide
  see axitinib (INN) |
| 2934 10 00 | 302962-49-8 | N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)thiazole-5-carboxamide
  see dasatinib (INN) |
| 2934 99 90 | 143491-57-0 | (2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
  see emtricitabine(INN) |
| 2934 99 90 | 98819-76-2 | (2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine
  see esreboxetine (INN) |
| 2934 99 90 | 475479-34-6 | (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid
  see aleglitazar (INN) |
| 2934 99 90 | 377727-87-2 | 2-(2-furyl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl] piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[2,3-c]pyrimidin-5-amine
  see preladenant (INN) |
| 2934 99 90 | 189003-92-7 | 2-{7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1(2H)-yl}acetamide
  see trelanserin (INN) |
| 2934 99 90 | 134379-77-4 | 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one
  see dexelvucitabine (INN) |
| 2934 99 90 | 518048-05-0 | potassium 4-[N-(2-fluorobenzyl)carbamoyl]-1-methyl-2-[1-methyl-1-(5-methyl-1,3,4-oxadiazole-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyrimidine-5-olate
  see raltegravir (INN) |
| 2935 00 90 | 170569-88-7 | 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide
  see mavacoxib (INN) |
| 2935 00 90 | 186497-07-4 | N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
  see zibotentan (INN) |

CN code

CAS RN

Name

2915 39 00

2937 29 00

7753-60-8

17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate

see anecortave (INN)

2920 90 85

163133-43-5

4-(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl) propanoate

see naproxcinod (INN)

2924 29 98

194085-75-1

2-(2-chlorophenyl)-2-hydroxyethyl carbamate

see carisbamate (INN)

2933 39 99

103129-82-4

3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

see levamlodipine (INN)

2933 39 99

319460-85-0

N-methyl-2-{[3-((E)-2-pyridin-2-ylvinyl)-1H-indazol-6-yl]sulfanyl}benzamide

see axitinib (INN)

2934 10 00

302962-49-8

N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)thiazole-5-carboxamide

see dasatinib (INN)

2934 99 90

143491-57-0

(2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one

see emtricitabine(INN)

2934 99 90

98819-76-2

(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine

see esreboxetine (INN)

2934 99 90

475479-34-6

(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid

see aleglitazar (INN)

2934 99 90

377727-87-2

2-(2-furyl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl] piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[2,3-c]pyrimidin-5-amine

see preladenant (INN)

2934 99 90

189003-92-7

2-{7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1(2H)-yl}acetamide

see trelanserin (INN)

2934 99 90

134379-77-4

4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one

see dexelvucitabine (INN)

2934 99 90

518048-05-0

potassium 4-[N-(2-fluorobenzyl)carbamoyl]-1-methyl-2-[1-methyl-1-(5-methyl-1,3,4-oxadiazole-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyrimidine-5-olate

see raltegravir (INN)

2935 00 90

170569-88-7

4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide

see mavacoxib (INN)

2935 00 90

186497-07-4

N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

see zibotentan (INN)

---

DIRECTIVES

| 31.12.2010 | EN | Official Journal of the European Union | L 348/74 |
| --- | --- | --- | --- |

31.12.2010

EN

Official Journal of the European Union

L 348/74

---

DIRECTIVE 2010/84/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 15 December 2010

amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and Article 168(4)(c) thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national parliaments,

Having regard to the opinion of the European Economic and Social Committee (1),

Having regard to the opinion of the Committee of the Regions (2),

Having regard to the opinion of the European Data Protection Supervisor (3),

Acting in accordance with the ordinary legislative procedure (4),

Whereas:

| (1) | Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (5) lays down harmonised rules for the authorisation, supervision and pharmacovigilance of medicinal products for human use within the Union. |
| --- | --- |

(1)

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (5) lays down harmonised rules for the authorisation, supervision and pharmacovigilance of medicinal products for human use within the Union.

| (2) | Pharmacovigilance rules are necessary for the protection of public health in order to prevent, detect and assess adverse reactions to medicinal products placed on the Union market, as the full safety profile of medicinal products can only be known after they have been placed on the market. |
| --- | --- |

(2)

Pharmacovigilance rules are necessary for the protection of public health in order to prevent, detect and assess adverse reactions to medicinal products placed on the Union market, as the full safety profile of medicinal products can only be known after they have been placed on the market.

| (3) | In the light of the experience acquired and following an assessment by the Commission of the Union system of pharmacovigilance, it has become clear that it is necessary to take measures in order to improve the operation of Union law on the pharmacovigilance of medicinal products. |
| --- | --- |

(3)

In the light of the experience acquired and following an assessment by the Commission of the Union system of pharmacovigilance, it has become clear that it is necessary to take measures in order to improve the operation of Union law on the pharmacovigilance of medicinal products.

| (4) | While the fundamental objective of the regulation of medicinal products is to safeguard public health, this aim should nevertheless be achieved by means that do not impede the free movement of safe medicinal products within the Union. It has emerged from the assessment of the Union system of pharmacovigilance that divergent actions by Member States in relation to safety issues pertaining to medicinal products are creating obstacles to the free movement of medicinal products. In order to prevent or eliminate those obstacles the existing pharmacovigilance provisions at Union level should be strengthened and rationalised. |
| --- | --- |

(4)

While the fundamental objective of the regulation of medicinal products is to safeguard public health, this aim should nevertheless be achieved by means that do not impede the free movement of safe medicinal products within the Union. It has emerged from the assessment of the Union system of pharmacovigilance that divergent actions by Member States in relation to safety issues pertaining to medicinal products are creating obstacles to the free movement of medicinal products. In order to prevent or eliminate those obstacles the existing pharmacovigilance provisions at Union level should be strengthened and rationalised.

| (5) | For the sake of clarity, the definition of the term ‘adverse reaction’ should be amended to ensure that it covers noxious and unintended effects resulting not only from the authorised use of a medicinal product at normal doses, but also from medication errors and uses outside the terms of the marketing authorisation, including the misuse and abuse of the medicinal product. The suspicion of an adverse drug reaction, meaning that there is at least a reasonable possibility of there being a causal relationship between a medicinal product and an adverse event, should be sufficient reason for reporting. Therefore, the term ‘suspected adverse reaction’ should be used when referring to reporting obligations. Without prejudice to the existing Union and national provisions and practices on medical confidentiality, Member States should ensure that reporting and processing of personal data related to suspected adverse reactions, including those associated with medication errors is carried out on a confidential basis. This should not affect Member States’ obligations regarding the mutual exchange of information on pharmacovigilance issues or their obligation to make available to the public important information on pharmacovigilance concerns. Furthermore, the principle of confidentiality should not affect the obligations of the persons concerned to provide information under criminal law. |
| --- | --- |

(5)

For the sake of clarity, the definition of the term ‘adverse reaction’ should be amended to ensure that it covers noxious and unintended effects resulting not only from the authorised use of a medicinal product at normal doses, but also from medication errors and uses outside the terms of the marketing authorisation, including the misuse and abuse of the medicinal product. The suspicion of an adverse drug reaction, meaning that there is at least a reasonable possibility of there being a causal relationship between a medicinal product and an adverse event, should be sufficient reason for reporting. Therefore, the term ‘suspected adverse reaction’ should be used when referring to reporting obligations. Without prejudice to the existing Union and national provisions and practices on medical confidentiality, Member States should ensure that reporting and processing of personal data related to suspected adverse reactions, including those associated with medication errors is carried out on a confidential basis. This should not affect Member States’ obligations regarding the mutual exchange of information on pharmacovigilance issues or their obligation to make available to the public important information on pharmacovigilance concerns. Furthermore, the principle of confidentiality should not affect the obligations of the persons concerned to provide information under criminal law.

| (6) | The pollution of waters and soils with pharmaceutical residues is an emerging environmental problem. Member States should consider measures to monitor and evaluate the risk of environmental effects of such medicinal products, including those which may have an impact on public health. The Commission should, based, inter alia, on data received from the European Medicines Agency, the European Environment Agency and Member States, produce a report on the scale of the problem, along with an assessment on whether amendments to Union legislation on medicinal products or other relevant Union legislation are required. |
| --- | --- |

(6)

The pollution of waters and soils with pharmaceutical residues is an emerging environmental problem. Member States should consider measures to monitor and evaluate the risk of environmental effects of such medicinal products, including those which may have an impact on public health. The Commission should, based, inter alia, on data received from the European Medicines Agency, the European Environment Agency and Member States, produce a report on the scale of the problem, along with an assessment on whether amendments to Union legislation on medicinal products or other relevant Union legislation are required.

| (7) | The marketing authorisation holder should establish a pharmacovigilance system to ensure the monitoring and supervision of one or more of its authorised medicinal products, recorded in a pharmacovigilance system master file which should be permanently available for inspection. The competent authorities should undertake to supervise those pharmacovigilance systems. Applications for marketing authorisations should therefore be accompanied by a brief description of the corresponding pharmacovigilance system, which should include a reference to the location where the pharmacovigilance system master file for the medicinal product concerned is kept and available for inspection by the competent authorities. |
| --- | --- |

(7)

The marketing authorisation holder should establish a pharmacovigilance system to ensure the monitoring and supervision of one or more of its authorised medicinal products, recorded in a pharmacovigilance system master file which should be permanently available for inspection. The competent authorities should undertake to supervise those pharmacovigilance systems. Applications for marketing authorisations should therefore be accompanied by a brief description of the corresponding pharmacovigilance system, which should include a reference to the location where the pharmacovigilance system master file for the medicinal product concerned is kept and available for inspection by the competent authorities.

| (8) | Marketing authorisation holders should plan pharmacovigilance measures for each individual medicinal product in the context of a risk management system. The measures should be proportionate to the identified risks, the potential risks, and the need for additional information on the medicinal product. It should also be ensured that any key measures included in a risk management system are made conditions of the marketing authorisation. |
| --- | --- |

(8)

Marketing authorisation holders should plan pharmacovigilance measures for each individual medicinal product in the context of a risk management system. The measures should be proportionate to the identified risks, the potential risks, and the need for additional information on the medicinal product. It should also be ensured that any key measures included in a risk management system are made conditions of the marketing authorisation.

| (9) | It is necessary from a public health perspective to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, the efficacy of authorised medicinal products. Competent authorities should therefore be empowered to impose on the marketing authorisation holder the obligation to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose that obligation at the time of the granting of the marketing authorisation or later, and it should be a condition of the marketing authorisation. Such studies may be aimed at collecting data to enable the assessment of the safety or efficacy of medicinal products in everyday medical practice. |
| --- | --- |

(9)

It is necessary from a public health perspective to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, the efficacy of authorised medicinal products. Competent authorities should therefore be empowered to impose on the marketing authorisation holder the obligation to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose that obligation at the time of the granting of the marketing authorisation or later, and it should be a condition of the marketing authorisation. Such studies may be aimed at collecting data to enable the assessment of the safety or efficacy of medicinal products in everyday medical practice.

| (10) | It is essential that a strengthened system of pharmacovigilance not lead to the premature granting of marketing authorisations. However, some medicinal products are authorised subject to additional monitoring. This includes all medicinal products with a new active substance and biological medicinal products, including biosimilars, which are priorities for pharmacovigilance. Competent authorities may also require additional monitoring for specific medicinal products that are subject to the obligation to conduct a post-authorisation safety study or to conditions or restrictions with regard to the safe and effective use of the medicinal product. Medicinal products subject to additional monitoring should be identified as such by a black symbol and an appropriate standardised explanatory sentence in the summary of product characteristics and in the package leaflet. A publicly available list of medicinal products subject to additional monitoring should be kept up to date by the European Medicines Agency established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (6) (hereinafter referred to as the ‘Agency’). |
| --- | --- |

(10)

It is essential that a strengthened system of pharmacovigilance not lead to the premature granting of marketing authorisations. However, some medicinal products are authorised subject to additional monitoring. This includes all medicinal products with a new active substance and biological medicinal products, including biosimilars, which are priorities for pharmacovigilance. Competent authorities may also require additional monitoring for specific medicinal products that are subject to the obligation to conduct a post-authorisation safety study or to conditions or restrictions with regard to the safe and effective use of the medicinal product. Medicinal products subject to additional monitoring should be identified as such by a black symbol and an appropriate standardised explanatory sentence in the summary of product characteristics and in the package leaflet. A publicly available list of medicinal products subject to additional monitoring should be kept up to date by the European Medicines Agency established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (6) (hereinafter referred to as the ‘Agency’).

| (11) | The Commission should, in collaboration with the Agency and national competent authorities and following consultations with organisations representing patients, consumers, doctors and pharmacists, social health insurers, and other interested parties, present to the European Parliament and the Council an assessment report regarding the readability of the summaries of product characteristics and the package leaflets and their value to the healthcare professionals and the general public. Following an analysis of that data, the Commission should, if appropriate, make proposals to improve the layout and content of the summaries of product characteristics and of the package leaflets to ensure that they represent a valuable source of information for healthcare professionals and the general public respectively. |
| --- | --- |

(11)

The Commission should, in collaboration with the Agency and national competent authorities and following consultations with organisations representing patients, consumers, doctors and pharmacists, social health insurers, and other interested parties, present to the European Parliament and the Council an assessment report regarding the readability of the summaries of product characteristics and the package leaflets and their value to the healthcare professionals and the general public. Following an analysis of that data, the Commission should, if appropriate, make proposals to improve the layout and content of the summaries of product characteristics and of the package leaflets to ensure that they represent a valuable source of information for healthcare professionals and the general public respectively.

| (12) | Experience has shown that the responsibilities of marketing authorisation holders with regard to pharmacovigilance of authorised medicinal products should be clarified. The marketing authorisation holder should be responsible for continuously monitoring the safety of its medicinal products, for informing the authorities of any changes that might impact on the marketing authorisation, and for ensuring that the product information is kept up to date. As medicinal products could be used outside the terms of the marketing authorisation, the marketing authorisation holder’s responsibilities should include providing all available information, including the results of clinical trials or other studies, as well as reporting any use of the medicinal product which is outside the terms of the marketing authorisation. It is also appropriate to ensure that all relevant information collected on the safety of the medicinal product is taken into account when the marketing authorisation is being renewed. |
| --- | --- |

(12)

Experience has shown that the responsibilities of marketing authorisation holders with regard to pharmacovigilance of authorised medicinal products should be clarified. The marketing authorisation holder should be responsible for continuously monitoring the safety of its medicinal products, for informing the authorities of any changes that might impact on the marketing authorisation, and for ensuring that the product information is kept up to date. As medicinal products could be used outside the terms of the marketing authorisation, the marketing authorisation holder’s responsibilities should include providing all available information, including the results of clinical trials or other studies, as well as reporting any use of the medicinal product which is outside the terms of the marketing authorisation. It is also appropriate to ensure that all relevant information collected on the safety of the medicinal product is taken into account when the marketing authorisation is being renewed.

| (13) | In order to ensure close cooperation between the Member States in the area of pharmacovigilance, the mandate of the coordination group set up by Article 27 of Directive 2001/83/EC should be enlarged to include the examination of questions related to the pharmacovigilance of all medicinal products authorised by the Member States. In order to fulfil its new tasks, the coordination group should be further strengthened through the adoption of clear rules as regards the expertise required, the procedures for reaching agreements or positions, transparency, independence and professional secrecy of its members, and the need for cooperation between Union and national bodies. |
| --- | --- |

(13)

In order to ensure close cooperation between the Member States in the area of pharmacovigilance, the mandate of the coordination group set up by Article 27 of Directive 2001/83/EC should be enlarged to include the examination of questions related to the pharmacovigilance of all medicinal products authorised by the Member States. In order to fulfil its new tasks, the coordination group should be further strengthened through the adoption of clear rules as regards the expertise required, the procedures for reaching agreements or positions, transparency, independence and professional secrecy of its members, and the need for cooperation between Union and national bodies.

| (14) | With a view to ensuring the same level of scientific expertise in the area of pharmacovigilance decision-making at both Union and national levels, the coordination group should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee when fulfilling its pharmacovigilance tasks. |
| --- | --- |

(14)

With a view to ensuring the same level of scientific expertise in the area of pharmacovigilance decision-making at both Union and national levels, the coordination group should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee when fulfilling its pharmacovigilance tasks.

| (15) | In order to avoid duplication of work, the coordination group should agree on a single position for pharmacovigilance assessments concerning medicinal products authorised in more than one Member State. Agreement within the coordination group should suffice for pharmacovigilance measures to be implemented throughout the Union. Where no agreement is reached within the coordination group, the Commission should be authorised to adopt a decision concerning the necessary regulatory action in respect of the marketing authorisation, addressed to the Member States. |
| --- | --- |

(15)

In order to avoid duplication of work, the coordination group should agree on a single position for pharmacovigilance assessments concerning medicinal products authorised in more than one Member State. Agreement within the coordination group should suffice for pharmacovigilance measures to be implemented throughout the Union. Where no agreement is reached within the coordination group, the Commission should be authorised to adopt a decision concerning the necessary regulatory action in respect of the marketing authorisation, addressed to the Member States.

| (16) | A single assessment should also be conducted in the case of pharmacovigilance issues which concern medicinal products authorised by the Member States and medicinal products authorised in accordance with Regulation (EC) No 726/2004. In such cases, the Commission should adopt harmonised measures for all medicinal products concerned on the basis of an assessment at Union level. |
| --- | --- |

(16)

A single assessment should also be conducted in the case of pharmacovigilance issues which concern medicinal products authorised by the Member States and medicinal products authorised in accordance with Regulation (EC) No 726/2004. In such cases, the Commission should adopt harmonised measures for all medicinal products concerned on the basis of an assessment at Union level.

| (17) | Member States should operate a pharmacovigilance system to collect information that is useful for the monitoring of medicinal products, including information on suspected adverse reactions arising from use of a medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, including overdose, misuse, abuse and medication errors, and suspected adverse reactions associated with occupational exposure. Member States should ensure the quality of the pharmacovigilance system through the follow-up of cases of suspected adverse reactions. For those tasks, Member States should establish a permanent pharmacovigilance system, supported by the appropriate expertise, so that the obligations under this Directive can be fully met. |
| --- | --- |

(17)

Member States should operate a pharmacovigilance system to collect information that is useful for the monitoring of medicinal products, including information on suspected adverse reactions arising from use of a medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, including overdose, misuse, abuse and medication errors, and suspected adverse reactions associated with occupational exposure. Member States should ensure the quality of the pharmacovigilance system through the follow-up of cases of suspected adverse reactions. For those tasks, Member States should establish a permanent pharmacovigilance system, supported by the appropriate expertise, so that the obligations under this Directive can be fully met.

| (18) | In order to further increase the coordination of resources between the Member States, Member State should be authorised to delegate certain pharmacovigilance tasks to another Member State. |
| --- | --- |

(18)

In order to further increase the coordination of resources between the Member States, Member State should be authorised to delegate certain pharmacovigilance tasks to another Member State.

| (19) | In order to simplify the reporting of suspected adverse reactions, the marketing authorisation holders and the Member States should report those reactions only to the Union pharmacovigilance database and data-processing network referred to in Article 57(1)(d) of Regulation (EC) No 726/2004 (the ‘Eudravigilance database’). The Eudravigilance database should be equipped to immediately forward reports on suspected adverse reactions received from marketing authorisation holders to the Member States on whose territory the reaction occurred. |
| --- | --- |

(19)

In order to simplify the reporting of suspected adverse reactions, the marketing authorisation holders and the Member States should report those reactions only to the Union pharmacovigilance database and data-processing network referred to in Article 57(1)(d) of Regulation (EC) No 726/2004 (the ‘Eudravigilance database’). The Eudravigilance database should be equipped to immediately forward reports on suspected adverse reactions received from marketing authorisation holders to the Member States on whose territory the reaction occurred.

| (20) | In order to increase the level of transparency of the pharmacovigilance processes, the Member States should create and maintain medicines web-portals. To the same end, the marketing authorisation holders should provide the competent authorities with prior or simultaneous warnings about safety announcements and the competent authorities should also provide each other with advance notice of safety announcements. |
| --- | --- |

(20)

In order to increase the level of transparency of the pharmacovigilance processes, the Member States should create and maintain medicines web-portals. To the same end, the marketing authorisation holders should provide the competent authorities with prior or simultaneous warnings about safety announcements and the competent authorities should also provide each other with advance notice of safety announcements.

| (21) | Union rules in relation to pharmacovigilance should continue to rely on the crucial role of healthcare professionals in monitoring the safety of medicinal products, and should take account of the fact that patients are also well placed to report suspected adverse reactions to medicinal products. It is therefore appropriate to facilitate the reporting of suspected adverse reactions to medicinal products by both healthcare professionals and patients, and to make methods for such reporting available to them. |
| --- | --- |

(21)

Union rules in relation to pharmacovigilance should continue to rely on the crucial role of healthcare professionals in monitoring the safety of medicinal products, and should take account of the fact that patients are also well placed to report suspected adverse reactions to medicinal products. It is therefore appropriate to facilitate the reporting of suspected adverse reactions to medicinal products by both healthcare professionals and patients, and to make methods for such reporting available to them.

| (22) | As a result of the submission of all suspected adverse reaction data directly to the Eudravigilance database, it is appropriate to amend the scope of periodic safety update reports so that they present an analysis of the risk-benefit balance of a medicinal product rather than a detailed listing of individual case reports already submitted to the Eudravigilance database. |
| --- | --- |

(22)

As a result of the submission of all suspected adverse reaction data directly to the Eudravigilance database, it is appropriate to amend the scope of periodic safety update reports so that they present an analysis of the risk-benefit balance of a medicinal product rather than a detailed listing of individual case reports already submitted to the Eudravigilance database.

| (23) | Obligations imposed in respect of periodic safety update reports should be proportionate to the risks posed by medicinal products. Periodic safety update reporting should therefore be linked to the risk management system for newly authorised medicinal products and routine reporting should not be required for generic medicinal products, for medicinal products containing an active substance for which well-established medicinal use has been demonstrated, for homeopathic medicinal products or for traditional-use registered herbal medicinal products. However, in the interests of public health, the competent authorities should require periodic safety update reports for such medicinal products when concerns arise relating to pharmacovigilance data or as a result of the lack of available safety data when the use of the active substance concerned is concentrated in medicinal products for which periodic safety update reporting is not routinely required. |
| --- | --- |

(23)

Obligations imposed in respect of periodic safety update reports should be proportionate to the risks posed by medicinal products. Periodic safety update reporting should therefore be linked to the risk management system for newly authorised medicinal products and routine reporting should not be required for generic medicinal products, for medicinal products containing an active substance for which well-established medicinal use has been demonstrated, for homeopathic medicinal products or for traditional-use registered herbal medicinal products. However, in the interests of public health, the competent authorities should require periodic safety update reports for such medicinal products when concerns arise relating to pharmacovigilance data or as a result of the lack of available safety data when the use of the active substance concerned is concentrated in medicinal products for which periodic safety update reporting is not routinely required.

| (24) | It is necessary to increase the shared use of resources between competent authorities for the assessment of periodic safety update reports. A single assessment of periodic safety update reports for medicinal products authorised in more than one Member State should be provided for. Moreover, procedures should be established to set single frequency and submission dates of periodic safety update reports for all medicinal products containing the same active substance or the same combination of active substances. |
| --- | --- |

(24)

It is necessary to increase the shared use of resources between competent authorities for the assessment of periodic safety update reports. A single assessment of periodic safety update reports for medicinal products authorised in more than one Member State should be provided for. Moreover, procedures should be established to set single frequency and submission dates of periodic safety update reports for all medicinal products containing the same active substance or the same combination of active substances.

| (25) | Following a single assessment of periodic safety update reports, any resulting measures as regards the maintenance, variation, suspension or revocation of the marketing authorisations concerned should be adopted through a Union procedure leading to a harmonised result. |
| --- | --- |

(25)

Following a single assessment of periodic safety update reports, any resulting measures as regards the maintenance, variation, suspension or revocation of the marketing authorisations concerned should be adopted through a Union procedure leading to a harmonised result.

| (26) | The Member States should automatically submit certain safety issues related to medicinal products to the Agency thereby triggering a Union-wide assessment of the issue. Therefore it is appropriate to establish rules for an assessment procedure by the Pharmacovigilance Risk Assessment Committee, and for the subsequent follow-up as regards the marketing authorisations concerned with a view to the adoption of harmonised measures across the Union. |
| --- | --- |

(26)

The Member States should automatically submit certain safety issues related to medicinal products to the Agency thereby triggering a Union-wide assessment of the issue. Therefore it is appropriate to establish rules for an assessment procedure by the Pharmacovigilance Risk Assessment Committee, and for the subsequent follow-up as regards the marketing authorisations concerned with a view to the adoption of harmonised measures across the Union.

| (27) | In connection with the clarification and strengthening of the provisions relating to pharmacovigilance activities in Directive 2001/83/EC, it is also appropriate to further clarify the procedures for all Union-wide post-authorisation assessments of safety issues concerning medicinal products. To that end, the number of procedures for Union-wide assessment should be limited to two, one of which allows for a swift assessment and should be applied when urgent action is considered necessary. Regardless of whether the urgent procedure or the normal procedure is applied, and whether the medicinal product was authorised through the centralised or non-centralised procedure, the Pharmacovigilance Risk Assessment Committee should always give its recommendation when the reason for taking action is based on pharmacovigilance data. It is appropriate that the coordination group and the Committee for Medicinal Products for Human Use should rely on this recommendation when performing their assessment of the issue. |
| --- | --- |

(27)

In connection with the clarification and strengthening of the provisions relating to pharmacovigilance activities in Directive 2001/83/EC, it is also appropriate to further clarify the procedures for all Union-wide post-authorisation assessments of safety issues concerning medicinal products. To that end, the number of procedures for Union-wide assessment should be limited to two, one of which allows for a swift assessment and should be applied when urgent action is considered necessary. Regardless of whether the urgent procedure or the normal procedure is applied, and whether the medicinal product was authorised through the centralised or non-centralised procedure, the Pharmacovigilance Risk Assessment Committee should always give its recommendation when the reason for taking action is based on pharmacovigilance data. It is appropriate that the coordination group and the Committee for Medicinal Products for Human Use should rely on this recommendation when performing their assessment of the issue.

| (28) | It is necessary to introduce harmonised guiding principles for, and regulatory supervision of, post-authorisation safety studies that are requested by competent authorities and that are non-interventional, that are initiated, managed or financed by the marketing authorisation holder, and that involve the collection of data from patients or healthcare professionals and that therefore fall outside of the scope of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (7). The supervision of such studies should be the responsibility of the Pharmacovigilance Risk Assessment Committee. Studies requested after the marketing authorisation of a medicinal product by only one competent authority to be conducted in only one Member State should be supervised by the national competent authority of the Member State in which the study is to be conducted. Provision should also be made for the subsequent follow-up, if appropriate, as regards the marketing authorisations concerned with a view to the adoption of harmonised measures across the Union. |
| --- | --- |

(28)

It is necessary to introduce harmonised guiding principles for, and regulatory supervision of, post-authorisation safety studies that are requested by competent authorities and that are non-interventional, that are initiated, managed or financed by the marketing authorisation holder, and that involve the collection of data from patients or healthcare professionals and that therefore fall outside of the scope of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (7). The supervision of such studies should be the responsibility of the Pharmacovigilance Risk Assessment Committee. Studies requested after the marketing authorisation of a medicinal product by only one competent authority to be conducted in only one Member State should be supervised by the national competent authority of the Member State in which the study is to be conducted. Provision should also be made for the subsequent follow-up, if appropriate, as regards the marketing authorisations concerned with a view to the adoption of harmonised measures across the Union.

| (29) | In order to enforce the provisions relating to pharmacovigilance, the Member States should ensure that effective, proportionate and dissuasive penalties are applied to marketing authorisation holders for non-compliance with pharmacovigilance obligations. If the conditions included in the marketing authorisation are not fulfilled within the given deadline, the national competent authorities should have the power to review the marketing authorisation. |
| --- | --- |

(29)

In order to enforce the provisions relating to pharmacovigilance, the Member States should ensure that effective, proportionate and dissuasive penalties are applied to marketing authorisation holders for non-compliance with pharmacovigilance obligations. If the conditions included in the marketing authorisation are not fulfilled within the given deadline, the national competent authorities should have the power to review the marketing authorisation.

| (30) | In order to protect public health, the pharmacovigilance activities of national competent authorities should be adequately funded. It should be ensured that adequate funding is possible for pharmacovigilance activities by empowering the national competent authorities to charge fees to marketing authorisation holders. However, the management of those collected funds should be under the permanent control of the national competent authorities in order to guarantee their independence in the performance of those pharmacovigilance activities. |
| --- | --- |

(30)

In order to protect public health, the pharmacovigilance activities of national competent authorities should be adequately funded. It should be ensured that adequate funding is possible for pharmacovigilance activities by empowering the national competent authorities to charge fees to marketing authorisation holders. However, the management of those collected funds should be under the permanent control of the national competent authorities in order to guarantee their independence in the performance of those pharmacovigilance activities.

| (31) | It should be possible for Member States to allow the relevant actors, under certain conditions, to deviate from certain provisions of Directive 2001/83/EC related to the requirements for labelling and packaging in order to address severe availability problems related to the potential lack of authorised medicinal products or of medicinal products placed on the market or shortages thereof. |
| --- | --- |

(31)

It should be possible for Member States to allow the relevant actors, under certain conditions, to deviate from certain provisions of Directive 2001/83/EC related to the requirements for labelling and packaging in order to address severe availability problems related to the potential lack of authorised medicinal products or of medicinal products placed on the market or shortages thereof.

| (32) | Since the objective of this Directive, namely to improve the safety of medicinal products placed on the market in the Union in a harmonised way across the Member States, cannot be sufficiently achieved by the Member States and can, by reason of the scale of the measures, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty on European Union (TEU). In accordance with the principle of proportionality, as set out in that Article, this Directive does not go beyond what is necessary in order to achieve this objective. |
| --- | --- |

(32)

Since the objective of this Directive, namely to improve the safety of medicinal products placed on the market in the Union in a harmonised way across the Member States, cannot be sufficiently achieved by the Member States and can, by reason of the scale of the measures, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty on European Union (TEU). In accordance with the principle of proportionality, as set out in that Article, this Directive does not go beyond what is necessary in order to achieve this objective.

| (33) | This Directive shall apply without prejudice to Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (8) and Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (9). In order to detect, assess, understand and prevent adverse reactions, and to identify and take actions to reduce the risks of, and increase the benefits from, medicinal products for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting Union legislation relating to data protection. The purpose of safeguarding public health constitutes a substantial public interest and consequently the processing of personal data can be justified if identifiable health data are processed only when necessary and only when the parties involved assess this necessity at every stage of the pharmacovigilance process. |
| --- | --- |

(33)

This Directive shall apply without prejudice to Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (8) and Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (9). In order to detect, assess, understand and prevent adverse reactions, and to identify and take actions to reduce the risks of, and increase the benefits from, medicinal products for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting Union legislation relating to data protection. The purpose of safeguarding public health constitutes a substantial public interest and consequently the processing of personal data can be justified if identifiable health data are processed only when necessary and only when the parties involved assess this necessity at every stage of the pharmacovigilance process.

| (34) | The provisions on the monitoring of medicinal products in Directive 2001/83/EC constitute specific provisions within the meaning of Article 15(2) of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products (10). |
| --- | --- |

(34)

The provisions on the monitoring of medicinal products in Directive 2001/83/EC constitute specific provisions within the meaning of Article 15(2) of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products (10).

| (35) | The pharmacovigilance activities provided for in this Directive require that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well as the minimum requirements for the quality system for the performance of pharmacovigilance activities by the national competent authorities and marketing authorisation holders, the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities, and the minimum requirements for the monitoring of the data contained in the Eudravigilance database to determine whether there are new risks or whether risks have changed. The format and content of the electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans as well as the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In accordance with Article 291 of the Treaty on the Functioning of the European Union (TFEU), rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (11) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable. |
| --- | --- |

(35)

The pharmacovigilance activities provided for in this Directive require that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well as the minimum requirements for the quality system for the performance of pharmacovigilance activities by the national competent authorities and marketing authorisation holders, the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities, and the minimum requirements for the monitoring of the data contained in the Eudravigilance database to determine whether there are new risks or whether risks have changed. The format and content of the electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans as well as the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In accordance with Article 291 of the Treaty on the Functioning of the European Union (TFEU), rules and general principles concerning mechanisms for the control by Member States of the Commission’s exercise of implementing powers are to be laid down in advance by a regulation adopted in accordance with the ordinary legislative procedure. Pending the adoption of that new regulation, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (11) continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable.

| (36) | The Commission should be empowered to adopt delegated acts in accordance with Article 290 TFEU in order to supplement the provisions in Articles 21a and 22a of Directive 2001/83/EC. The Commission should be empowered to adopt supplementary measures laying down the situations in which post-authorisation efficacy studies may be required. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. |
| --- | --- |

(36)

The Commission should be empowered to adopt delegated acts in accordance with Article 290 TFEU in order to supplement the provisions in Articles 21a and 22a of Directive 2001/83/EC. The Commission should be empowered to adopt supplementary measures laying down the situations in which post-authorisation efficacy studies may be required. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level.

| (37) | In accordance with point 34 of the Interinstitutional Agreement on better law-making (12), Member States are encouraged to draw up, for themselves and in the interests of the Union, their own tables illustrating, as far as possible, the correlation between this Directive and the transposition measures, and to make them public. |
| --- | --- |

(37)

In accordance with point 34 of the Interinstitutional Agreement on better law-making (12), Member States are encouraged to draw up, for themselves and in the interests of the Union, their own tables illustrating, as far as possible, the correlation between this Directive and the transposition measures, and to make them public.

| (38) | Directive 2001/83/EC should be amended accordingly, |
| --- | --- |

(38)

Directive 2001/83/EC should be amended accordingly,

HAVE ADOPTED THIS DIRECTIVE:

Article 1

Amendments to Directive 2001/83/EC

Directive 2001/83/EC is hereby amended as follows:

| 1. | Article 1 is amended as follows:






  (a) | point 11 is replaced by the following:
  ‘11.   Adverse reaction: A response to a medicinal product which is noxious and unintended.’; |
| --- | --- | --- |

1.

Article 1 is amended as follows:

(a)

point 11 is replaced by the following:

‘11.   Adverse reaction: A response to a medicinal product which is noxious and unintended.’;

Adverse reaction

| (b) | point 14 is deleted; |
| --- | --- |

(b)

point 14 is deleted;

| (c) | point 15 is replaced by the following:
  ‘15.   Post-authorisation safety study: Any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures.’; |
| --- | --- |

(c)

point 15 is replaced by the following:

‘15.   Post-authorisation safety study: Any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures.’;

Post-authorisation safety study

| (d) | the following points are inserted:
  ‘28b.   Risk management system: a set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to a medicinal product, including the assessment of the effectiveness of those activities and interventions.
  28c.   Risk management plan: a detailed description of the risk management system.
  28d.   Pharmacovigilance system: a system used by the marketing authorisation holder and by Member States to fulfil the tasks and responsibilities listed in Title IX and designed to monitor the safety of authorised medicinal products and detect any change to their risk-benefit balance.
  28e.   Pharmacovigilance system master file: A detailed description of the pharmacovigilance system used by the marketing authorisation holder with respect to one or more authorised medicinal products.’. |
| --- | --- |

(d)

the following points are inserted:

‘28b.   Risk management system: a set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to a medicinal product, including the assessment of the effectiveness of those activities and interventions.

Risk management system

28c.   Risk management plan: a detailed description of the risk management system.

Risk management plan

28d.   Pharmacovigilance system: a system used by the marketing authorisation holder and by Member States to fulfil the tasks and responsibilities listed in Title IX and designed to monitor the safety of authorised medicinal products and detect any change to their risk-benefit balance.

Pharmacovigilance system

28e.   Pharmacovigilance system master file: A detailed description of the pharmacovigilance system used by the marketing authorisation holder with respect to one or more authorised medicinal products.’.

Pharmacovigilance system master file

| 2. | Article 8(3) is amended as follows:






  (a) | point (ia) is replaced by the following:






  ‘(ia) | A summary of the applicant’s pharmacovigilance system which shall include the following elements:






  — | proof that the applicant has at his disposal a qualified person responsible for pharmacovigilance, |
| --- | --- | --- | --- | --- |

2.

Article 8(3) is amended as follows:

(a)

point (ia) is replaced by the following:

‘(ia)

A summary of the applicant’s pharmacovigilance system which shall include the following elements:

—

proof that the applicant has at his disposal a qualified person responsible for pharmacovigilance,

| — | the Member States in which the qualified person resides and carries out his/her tasks, |
| --- | --- |

—

the Member States in which the qualified person resides and carries out his/her tasks,

| — | the contact details of the qualified person, |
| --- | --- |

—

the contact details of the qualified person,

| — | a statement signed by the applicant to the effect that the applicant has the necessary means to fulfil the tasks and responsibilities listed in Title IX, |
| --- | --- |

—

a statement signed by the applicant to the effect that the applicant has the necessary means to fulfil the tasks and responsibilities listed in Title IX,

| — | a reference to the location where the pharmacovigilance system master file for the medicinal product is kept.’, |
| --- | --- |

—

a reference to the location where the pharmacovigilance system master file for the medicinal product is kept.’,

| (b) | the following point is inserted after point (ia):






  ‘(iaa) | The risk management plan describing the risk management system which the applicant will introduce for the medicinal product concerned, together with a summary thereof.’; |
| --- | --- | --- |

(b)

the following point is inserted after point (ia):

‘(iaa)

The risk management plan describing the risk management system which the applicant will introduce for the medicinal product concerned, together with a summary thereof.’;

| (c) | point (l) is replaced by the following:






  ‘(l) | Copies of the following:






  — | any authorisation, obtained in another Member State or in a third country, to place the medicinal product on the market, a summary of the safety data including the data contained in the periodic safety update reports, where available, and suspected adverse reactions reports, together with a list of those Member States in which an application for authorisation submitted in accordance with this Directive is under examination; |
| --- | --- | --- | --- |

(c)

point (l) is replaced by the following:

‘(l)

Copies of the following:

—

any authorisation, obtained in another Member State or in a third country, to place the medicinal product on the market, a summary of the safety data including the data contained in the periodic safety update reports, where available, and suspected adverse reactions reports, together with a list of those Member States in which an application for authorisation submitted in accordance with this Directive is under examination;

| — | the summary of the product characteristics proposed by the applicant in accordance with Article 11 or approved by the competent authorities of the Member State in accordance with Article 21 and the package leaflet proposed in accordance with Article 59 or approved by the competent authorities of the Member State in accordance with Article 61; |
| --- | --- |

—

the summary of the product characteristics proposed by the applicant in accordance with Article 11 or approved by the competent authorities of the Member State in accordance with Article 21 and the package leaflet proposed in accordance with Article 59 or approved by the competent authorities of the Member State in accordance with Article 61;

| — | details of any decision to refuse authorisation, whether in the Union or in a third country, and the reasons for such a decision.’, |
| --- | --- |

—

details of any decision to refuse authorisation, whether in the Union or in a third country, and the reasons for such a decision.’,

| (d) | point (n) is deleted; |
| --- | --- |

(d)

point (n) is deleted;

| (e) | the following subparagraphs are added after the second subparagraph:
  ‘The risk management system referred to in point (iaa) of the first subparagraph shall be proportionate to the identified risks and the potential risks of the medicinal product, and the need for post-authorisation safety data.
  The information referred to in the first subparagraph shall be updated where and when appropriate.’. |
| --- | --- |

(e)

the following subparagraphs are added after the second subparagraph:

‘The risk management system referred to in point (iaa) of the first subparagraph shall be proportionate to the identified risks and the potential risks of the medicinal product, and the need for post-authorisation safety data.

The information referred to in the first subparagraph shall be updated where and when appropriate.’.

| 3. | In Article 11 the following subparagraphs are added:
  ‘For medicinal products included on the list referred to in Article 23 of Regulation (EC) No 726/2004, the summary of product characteristics shall include the statement: “This medicinal product is subject to additional monitoring”. This statement shall be preceded by the black symbol referred to in Article 23 of Regulation (EC) No 726/2004 and followed by an appropriate standardised explanatory sentence.
  For all medicinal products, a standard text shall be included expressly asking healthcare professionals to report any suspected adverse reaction in accordance with the national spontaneous reporting system referred to in Article 107a(1). Different ways of reporting, including electronic reporting, shall be available in compliance with the second subparagraph of Article 107a(1).’. |
| --- | --- |

3.

In Article 11 the following subparagraphs are added:

‘For medicinal products included on the list referred to in Article 23 of Regulation (EC) No 726/2004, the summary of product characteristics shall include the statement: “This medicinal product is subject to additional monitoring”. This statement shall be preceded by the black symbol referred to in Article 23 of Regulation (EC) No 726/2004 and followed by an appropriate standardised explanatory sentence.

For all medicinal products, a standard text shall be included expressly asking healthcare professionals to report any suspected adverse reaction in accordance with the national spontaneous reporting system referred to in Article 107a(1). Different ways of reporting, including electronic reporting, shall be available in compliance with the second subparagraph of Article 107a(1).’.

| 4. | Article 16g(1) is replaced by the following:

  ‘1.   Article 3(1) and (2), Article 4(4), Article 6(1), Article 12, Article 17(1), Articles 19, 20, 23, 24, 25, 40 to 52, 70 to 85, 101 to 108b, Article 111(1) and (3), Articles 112, 116, 117, 118, 122, 123, 125, the second paragraph of Article 126, and Article 127 of this Directive as well as Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use (*1) shall apply, by analogy, to traditional-use registration granted under this Chapter.


  (*1)  
  OJ L 262, 14.10.2003, p. 22.’." |
| --- | --- |

4.

Article 16g(1) is replaced by the following:

‘1.   Article 3(1) and (2), Article 4(4), Article 6(1), Article 12, Article 17(1), Articles 19, 20, 23, 24, 25, 40 to 52, 70 to 85, 101 to 108b, Article 111(1) and (3), Articles 112, 116, 117, 118, 122, 123, 125, the second paragraph of Article 126, and Article 127 of this Directive as well as Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use (*1) shall apply, by analogy, to traditional-use registration granted under this Chapter.

(*1)  
  OJ L 262, 14.10.2003, p. 22.’."

*1

| 5. | Article 17 is amended as follows:






  (a) | in the second subparagraph of paragraph 1, the words ‘Articles 27’ are replaced by the words ‘Articles 28’; |
| --- | --- | --- |

5.

Article 17 is amended as follows:

(a)

in the second subparagraph of paragraph 1, the words ‘Articles 27’ are replaced by the words ‘Articles 28’;

| (b) | in paragraph 2, the words ‘Articles 27’ are replaced by the words ‘Articles 28’; |
| --- | --- |

(b)

in paragraph 2, the words ‘Articles 27’ are replaced by the words ‘Articles 28’;

| 6. | In Article 18, the words ‘Articles 27’ are replaced by the words ‘Articles 28’. |
| --- | --- |

6.

In Article 18, the words ‘Articles 27’ are replaced by the words ‘Articles 28’.

| 7. | In Article 21, paragraphs 3 and 4 are replaced by the following:

  ‘3.   The national competent authorities shall, without delay, make publicly available the marketing authorisation together with the package leaflet, the summary of the product characteristics and any conditions established in accordance with Articles 21a, 22 and 22a, together with any deadlines for the fulfilment of those conditions for each medicinal product which they have authorised.


  4.   The national competent authorities shall draw up an assessment report and make comments on the file as regards the results of the pharmaceutical and pre-clinical tests, the clinical trials, the risk management system and the pharmacovigilance system of the medicinal product concerned. The assessment report shall be updated whenever new information becomes available which is important for the evaluation of the quality, safety or efficacy of the medicinal product concerned.
  The national competent authorities shall make the assessment report publicly accessible without delay, together with the reasons for their opinion, after deletion of any information of a commercially confidential nature. The justification shall be provided separately for each indication applied for.
  The public assessment report shall include a summary written in a manner that is understandable to the public. The summary shall contain, in particular, a section relating to the conditions of use of the medicinal product.’. |
| --- | --- |

7.

In Article 21, paragraphs 3 and 4 are replaced by the following:

‘3.   The national competent authorities shall, without delay, make publicly available the marketing authorisation together with the package leaflet, the summary of the product characteristics and any conditions established in accordance with Articles 21a, 22 and 22a, together with any deadlines for the fulfilment of those conditions for each medicinal product which they have authorised.

4.   The national competent authorities shall draw up an assessment report and make comments on the file as regards the results of the pharmaceutical and pre-clinical tests, the clinical trials, the risk management system and the pharmacovigilance system of the medicinal product concerned. The assessment report shall be updated whenever new information becomes available which is important for the evaluation of the quality, safety or efficacy of the medicinal product concerned.

The national competent authorities shall make the assessment report publicly accessible without delay, together with the reasons for their opinion, after deletion of any information of a commercially confidential nature. The justification shall be provided separately for each indication applied for.

The public assessment report shall include a summary written in a manner that is understandable to the public. The summary shall contain, in particular, a section relating to the conditions of use of the medicinal product.’.

| 8. | The following Article is inserted:

  ‘Article 21a
  In addition to the provisions laid down in Article 19, a marketing authorisation for a medicinal product may be granted subject to one or more of the following conditions:






  (a) | to take certain measures for ensuring the safe use of the medicinal product to be included in the risk management system; |
| --- | --- | --- |

8.

The following Article is inserted:

‘Article 21a

In addition to the provisions laid down in Article 19, a marketing authorisation for a medicinal product may be granted subject to one or more of the following conditions:

(a)

to take certain measures for ensuring the safe use of the medicinal product to be included in the risk management system;

| (b) | to conduct post-authorisation safety studies; |
| --- | --- |

(b)

to conduct post-authorisation safety studies;

| (c) | to comply with obligations on the recording or reporting of suspected adverse reactions which are stricter than those referred to in Title IX; |
| --- | --- |

(c)

to comply with obligations on the recording or reporting of suspected adverse reactions which are stricter than those referred to in Title IX;

| (d) | any other conditions or restrictions with regard to the safe and effective use of the medicinal product; |
| --- | --- |

(d)

any other conditions or restrictions with regard to the safe and effective use of the medicinal product;

| (e) | the existence of an adequate pharmacovigilance system; |
| --- | --- |

(e)

the existence of an adequate pharmacovigilance system;

| (f) | to conduct post-authorisation efficacy studies where concerns relating to some aspects of the efficacy of the medicinal product are identified and can be resolved only after the medicinal product has been marketed. Such an obligation to conduct such studies shall be based on the delegated acts adopted pursuant to Article 22b while taking into account the scientific guidance referred to in Article 108a. |
| --- | --- |

(f)

to conduct post-authorisation efficacy studies where concerns relating to some aspects of the efficacy of the medicinal product are identified and can be resolved only after the medicinal product has been marketed. Such an obligation to conduct such studies shall be based on the delegated acts adopted pursuant to Article 22b while taking into account the scientific guidance referred to in Article 108a.

The marketing authorisation shall lay down deadlines for the fulfilment of these conditions where necessary.’.

| 9. | Article 22 is replaced by the following:

  ‘Article 22
  In exceptional circumstances and following consultation with the applicant, the marketing authorisation may be granted subject to certain conditions, in particular relating to the safety of the medicinal product, notification to the national competent authorities of any incident relating to its use, and action to be taken.
  The marketing authorisation may be granted only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use, for objective, verifiable reasons and must be based on one of the grounds set out in Annex I.
  Continuation of the marketing authorisation shall be linked to the annual reassessment of these conditions.’. |
| --- | --- |

9.

Article 22 is replaced by the following:

‘Article 22

In exceptional circumstances and following consultation with the applicant, the marketing authorisation may be granted subject to certain conditions, in particular relating to the safety of the medicinal product, notification to the national competent authorities of any incident relating to its use, and action to be taken.

The marketing authorisation may be granted only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use, for objective, verifiable reasons and must be based on one of the grounds set out in Annex I.

Continuation of the marketing authorisation shall be linked to the annual reassessment of these conditions.’.

| 10. | The following Articles are inserted:

  ‘Article 22a

  1.   After the granting of a marketing authorisation, the national competent authority may impose an obligation on the marketing authorisation holder:






  (a) | to conduct a post-authorisation safety study if there are concerns about the risks of an authorised medicinal product. If the same concerns apply to more than one medicinal product, the national competent authority shall, following consultation with the Pharmacovigilance Risk Assessment Committee, encourage the marketing authorisation holders concerned to conduct a joint post-authorisation safety study; |
| --- | --- | --- |

10.

The following Articles are inserted:

‘Article 22a

1.   After the granting of a marketing authorisation, the national competent authority may impose an obligation on the marketing authorisation holder:

(a)

to conduct a post-authorisation safety study if there are concerns about the risks of an authorised medicinal product. If the same concerns apply to more than one medicinal product, the national competent authority shall, following consultation with the Pharmacovigilance Risk Assessment Committee, encourage the marketing authorisation holders concerned to conduct a joint post-authorisation safety study;

| (b) | to conduct a post-authorisation efficacy study when the understanding of the disease or the clinical methodology indicate that previous efficacy evaluations might have to be revised significantly. The obligation to conduct the post-authorisation efficacy study shall be based on the delegated acts adopted pursuant to Article 22b while taking into account the scientific guidance referred to in Article 108a. |
| --- | --- |

(b)

to conduct a post-authorisation efficacy study when the understanding of the disease or the clinical methodology indicate that previous efficacy evaluations might have to be revised significantly. The obligation to conduct the post-authorisation efficacy study shall be based on the delegated acts adopted pursuant to Article 22b while taking into account the scientific guidance referred to in Article 108a.

The imposition of such an obligation shall be duly justified, notified in writing, and shall include the objectives and timeframe for submission and conduct of the study.

2.   The national competent authority shall provide the marketing authorisation holder with an opportunity to present written observations in response to the imposition of the obligation within a time limit which it shall specify, if the marketing authorisation holder so requests within 30 days of receipt of the written notification of the obligation.

3.   On the basis of the written observations submitted by the marketing authorisation holder, the national competent authority shall withdraw or confirm the obligation. Where the national competent authority confirms the obligation, the marketing authorisation shall be varied to include the obligation as a condition of the marketing authorisation and the risk management system shall be updated accordingly.

Article 22b

1.   In order to determine the situations in which post-authorisation efficacy studies may be required under Articles 21a and 22a of this Directive, the Commission may adopt, by means of delegated acts in accordance with Article 121a, and subject to the conditions of Articles 121b and 121c, measures supplementing the provisions in Articles 21a and 22a.

2.   When adopting such delegated acts, the Commission shall act in accordance with the provisions of this Directive.

Article 22c

1.   The marketing authorisation holder shall incorporate any conditions referred to in Articles 21a, 22 or 22a in his risk management system.

2.   The Member States shall inform the Agency of the marketing authorisations that they have granted subject to conditions pursuant to Articles 21a, 22 or 22a.’.

| 11. | Article 23 is replaced by the following:

  ‘Article 23

  1.   After a marketing authorisation has been granted, the marketing authorisation holder shall, in respect of the methods of manufacture and control provided for in Article 8(3)(d) and (h), take account of scientific and technical progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods.
  Those changes shall be subject to the approval of the competent authority of the Member State concerned.


  2.   The marketing authorisation holder shall forthwith provide the national competent authority with any new information which might entail the amendment of the particulars or documents referred to in Article 8(3), Articles 10, 10a, 10b and 11, or Article 32(5), or Annex I.
  In particular, the marketing authorisation holder shall forthwith inform the national competent authority of any prohibition or restriction imposed by the competent authorities of any country in which the medicinal product is marketed and of any other new information which might influence the evaluation of the benefits and risks of the medicinal product concerned. The information shall include both positive and negative results of clinical trials or other studies in all indications and populations, whether or not included in the marketing authorisation, as well as data on the use of the medicinal product where such use is outside the terms of the marketing authorisation.


  3.   The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge, including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004.


  4.   In order to be able to continuously assess the risk-benefit balance, the national competent authority may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.
  The national competent authority may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest 7 days after receipt of the request.’. |
| --- | --- |

11.

Article 23 is replaced by the following:

‘Article 23

1.   After a marketing authorisation has been granted, the marketing authorisation holder shall, in respect of the methods of manufacture and control provided for in Article 8(3)(d) and (h), take account of scientific and technical progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods.

Those changes shall be subject to the approval of the competent authority of the Member State concerned.

2.   The marketing authorisation holder shall forthwith provide the national competent authority with any new information which might entail the amendment of the particulars or documents referred to in Article 8(3), Articles 10, 10a, 10b and 11, or Article 32(5), or Annex I.

In particular, the marketing authorisation holder shall forthwith inform the national competent authority of any prohibition or restriction imposed by the competent authorities of any country in which the medicinal product is marketed and of any other new information which might influence the evaluation of the benefits and risks of the medicinal product concerned. The information shall include both positive and negative results of clinical trials or other studies in all indications and populations, whether or not included in the marketing authorisation, as well as data on the use of the medicinal product where such use is outside the terms of the marketing authorisation.

3.   The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge, including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004.

4.   In order to be able to continuously assess the risk-benefit balance, the national competent authority may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.

The national competent authority may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest 7 days after receipt of the request.’.

| 12. | Article 24 is amended as follows:






  (a) | in paragraph 2, the second subparagraph is replaced by the following:
  ‘To this end, the marketing authorisation holder shall provide the national competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Title IX, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.’; |
| --- | --- | --- |

12.

Article 24 is amended as follows:

(a)

in paragraph 2, the second subparagraph is replaced by the following:

‘To this end, the marketing authorisation holder shall provide the national competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Title IX, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.’;

| (b) | paragraph 3 is replaced by the following:

  ‘3.   Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the national competent authority decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.’. |
| --- | --- |

(b)

paragraph 3 is replaced by the following:

‘3.   Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the national competent authority decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.’.

| 13. | The title ‘Chapter 4 Mutual recognition and decentralised procedure’ is deleted. |
| --- | --- |

13.

The title ‘Chapter 4 Mutual recognition and decentralised procedure’ is deleted.

| 14. | Article 27 is amended as follows:






  (a) | paragraphs 1 and 2 are replaced by the following:

  ‘1.   A coordination group shall be set up for the following purposes:






  (a) | the examination of any question relating to a marketing authorisation of a medicinal product in two or more Member States in accordance with the procedures laid down in Chapter 4; |
| --- | --- | --- | --- |

14.

Article 27 is amended as follows:

(a)

paragraphs 1 and 2 are replaced by the following:

‘1.   A coordination group shall be set up for the following purposes:

(a)

the examination of any question relating to a marketing authorisation of a medicinal product in two or more Member States in accordance with the procedures laid down in Chapter 4;

| (b) | the examination of questions related to the pharmacovigilance of medicinal products authorised by the Member States, in accordance with Articles 107c, 107e, 107g, 107k and 107q; |
| --- | --- |

(b)

the examination of questions related to the pharmacovigilance of medicinal products authorised by the Member States, in accordance with Articles 107c, 107e, 107g, 107k and 107q;

| (c) | the examination of questions relating to variations of marketing authorisations granted by the Member States, in accordance with Article 35(1). |
| --- | --- |

(c)

the examination of questions relating to variations of marketing authorisations granted by the Member States, in accordance with Article 35(1).

The Agency shall provide the secretariat of this coordination group.

For the fulfilment of its pharmacovigilance tasks, including approving risk management systems and monitoring their effectiveness, the coordination group shall rely on the scientific assessment and the recommendations of the Pharmacovigilance Risk Assessment Committee provided for in Article 56(1)(aa) of Regulation (EC) No 726/2004.

2.   The coordination group shall be composed of one representative per Member State appointed for a renewable period of 3 years. Member States may appoint an alternate for a renewable period of 3 years. Members of the coordination group may arrange to be accompanied by experts.

Members of the coordination group and experts shall, for the fulfilment of their tasks, rely on the scientific and regulatory resources available to national competent authorities. Each national competent authority shall monitor the level of expertise of the evaluations carried out and facilitate the activities of nominated coordination group members and experts.

Article 63 of Regulation (EC) No 726/2004 shall apply to the coordination group as regards transparency and the independence of its members.’;

| (b) | the following paragraphs are added:

  ‘4.   The Executive Director of the Agency or his representative and representatives of the Commission shall be entitled to attend all meetings of the coordination group.


  5.   The members of the coordination group shall ensure that there is appropriate coordination between the tasks of that group and the work of national competent authorities, including the consultative bodies concerned with the marketing authorisation.


  6.   Save where otherwise provided for in this Directive, the Member States represented within the coordination group shall use their best endeavours to reach a position by consensus on the action to be taken. If such a consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall prevail.


  7.   Members of the coordination group shall be required, even after their duties have ceased, not to disclose information of the kind covered by the obligation of professional secrecy.’. |
| --- | --- |

(b)

the following paragraphs are added:

‘4.   The Executive Director of the Agency or his representative and representatives of the Commission shall be entitled to attend all meetings of the coordination group.

5.   The members of the coordination group shall ensure that there is appropriate coordination between the tasks of that group and the work of national competent authorities, including the consultative bodies concerned with the marketing authorisation.

6.   Save where otherwise provided for in this Directive, the Member States represented within the coordination group shall use their best endeavours to reach a position by consensus on the action to be taken. If such a consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall prevail.

7.   Members of the coordination group shall be required, even after their duties have ceased, not to disclose information of the kind covered by the obligation of professional secrecy.’.

| 15. | After Article 27 the following heading is inserted:

  ‘
  CHAPTER 4



  Mutual recognition and decentralised procedure

  ’. |
| --- | --- |

15.

After Article 27 the following heading is inserted:

‘
  CHAPTER 4

CHAPTER 4

Mutual recognition and decentralised procedure

  ’.

Mutual recognition and decentralised procedure

| 16. | Article 31(1) is amended as follows:






  (a) | the first subparagraph is replaced by the following:
  ‘The Member States, the Commission, the applicant or the marketing authorisation holder shall, in specific cases where the interests of the Union are involved, refer the matter to the Committee for application of the procedure laid down in Articles 32, 33 and 34 before any decision is reached on an application for a marketing authorisation or on the suspension or revocation of a marketing authorisation, or on any other variation of the marketing authorisation which appears necessary.’; |
| --- | --- | --- |

16.

Article 31(1) is amended as follows:

(a)

the first subparagraph is replaced by the following:

‘The Member States, the Commission, the applicant or the marketing authorisation holder shall, in specific cases where the interests of the Union are involved, refer the matter to the Committee for application of the procedure laid down in Articles 32, 33 and 34 before any decision is reached on an application for a marketing authorisation or on the suspension or revocation of a marketing authorisation, or on any other variation of the marketing authorisation which appears necessary.’;

| (b) | the following subparagraphs are inserted after the first subparagraph:
  ‘Where the referral results from the evaluation of data relating to pharmacovigilance of an authorised medicinal product, the matter shall be referred to the Pharmacovigilance Risk Assessment Committee and Article 107j(2) may be applied. The Pharmacovigilance Risk Assessment Committee shall issue a recommendation according to the procedure laid down in Article 32. The final recommendation shall be forwarded to the Committee for Medicinal Products for Human Use or to the coordination group, as appropriate, and the procedure laid down in Article 107k shall apply.
  However, where urgent action is considered necessary, the procedure laid down in Articles 107i to 107k shall apply.’. |
| --- | --- |

(b)

the following subparagraphs are inserted after the first subparagraph:

‘Where the referral results from the evaluation of data relating to pharmacovigilance of an authorised medicinal product, the matter shall be referred to the Pharmacovigilance Risk Assessment Committee and Article 107j(2) may be applied. The Pharmacovigilance Risk Assessment Committee shall issue a recommendation according to the procedure laid down in Article 32. The final recommendation shall be forwarded to the Committee for Medicinal Products for Human Use or to the coordination group, as appropriate, and the procedure laid down in Article 107k shall apply.

However, where urgent action is considered necessary, the procedure laid down in Articles 107i to 107k shall apply.’.

| 17. | Article 36 is deleted. |
| --- | --- |

17.

Article 36 is deleted.

| 18. | Article 59 is amended as follows:






  (a) | paragraph 1 is amended as follows:






  (i) | point (e) is replaced by:






  ‘(e) | a description of the adverse reactions which may occur under normal use of the medicinal product and, if necessary, the action to be taken in such a case.’; |
| --- | --- | --- | --- | --- |

18.

Article 59 is amended as follows:

(a)

paragraph 1 is amended as follows:

(i)

point (e) is replaced by:

‘(e)

a description of the adverse reactions which may occur under normal use of the medicinal product and, if necessary, the action to be taken in such a case.’;

| (ii) | the following subparagraphs are added:
  ‘For medicinal products included in the list referred to in Article 23 of Regulation (EC) No 726/2004, the following additional statement shall be included “This medicinal product is subject to additional monitoring”. This statement shall be preceded by the black symbol referred to in Article 23 of Regulation (EC) No 726/2004 and followed by an appropriate standardised explanatory sentence.
  For all medicinal products, a standardised text shall be included, expressly asking patients to communicate any suspected adverse reaction to his/her doctor, pharmacist, healthcare professional or directly to the national spontaneous reporting system referred to in Article 107a(1), and specifying the different ways of reporting available (electronic reporting, postal address and/or others) in compliance with the second subparagraph of Article 107a(1).’; |
| --- | --- |

(ii)

the following subparagraphs are added:

‘For medicinal products included in the list referred to in Article 23 of Regulation (EC) No 726/2004, the following additional statement shall be included “This medicinal product is subject to additional monitoring”. This statement shall be preceded by the black symbol referred to in Article 23 of Regulation (EC) No 726/2004 and followed by an appropriate standardised explanatory sentence.

For all medicinal products, a standardised text shall be included, expressly asking patients to communicate any suspected adverse reaction to his/her doctor, pharmacist, healthcare professional or directly to the national spontaneous reporting system referred to in Article 107a(1), and specifying the different ways of reporting available (electronic reporting, postal address and/or others) in compliance with the second subparagraph of Article 107a(1).’;

| (b) | the following paragraph is added:

  ‘4.   By 1 January 2013, the Commission shall present to the European Parliament and the Council an assessment report on current shortcomings in the summary of product characteristics and the package leaflet and how they could be improved in order to better meet the needs of patients and healthcare professionals. The Commission shall, if appropriate, and on the basis of the report, and consultation with appropriate stakeholders, present proposals in order to improve the readability, layout and content of these documents. ’ |
| --- | --- |

(b)

the following paragraph is added:

‘4.   By 1 January 2013, the Commission shall present to the European Parliament and the Council an assessment report on current shortcomings in the summary of product characteristics and the package leaflet and how they could be improved in order to better meet the needs of patients and healthcare professionals. The Commission shall, if appropriate, and on the basis of the report, and consultation with appropriate stakeholders, present proposals in order to improve the readability, layout and content of these documents. ’

| 19. | Article 63(3) is replaced by the following:

  ‘3.   When the medicinal product is not intended to be delivered directly to the patient, or where there are severe problems in respect of the availability of the medicinal product, the competent authorities may, subject to measures they consider necessary to safeguard human health, grant an exemption to the obligation that certain particulars should appear on the labelling and in the package leaflet. They may also grant a full or partial exemption to the obligation that the labelling and the package leaflet must be in the official language or languages of the Member State in which the medicinal product is placed on the market.’. |
| --- | --- |

19.

Article 63(3) is replaced by the following:

‘3.   When the medicinal product is not intended to be delivered directly to the patient, or where there are severe problems in respect of the availability of the medicinal product, the competent authorities may, subject to measures they consider necessary to safeguard human health, grant an exemption to the obligation that certain particulars should appear on the labelling and in the package leaflet. They may also grant a full or partial exemption to the obligation that the labelling and the package leaflet must be in the official language or languages of the Member State in which the medicinal product is placed on the market.’.

| 20. | Title IX is replaced by the following:


  ‘TITLE IX


  PHARMACOVIGILANCE




  CHAPTER 1




  General provisions




  Article 101

  1.   Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and their participation in Union pharmacovigilance activities.
  The pharmacovigilance system shall be used to collect information on the risks of medicinal products as regards patients’ or public health. That information shall in particular refer to adverse reactions in human beings, arising from use of the medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, and to adverse reactions associated with occupational exposure.


  2.   Member States shall, by means of the pharmacovigilance system referred to in paragraph 1, evaluate all information scientifically, consider options for risk minimisation and prevention and take regulatory action concerning the marketing authorisation as necessary. They shall perform a regular audit of their pharmacovigilance system and report the results to the Commission on 21 September 2013 at the latest and then every 2 years thereafter.


  3.   Each Member State shall designate a competent authority for the performance of pharmacovigilance tasks.


  4.   The Commission may request Member States to participate, under the coordination of the Agency, in international harmonisation and standardisation of technical measures in relation to pharmacovigilance.



  Article 102
  The Member States shall:






  (a) | take all appropriate measures to encourage patients, doctors, pharmacists and other healthcare professionals to report suspected adverse reactions to the national competent authority; for these tasks, organisations representing consumers, patients and healthcare professionals may be involved as appropriate; |
| --- | --- | --- |

20.

Title IX is replaced by the following:

‘TITLE IX

PHARMACOVIGILANCE

CHAPTER 1

General provisions

Article 101

1.   Member States shall operate a pharmacovigilance system for the fulfilment of their pharmacovigilance tasks and their participation in Union pharmacovigilance activities.

The pharmacovigilance system shall be used to collect information on the risks of medicinal products as regards patients’ or public health. That information shall in particular refer to adverse reactions in human beings, arising from use of the medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, and to adverse reactions associated with occupational exposure.

2.   Member States shall, by means of the pharmacovigilance system referred to in paragraph 1, evaluate all information scientifically, consider options for risk minimisation and prevention and take regulatory action concerning the marketing authorisation as necessary. They shall perform a regular audit of their pharmacovigilance system and report the results to the Commission on 21 September 2013 at the latest and then every 2 years thereafter.

3.   Each Member State shall designate a competent authority for the performance of pharmacovigilance tasks.

4.   The Commission may request Member States to participate, under the coordination of the Agency, in international harmonisation and standardisation of technical measures in relation to pharmacovigilance.

Article 102

The Member States shall:

(a)

take all appropriate measures to encourage patients, doctors, pharmacists and other healthcare professionals to report suspected adverse reactions to the national competent authority; for these tasks, organisations representing consumers, patients and healthcare professionals may be involved as appropriate;

| (b) | facilitate patient reporting through the provision of alternative reporting formats in addition to web-based formats; |
| --- | --- |

(b)

facilitate patient reporting through the provision of alternative reporting formats in addition to web-based formats;

| (c) | take all appropriate measures to obtain accurate and verifiable data for the scientific evaluation of suspected adverse reaction reports; |
| --- | --- |

(c)

take all appropriate measures to obtain accurate and verifiable data for the scientific evaluation of suspected adverse reaction reports;

| (d) | ensure that the public is given important information on pharmacovigilance concerns relating to the use of a medicinal product in a timely manner through publication on the web-portal and through other means of publicly available information as necessary; |
| --- | --- |

(d)

ensure that the public is given important information on pharmacovigilance concerns relating to the use of a medicinal product in a timely manner through publication on the web-portal and through other means of publicly available information as necessary;

| (e) | ensure, through the methods for collecting information and where necessary through the follow-up of suspected adverse reaction reports, that all appropriate measures are taken to identify clearly any biological medicinal product prescribed, dispensed, or sold in their territory which is the subject of a suspected adverse reaction report, with due regard to the name of the medicinal product, in accordance with Article 1(20), and the batch number; |
| --- | --- |

(e)

ensure, through the methods for collecting information and where necessary through the follow-up of suspected adverse reaction reports, that all appropriate measures are taken to identify clearly any biological medicinal product prescribed, dispensed, or sold in their territory which is the subject of a suspected adverse reaction report, with due regard to the name of the medicinal product, in accordance with Article 1(20), and the batch number;

| (f) | take the necessary measures to ensure that a marketing authorisation holder who fails to discharge the obligations laid down in this Title is subject to effective, proportionate and dissuasive penalties. |
| --- | --- |

(f)

take the necessary measures to ensure that a marketing authorisation holder who fails to discharge the obligations laid down in this Title is subject to effective, proportionate and dissuasive penalties.

For the purposes of point (a) and (e) of the first paragraph the Member States may impose specific obligations on doctors, pharmacists and other health-care professionals.

Article 103

A Member State may delegate any of the tasks entrusted to it under this Title to another Member State subject to a written agreement of the latter. Each Member State may represent no more than one other Member State.

The delegating Member State shall inform the Commission, the Agency and all other Member States of the delegation in writing. The delegating Member State and the Agency shall make that information public.

Article 104

1.   The marketing authorisation holder shall operate a pharmacovigilance system for the fulfilment of his pharmacovigilance tasks equivalent to the relevant Member State’s pharmacovigilance system provided for under Article 101(1).

2.   The marketing authorisation holder shall by means of the pharmacovigilance system referred to in paragraph 1 evaluate all information scientifically, consider options for risk minimisation and prevention and take appropriate measures as necessary.

The marketing authorisation holder shall perform a regular audit of his pharmacovigilance system. He shall place a note concerning the main findings of the audit on the pharmacovigilance system master file and, based on the audit findings, ensure that an appropriate corrective action plan is prepared and implemented. Once the corrective actions have been fully implemented, the note may be removed.

3.   As part of the pharmacovigilance system, the marketing authorisation holder shall:

| (a) | have permanently and continuously at his disposal an appropriately qualified person responsible for pharmacovigilance; |
| --- | --- |

(a)

have permanently and continuously at his disposal an appropriately qualified person responsible for pharmacovigilance;

| (b) | maintain and make available on request a pharmacovigilance system master file; |
| --- | --- |

(b)

maintain and make available on request a pharmacovigilance system master file;

| (c) | operate a risk management system for each medicinal product; |
| --- | --- |

(c)

operate a risk management system for each medicinal product;

| (d) | monitor the outcome of risk minimisation measures which are contained in the risk management plan or which are laid down as conditions of the marketing authorisation pursuant to Articles 21a, 22 or 22a; |
| --- | --- |

(d)

monitor the outcome of risk minimisation measures which are contained in the risk management plan or which are laid down as conditions of the marketing authorisation pursuant to Articles 21a, 22 or 22a;

| (e) | update the risk management system and monitor pharmacovigilance data to determine whether there are new risks or whether risks have changed or whether there are changes to the benefit-risk balance of medicinal products. |
| --- | --- |

(e)

update the risk management system and monitor pharmacovigilance data to determine whether there are new risks or whether risks have changed or whether there are changes to the benefit-risk balance of medicinal products.

The qualified person referred to in point (a) of the first subparagraph shall reside and operate in the Union and shall be responsible for the establishment and maintenance of the pharmacovigilance system. The marketing authorisation holder shall submit the name and contact details of the qualified person to the competent authority and the Agency.

4.   Notwithstanding the provisions of paragraph 3, national competent authorities may request the nomination of a contact person for pharmacovigilance issues at national level reporting to the qualified person responsible for pharmacovigilance activities.

Article 104a

1.   Without prejudice to paragraphs 2, 3 and 4 of this Article, holders of marketing authorisations granted before 21 July 2012 shall, by way of derogation from Article 104(3)(c), not be required to operate a risk management system for each medicinal product.

2.   The national competent authority may impose an obligation on a marketing authorisation holder to operate a risk management system, as referred to in Article 104(3)(c), if there are concerns about the risks affecting the risk-benefit balance of an authorised medicinal product. In that context, the national competent authority shall also oblige the marketing authorisation holder to submit a detailed description of the risk-management system which he intends to introduce for the medicinal product concerned.

The imposition of such obligations shall be duly justified, notified in writing and shall include the timeframe for submission of the detailed description of the risk-management system.

3.   The national competent authority shall provide the marketing authorisation holder with an opportunity to present written observations in response to the imposition of the obligation within a time limit which it shall specify, if the marketing authorisation holder so requests within 30 days of receipt of the written notification of the obligation.

4.   On the basis of the written observations submitted by the marketing authorisation holder, the national competent authority shall withdraw or confirm the obligation. Where the national competent authority confirms the obligation, the marketing authorisation shall be varied accordingly to include the measures to be taken as part of the risk management system as conditions of the marketing authorisation referred to in point (a) of Article 21a.

Article 105

The management of funds intended for activities connected with pharmacovigilance, the operation of communication networks and market surveillance shall be under the permanent control of the national competent authorities in order to guarantee their independence in the performance of those pharmacovigilance activities.

The first paragraph shall not preclude the national competent authorities from charging fees to marketing authorisation holders for performing those activities by the national competent authorities on the condition that their independence in the performance of those pharmacovigilance activities is strictly guaranteed.

CHAPTER 2

Transparency and communications

Article 106

Each Member State shall set up and maintain a national medicines web-portal which shall be linked to the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004. By means of the national medicines web-portals, the Member States shall make publicly available at least the following:

| (a) | public assessment reports, together with a summary thereof; |
| --- | --- |

(a)

public assessment reports, together with a summary thereof;

| (b) | summaries of product characteristics and package leaflets; |
| --- | --- |

(b)

summaries of product characteristics and package leaflets;

| (c) | summaries of risk management plans for medicinal products authorised in accordance with this Directive; |
| --- | --- |

(c)

summaries of risk management plans for medicinal products authorised in accordance with this Directive;

| (d) | the list of medicinal products referred to in Article 23 of Regulation (EC) No 726/2004; |
| --- | --- |

(d)

the list of medicinal products referred to in Article 23 of Regulation (EC) No 726/2004;

| (e) | information on the different ways of reporting suspected adverse reactions to medicinal products to national competent authorities by healthcare professionals and patients, including the web-based structured forms referred to in Article 25 of Regulation (EC) No 726/2004. |
| --- | --- |

(e)

information on the different ways of reporting suspected adverse reactions to medicinal products to national competent authorities by healthcare professionals and patients, including the web-based structured forms referred to in Article 25 of Regulation (EC) No 726/2004.

Article 106a

1.   As soon as the marketing authorisation holder intends to make a public announcement relating to information on pharmacovigilance concerns in relation to the use of a medicinal product, and in any event at the same time or before the public announcement is made, he shall be required to inform the national competent authorities, the Agency and the Commission.

The marketing authorisation holder shall ensure that information to the public is presented objectively and is not misleading.

2.   Unless urgent public announcements are required for the protection of public health, the Member States, the Agency and the Commission shall inform each other not less than 24 hours prior to a public announcement relating to information on pharmacovigilance concerns.

3.   For active substances contained in medicinal products authorised in more than one Member State, the Agency shall be responsible for the coordination between national competent authorities of safety announcements and shall provide timetables for the information being made public.

Under the coordination of the Agency, the Member States shall make all reasonable efforts to agree on a common message in relation to the safety of the medicinal product concerned and the timetables for their distribution. The Pharmacovigilance Risk Assessment Committee shall, at the request of the Agency, provide advice on those safety announcements.

4.   When the Agency or national competent authorities make public information referred to in paragraphs 2 and 3, any information of a personal or commercially confidential nature shall be deleted unless its public disclosure is necessary for the protection of public health.

CHAPTER 3

Recording, reporting and assessment of pharmacovigilance data

Section 1

Recording and reporting of suspected adverse reactions

Article 107

1.   Marketing authorisation holders shall record all suspected adverse reactions in the Union or in third countries which are brought to their attention, whether reported spontaneously by patients or healthcare professionals, or occurring in the context of a post-authorisation study.

Marketing authorisation holders shall ensure that those reports are accessible at a single point within the Union.

By way of derogation from the first subparagraph, suspected adverse reactions occurring in the context of a clinical trial shall be recorded and reported in accordance with Directive 2001/20/EC.

2.   Marketing authorisation holders shall not refuse to consider reports of suspected adverse reactions received electronically or by any other appropriate means from patients and healthcare professionals.

3.   Marketing authorisation holders shall submit electronically to the database and data-processing network referred to in Article 24 of Regulation (EC) No 726/2004 (hereinafter referred to as the “Eudravigilance database”) information on all serious suspected adverse reactions that occur in the Union and in third countries within 15 days following the day on which the marketing authorisation holder concerned gained knowledge of the event.

Marketing authorisation holders shall submit electronically to the Eudravigilance database information on all non-serious suspected adverse reactions that occur in the Union, within 90 days following the day on which the marketing authorisation holder concerned gained knowledge of the event.

For medicinal products containing the active substances referred to in the list of publications monitored by the Agency pursuant to Article 27 of Regulation (EC) No 726/2004, marketing authorisation holders shall not be required to report to the Eudravigilance database the suspected adverse reactions recorded in the listed medical literature, but they shall monitor all other medical literature and report any suspected adverse reactions.

4.   Marketing authorisation holders shall establish procedures in order to obtain accurate and verifiable data for the scientific evaluation of suspected adverse reaction reports. They shall also collect follow-up information on these reports and submit the updates to the Eudravigilance database.

5.   Marketing authorisation holders shall collaborate with the Agency and the Member States in the detection of duplicates of suspected adverse reaction reports.

Article 107a

1.   Each Member State shall record all suspected adverse reactions that occur in its territory which are brought to its attention from healthcare professionals and patients. Member States shall involve patients and healthcare professionals, as appropriate, in the follow-up of any reports they receive in order to comply with Article 102(c) and (e).

Member States shall ensure that reports of such reactions may be submitted by means of the national medicines web-portals or by other means.

2.   For reports submitted by a marketing authorisation holder, Member States on whose territory the suspected adverse reaction occurred may involve the marketing authorisation holder in the follow-up of the reports.

3.   Member States shall collaborate with the Agency and the marketing authorisation holders in the detection of duplicates of suspected adverse reaction reports.

4.   Member States shall, within 15 days following the receipt of the reports of serious suspected adverse reactions referred to in paragraph 1, submit the reports electronically to the Eudravigilance database.

They shall, within 90 days from the receipt of reports referred to in paragraph 1, submit reports of non-serious suspected adverse reactions electronically to the Eudravigilance database.

Marketing authorisation holders shall access those reports through the Eudravigilance database.

5.   Member States shall ensure that reports of suspected adverse reactions arising from an error associated with the use of a medicinal product that are brought to their attention are made available to the Eudravigilance database and to any authorities, bodies, organisations and/or institutions, responsible for patient safety within that Member State. They shall also ensure that the authorities responsible for medicinal products within that Member State are informed of any suspected adverse reactions brought to the attention of any other authority within that Member State. These reports shall be appropriately identified in the forms referred to in Article 25 of Regulation (EC) No 726/2004.

6.   Unless there are justifiable grounds resulting from pharmacovigilance activities, individual Member States shall not impose any additional obligations on marketing authorisation holders for the reporting of suspected adverse reactions.

Section 2

Periodic safety update reports

Article 107b

1.   Marketing authorisation holders shall submit to the Agency periodic safety update reports containing:

| (a) | summaries of data relevant to the benefits and risks of the medicinal product, including results of all studies with a consideration of their potential impact on the marketing authorisation; |
| --- | --- |

(a)

summaries of data relevant to the benefits and risks of the medicinal product, including results of all studies with a consideration of their potential impact on the marketing authorisation;

| (b) | a scientific evaluation of the risk-benefit balance of the medicinal product; |
| --- | --- |

(b)

a scientific evaluation of the risk-benefit balance of the medicinal product;

| (c) | all data relating to the volume of sales of the medicinal product and any data in possession of the marketing authorisation holder relating to the volume of prescriptions, including an estimate of the population exposed to the medicinal product. |
| --- | --- |

(c)

all data relating to the volume of sales of the medicinal product and any data in possession of the marketing authorisation holder relating to the volume of prescriptions, including an estimate of the population exposed to the medicinal product.

The evaluation referred to in point (b) shall be based on all available data, including data from clinical trials in unauthorised indications and populations.

The periodic safety update reports shall be submitted electronically.

2.   The Agency shall make available the reports referred to in paragraph 1 to the national competent authorities, the members of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use and the coordination group by means of the repository referred to in Article 25a of Regulation (EC) No 726/2004.

3.   By way of derogation from paragraph 1 of this Article, the holders of marketing authorisations for medicinal products referred to in Article 10(1), or Article 10a, and the holders of registrations for medicinal products referred to in Articles 14 or 16a, shall submit periodic safety update reports for such medicinal products in the following cases:

| (a) | where such obligation has been laid down as a condition in the marketing authorisation in accordance with Article 21a or Article 22; or |
| --- | --- |

(a)

where such obligation has been laid down as a condition in the marketing authorisation in accordance with Article 21a or Article 22; or

| (b) | when requested by a competent authority on the basis of concerns relating to pharmacovigilance data or due to the lack of periodic safety update reports relating to an active substance after the marketing authorisation has been granted. The assessment reports of the requested periodic safety update reports shall be communicated to the Pharmacovigilance Risk Assessment Committee, which shall consider whether there is a need for a single assessment report for all marketing authorisations for medicinal products containing the same active substance and inform the coordination group or the Committee for Medicinal Products for Human Use accordingly, in order to apply the procedures laid down in Article 107c(4) and Article 107e. |
| --- | --- |

(b)

when requested by a competent authority on the basis of concerns relating to pharmacovigilance data or due to the lack of periodic safety update reports relating to an active substance after the marketing authorisation has been granted. The assessment reports of the requested periodic safety update reports shall be communicated to the Pharmacovigilance Risk Assessment Committee, which shall consider whether there is a need for a single assessment report for all marketing authorisations for medicinal products containing the same active substance and inform the coordination group or the Committee for Medicinal Products for Human Use accordingly, in order to apply the procedures laid down in Article 107c(4) and Article 107e.

Article 107c

1.   The frequency with which the periodic safety update reports are to be submitted shall be specified in the marketing authorisation.

The dates of submission according to the specified frequency shall be calculated from the date of the authorisation.

2.   Holders of marketing authorisations which were granted before 21 July 2012, and for which the frequency and dates of submission of the periodic safety update reports are not laid down as a condition to the marketing authorisation, shall submit the periodic safety update reports in accordance with the second subparagraph of this paragraph until another frequency or other dates of submission of the reports are laid down in the marketing authorisation or determined in accordance with paragraphs 4, 5 or 6.

Periodic safety update reports shall be submitted to the competent authorities immediately upon request or in accordance with the following:

| (a) | where a medicinal product has not yet been placed on the market, at least every 6 months following authorisation and until the placing on the market; |
| --- | --- |

(a)

where a medicinal product has not yet been placed on the market, at least every 6 months following authorisation and until the placing on the market;

| (b) | where a medicinal product has been placed on the market, at least every 6 months during the first 2 years following the initial placing on the market, once a year for the following 2 years and at three-yearly intervals thereafter. |
| --- | --- |

(b)

where a medicinal product has been placed on the market, at least every 6 months during the first 2 years following the initial placing on the market, once a year for the following 2 years and at three-yearly intervals thereafter.

3.   Paragraph 2 shall also apply to medicinal products which are authorised only in one Member State and for which paragraph 4 does not apply.

4.   Where medicinal products that are subject to different marketing authorisations contain the same active substance or the same combination of active substances, the frequency and dates of submission of the periodic safety update reports resulting from the application of paragraphs 1 and 2 may be amended and harmonised to enable a single assessment to be made in the context of a periodic safety update report work-sharing procedure and to set a Union reference date from which the submission dates are calculated.

This harmonised frequency for the submission of the reports and the Union reference date may be determined, after consultation of the Pharmacovigilance Risk Assessment Committee, by one of the following:

| (a) | the Committee for Medicinal Products for Human Use, where at least one of the marketing authorisations for the medicinal products containing the active substance concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004; |
| --- | --- |

(a)

the Committee for Medicinal Products for Human Use, where at least one of the marketing authorisations for the medicinal products containing the active substance concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004;

| (b) | the coordination group, in other cases than those referred to in point (a). |
| --- | --- |

(b)

the coordination group, in other cases than those referred to in point (a).

The harmonised frequency for the submission of the reports determined pursuant to the first and second subparagraphs shall be made public by the Agency. Marketing authorisation holders shall submit an application for a variation of the marketing authorisation accordingly.

5.   For the purposes of paragraph 4, the Union reference date for medicinal products containing the same active substance or the same combination of active substances shall be one of the following:

| (a) | the date of the first marketing authorisation in the Union of a medicinal product containing that active substance or that combination active substances; |
| --- | --- |

(a)

the date of the first marketing authorisation in the Union of a medicinal product containing that active substance or that combination active substances;

| (b) | if the date referred to in point (a) cannot be ascertained, the earliest of the known dates of the marketing authorisations for a medicinal product containing that active substance or that combination of active substances. |
| --- | --- |

(b)

if the date referred to in point (a) cannot be ascertained, the earliest of the known dates of the marketing authorisations for a medicinal product containing that active substance or that combination of active substances.

6.   Marketing authorisation holders shall be allowed to submit requests to the Committee for Medicinal Products for Human Use or the coordination group, as appropriate, to determine Union reference dates or to change the frequency of submission periodic safety update reports on one of the following grounds:

| (a) | for reasons relating to public health; |
| --- | --- |

(a)

for reasons relating to public health;

| (b) | in order to avoid a duplication of the assessment; |
| --- | --- |

(b)

in order to avoid a duplication of the assessment;

| (c) | in order to achieve international harmonisation. |
| --- | --- |

(c)

in order to achieve international harmonisation.

Such requests shall be submitted in writing and shall be duly justified. The Committee for Medicinal Products for Human Use or the coordination group shall, following the consultation with the Pharmacovigilance Risk Assessment Committee, shall either approve or deny such requests. Any change in the dates or the frequency of submission of periodic safety update reports shall be made public by the Agency. The marketing authorisation holders shall accordingly submit an application for a variation of the marketing authorisation.

7.   The Agency shall make public a list of Union reference dates and frequency of submission of periodic safety update reports by means of the European medicines web-portal.

Any change to the dates of submission and frequency of periodic safety update reports specified in the marketing authorisation as a result of the application of paragraphs 4, 5 and 6 shall take effect 6 months after the date of such publication.

Article 107d

The national competent authorities shall assess periodic safety update reports to determine whether there are new risks or whether risks have changed or whether there are changes to the risk-benefit balance of medicinal products.

Article 107e

1.   A single assessment of periodic safety update reports shall be performed for medicinal products authorised in more than one Member State and, in the cases of paragraphs 4 to 6 of Article 107c, for all medicinal products containing the same active substance or the same combination of active substances and for which a Union reference date and frequency of periodic safety update reports has been established.

The single assessment shall be conducted by either of the following:

| (a) | a Member State appointed by the coordination group where none of the marketing authorisations concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004; or |
| --- | --- |

(a)

a Member State appointed by the coordination group where none of the marketing authorisations concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004; or

| (b) | a rapporteur appointed by the Pharmacovigilance Risk Assessment Committee, where at least one of the marketing authorisations concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004. |
| --- | --- |

(b)

a rapporteur appointed by the Pharmacovigilance Risk Assessment Committee, where at least one of the marketing authorisations concerned has been granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004.

When selecting the Member State in accordance with point (a) of the second subparagraph, the coordination group shall take into account whether any Member State is acting as a reference Member State, in accordance with Article 28(1).

2.   The Member State or rapporteur, as appropriate, shall prepare an assessment report within 60 days of receipt of the periodic safety update report and send it to the Agency and to the Member States concerned. The Agency shall send the report to the marketing authorisation holder.

Within 30 days of receipt of the assessment report, the Member States and the marketing authorisation holder may submit comments to the Agency and to the rapporteur or Member State.

3.   Following the receipt of the comments referred to in paragraph 2, the rapporteur or Member State shall within 15 days update the assessment report taking into account any comments submitted, and forward it to the Pharmacovigilance Risk Assessment Committee. The Pharmacovigilance Risk Assessment Committee shall adopt the assessment report with or without further changes at its next meeting and issue a recommendation. The recommendation shall mention the divergent positions with the grounds on which they are based. The Agency shall include the adopted assessment report and the recommendation in the repository set up under Article 25a of Regulation (EC) No 726/2004 and forward both to the marketing authorisation holder.

Article 107f

Following the assessment of periodic safety update reports, the national competent authorities shall consider whether any action concerning the marketing authorisation for the medicinal product concerned is necessary.

They shall maintain, vary, suspend or revoke the marketing authorisation as appropriate.

Article 107g

1.   In the case of a single assessment of periodic safety update reports that recommends any action concerning more than one marketing authorisation in accordance with Article 107e(1) which does not include any marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the coordination group shall, within 30 days of receipt of the report of the Pharmacovigilance Risk Assessment Committee, consider the report and reach a position on the maintenance, variation, suspension or revocation of the marketing authorisations concerned, including a timetable for the implementation of the agreed position.

2.   If, within the coordination group, the Member States represented reach agreement on the action to be taken by consensus, the chairman shall record the agreement and send it to the marketing authorisation holder and the Member States. The Member States shall adopt necessary measures to maintain, vary, suspend or revoke the marketing authorisations concerned in accordance with the timetable for implementation determined in the agreement.

In the event of a variation, the marketing authorisation holder shall submit to the national competent authorities an appropriate application for a modification, including an updated summary of product characteristics and package leaflet within the determined timetable for implementation.

If an agreement by consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall be forwarded to the Commission which shall apply the procedure laid down in Articles 33 and 34.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of Member States differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or the majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.

3.   In the case of a single assessment of periodic safety update reports that recommends any action concerning more than one marketing authorisation in accordance with Article 107e(1) which includes at least one marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the Committee for Medicinal Products for Human Use shall, within 30 days of receipt of the report of the Pharmacovigilance Risk Assessment Committee, consider the report and adopt an opinion on the maintenance, variation, suspension or revocation of the marketing authorisations concerned, including a timetable for the implementation of the opinion.

Where this opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

4.   On the basis of the opinion of the Committee for Medicinal Products for Human Use referred to in paragraph 3, the Commission shall:

| (a) | adopt a decision addressed to the Member States concerning the measures to be taken in respect of marketing authorisations granted by the Member States and concerned by the procedure provided for in this section; and |
| --- | --- |

(a)

adopt a decision addressed to the Member States concerning the measures to be taken in respect of marketing authorisations granted by the Member States and concerned by the procedure provided for in this section; and

| (b) | where the opinion states that regulatory action concerning the marketing authorisation is necessary, adopt a decision to vary, suspend or revoke the marketing authorisations granted in accordance with the centralised procedure provided for in Regulation (EC) No 726/2004 and concerned by the procedure provided for in this section. |
| --- | --- |

(b)

where the opinion states that regulatory action concerning the marketing authorisation is necessary, adopt a decision to vary, suspend or revoke the marketing authorisations granted in accordance with the centralised procedure provided for in Regulation (EC) No 726/2004 and concerned by the procedure provided for in this section.

Articles 33 and 34 of this Directive shall apply to the adoption of the decision referred to in point (a) of the first subparagraph of this paragraph and to its implementation by the Member States.

Article 10 of Regulation (EC) No 726/2004 shall apply to the decision referred to in point (b) of the first subparagraph of this paragraph. Where the Commission adopts such decision, it may also adopt a decision addressed to the Member States pursuant to Article 127a of this Directive.

Section 3

Signal detection

Article 107h

1.   Regarding medicinal products authorised in accordance with this Directive, national competent authorities in collaboration with the Agency, shall take the following measures:

| (a) | monitor the outcome of risk minimisation measures contained in risk management plans and of the conditions referred to in Articles 21a, 22 or 22a; |
| --- | --- |

(a)

monitor the outcome of risk minimisation measures contained in risk management plans and of the conditions referred to in Articles 21a, 22 or 22a;

| (b) | assess updates to the risk management system; |
| --- | --- |

(b)

assess updates to the risk management system;

| (c) | monitor the data in the Eudravigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance. |
| --- | --- |

(c)

monitor the data in the Eudravigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance.

2.   The Pharmacovigilance Risk Assessment Committee shall perform the initial analysis and prioritisation of signals of new risks or risks that have changed or changes to the risk-benefit balance. Where it considers that follow-up action may be necessary, the assessment of those signals and agreement on any subsequent action concerning the marketing authorisation shall be conducted in a timescale commensurate with the extent and seriousness of the issue.

3.   The Agency and national competent authorities and the marketing authorisation holder shall inform each other in the event of new risks or risks that have changed or changes to the risk-benefit balance being detected.

Member States shall ensure that marketing authorisation holders inform the Agency and national competent authorities in the event of new risks or risks that have changed or when changes to the risk-benefit balance have been detected.

Section 4

Urgent Union procedure

Article 107i

1.   A Member State or the Commission, as appropriate, shall initiate the procedure provided for in this section, by informing the other Member States, the Agency and the Commission when urgent action is considered necessary, as a result of the evaluation of data resulting from pharmacovigilance activities, in any of the following cases:

| (a) | it considers suspending or revoking a marketing authorisation; |
| --- | --- |

(a)

it considers suspending or revoking a marketing authorisation;

| (b) | it considers prohibiting the supply of a medicinal product; |
| --- | --- |

(b)

it considers prohibiting the supply of a medicinal product;

| (c) | it considers refusing the renewal of a marketing authorisation; |
| --- | --- |

(c)

it considers refusing the renewal of a marketing authorisation;

| (d) | it is informed by the marketing authorisation holder that, on the basis of safety concerns, he has interrupted the placing on the market of a medicinal product or has taken action to have a marketing authorisation withdrawn, or that he intends to do so; |
| --- | --- |

(d)

it is informed by the marketing authorisation holder that, on the basis of safety concerns, he has interrupted the placing on the market of a medicinal product or has taken action to have a marketing authorisation withdrawn, or that he intends to do so;

| (e) | it considers that a new contraindication, a reduction in the recommended dose, or a restriction to the indications is necessary. |
| --- | --- |

(e)

it considers that a new contraindication, a reduction in the recommended dose, or a restriction to the indications is necessary.

The Agency shall verify whether the safety concern relates to medicinal products other than the one covered by the information, or whether it is common to all products belonging to the same range or therapeutic class.

Where the medicinal product involved is authorised in more than one Member State, the Agency shall without undue delay inform the initiator of the procedure of the outcome of this verification, and the procedures laid down in Articles 107j and 107k shall apply. Otherwise, the safety concern shall be addressed by the Member State concerned. The Agency or the Member State, as applicable, shall make information that the procedure has been initiated available to marketing authorisation holders.

2.   Without prejudice to the provisions of paragraph 1 of this Article, and Articles 107j and 107k, a Member State may, where urgent action is necessary to protect public health, suspend the marketing authorisation and prohibit the use of the medicinal product concerned on its territory until a definitive decision is adopted. It shall inform the Commission, the Agency and the other Member States no later than the following working day of the reasons for its action.

3.   At any stage of the procedure laid down in Articles 107j to 107k, the Commission may request Member States in which the medicinal product is authorised to take temporary measures immediately.

Where the scope of the procedure, as determined in accordance with paragraph 1, includes medicinal products authorised in accordance with Regulation (EC) No 726/2004, the Commission may, at any stage of the procedure initiated under this section, take temporary measures immediately in relation to those marketing authorisations.

4.   The information referred to in this Article may relate to individual medicinal products or to a range of medicinal products or a therapeutic class.

If the Agency identifies that the safety concern relates to more medicinal products than those which are covered by the information or that it is common to all medicinal products belonging to the same range or therapeutic class, it shall extend the scope of the procedure accordingly.

Where the scope of the procedure initiated under this Article concerns a range of medicinal products or therapeutic class, medicinal products authorised in accordance with Regulation (EC) No 726/2004 which belong to that range or class shall also be included in the procedure.

5.   At the time of the information referred to in paragraph 1, the Member State shall make available to the Agency all relevant scientific information that it has at its disposal and any assessment by the Member State.

Article 107j

1.   Following receipt of the information referred to in Article 107i(1), the Agency shall publicly announce the initiation of the procedure by means of the European medicines web-portal. In parallel, Member States may publicly announce the initiation on their national medicines web-portals.

The announcement shall specify the matter submitted to the Agency in accordance with Article 107i, and the medicinal products and, where applicable, the active substances concerned. It shall contain information on the right of the marketing authorisation holders, healthcare professionals and the public to submit to the Agency information relevant to the procedure and it shall state how such information may be submitted.

2.   The Pharmacovigilance Risk Assessment Committee shall assess the matter which has been submitted to the Agency in accordance with Article 107i. The rapporteur shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use and the Reference Member State for the medicinal products concerned.

For the purposes of that assessment, the marketing authorisation holder may submit comments in writing.

Where the urgency of the matter permits, the Pharmacovigilance Risk Assessment Committee may hold public hearings, where it considers that this is appropriate on justified grounds particularly with regard to the extent and seriousness of the safety concern. The hearings shall be held in accordance with the modalities specified by the Agency and shall be announced by means of the European medicines web-portal. The announcement shall specify the modalities of participation.

In the public hearing, due regard shall be given to the therapeutic effect of the medicinal product.

The Agency shall, in consultation with the parties concerned, draw up Rules of Procedure on the organisation and conduct of public hearings, in accordance with Article 78 of Regulation (EC) No 726/2004.

Where a marketing authorisation holder or another person intending to submit information has confidential data relevant to the subject matter of the procedure, he may request permission to present that data to the Pharmacovigilance Risk Assessment Committee in a non-public hearing.

3.   Within 60 days of the information being submitted, the Pharmacovigilance Risk Assessment Committee shall make a recommendation, stating the reasons on which it is based, having due regard to the therapeutic effect of the medicinal product. The recommendation shall mention the divergent positions and the grounds on which they are based. In the case of urgency, and on the basis of a proposal by its chairman, the Pharmacovigilance Risk Assessment Committee may agree to a shorter deadline. The recommendation shall include any or a combination of the following conclusions:

| (a) | no further evaluation or action is required at Union level; |
| --- | --- |

(a)

no further evaluation or action is required at Union level;

| (b) | the marketing authorisation holder should conduct further evaluation of data together with the follow-up of the results of that evaluation; |
| --- | --- |

(b)

the marketing authorisation holder should conduct further evaluation of data together with the follow-up of the results of that evaluation;

| (c) | the marketing authorisation holder should sponsor a post-authorisation safety study together with the follow up evaluation of the results of that study; |
| --- | --- |

(c)

the marketing authorisation holder should sponsor a post-authorisation safety study together with the follow up evaluation of the results of that study;

| (d) | the Member States or marketing authorisation holder should implement risk minimisation measures; |
| --- | --- |

(d)

the Member States or marketing authorisation holder should implement risk minimisation measures;

| (e) | the marketing authorisation should be suspended, revoked or not renewed; |
| --- | --- |

(e)

the marketing authorisation should be suspended, revoked or not renewed;

| (f) | the marketing authorisation should be varied. |
| --- | --- |

(f)

the marketing authorisation should be varied.

For the purposes of point (d) of the first subparagraph, the recommendation shall specify the risk minimisation measures recommended and any conditions or restrictions to which the marketing authorisation should be made subject.

Where, in the cases referred to in point (f) of the first subparagraph, it is recommended to change or add information in the summary of product characteristics or the labelling or package leaflet, the recommendation shall suggest the wording of such changed or added information and where in the summary of the product characteristics, labelling or package leaflet such wording should be placed.

Article 107k

1.   Where the scope of the procedure, as determined in accordance with Article 107i(4), does not include any marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the coordination group shall, within 30 days of receipt of the recommendation of the Pharmacovigilance Risk Assessment Committee, consider the recommendation and reach a position on the maintenance, variation, suspension, revocation or refusal of the renewal of the marketing authorisation concerned, including a timetable for the implementation of the agreed position. Where an urgent adoption of the position is necessary, and on the basis of a proposal by its chairman, the coordination group may agree to a shorter deadline.

2.   If, within the coordination group, the Member States represented reach agreement on the action to be taken by consensus, the chairman shall record the agreement and send it to the marketing authorisation holder and the Member States. The Member States shall adopt necessary measures to maintain, vary, suspend, revoke or refuse renewal of the marketing authorisation concerned in accordance with the implementation timetable determined in the agreement.

In the event that a variation is agreed upon, the marketing authorisation holder shall submit to the national competent authorities an appropriate application for a variation, including an updated summary of product characteristics and package leaflet within the determined timetable for implementation.

If an agreement by consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall be forwarded to the Commission which shall apply the procedure laid down in Articles 33 and 34. However, by way of derogation from Article 34(1), the procedure referred to in Article 121(2) shall apply.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of the Member States represented within the coordination group differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.

3.   Where the scope of the procedure, as determined in accordance with Article 107i(4), includes at least one marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the Committee for Medicinal Products for Human Use shall, within 30 days of receipt of the recommendation of the Pharmacovigilance Risk Assessment Committee, consider the recommendation and adopt an opinion on the maintenance, variation, suspension, revocation or refusal of the renewal of the marketing authorisations concerned. Where an urgent adoption of the opinion is necessary, and on the basis of a proposal by its chairman, the Committee for Medicinal Products for Human Use may agree to a shorter deadline.

Where the opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

4.   On the basis of the opinion of the Committee for Medicinal Products for Human Use referred to in paragraph 3, the Commission shall:

| (a) | adopt a decision addressed to the Member States concerning the measures to be taken in respect of marketing authorisations that are granted by the Member States and that are subject to the procedure provided for in this section; and |
| --- | --- |

(a)

adopt a decision addressed to the Member States concerning the measures to be taken in respect of marketing authorisations that are granted by the Member States and that are subject to the procedure provided for in this section; and

| (b) | where the opinion is that regulatory action is necessary, adopt a decision to vary, suspend, revoke or refuse renewal of the marketing authorisations granted in accordance with Regulation (EC) No 726/2004 and subject to the procedure provided for in this section. |
| --- | --- |

(b)

where the opinion is that regulatory action is necessary, adopt a decision to vary, suspend, revoke or refuse renewal of the marketing authorisations granted in accordance with Regulation (EC) No 726/2004 and subject to the procedure provided for in this section.

Articles 33 and 34 of this Directive shall apply to the adoption of the decision referred to in point (a) of the first subparagraph of this paragraph and to its implementation by the Member States. However, by way of derogation from Article 34(1) of this Directive, the procedure referred to in Article 121(2) thereof shall apply.

Article 10 of Regulation (EC) No 726/2004 shall apply to the decision referred to in point (b) of the first subparagraph of this paragraph. However, by way of derogation from Article 10(2) of that Regulation, the procedure referred to in Article 87(2) thereof shall apply. Where the Commission adopts such decision, it may also adopt a decision addressed to the Member States pursuant to Article 127a of this Directive.

Section 5

Publication of assessments

Article 107l

The Agency shall make public the final assessment conclusions, recommendations, opinions and decisions referred to in Articles 107b to 107k by means of the European medicines web-portal.

CHAPTER 4

Supervision of post-authorisation safety studies

Article 107m

1.   This Chapter applies to non-interventional post-authorisation safety studies which are initiated, managed or financed by the marketing authorisation holder voluntarily or pursuant to obligations imposed in accordance with Articles 21a or 22a, and which involve the collection of safety data from patients or healthcare professionals.

2.   This Chapter is without prejudice to national and Union requirements for ensuring the well-being and rights of participants in non-interventional post-authorisation safety studies.

3.   The studies shall not be performed where the act of conducting the study promotes the use of a medicinal product.

4.   Payments to healthcare professionals for participating in non-interventional post-authorisation safety studies shall be restricted to the compensation for time and expenses incurred.

5.   The national competent authority may require the marketing authorisation holder to submit the protocol and the progress reports to the competent authorities of the Member States in which the study is conducted.

6.   The marketing authorisation holder shall send the final report to the competent authorities of the Member States in which the study was conducted within 12 months of the end of data collection.

7.   While a study is being conducted, the marketing authorisation holder shall monitor the data generated and consider its implications for the risk-benefit balance of the medicinal product concerned.

Any new information which might influence the evaluation of the risk-benefit balance of the medicinal product shall be communicated to the competent authorities of the Member State in which the medicinal product has been authorised in accordance with Article 23.

The obligation laid down in the second subparagraph is without prejudice to the information on the results of studies that the marketing authorisation holder shall make available by means of the periodic safety update reports as laid down in Article 107b.

8.   Articles 107n to 107q shall apply exclusively to studies referred to in paragraph 1 which are conducted pursuant to an obligation imposed in accordance with Articles 21a or 22a.

Article 107n

1.   Before a study is conducted, the marketing authorisation holder shall submit a draft protocol to the Pharmacovigilance Risk Assessment Committee, except for studies to be conducted in only one Member State that requests the study according to Article 22a. For such studies, the marketing authorisation holder shall submit a draft protocol to the national competent authority of the Member State in which the study is conducted.

2.   Within 60 days of the submission of the draft protocol the national competent authority or the Pharmacovigilance Risk Assessment Committee, as appropriate, shall issue:

| (a) | a letter endorsing the draft protocol; |
| --- | --- |

(a)

a letter endorsing the draft protocol;

| (b) | a letter of objection, which shall set out in detail the grounds for the objection, in any of the following cases:






  (i) | it considers that the conduct of the study promotes the use of a medicinal product; |
| --- | --- | --- |

(b)

a letter of objection, which shall set out in detail the grounds for the objection, in any of the following cases:

(i)

it considers that the conduct of the study promotes the use of a medicinal product;

| (ii) | it considers that the design of the study does not fulfil the study objectives; or |
| --- | --- |

(ii)

it considers that the design of the study does not fulfil the study objectives; or

| (c) | a letter notifying the marketing authorisation holder that the study is a clinical trial falling under the scope of Directive 2001/20/EC. |
| --- | --- |

(c)

a letter notifying the marketing authorisation holder that the study is a clinical trial falling under the scope of Directive 2001/20/EC.

3.   The study may commence only when the written endorsement from the national competent authority or the Pharmacovigilance Risk Assessment Committee, as appropriate, has been issued.

Where a letter of endorsement as referred to in paragraph 2(a) has been issued, the marketing authorisation holder shall forward the protocol to the competent authorities of the Member States in which the study is to be conducted and may thereafter commence the study according to the endorsed protocol.

Article 107o

After a study has been commenced, any substantial amendments to the protocol shall be submitted, before their implementation, to the national competent authority or to the Pharmacovigilance Risk Assessment Committee, as appropriate. The national competent authority or the Pharmacovigilance Risk Assessment Committee, as appropriate, shall assess the amendments and inform the marketing authorisation holder of its endorsement or objection. Where applicable, the marketing authorisation holder shall inform Member States in which the study is conducted.

Article 107p

1.   Upon completion of the study, a final study report shall be submitted to the national competent authority or the Pharmacovigilance Risk Assessment Committee within 12 months of the end of data collection unless a written waiver has been granted by the national competent authority or the Pharmacovigilance Risk Assessment Committee, as appropriate.

2.   The marketing authorisation holder shall evaluate whether the results of the study have an impact on the marketing authorisation and shall, if necessary, submit to the national competent authorities an application to vary the marketing authorisation.

3.   Together with the final study report, the marketing authorisation holder shall electronically submit an abstract of the study results to the national competent authority or the Pharmacovigilance Risk Assessment Committee.

Article 107q

1.   Based on the results of the study and after consultation of the marketing authorisation holder, the Pharmacovigilance Risk Assessment Committee may make recommendations concerning the marketing authorisation, stating the reasons on which they are based. The recommendations shall mention the divergent positions and the grounds on which they are based.

2.   When recommendations for the variation, suspension or revocation of the marketing authorisation are made for a medicinal product authorised by the Member States pursuant to this Directive, the Member States represented within the coordination group shall agree a position on the matter taking into account the recommendation referred to in paragraph 1 and including a timetable for the implementation of the agreed position.

If, within the coordination group, the Member States represented reach agreement on the action to be taken by consensus, the chairman shall record the agreement and send it to the marketing authorisation holder and the Member States. The Member States shall adopt necessary measures to vary, suspend or revoke the marketing authorisation concerned in accordance with the implementation timetable determined in the agreement.

In the event that a variation is agreed upon, the marketing authorisation holder shall submit to the national competent authorities an appropriate application for a variation, including an updated summary of product characteristics and package leaflet within the determined timetable for implementation.

The agreement shall be made public on the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004.

If an agreement by consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall be forwarded to the Commission, which shall apply the procedure laid down in Articles 33 and 34.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of Member States differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.

CHAPTER 5

Implementation, Delegation and Guidance

Article 108

In order to harmonise the performance of the pharmacovigilance activities provided for in this Directive, the Commission shall adopt implementing measures in the following areas for which pharmacovigilance activities are provided for in Article 8(3), and in Articles 101, 104, 104a, 107, 107a, 107b, 107h, 107n and 107p:

| (a) | the content and maintenance of the pharmacovigilance system master file kept by the marketing authorisation holder; |
| --- | --- |

(a)

the content and maintenance of the pharmacovigilance system master file kept by the marketing authorisation holder;

| (b) | the minimum requirements for the quality system for the performance of pharmacovigilance activities by the national competent authorities and the marketing authorisation holder; |
| --- | --- |

(b)

the minimum requirements for the quality system for the performance of pharmacovigilance activities by the national competent authorities and the marketing authorisation holder;

| (c) | the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities; |
| --- | --- |

(c)

the use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities;

| (d) | the minimum requirements for the monitoring of data in the Eudravigilance database to determine whether there are new risks or whether risks have changed; |
| --- | --- |

(d)

the minimum requirements for the monitoring of data in the Eudravigilance database to determine whether there are new risks or whether risks have changed;

| (e) | the format and content of the electronic transmission of suspected adverse reactions by Member States and the marketing authorisation holder; |
| --- | --- |

(e)

the format and content of the electronic transmission of suspected adverse reactions by Member States and the marketing authorisation holder;

| (f) | the format and content of electronic periodic safety update reports and risk management plans; |
| --- | --- |

(f)

the format and content of electronic periodic safety update reports and risk management plans;

| (g) | the format of protocols, abstracts and final study reports for the post-authorisation safety studies. |
| --- | --- |

(g)

the format of protocols, abstracts and final study reports for the post-authorisation safety studies.

Those measures shall take account of the work on international harmonisation carried out in the area of pharmacovigilance and shall, where necessary, be revised to take account of technical and scientific progress. Those measures shall be adopted in accordance with the regulatory procedure referred to in Article 121(2).

Article 108a

In order to facilitate the performance of pharmacovigilance activities within the Union, the Agency shall, in cooperation with competent authorities and other interested parties, draw up:

| (a) | guidance on good pharmacovigilance practices for both competent authorities and marketing authorisation holders; |
| --- | --- |

(a)

guidance on good pharmacovigilance practices for both competent authorities and marketing authorisation holders;

| (b) | scientific guidance on post-authorisation efficacy studies. |
| --- | --- |

(b)

scientific guidance on post-authorisation efficacy studies.

Article 108b

The Commission shall make public a report on the performance of pharmacovigilance tasks by the Member States on 21 July 2015 at the latest and then every 3 years thereafter.’.

| 21. | Article 111 is amended as follows:






  (a) | paragraph 1 is amended as follows:






  (i) | the first subparagraph is replaced by the following:
  ‘The competent authority of the Member State concerned shall, in cooperation with the Agency, ensure that the legal requirements governing medicinal products are complied with, by means of inspections, if necessary unannounced, and, where appropriate, by asking an Official Medicines Control Laboratory or a laboratory designated for that purpose to carry out tests on samples. This cooperation shall consist in sharing information with the Agency on both inspections that are planned and that have been conducted. Member States and the Agency shall cooperate in the coordination of inspections in third countries.’; |
| --- | --- | --- | --- |

21.

Article 111 is amended as follows:

(a)

paragraph 1 is amended as follows:

(i)

the first subparagraph is replaced by the following:

‘The competent authority of the Member State concerned shall, in cooperation with the Agency, ensure that the legal requirements governing medicinal products are complied with, by means of inspections, if necessary unannounced, and, where appropriate, by asking an Official Medicines Control Laboratory or a laboratory designated for that purpose to carry out tests on samples. This cooperation shall consist in sharing information with the Agency on both inspections that are planned and that have been conducted. Member States and the Agency shall cooperate in the coordination of inspections in third countries.’;

| (ii) | in the fifth subparagraph, point (d) is replaced by the following:






  ‘(d) | inspect the premises, records, documents and pharmacovigilance system master file of the marketing authorisation holder or any firms employed by the marketing authorisation holder to perform the activities described in Title IX.’; |
| --- | --- | --- |

(ii)

in the fifth subparagraph, point (d) is replaced by the following:

‘(d)

inspect the premises, records, documents and pharmacovigilance system master file of the marketing authorisation holder or any firms employed by the marketing authorisation holder to perform the activities described in Title IX.’;

| (b) | paragraph 3 is replaced by the following:

  ‘3.   After every inspection referred to in paragraph 1, the competent authority shall report on whether the inspected entity complies with the principles and guidelines of good manufacturing practice and good distribution practices referred to in Articles 47 and 84, or whether the marketing authorisation holder complies with the requirements laid down in Title IX.
  The competent authority which carried out the inspection shall communicate the content of those reports to the inspected entity.
  Before adopting the report, the competent authority shall give the inspected entity concerned the opportunity to submit comments.’; |
| --- | --- |

(b)

paragraph 3 is replaced by the following:

‘3.   After every inspection referred to in paragraph 1, the competent authority shall report on whether the inspected entity complies with the principles and guidelines of good manufacturing practice and good distribution practices referred to in Articles 47 and 84, or whether the marketing authorisation holder complies with the requirements laid down in Title IX.

The competent authority which carried out the inspection shall communicate the content of those reports to the inspected entity.

Before adopting the report, the competent authority shall give the inspected entity concerned the opportunity to submit comments.’;

| (c) | paragraph 7 is replaced by the following:

  ‘7.   If the outcome of the inspection as referred to in points (a), (b) and (c) of paragraph 1 or the outcome of an inspection of a distributor of medicinal products or active substances or a manufacturer of excipients used as starting materials is that the inspected entity does not comply with the legal requirements and/or the principles and guidelines of good manufacturing practice or good distribution practices as provided for by Union law, the information shall be entered in the Union database as provided for in paragraph 6.’; |
| --- | --- |

(c)

paragraph 7 is replaced by the following:

‘7.   If the outcome of the inspection as referred to in points (a), (b) and (c) of paragraph 1 or the outcome of an inspection of a distributor of medicinal products or active substances or a manufacturer of excipients used as starting materials is that the inspected entity does not comply with the legal requirements and/or the principles and guidelines of good manufacturing practice or good distribution practices as provided for by Union law, the information shall be entered in the Union database as provided for in paragraph 6.’;

| (d) | the following paragraph is added:

  ‘8.   If the outcome of the inspection referred to in paragraph 1(d) is that the marketing authorisation holder does not comply with the pharmacovigilance system as described in the pharmacovigilance system master file and with Title IX, the competent authority of the Member State concerned shall bring the deficiencies to the attention of the marketing authorisation holder and give him the opportunity to submit comments.
  In such case the Member State concerned shall inform the other Member States, the Agency and the Commission.
  Where appropriate, the Member State concerned shall take the necessary measures to ensure that a marketing authorisation holder is subject to effective, proportionate and dissuasive penalties.’. |
| --- | --- |

(d)

the following paragraph is added:

‘8.   If the outcome of the inspection referred to in paragraph 1(d) is that the marketing authorisation holder does not comply with the pharmacovigilance system as described in the pharmacovigilance system master file and with Title IX, the competent authority of the Member State concerned shall bring the deficiencies to the attention of the marketing authorisation holder and give him the opportunity to submit comments.

In such case the Member State concerned shall inform the other Member States, the Agency and the Commission.

Where appropriate, the Member State concerned shall take the necessary measures to ensure that a marketing authorisation holder is subject to effective, proportionate and dissuasive penalties.’.

| 22. | Article 116 is replaced by the following:

  ‘Article 116
  The competent authorities shall suspend, revoke or vary a marketing authorisation if the view is taken that the medicinal product is harmful or that it lacks therapeutic efficacy, or that the risk-benefit balance is not favourable, or that its qualitative and quantitative composition is not as declared. Therapeutic efficacy shall be considered to be lacking when it is concluded that therapeutic results cannot be obtained from the medicinal product.
  A marketing authorisation may also be suspended, revoked or varied where the particulars supporting the application as provided for in Articles 8, 10 or 11 are incorrect or have not been amended in accordance with Article 23, or where any conditions referred to in Articles 21a, 22 or 22a have not been fulfilled or where the controls referred to in Article 112 have not been carried out.’. |
| --- | --- |

22.

Article 116 is replaced by the following:

‘Article 116

The competent authorities shall suspend, revoke or vary a marketing authorisation if the view is taken that the medicinal product is harmful or that it lacks therapeutic efficacy, or that the risk-benefit balance is not favourable, or that its qualitative and quantitative composition is not as declared. Therapeutic efficacy shall be considered to be lacking when it is concluded that therapeutic results cannot be obtained from the medicinal product.

A marketing authorisation may also be suspended, revoked or varied where the particulars supporting the application as provided for in Articles 8, 10 or 11 are incorrect or have not been amended in accordance with Article 23, or where any conditions referred to in Articles 21a, 22 or 22a have not been fulfilled or where the controls referred to in Article 112 have not been carried out.’.

| 23. | Article 117 is amended as follows:






  (a) | paragraph 1 is amended as follows:






  (i) | point (a) is replaced by the following:






  ‘(a) | the medicinal product is harmful; or’; |
| --- | --- | --- | --- | --- |

23.

Article 117 is amended as follows:

(a)

paragraph 1 is amended as follows:

(i)

point (a) is replaced by the following:

‘(a)

the medicinal product is harmful; or’;

| (ii) | point (c) is replaced by the following:






  ‘(c) | the risk-benefit balance is not favourable; or’; |
| --- | --- | --- |

(ii)

point (c) is replaced by the following:

‘(c)

the risk-benefit balance is not favourable; or’;

| (b) | the following paragraph is added:

  ‘3.   The competent authority may, for a medicinal product for which the supply has been prohibited or which has been withdrawn from the market in accordance with paragraphs 1 and 2, in exceptional circumstances during a transitional period allow the supply of the medicinal product to patients who are already being treated with the medicinal product.’. |
| --- | --- |

(b)

the following paragraph is added:

‘3.   The competent authority may, for a medicinal product for which the supply has been prohibited or which has been withdrawn from the market in accordance with paragraphs 1 and 2, in exceptional circumstances during a transitional period allow the supply of the medicinal product to patients who are already being treated with the medicinal product.’.

| 24. | The following Articles are inserted:

  ‘Article 121a

  1.   The power to adopt the delegated acts referred to in Article 22b shall be conferred on the Commission for a period of 5 years from 20 January 2011. The Commission shall draw up a report in respect of the delegated powers not later than 6 months before the end of the 5 year period. The delegation of powers shall be automatically extended for periods of an identical duration, unless the European Parliament or the Council revokes it in accordance with Article 121b.


  2.   As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.


  3.   The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in Articles 121b and 121c.



  Article 121b

  1.   The delegation of powers referred to in Article 22b may be revoked at any time by the European Parliament or by the Council.


  2.   The institution which has commenced an internal procedure for deciding whether to revoke the delegation of powers shall endeavour to inform the other institution and the Commission within a reasonable time before the final decision is taken, indicating the delegated powers which could be subject to revocation and possible reasons for a revocation.


  3.   The decision of revocation shall put an end to the delegation of the powers specified in that decision. It shall take effect immediately or at a later date specified therein. It shall not affect the validity of the delegated acts already in force. It shall be published in the Official Journal of the European Union.



  Article 121c

  1.   The European Parliament or the Council may object to a delegated act within a period of 2 months from the date of notification.
  At the initiative of the European Parliament or the Council that period shall be extended by 2 months.


  2.   If, on expiry of the period referred to in paragraph 1, neither the European Parliament nor the Council has objected to the delegated act, it shall be published in the Official Journal of the European Union and shall enter into force on the date stated therein.
  The delegated act may be published in the Official Journal of the European Union and enter into force before the expiry of that period if the European Parliament and the Council have both informed the Commission of their intention not to raise objections.


  3.   If either the European Parliament or the Council objects to the delegated act within the period referred to in paragraph 1, it shall not enter into force. The institution which objects shall state the reasons for objecting to the delegated act.’. |
| --- | --- |

24.

The following Articles are inserted:

‘Article 121a

1.   The power to adopt the delegated acts referred to in Article 22b shall be conferred on the Commission for a period of 5 years from 20 January 2011. The Commission shall draw up a report in respect of the delegated powers not later than 6 months before the end of the 5 year period. The delegation of powers shall be automatically extended for periods of an identical duration, unless the European Parliament or the Council revokes it in accordance with Article 121b.

2.   As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.

3.   The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in Articles 121b and 121c.

Article 121b

1.   The delegation of powers referred to in Article 22b may be revoked at any time by the European Parliament or by the Council.

2.   The institution which has commenced an internal procedure for deciding whether to revoke the delegation of powers shall endeavour to inform the other institution and the Commission within a reasonable time before the final decision is taken, indicating the delegated powers which could be subject to revocation and possible reasons for a revocation.

3.   The decision of revocation shall put an end to the delegation of the powers specified in that decision. It shall take effect immediately or at a later date specified therein. It shall not affect the validity of the delegated acts already in force. It shall be published in the Official Journal of the European Union.

Article 121c

1.   The European Parliament or the Council may object to a delegated act within a period of 2 months from the date of notification.

At the initiative of the European Parliament or the Council that period shall be extended by 2 months.

2.   If, on expiry of the period referred to in paragraph 1, neither the European Parliament nor the Council has objected to the delegated act, it shall be published in the Official Journal of the European Union and shall enter into force on the date stated therein.

The delegated act may be published in the Official Journal of the European Union and enter into force before the expiry of that period if the European Parliament and the Council have both informed the Commission of their intention not to raise objections.

3.   If either the European Parliament or the Council objects to the delegated act within the period referred to in paragraph 1, it shall not enter into force. The institution which objects shall state the reasons for objecting to the delegated act.’.

| 25. | Article 122(2) is replaced by the following:

  ‘2.   Upon reasoned request, Member States shall send electronically the reports referred to in Article 111(3) to the competent authorities of another Member State or to the Agency.’. |
| --- | --- |

25.

Article 122(2) is replaced by the following:

‘2.   Upon reasoned request, Member States shall send electronically the reports referred to in Article 111(3) to the competent authorities of another Member State or to the Agency.’.

| 26. | Article 123(4) is replaced by the following:

  ‘4.   The Agency shall make public annually a list of the medicinal products for which marketing authorisations have been refused, revoked or suspended, whose supply has been prohibited or which have been withdrawn from the market.’. |
| --- | --- |

26.

Article 123(4) is replaced by the following:

‘4.   The Agency shall make public annually a list of the medicinal products for which marketing authorisations have been refused, revoked or suspended, whose supply has been prohibited or which have been withdrawn from the market.’.

| 27. | In Article 126a, paragraphs 2 and 3 are replaced by the following:

  ‘2.   When a Member State avails itself of this possibility, it shall adopt the necessary measures in order to ensure that the requirements of this Directive are complied with, in particular those referred to in Titles V, VI, VIII, IX and XI. Member States may decide that Article 63(1) and (2) shall not apply to medicinal products authorised under paragraph 1.


  3.   Before granting such a marketing authorisation, a Member State:






  (a) | shall notify the marketing authorisation holder, in the Member State in which the medicinal product concerned is authorised, of the proposal to grant a marketing authorisation under this Article in respect of the medicinal product concerned. |
| --- | --- | --- |

27.

In Article 126a, paragraphs 2 and 3 are replaced by the following:

‘2.   When a Member State avails itself of this possibility, it shall adopt the necessary measures in order to ensure that the requirements of this Directive are complied with, in particular those referred to in Titles V, VI, VIII, IX and XI. Member States may decide that Article 63(1) and (2) shall not apply to medicinal products authorised under paragraph 1.

3.   Before granting such a marketing authorisation, a Member State:

(a)

shall notify the marketing authorisation holder, in the Member State in which the medicinal product concerned is authorised, of the proposal to grant a marketing authorisation under this Article in respect of the medicinal product concerned.

| (b) | may request the competent authority in that Member State to submit copies of the assessment report referred to in Article 21(4) and of the marketing authorisation in force in respect of the medicinal product concerned. If so requested, the competent authority in that Member State shall supply, within 30 days of receipt of the request, a copy of the assessment report and the marketing authorisation in respect of the medicinal product concerned.’. |
| --- | --- |

(b)

may request the competent authority in that Member State to submit copies of the assessment report referred to in Article 21(4) and of the marketing authorisation in force in respect of the medicinal product concerned. If so requested, the competent authority in that Member State shall supply, within 30 days of receipt of the request, a copy of the assessment report and the marketing authorisation in respect of the medicinal product concerned.’.

| 28. | Article 127a is replaced by the following:

  ‘Article 127a
  When a medicinal product is to be authorised in accordance with Regulation (EC) No 726/2004, and the Committee for Medicinal Products for Human Use in its opinion refers to recommended conditions or restrictions as provided for in points (c), (ca), (cb) or (cc) of Article 9(4) thereof, the Commission may adopt a decision addressed to the Member States, in accordance with Articles 33 and 34 of this Directive, for the implementation of those conditions or restrictions.’. |
| --- | --- |

28.

Article 127a is replaced by the following:

‘Article 127a

When a medicinal product is to be authorised in accordance with Regulation (EC) No 726/2004, and the Committee for Medicinal Products for Human Use in its opinion refers to recommended conditions or restrictions as provided for in points (c), (ca), (cb) or (cc) of Article 9(4) thereof, the Commission may adopt a decision addressed to the Member States, in accordance with Articles 33 and 34 of this Directive, for the implementation of those conditions or restrictions.’.

Article 2

Transitional provisions

1.   With regard to the obligation on the part of the marketing authorisation holder to maintain and make available on request a pharmacovigilance system master file in respect of one or more medicinal products provided for in Article 104(3)(b) of Directive 2001/83/EC as amended by this Directive, the Member States shall ensure that that obligation applies to marketing authorisations granted before 21 July 2011 as from either:

| a) | the date on which those marketing authorisations are renewed; or |
| --- | --- |

a)

the date on which those marketing authorisations are renewed; or

| b) | the expiry of a period of 3 years starting from 21 July 2011, |
| --- | --- |

b)

the expiry of a period of 3 years starting from 21 July 2011,

whichever is earlier.

2.   The Member States shall ensure that the procedure provided for in Articles 107m to 107q of Directive 2001/83/EC as amended by this Directive applies only to studies which have commenced after 21 July 2011.

3.   With regard to the obligation on the part of the marketing authorisation holder to submit information on suspected adverse reactions electronically to the Eudravigilance database, provided for in Article 107(3) of Directive 2001/83/EC as amended by this Directive, the Member States shall ensure that this obligation applies as from 6 months after the functionalities of the database are established and have been announced by the Agency.

4.   Until the Agency can ensure the functionalities of the Eudravigilance database as specified in Article 24 of Regulation (EC) No 726/2004 as amended by Regulation (EU) No 1235/2010 (13) of the European Parliament and of the Council, marketing authorisation holders shall report, within 15 days of the day on which the holder concerned gained knowledge of the event, all serious suspected adverse reactions that occur in the Union, to the competent authority of the Member State on whose territory the incident occurred and shall report all serious suspected adverse reactions that occur on the territory of a third country to the Agency and, if requested, to the competent authorities of the Member States in which the medicinal product is authorised.

5.   Until the Agency can ensure the functionalities of the Eudravigilance database as specified in Article 24 of Regulation (EC) No 726/2004 as amended by Regulation (EU) No 1235/2010, the competent authority of a Member State may require marketing authorisation holders to report to it all non-serious suspected adverse reactions that occur on the territory of that Member State, within 90 days of the day on which the marketing authorisation holder concerned gained knowledge of the event.

6.   During this period, Member States shall ensure that the reports referred to in paragraph 4 that relate to events that occurred in their territory are promptly made available to the Eudravigilance database, and in any case within 15 days of the notification of suspected serious adverse reactions.

7.   With regard to the obligation on the part of the marketing authorisation holder to submit periodic safety update reports to the Agency as provided for in Article 107b(1) of Directive 2001/83/EC as amended by this Directive, the national competent authorities shall ensure that this obligation applies as from 12 months after the functionalities of the repository have been established and have been announced by the Agency.

Until the Agency can ensure the functionalities agreed for the repository of the periodic safety update reports, the marketing authorisation holders shall submit the periodic safety reports to all Member States in which the medicinal product has been authorised.

Article 3

Transposition

1.   Member States shall adopt and publish, by 21 July 2012 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive. They shall forthwith communicate to the Commission the text of those provisions.

They shall apply those provisions from 21 July 2012.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2.   Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 4

Entry into force

This Directive shall enter into force on the 20th day following its publication in the Official Journal of the European Union.

Official Journal of the European Union

Article 5

Addressees

This Directive is addressed to the Member States.

Done at Strasbourg, 15 December 2010.

For the European Parliament

The President

J. BUZEK

For the Council

The President

O. CHASTEL

---

(1)  
  OJ C 306, 16.12.2009, p. 28.

1

(2)  
  OJ C 79, 27.3.2010, p. 50.

2

(3)  
  OJ C 229, 23.9.2009, p. 19.

3

(4)  Position of the European Parliament of 22 September 2010 [not yet published in the Official Journal] and Council Decision of 29 November 2010.

4

(5)  
  OJ L 311, 28.11.2001, p. 67.

5

(6)  
  OJ L 136, 30.4.2004, p. 1.

6

(7)  
  OJ L 121, 1.5.2001, p. 34.

7

(8)  
  OJ L 281, 23.11.1995, p. 31.

8

(9)  
  OJ L 8, 12.1.2001, p. 1.

9

(10)  
  OJ L 218, 13.8.2008, p. 30.

10

(11)  
  OJ L 184, 17.7.1999, p. 23.

11

(12)  
  OJ C 321, 31.12.2003, p. 1.

12

(13)  See page 1 of this Official Journal.

13

---